APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156 FOR U.S. PATENT 4,572,912

Applicant

: Sankyo Co. Ltd.

RECEIVED

Patent Issue Date: February 25, 1986

FEB 2 7 1997

Application

Serial No.

: 06/644,996

PATENT EXTENSION A/C PATENTS

Application

Filing Date

: August 28, 1984

Inventors

: Takao YOSHIOKA, Eiici KITAZAWA, Tomoyuki KURUMADA, Mitsuo YAMAZAKI

and Kazuo HASEGAWA

For

: THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS

CONTAINING THEM

Attorneys for

Applicant

In without a man.

: Frishauf, Holtz, Goodman,

Langer & Chick, P.C.

Attorney Docket

: 84566/HG

SUMMARY OF CONTENTS(i)
TABLE OF CONTENTS for Application(i:	i)
TABLE OF EXHIBITS for Application(ii:	i)
* * *	
TRANSMITTAL OF AN APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156	

DECLARATION of Akio Nakamura, dated February 17, 1997, on behalf of the Applicant, Sankyo Co., Ltd.

LETTER OF LICENSEE by Charles W. Ashbrook, Esq., dated January 31, 1997

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156

EXHIBITS

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156

TABLE OF CONTENTS

		<u>Page</u>
(1)	Identification of Approved Product	2,3
(2)	Identification of Federal Statute Under which Regulatory Review Occurred	4
(3)	Identification of Date on Which Product Received Permission For Commercial Marketing or Use	4
(4)	Identification of Active Ingredient	4
(5)	Statement Re: 60 Day Period for Submission of Application	5
(6)	Identification of Patent	5,6
(7)	Statement Re: Copy of Patent	6
(8)	Statement Re: Certificate of Correction	6
(9)	List of Applicable Patent Claims Demonstrating that the Claims Read on the Approved Product	6 to 20
(10)	Statement Re: Relevant Dates Pursuant to 35 USC 156(g)	21 to 24
(11)	Statement Re: Brief Description of Significant Activities During Regulatory Review Period	25
(12)	Statement that Patent is Eligible for Extension and Statement as to the Length of Extension Claimed	26 to 31
(13)	Statement Re: Duty of Disclosure	32
(14)	Statement Re: Fee	32
(15)	Statement Re: Attorneys	32
(16)	Statement Re: Certified Duplicate of Application	32
(17)	Statement Re: Declaration	32

TABLE OF EXHIBITS

Exhibit No.	Description
1	Package Insert for REZULIN™
2A	Approval Letter for PRELAY™ Including Package Insert
2 B	Approval Letter for REZULIN™
3,	Recorded Assignment
4	Patent
5	Certificate of Correction
6	Maintenance Fee Payment Receipts
7	IND Submission Letter
8	IND Acknowledgement Letter
9	October 12, 1990 IND Transfer Letter
10A	April 26, 1991 IND Transfer Letter
10B	May 31, 1991 IND Transfer Letter
11A	NDA Submission Letter for PRELAY™
11B	NDA Submission Letter for REZULIN™
12	IND Log
13	NDA Log

TRANSMITTAL

Attorney Docket No. <u>84566/HG</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Sankyo Co. Ltd.

U.S. Patent No.: 4,572,912

Issue Date February 25, 1986

Application

.

Serial No. 06/644,996

Application

Filing Date August 28, 1984

Inventors : Takao YOSHIOKA, Eiici KITAZAWA,

Tomoyuki KURUMADA, Mitsuo YAMAZAKI and

Kazuo HASEGAWA

For THIAZOLIDINE DERIVATIVES, THEIR

PREPARATION AND COMPOSITIONS

CONTAINING THEM

Attorneys for

Applicant Frishauf, Holtz, Goodman,

Langer & Chick, P.C.

FEB 2 7 1997

RFCEIVED

PATENT EXTENSION A/C PATENTS

TRANSMITTAL OF AN APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156

Box Patent Extension Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

Transmitted herewith is an APPLICATION FOR EXTENSION OF PATENT TERM (including an original and a certified duplicate original and attachments thereto, with a DECLARATION, signed by an officer of the Applicant, and with a LETTER OF THE LICENSEE, dated January 31, 1997, signed by Charles W. Ashbrook, Esq., Assistant General Counsel of the licensee) of the above-captioned patent for a product approved on January 29, 1997.

[X]The APPLICATION FOR EXTENSION OF PATENT TERM is being handcarried to the U.S. Patent and Trademark Office.

[X] Enclosed is a check for the prescribed fee in the amount of \$1,090.00 for the application presented.

In the event the actual fee differs from the check enclosed herewith, it is requested that the overpayment or underpayment be credited or charged to Deposit Account No. 06-1378.

Respectfully submitted,

Date: 26 Feb. 1997

HERBERT GOODMAN REG. NO. 17,081

FRISHAUF, HOLTZ, GOODMAN,
LANGER & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. No. (212) 319-4900
Fax No. (212) 319-5101
HG/ma

Attachments:

- [X] An original APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156 and attachments thereto, with a DECLARATION and a LETTER OF THE LICENSEE
- [X] A certified DUPLICATE APPLICATION FOR EXTENSION OF PATENT TERM and attachments thereto, with the DECLARATION and the LETTER OF THE LICENSEE
- [X] Three (3) working copies of APPLICATION FOR EXTENSION OF PATENT TERM and attachments thereto, with the DECLARATION and the LETTER OF THE LICENSEE

Certified Duplicate

The undersigned hereby certifies that the attached APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 USC 156 for U.S. Patent 4,572,912 and Exhibits are true copies of the original Application for Extension of Patent Term and Exhibits.

HERBERT GOODMAN REG. NO. 17,081

The state of the s

DECLARATION

Attorney Docket No. 84566/HG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Sankyo Co. Ltd.

U.S. Patent No.: 4,572,912

FEB 27 1997 Issue Date February 25, 1986

PATENT EXTENSION Application AIC PATENTS : 06/644,996 Serial No.

RECEIVED

Application

Filing Date : August 28, 1984

Takao YOSHIOKA, Eiici KITAZAWA, Inventors

Tomoyuki KURUMADA, Mitsuo YAMAZAKI and

Kazuo HASEGAWA

: THIAZOLIDINE DERIVATIVES, THEIR For

PREPARATION AND COMPOSITIONS

CONTAINING THEM

Attorneys for

Frishauf, Holtz, Goodman, Applicant

Langer & Chick, P.C.

DECLARATION

Box Patent Extension Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

- Akio Nakamura , am an officer of Sankyo Co., Ltd., and have general authority from Sankyo Co., Ltd., to act on its behalf in patent matters, and declare as follows:
- 1. Sankyo Co., Ltd., is a corporation of Japan, having a place of business at 5-1, Nihonbashi Honcho, 3-chome, Chuo-ku, Tokyo 103, Japan (hereinafter referred to as "Sankyo").

Sankyo is the owner of United States Patent No. 4,572,912 by an assignment recorded in the United States Patent and Trademark Office on August 28, 1994, at Reel 4313, Frames 986 and 987.

In my capacity as an officer of Sankyo, I have reviewed 2.

and understand the contents of the <u>Application for Extension of Patent Term for United States Patent No. 4,572,912</u> submitted herewith pursuant to 35 USC 156.

- 3. I believe that the above-identified patent is subject to an extension pursuant to 37 CFR 1.710.
- 4. I believe that a 1534 day extension of the term of the patent is fully justified under 35 USC 156 and the applicable regulations.
- 5. I believe that the patent for which the extension is being sought meets the conditions for extension of the term of a patent as set forth in 37 CFR 1.720.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made re punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application for extension of patent term and United States Patent No. 4,572,912.

Name Akio Nakamura

e Akio Nakamura

Director, Patent Department

Corporate Title

Tokyo, Japan , February 17, 1997
Place Date

LICENSEE LETTER

Warner-Lambert Company 2800 Plymouth Road Ann Arbor, Michigan 48105 Legal Division (313) 996-7000 Telev: 297751 and

Telex: 297751 (WLPD UR) Telecopy: 313-996-1553



Charles W. Ashbrook

Telephone: (313) 996-5215

January 31, 1997

Via Federal Express

Box Patent Extension Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED

FEB 2 7 1997

Re:

Application for Term Extension of U.S. Patent No. 4,572,912

PATENT EXTENSION A/C PATENTS

Sir:

- I, Charles W. Ashbrook, as Assistant General Counsel of Pharmaceutical Patents for Warner-Lambert Company, having general authority from Warner-Lambert Company to act on its behalf in patent matters, state as follows:
- 1. Warner-Lambert Company, specifically its Parke-Davis Pharmaceutical Research Division, has a place of business at 2800 Plymouth Road, Ann Arbor, Michigan 48105.
- 2. Warner-Lambert Company is a licensee of U.S. Patent No. 4,572, 912, pursuant to a license agreement with Sankyo Co. Ltd., the record owner of U.S. Patent No. 4,572,912.
- 3. U.S. Patent No. 4,572,912 covers a compound known as troglitazone, the active ingredient in REZULINTM and PRELAYTM.
- 4. Parke-Davis Pharmaceutical Research Division and Warner-Lambert Company participated in the clinical evaluation and registration of REZULINTM and PRELAYTM, pursuant to NDA 20-720 which is owned by Warner-Lambert Company.

5. Warner-Lambert Company hereby authorizes Sankyo Co. Ltd., to rely on the activities of Warner-Lambert Company and its Parke-Davis Pharmaceutical Research Division pursuant to NDA 20-720 to file an application under 35 U.S.C. § 156 for extension of the term of U.S. Patent No. 4,572,912.

Very truly yours, Charles W. Ashlirook

Charles W. Ashbrook

Assistant General Counsel, Pharmaceutical

Patents

APPLICATION

RECEIVED

PATENT EXTENSION

AC PATENTS

Attorney Docket No. 84566/HG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Sankyo Co. Ltd.

U.S. Patent No.: 4,572,912

: February 25, 1986 Issue Date

Application

Serial No. 06/644,996

Application

Filing Date August 28, 1984

Inventors Takao YOSHIOKA, Eiici KITAZAWA,

Tomoyuki KURUMADA, Mitsuo YAMAZAKI and

Kazuo HASEGAWA

THIAZOLIDINE DERIVATIVES, THEIR For

PREPARATION AND COMPOSITIONS

CONTAINING THEM

Attorneys for

Applicant Frishauf, Holtz, Goodman,

Langer & Chick, P.C.

APPLICATION FOR EXTENSION OF PATENT TERM <u>UNDER 35 USC 156</u>

Box Patent Extension Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

Pursuant to 201(a) of the Drug Price Competition and Patent Term Restoration Act of 1984, and in accordance with the provisions of 35 USC 156, Sankyo Co., Ltd., a corporation of Japan, having a place of business at 5-1, Nihonbashi Honcho, 3-chome, Chuo-ku, Tokyo 103, Japan (hereinafter referred to as "Sankyo" or "Applicant"), the assignee of record of United States Patent No. 4,572,912, hereby applies for an extension of 1534 days of the term of United States Patent No. 4,572,912, issued February 25, 1986 on patent application Serial No.

06/644,996 filed August 28, 1984.

The following information is submitted in accordance with 35 USC § 156(d) and 37 CFR § 1.740, and follows the numerical format set forth in 37 CFR § 1.740.

(1) A complete identification of the approved product as by appropriate chemical and generic name, physical structure or characteristics:

The approved products are $PRELAY^{\mathbb{M}}$ and $REZULIN^{\mathbb{M}}$. The active ingredient in both $PRELAY^{\mathbb{M}}$ and $REZULIN^{\mathbb{M}}$ is troglitazone.

PRELAY™ is a trademark of Sankyo U.S.A. Corporation, having an office at 780 Third Avenue, Suite 4700, New York, New York 10017. Sankyo U.S.A. Corporation is a subsidiary of Sankyo Co., Ltd.

REZULIN™ is a trademark of the Warner-Lambert Company. The Warner-Lambert Company, which has places of business at 201 Tabor Road, Morris Plains, New Jersey 07950 and 2800 Plymouth Road, P.O. Box 1047, Ann Arbor, Michigan 48106-1047, has been licensed in the United States by the Applicant, Sankyo, under United States Patent No. 4,572,912. A LETTER OF THE LICENSEE, of the Warner-Lambert Company, is being submitted concomitantly herewith which provides authorization to Sankyo Co., Ltd. to rely on the activities and data of the Warner-Lambert Company including its Parke-Davis Pharmaceutical Research Division before the Food and Drug Administration in obtaining approval of the drug REZULIN™ for the purpose of obtaining a patent term extension for United States Patent No. 4,572,912.

Troglitazone is designated chemically as (±)-5-[[4-[3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione. Troglitazone can also be designated chemically as (±)-5-[4-(6-hydroxy-2,5,7,8-

tetramethylchroman-2-ylmethoxy) benzyl]thiazolidine-2,4-dione. The empirical formula of troglitazone is $C_{24}H_{27}NO_5S$ and has a molecular weight of 441.55 daltons.

Troglitazone is also known as "CS-045", "CI-991", "GR92132X" and "PD137070".

The plane structural formula of troglitazone is as follows:

PRELAY™ (troglitazone) and REZULIN™ (troglitazone) are both a pharmaceutical for oral administration. The Product Information sheet for the approved product (hereinafter the term "product" or "approved product" refers to both PRELAY™ and REZULIN™) is the PACKAGE INSERT. A copy of the PACKAGE INSERT for PRELAY™ (containing FDA handwritten notations) is attached to Exhibit 2A. It is noted that the trademark REZULIN™ in said PACKAGE INSERT for PRELAY™ should be the trademark --PRELAY™--. A copy of the PACKAGE INSERT for REZULIN™ at the time of approval is enclosed herewith as Exhibit 1. Exhibit 1 corresponds to the PACKAGE INSERT attached to Exhibit 2A.

(2) A complete identification of the Federal statute including the applicable provision of law under which the regulatory review occurred:

The regulatory review occurred under § 505(b) of the Federal Food, Drug and Cosmetic Act ("FFDCA"), 21 USC § 301 et seq.

Section 505 provides for the submission and approval of new drug applications ("NDAs") for products.

(3) An identification of the date on which the product received permission for commercial marketing or use under the provision of law under which the applicable regulatory review period occurred:

PRELAY™ (troglitazone) and REZULIN™ (troglitazone) were both approved by the Food and Drug Administration ("FDA") for commercial marketing pursuant to § 505(b) of the FFDCA on January 29, 1997; see Exhibit 2A (APPROVAL LETTER for PRELAY™) and Exhibit 2B (APPROVAL LETTER for REZULIN™).

(4) In the case of a human drug product, an identification of each active ingredient in the product and as to each active ingredient, a statement that it has not been previously approved for commercial marketing or use under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act, or a statement of when the active ingredient was approved for commercial marketing or use (either alone or in combination with other active ingredients), the use for which it was approved, and the provision of law under which it was approved.

The active ingredient in both PRELAY™ and REZULIN™ is troglitazone. Neither troglitazone, nor any salt or ester of troglitazone, nor any other form of troglitazone have been previously approved for commercial marketing or use under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum Toxin Act.

(5) A statement that the application is being submitted within the sixty day period permitted for submission pursuant to § 1.720(f) and an identification of the date of the last day on which the application could be submitted.

U.S. Patent No. 4,572,912

The product was approved for commercial marketing on January 29, 1997, and the last day within the sixty (60) day period permitted for submission of an application for extension (pursuant to 37 CFR 1.720(f)) of the patent is March 29, 1997. The date of submission of the present application is no later than March 29, 1997, and therefore, the present application has been timely filed.

(6) A complete identification of the patent for which an extension is being sought by the name of the inventor, the patent number, the date of issue, and the date of expiration:

U.S. Patent No.: 4,572,912

Issue Date : February 25, 1986

Inventors : Takao YOSHIOKA, Eiici KITAZAWA,

Tomoyuki KURUMADA, Mitsuo YAMAZAKI and

Kazuo HASEGAWA, all of Japan

Title : THIAZOLIDINE DERIVATIVES, THEIR

PREPARATION AND COMPOSITIONS

CONTAINING THEM

Application

Serial No. : 06/644,996

Application

Filing Date : August 28, 1984

Expiration Date (unless

extended) : August 28, 2004

The application is assigned from the inventors to the Applicant by an assignment recorded on August 28, 1984, in the United States Patent and Trademark Office at Reel 4313, Frames

U.S. Patent No. 4,572,912

986 and 987. A copy of the recorded Assignment is attached as Exhibit 3.

(7) A copy of the patent for which an extension is being sought including the entire specification (including claims) and drawings:

A copy of U.S. Patent 4,572,912 is attached as Exhibit 4 (PATENT).

(8) A copy of any disclaimer, certificate of correction, receipt of maintenance fee payment, or reexamination certificate issued in the patent:

No disclaimer or reexamination certificate has been issued.

A Certificate of Correction for United States Patent No. 4,572,912 was issued on January 20, 1987. A copy of said Certificate of Correction is attached herewith as Exhibit 5.

Maintenance fee payments were made to the U.S. Patent and Trademark Office for United States Patent No. 4,572,912 on April 25, 1989 and March 22, 1993. Copies of the receipts for such maintenance fee payments, received from the Patent and Trademark Office, are attached hereto as Exhibit 6.

(9) A statement that the patent claims the approved product or a method of using or manufacturing the approved product, and a showing which lists each applicable patent claim and demonstrates the manner in which each applicable patent claim reads on the approved product or a method of using or manufacturing the approved product:

United States Patent No. 4,572,912 claims troglitazone

(PRELAY™ and REZULIN™). Both PRELAY™ and REZULIN™ are in tablet

form. Both PRELAY™ and REZULIN™ are approved in tablet strengths

of 200 mg/tablet and 400 mg/tablet.

Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 19, 24, 25, 26,

27, 28, 29, 30, 31, 32, 33, 34 and 35, which were allowed in United States Patent No. 4,572,912, each includes troglitazone within its scope. Note in particular the structural formulae set out in Claims 1 and 19 in United States Patent No. 4,572,912.

Claims 1 to 11, 19 and 24 to 35 of United States Patent No. 4,572,912 are set forth as follows:

1. Compounds of formula (I):

$$R^4$$
 R^5
 W
 $(CH_2)_n$
 CH_2
 CH_2
 CH_2
 NH
 NH

in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group;

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O. S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3;

W represents the —CH₂—, >CO or >CH—OR⁶ group (in which R⁶ represents any one of the atoms or groups defined for R³ and may be the same as or different from R³); and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

2. Compounds as claimed in claim 1. in which; R³ represents hydrogen, a C₁-C₆ aliphatic acyl group, one of said aromatic acyl groups or one of said heterocyclic acyl groups.

3. Compounds as claimed in claim 1, in which: Y represents an oxygen atom; R1 and R2 are the same or different and each represents hydrogen or a C1-C5 alkyl group; R3 represents hydrogen, a C1-Co aliphatic acyl group, one of said aromatic acyl groups or a pyridinecarbonyl group; and R⁴ and R⁵ are the same or different and each represents hydrogen, a C1-C3 alkyl group or a C₁ or C₂ alkoxy group.

4. Compounds as claimed in claim 3, in which: R¹, R², R4 and R5 are the same or different and each represents hydrogen or a C₁-C₅ alkyl group; n is 1 or 2; and W

represents the —CH2— or >CO group.

5. Compounds as claimed in claim 4, in which R³ represents a hydrogen atom, a C1-C5 aliphatic acyl

group, or the benzoyl or nicotinoyl group.

6. Compounds as claimed in claim 5, in which: R1 and R4 are the same or different and each represents a C1-C5 alkyl group; R2 and R5 are the same or different and each represents the hydrogen atom or the methyl group; and R3 represents hydrogen or a C1-C4 aliphatic

acyl group.

- 7. Compounds as claimed in claim 1, in which: W represents the -CH2- or >CO group; Y and Z both represent oxygen atoms; n is 1 or 2; R1 and R4 are the same or different and each represents a C1-C4 alkyl group: R2 and R5 are the same or different and each represents the hydrogen atom or the methyl group; and R³ represents hydrogen or a C₁-C₄ aliphatic acyl group.
 - 8. Compounds as claimed in claim 7, in which n is 1.
- 9. Compounds as claimed in claim 7 or claim 8, in which W represents the -CH2- group.
- 10. Compounds as claimed in claim 1, selected from the group consisting of:
 - 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)ethoxy]benzyl}thiazolidine-2,4-dione
 - 5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2yl)ethoxy]benzyl}thiazolidine-2,4-dione
 - 5-{4-[2-(6-hydroxy-7.8-dimethoxy-2,5-dimethylchro-

man-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione 5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2-isobutyl-5.7.8-trimethylchroman-2-vlmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2.5.7.8-tetramethylchroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(2-ethyl-6-hydroxy-5.7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-5,7.8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-2.7-dimethylchroman-2-ylmethoxy)-benzyl]-2-iminothiazolidin-4-one

5-[4-(6-acetoxy-2.5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-benzoyloxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-butyryloxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(2.5,7.8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2-isobutyl-5.7,8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4dione

5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-2-isobutyl-5.7.8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-acetoxy-2.5.7.8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-acetoxy-5.7,8-trimethylchroman-2-ylmethox-y)benzyl]-2-iminothiazolidin-4-one

5-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)e-thoxy]benzyl}-2-iminothiazolidin-4-one

5-{4-[2-(6-acetoxy-7.8-dimethoxy-2.5-dimethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one and pharmaceutically acceptable salts thereof.

11. The compound as claimed in claim 1.

5-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2.4-dione and pharmaceutically acceptable salts thereof.

19. Compounds of formula (la):

$$\begin{array}{c|c}
R^4 & C & C \\
R^5 & C & C \\
R^7 & C$$

in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group; R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇

cycloalkane)carbonyl: benzoyl. benzoyl substituted with one to three substitutents selected from the group of C₁-C₄ alkyl. C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino: naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero

atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3; and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

24. A pharmaceutical composition for the treatment of hyperlipaemia or hyperglycaemia, which comprises at least one active compound in admixture with a pharmaceutically acceptable carrier or diluent, wherein said active compound is selected from compounds of formula (I):

$$\begin{array}{c|c}
R^4 & R^5 & (I) \\
\hline
R^3O & R^2 & (CH_2)_n - O - (CH_2 - CH_2 -$$

in which:

R1 and R2 are the same or different and each repre-

sents hydrogen or a C1-C5 alkyl group;

R3 represents hydrogen; C1-C6 aliphatic acyl; (C5-C7 cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl. C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C1-C4 alkyl)amino; naphthoyl: 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero atoms; phenyl(C2-C3)aliphatic acyl; cinnamoyl; (C1-C6 alkoxy)carbonyl; or benzoyloxycarbonyl;

R4 and R5 are the same or different and each represents hydrogen, a C1-C5 alkyl group or a C1-C5 alkoxy group, or R4 and R5 together represent a

C1-C4 alkylenedioxy group;

n is 1, 2 or 3;

W represents the -CH2-, >CO or >CH-OR6 group (in which R6 represents any one of the atoms or groups defined for R3 and may be the same as or different from R3); and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharma-

ceutically acceptable salts thereof.

25. Compositions as claimed in claim 24, in which: R3 represents hydrogen, a C1-C6 aliphatic acyl group, one of said aromatic acyl groups or one of said heterocyclic

acyl groups.

- 26. Compositions as claimed in claim 24, in which: Y represents an oxygen atom; R1 and R2 are the same or different and each represents hydrogen or a C1-C3 alkyl group; R3 represents hydrogen, a C1-C6 aliphatic acyl group, one of said aromatic acyl groups or a pyridinecarbonyl group; and R4 and R5 are the same or different and each represents hydrogen, a C1-C5 alkyl group or a C1 or C2 alkoxy group.
- 27. Compositions as claimed in claim 26, in which: R1, R2, R4 and R5 are the same or different and each represents hydrogen or a C1-C5 alkyl group; n is 1 or 2; and W represents the -CH2- or >CO group.

28. Compositions as claimed in claim 27, in which R3 represents a hydrogen atom, a C1-C5 aliphatic acyl

group, or the benzoyl or nicotinoyl group.

- 29. Compositions as claimed in claim 28, in which: R¹ and R⁴ are the same or different and each represents a C₁-C₅ alkyl group; R² and R⁵ are the same or different and each represents the hydrogen atom or the methyl group; and R³ represents hydrogen or a C₁-C₄ aliphatic acyl group.
- 30. Compositions as claimed in claim 24, in which: W represents the $-CH_2-$ or >CO group; Y and Z both represent oxygen atoms; n is 1 or 2; R^1 and R^4 are the same or different and each represents a C_1-C_4 alkyl group; R^2 and R^5 are the same or different and each represents the hydrogen atom or the methyl group; and R^3 represents hydrogen or a C_1-C_4 aliphatic acyl group.
- 31. Compositions as claimed in claim 30, in which n is 1.
- 32. Compositions as claimed in claim 30 or claim 17, in which W represents the —CH₂— group.
- 33. Compositions as claimed in claim 24, wherein said active compound is selected from the group consisting of:
 - 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione
 - 5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethox-y)benzyl]thiazolidine-2,4-dione
 - 5-{4-[2-(6-hydroxy-2.5,7,8-tetramethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
 - 5-{4-{2-(7-t-butyl-6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione
 - 5-{4-[2-(6-hydroxy-7,8-dimethoxy-2.5-dimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
 - 5-[4-(6-hydroxy-2.7-dimethylchroman-2-ylmethoxy)-benzyl]thiazolidine-2.4-dione
 - 5-[4-(6-hydroxy-2-isobutyl-5.7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 5-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(2-ethyl-6-hydroxy-5.7.8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethox-y)benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)-benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione
 - 5-[4-(6-benzoyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

- 5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(2.5.7.8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-2.5.7.8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
 - 5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
 - 5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4dione
 - 5-[4-(6-hydroxy-2.5.7.8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
 - 5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethyl-4-oxo-chroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-
 - 5-[4-(6-acetoxy-2.5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
 - 5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethox-y)benzyl]-2-iminothiazolidin-4-one
 - 5-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)e-thoxy]benzyl}-2-iminothiazolidin-4-one
- 5-{4-[2-(6-actoxy-7,8-dimethoxy-2,5-dimethylchro-man-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one and pharmaceutically acceptable salts thereof.

34. Compositions as claimed in claim 24, wherein said

active compound is selected from the group consisting

- 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-acetoxy-2.5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-butyryloxy-2.5,7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

35. Compositions as claimed in claim 24, in which said active compound is selected from compounds of formula (1a):

· in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group;

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₃-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3; and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

Claim 1

Claim 1 recites compounds of the formula

$$\begin{array}{c}
R^4 \\
R^5 \\
R^3O
\end{array}$$

$$\begin{array}{c}
R^1 \\
CH_2)_n - O - CH_2 - CH - C=Y \\
S & NH
\end{array}$$

, wherein R^1 , R^2 , R^4 and R^5 can be $C_1 - C_5$ alkyl, R^3 can be

U.S. Patent No. 4,572,912

hydrogen, W can be $-CH_2-$, n can be 1 and Y and Z can be oxygen. Thus claim 1 covers troglitazone.

Claim 2

In claim 2, which depends on claim 1, R^3 can be hydrogen. Thus claim 2 covers troglitazone.

Claim 3

In claim 3, which depends on claim 1, Y is oxygen, R^1 , R^2 , R^4 and R^5 can be C_1 - C_5 alkyl, and R^3 can be hydrogen. Accordingly, claim 3 covers troglitazone.

Claim 4

Claim 4 depends on claim 3 and recites that R^1 , R^2 , R^4 and R^5 can be C_1 - C_5 alkyl, n can be 1 and W can be -CH₂-. Therefore claim 4 covers troglitazone.

Claim 5

Claim 5 depends on claim 4 and recites that R³ can be a hydrogen atom. Thus claim 5 encompasses troglitazone.

Claim 6

Claim 6 depends on claim 5 and specifies that R^1 and R^4 are each a C_1 - C_5 alkyl group. In claim 6, R^2 and R^5 can be a methyl group and R^3 can be hydrogen. Therefore claim 6 covers troglitazone.

Claim 7

Claim 7 depends on claim 1 and specifies that Y and Z are both oxygen atoms. In claim 7, W can be $-CH_2-$, n can be 1, R^1

U.S. Patent No. 4,572,912

and R^4 can each be a C_1 - C_4 alkyl group, R^2 and R^5 can be a methyl group and R^3 can be hydrogen. Accordingly, troglitazone is covered by claim 7.

Claim 8

Claim 8 depends on claim 7 and calls for n to be 1. Thus claim 8 covers troglitazone.

Claim 9

In claim 9, which depends on claims 7 and 8, W is specified as a -CH₂- group. Accordingly, troglitazone is embraced by claim 9.

Claim 10

Claim 10 depends on claim 1. The first compound recited in claim 10 is 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, which is troglitazone.

Claim 11

Claim 11 of United States Patent No. 4,572,912 specifically recites 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof. Troglitazone is thus covered by claim 11.

Claim 19

Claim 19 recites compounds of the following formula:

$$\begin{array}{c|c}
R^{4} & CH_{2} & CH_$$

In claim 19, R^1 , R^2 , R^4 and R^5 can be C_1 - C_5 alkyl, R^3 can be hydrogen, n can be 1, and Y and Z can each be an oxygen atom. Thus claim 19 covers troglitazone.

Claim 24

Claim 24 recites a pharmaceutical composition for the treatment of hyperlipaemia or hyperglycaemia, which comprises at least one active compound in admixture with a pharmaceutically acceptable carrier or diluent, wherein the active compound is selected from compounds of formula (I):

wherein R^1 , R^2 , R^4 and R^5 can be C_1 - C_5 alkyl, R^3 can be hydrogen, W can be -CH₂-, n can be 1 and Y and Z can be oxygen. Thus troglitazone is covered by the compounds embraced by claim 24.

Claim 25

Claim 25 depends on claim 24. In claim 24, R³ can be hydrogen and thus troglitazone is a compound that is covered by claim 25.

Claim 26

Claim 26 depends on claim 24 and specifies that Y is an oxygen atom and R^3 is a hydrogen atom. In claim 26, R^1 , R^2 , R^4 and R^5 can be a C_1 - C_5 alkyl group. Thus troglitazone is one of the compounds defined in claim 26.

Claim 27

Claim 27 depends on claim 26. In claim 26, R^1 , R^2 , R^4 and R^5 can be a C_1 - C_5 alkyl group, n can be 1 and W can be - CH_2 -. Accordingly, troglitazone is embraced by the compounds defined by claim 27.

Claim 28

Claim 28 depends on claim 27. In claim 28, R³ can be hydrogen. Therefore troglitazone is covered by the compounds defined by claim 28.

Claim 29

Claim 29 depends on claim 28. In claim 29, R^1 and R^4 can be a C_1 - C_5 alkyl group, R^2 and R^5 can be a methyl group and R^3 can be hydrogen. Thus the compounds defined by claim 29 includes troglitazone.

Claim 30

Claim 30 depends on claim 24 and specifies that Y and Z are both oxygen atoms. In claim 30, W can be $-CH_2-$, n can be 1, R^1- and R^4 can be a C_1-C_4 alkyl group, R^2 and R^5 can be a methyl group and R^3 can be hydrogen. Thus troglitazone is covered by the

compounds defined in claim 30.

Claim 31

Claim 31 depends on claim 30 and specifies that n is 1.

Accordingly, the compounds defined by claim 31 embrace troglitazone.

Claim 32

Claim 32 depends on claim 30 and specifies that W is the -CH₂- group. Therefore the compounds defined by claim 32 include troglitazone.

Claim 33

Claim 33 depends on claim 24. The first compound recited in claim 33 is 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, which is troglitazone.

Claim 34

Claim 34 depends on claim 24.

The first compound recited in claim 34 is 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, which is troglitazone.

Claim 35

Claim 35 depends on claim 24 and recites compounds of the following formula:

$$\begin{array}{c|c}
R^4 & CH_2-CH & C=Y \\
R^3O & R^2 & NH
\end{array}$$

U.S. Patent No. 4,572,912

In claim 35, R^1 , R^2 , R^4 and R^5 can be C_1 - C_5 alkyl, R^3 can be hydrogen, n can be 1 and Y and Z can be oxygen. Thus troglitazone is covered by the compounds defined in claim 35.

- (10) A statement beginning on a new page, of the relevant dates and information pursuant to 35 USC § 156(g) in order to enable the Secretary of health and Human Services or the Secretary of Agriculture, as appropriate, to determine the applicable regulatory review period as follows:
 - (i) For a patent claiming a human drug, antibiotic, or human biological product, the effective date of the investigational new drug (IND) application and the IND number; the date on which a new drug application (NDA) or a Product License Application (PLA) was initially submitted and the NDA or PLA number and the date on which the NDA was approved or the Product License issued;

On January 30, 1989, Sankyo submitted to the Food and Drug Administration (hereinafter sometimes referred to as the "FDA") a "Notice of Claimed Investigational Exemption for a New Drug" (IND) for CS-045 (troglitazone). A copy of each of the IND Form FDA 1571 and the IND submission letter (submitted by Oxford Research International Corp. (hereinafter referred to as "Oxford") as the agent for Sankyo) are submitted herewith (along with a copy of a letter dated January 4, 1989 from Sankyo to the FDA appointing Oxford as the agent of Sankyo) as Exhibit 7 (IND SUBMISSION LETTER).

The IND was assigned number 32,703. The IND became effective on March 9, 1989, which is thirty days after receipt of the IND by the FDA; see Exhibit 8 (IND ACKNOWLEDGEMENT LETTER) attached hereto. This establishes the beginning of the

"regulatory review period" under 35 USC § 156(g)(1) as of March 9, 1989.

In a letter dated October 12, 1990 to the Food and Drug Administration by Sankyo U.S.A. Corporation, notification was given that effective October 12, 1990, IND #32,703 was being transferred from Sankyo Co. Ltd., Tokyo, to Sankyo U.S.A. Corporation and that Sankyo U.S.A. Corporation would be the sponsor for IND #32,703. A copy of said October 12, 1990 letter is submitted herewith as Exhibit 9 (OCTOBER 12, 1990 IND TRANSFER LETTER).

In a letter dated April 26, 1991 to the Food and Drug Administration by Sankyo U.S.A. Corporation, the Food and Drug Administration was notified that sponsorship of IND #32,703 was transferred from Sankyo U.S.A. Corporation to the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company. A copy of said April 26, 1991 letter is attached hereto as Exhibit 10A (April 26, 1991 IND TRANSFER LETTER).

In a letter dated May 13, 1991 to the Food and Drug
Administration by the Parke-Davis Pharmaceutical Research
Division of the Warner-Lambert Company, the Food and Drug
Administration was further notified that sponsorship of IND
#32,703 was transferred from Sankyo U.S.A. Corporation to the
Parke-Davis Pharmaceutical Research Division of the Warner-

Lambert Company. A copy of said May 13, 1991 letter is attached hereto as Exhibit 10B (MAY 13, 1991 IND TRANSFER LETTER).

On July 31, 1996, a new drug application (NDA 20-719), was submitted under § 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) and § 314.50 of Title 21 Code of Federal Regulations for PRELAY™ (troglitazone) by Sankyo U.S.A. Corporation.

Also on July 31, 1996, a new drug application (NDA 20-720) was submitted under § 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) and § 314.50 of Title 21 Code of Federal Regulations for REZULIN™ (troglitazone) by the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company.

The data contained in both NDA 20-719 and NDA 20-720 were developed by the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company, as well as the Applicant (Sankyo Co., Ltd.), Sankyo U.S.A. Corporation, Sankyo Europe GmbH and Glaxo Wellcome Ltd. (U.K.), a licensee of the Applicant for Europe.

A copy of the cover letter dated July 31, 1996 attached to NDA 20-719 submitted by Sankyo U.S.A. Corporation and the Form FDA 356h are provided herewith as Exhibit 11A (NDA SUBMISSION LETTER).

A copy of the cover letter dated July 31, 1996 attached to the NDA 20-720 of Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company and the Form FDA 356h are provided herewith as Exhibit 11B (NDA SUBMISSION LETTER).

NDA 20-719 for PRELAY™ was approved on January 29, 1997.

Attached as Exhibit 2A (APPROVAL LETTER) is a copy of a letter dated January 29, 1997 from the FDA to Sankyo U.S.A. Corporation approving NDA 20-719 for PRELAY™ (troglitazone).

NDA 20-720 for REZULIN™ was approved on January 29, 1997. Attached as Exhibit 2B (APPROVAL LETTER) is a copy of a letter dated January 29, 1997 from the FDA to the Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company approving NDA 20-720 for REZULIN™ (troglitazone).

Thus, for the purposes of determining the "regulatory review period" under 35 USC § 156(g)(1), January 29, 1997 is the date of the first approval of troglitazone, which is the active ingredient in both PRELAY[™] and REZULIN[™].

Summary of the Most Relevant Dates:

January 30, 1989: IND for troglitazone submitted

March 9, 1989: IND 32,703 for troglitazone became effective

July 31, 1996: NDA 20-719 for PRELAY™ and NDA 20-720 for

REZULIN™ were submitted

January 29, 1997: NDA 20-719 for PRELAY™ and NDA 20-720 for

REZULIN™ were approved

(11) A brief description, beginning on a new page, of the significant activities undertaken by the marketing applicant during the applicable regulatory review period with respect to the approved product and the significant dates applicable to such activities:

As described above in item (10) above, an IND for troglitazone (PRELAY™ and REZULIN™) was submitted on January 30, 1989, which became effective on March 9, 1989. The studies under the IND are summarized in the attached Exhibit 12 (IND LOG)*. These studies were used to support both NDA 20-719 submitted on July 31, 1996 by Sankyo U.S.A. Corporation and NDA 20-720 submitted on July 31, 1996 by the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company.

Subsequent to the submission of the aforesaid NDAs, Warner-Lambert Company personnel had numerous contacts and meetings with FDA personnel with respect to the new drug application and these are summarized in the attached Exhibit 13, (NDA LOG)*.

^{*} Confidential and non-relevant material has been redacted.

U.S. Patent No. 4,572,912

(12) A statement, beginning on a new page, that in the opinion of the applicant the patent is eligible for the extension and a statement as to the length of the extension claimed, including how the length of extension was determined:

Statement of Eligibility of the Patent for Extension Under § 35 USC 156(a) and (c)(4)

Section 156(a) provides, in relevant part, that the term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended if (1) the term of the patent has not expired before an application for extension is submitted, (2) the term of the patent has never been extended, (3) the application for extension is submitted by the owner of record of the patent or its agent in accordance with 35 USC § 156(d), (4) the product has been subject to a regulatory review period before its commercial marketing or use, and (5) the permission for the commercial marketing or use of the product after such regulatory review period is the first permitted commercial marketing or use of the product under the provision of law under which such regulatory review period occurred; and § 156(c)(4) provides, that in no event shall more than one patent be extended for the same regulatory review period for any product.

As described by corresponding number, each of these elements is satisfied here as follows:

- (1) The statutory term of U.S. Patent No. 4,572,912 expires on August 28, 2004. This Application has, therefore, been submitted before the expiration of the patent term.
 - (2) The term of this patent has never been extended.
- (3) This Application is submitted by Sankyo Co., Ltd., the owner of record. This Application is submitted in accordance with 35 USC § 156(d) in that it is submitted within the sixty-day period beginning on the date, January 29, 1997, that the product received permission for marketing under the Federal Food, Drug and Cosmetic Act and contains the information required under 35 USC 156(d).
- (4) As evidenced by the January 29, 1997 letters from the FDA, Exhibit 2A, (APPROVAL LETTER) and Exhibit 2B (APPROVAL LETTER), the product was subject to a regulatory review period under § 505(b)(1) of the FFDCA before its commercial marketing or use.
- (5) The permission for the commercial marketing of PRELAY™ (troglitazone) and REZULIN™ (troglitazone) after regulatory review under § 505(b)(1) is the first permitted commercial marketing of troglitazone. This is confirmed by the absence of any approved new drug application under which troglitazone could be commercially marketed prior to January 29, 1997.

Statement as to Length of Extension Claimed

In Accordance with 37 CFR Section 1.775

The term of U.S. Patent No. 4,572,912 should be extended for a period of 1534 days to November 9, 2008.

The period of extension is determined in accordance with 35 USC § 156 and follows the format set forth in 37 CFR § 1.775(c) and (d).

37 CFR § 1.775(c) The length of the regulatory review period for a human drug, antibiotic drug or human biological product will be determined by the Secretary of Health and Human Services. Under 35 USC § 156(g)(1)(B), it is the sum of --

(1) The number of days in the period beginning on the date an exemption under subsection (i) of Section 505 or subsection (d) of Section 507 of the Federal Food, Drug and Cosmetic Act became effective for the approved product and ending on the date the application was initially submitted for such product under those sections or under Section 351 of the public Health Service Act;

The number of days between the effective date of the initial IND, March 9, 1989, and the initial submission of each of NDA 20-719 and NDA 20-720, July 31, 1996, is a period of 2,702 days and

(2) The number of days in the period beginning on the date the application was initially submitted for the approved product under Section 351 of the Public Health Service Act, subsection (b) of Section 505 or Section 507 of the Federal Food, Drug and Cosmetic Act and ending on the date such application was approved under such section.

The number of days between the initial submission of NDA 20-719 and NDA 20-720, July 31, 1996, to approval of NDA 20-719 and NDA 20-720, January 29, 1997, is a period of 183 days.

37 CFR § 1.775(d) The term of the patent as extended for a human drug, antibiotic drug or human biological product will be determined by --

- (1) Subtracting from the number of days determined by the Secretary of Health and Human Services to be in the regulatory review period:
 - (i) The number of days in the periods of paragraphs (c) (1) and (c) (2) of this section which were on and before the date on which the patent issued;

The number of days in the period of the IND, effective on March 9, 1989, which were on or before February 25, 1986, the date the patent was issued, is a period of 0 days, 2,702 days minus 0 days equals 2,702 days, and

the number of days in the period of the NDA initial submission of both NDA 20-719 and NDA 20-720 on July 31, 1996, and approval on January 29, 1997, which were on or before February 25, 1986, the date the patent was issued, is a period of 0 days,

- 183 days minus 0 days equals 183 days.
- (ii) The number of days in the periods of paragraphs (c) (1) and (c) (2) of this section during which it is determined under 35 USC § 156(d) (2) (B) by the Secretary of Health and Human Services that applicant did not act with due diligence;

The number of days the Applicant did not act with due diligence is 0 days,

therefore,

- 2,702 days minus 0 days equals 2,702 days.
- 183 days minus 0 days equals 183 days.
- (iii) One-half the number of days remaining in the period defined by paragraph (c)(1) of this section after that period is reduced in accordance with paragraphs (d)(1)(i) and (ii) of this section; half days will be ignored for purposes of subtraction;

One-half of 2,702 days equals 1,351 days.

Thus U.S. Patent No. 4,572,912 should be entitled to an extension of 1534 days (1,351 days plus 183 days).

(2) By adding the number of days determined in paragraph (d)(1) of this section to the original term of the patent as shortened by any terminal disclaimer;

Adding 1534 days to August 28, 2004, the original term of the patent (no terminal disclaimer was made), extends the term to November 9, 2008.

(3) By adding 14 years to the date of approval of the application under Section 351 of the Public Health Service Act, or subsection (b) of Section 505 or Section 507 of the Federal Food, Drug and Cosmetic Act;

Adding 14 years to January 29, 1997, the date of approval of the Application, results in the date of January 29, 2011.

(4) By comparing the dates for the ends of the periods obtained pursuant to paragraphs (d)(2) and (d)(3) of this Section with each other and selecting the earlier date;

The earlier date is November 9, 2008.

- (5) If the original patent was issued after September 24, 1984,
 - (i) By adding 5 years to the original expiration date of the patent or any earlier date set by terminal disclaimer; and
 - (ii) By comparing the dates obtained pursuant to paragraphs (d)(4) and (d)(5)(i) of this Section with each other and selecting the earlier date;
 - (A) Adding 5 years to the original expiration date of the patent or earlier date set by terminal disclaimer; and
- (A) Adding 5 years to the original expiration date of the patent (August 28, 2004) gives the date of August 28, 2009.
 - (B) By comparing the dates obtained pursuant to paragraphs (d) (4) and (d) (5) (i) of this section with each other and selecting the earlier date;
- (B) Comparing November 9, 2008 and August 28, 2009, the earlier date is November 9, 2008 and therefore the patent term should be extended to November 9, 2008.
 - (6) If the original patent was issued before September 24, 1984,

This is not applicable for the subject patent.

(ii) If a request was submitted for an exemption under Subsection (i) of Section 505 or Subsection (d) of Section 507 of the Federal Food, Drug, or Cosmetic Act before September 24, 1984 and the commercial marketing or use of the product was not approved before September 24, 1984, by --

This is not applicable for the patent.

(13) Applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and to the Secretary of Health and Human Services any information which is material to any determination to be made relative to the application for extension.

Applicant is unaware of any additional information material to this Application for extension.

(14) Prescribed Fee:

A check in payment of the prescribed fee for receiving and acting upon the application for extension in the amount of One Thousand Ninety Dollars (\$1,090.00) is enclosed herewith.

(15) The name, address and telephone number of the person to whom inquiries and correspondence relating to the application for patent term extension are to be directed:

Herbert Goodman, Esq. FRISHAUF, HOLTZ, GOODMAN, LANGER & CHICK, P.C. 767 Third Avenue - 25th Floor New York, New York 10017-2023 (212) 319-4900

(16) A duplicate of the application papers, certified as such.

A duplicate of the application papers, certified as such, is submitted herewith.

(17) An oath or Declaration as set forth in paragraph (b) of 37 CFR 1.740.

A signed declaration by the Applicant is submitted herewith in compliance with 37 CFR 1.740(a)(17).

FRISHAUF, HOLTZ, GOODMAN,
LANGER & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. No. (212) 319-4900
Fax No. (212) 319-5101
HG/ma

Respectfully submitted,

/HÉRBÉRT GOÓDMAN REG. NO. 17,081 EXHIBITS

EXHIBIT 1

EXHIBIT 1 PACKAGE INSERT FOR REZULIN™

Rezulin[™]

(Troglitazone) Tablets

DESCRIPTION

DESCRIPTION
Razinia¹⁰⁰ (troplizazone) is an oral antihyperglycemic agent which acts primarily by decreasing insulin resistance. Rezufin is used in the management of type II disbets reformation-dependent disbets in (MDDM) also known as adult-onsot disbets). It improves sensitivity to insulin in muste and adjoces tissue and classes, It improves sensitivity to insulin in muste and adjoces tissue and classes are resisted to the resistance of the resistance and the resistance of the resistance inhibitor. The molecules contains 2 chiral centers, who each of the 4 stereoisomers having similar pharmacologic effects. The structural formula is as shown.

$$\begin{array}{c} \text{CH}_3 \\ \text{HO} \\ \end{array} \begin{array}{c} \text{CH}_3 \\ \text{CH}_4 \\ \text{CH}_5 \end{array} \begin{array}{c} \text{CH}_2 \\ \text{CH}_2 \\ \text{O} \end{array} \begin{array}{c} \text{CH}_3 \\ \text$$

Trogitazone is a white to yellowish crystalline compound it may have a taint, characteristic odor. Trogitazone has a molecular formula of C_pH_pNO_pS and a molecular weight of 441.55 datons. It is soluble in NN-dimetrylformanide or scetone; sparingly soluble in ethyl scetting, ethiphic or soluble in extra ethiphic soluble ethiphic ethip

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY

Mechanism of Action

Troglazone is a thiazoidinedione smidiabetic agent that lower blood glucose by improving jurged cell response to insulin. It has a unique mechanism of action that growing jurged cell response to insulin. It has a unique mechanism of action that glucose output and increases Insulin-dependent glucose disposal in sidelatid mascle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that responsive pense crical for the control of glucose and lipid metabolism. Unlose suflomyturess, trogliszone is not an insulin secretagojue.

In animal models of diabetes, trogliszone reduces the hyperglycenia, hyperinsulinemia, and hypertriplyconicalmic characteristic of insulin-resistant states such as type II diabetes. Plasma factate and leatone body for motion are also decreased. Other sections with the programment of th

Since trogitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin.

Pharmacokinetics and Drug Metabolism
Maximum plasma concentration (Crusx) and the area under plasma concentration
the curve (AUC) of troglitzone increase proportionally with horeasing doses
over the dose range of 200 to 600 mg/day (Table 1). Following daily drug administration, steady-state plasma concentrations of troglitzone are reached within 3 to
5 days.

TABLE 1, Mean (±1 SD) Steady-State Pharmacokinetics of

Troglitazone in 21 Normal Volunteers					
Dose (mg/day)	Cmax (µg/mL)	AUC (0-24) (µg·hr/mL)	CL/F* (mL/min)		
200	0.90 (0.36)	7.4 (2.4)	500 (187)		
400	1.61 (0.69)	13.4 (5.5)	601 (324)		
600	2.82 (1.03)	22.1 (6.8)	496 (166)		

*CL/F = Apparent oral clearance.

Absorption: Trogifazone is absorbed rapidly following oral administration; the time for maximum plasma concentration (trust) occurs within 2 to 3 hours. Food increases the extent of absorption by 30% to 85%; thus Rezulin should be taken with a meat to enhance systamic drug evallability.

sucreases the extant or assorption by 30% to 85%; thus Resulfin should be taken with a meal to enhance systemic drug evalishability. (Fr) of trogilizazone todowing multiple-dose estiministration ranges from 10.5 to 28.5 U/g of body weight. Trogilizazone is extransively bound (>469%) to serum abumin. (**Citogilizazone partitions into red blood calls (**Pos*) of whote blood calls (**Pos*). What has been a simple 400 mg dose of (**Citogilizazone alter if days of treatment with 400 mg trogilizazone talleds; the (**Citogilizazone alter if days of treatment with 400 mg trogilizazone talleds; the (**Citogilizazone alter if days of treatment with 400 mg trogilizazone talleds; the inclined by the quinone metabolite (Metabolite 3). Only 3.1% of the dose was detected in the urine; this was primarily in the form of the gluconoide conjugate (Metabolite 2), which is present in negligible amounts in the plasma. In both nor-mal volunteers and patients with type II (dilabetes, steady-state sievels of Metabolite 3 to 17 times that of trogilizazone and Metabolite 3.1.14.2, 2.46, 2.86, 2.06. 2.1.1, and 3.44 in the presence and absence of known inhibition of these enzymes (**Citogilizazone incubated with expressed human P450 1.41, 1.42, 2.46, 2.86, 2.06. 2.1.1, and 3.44 in the presence and absence of known inhibitions of these enzymes whetholds of with human liver microsome environment and the first talled to further installed and the profile of trogilizazone analysis the 7 microsome environment and analysis.

Metabolite 3 with human over microscrores suggesse uses as the suspension of metabolism. The inhibitory profile of trogitizance against the 7 major P450 isozymes was characterized using human liver microscomes. Trogitizance was bound to inhibit 3A4, 2C9, and 2C18 by 40% to 57% at a concentration of 11 pylmt. Since the highest peak concentrations expected to be achieved on 600 mg once daily is in the range of 1 to 3 pylmt, inhibition may not be dinically important. The results of in vivo drug interactions audices tend to support this observation (see Drug Interactions); nevertheless, caution should be observed when Rezutin is used in combination with drugs known to be metabolized by one of these enzymes. The inhibitory characteristics of Metabolism 3 have not been investigated directly.

Exercision: Flowing oral administration of If-Circofitazone, approximately 83% of the radioactivity is recovered in time (55%) and urine (5%). Unchanged trogitizance is not recovered in urine 500 lowing oral administration. Mean plasma elimination to half-like of logitizazone ranges from 15 to 34 hours.

tion half-lie of trogifizzone ranges from 16 to 34 hours.

Special Poputations

Renal Insufficiency: in patients with various degrees of renal function, the apparent clearance of total and unbound trogifizzone and the plasms elimination half-lie of trogifizzone, Metabolita 1, and Metabolita 3 do not correlate with creatinize clearance. Thus, dose adjustment in patients with renal dysfunction is not necessary (see DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency: Trogifizzone, Metabolita 1, and Metabolita 2 plasma concentrations in patients with orthoric fiver disease (Chitds-Puph Grade 8 or C) were increased by approximately 30%, 400% and 100%, respectively, compared to those in healthy subjects without hepatic dysfunction. There was no change in patients protein binding. No adverse ovents were noted in any group that were with hepatic disease.

Gertatrics: Steady-etate pharmacokinetics of trogitazone, Metabolita 3 in healthy elderly subjects are comparable to those seen in young actits.

Pediatrics: Pharmacokinetic data in the pediatric population are not evallable. Gender: Plasma concentrations of troglitazone and its metabolites are similar in men and women.

men and women. Ethnicity: Pharmacokinetics of troglitazone and its metabolites are similar among various ethnic groups.

Rezulin^{te} (Troglitzzone) Tablets

Pharmacodynamics and Clinical Effects

Pharmacodynamics and Citrical Effects
Clinical studies demonstrate that Reansin improves insude sensitivity in insuferresistant patients. Re2nsin improves insude sensitivity in insuferresistant patients. Re2nsin impraesa insufer-dependent placeae disposal, reduces
topping placeae operations, and sensitivity and placeae disposal, reduces
topping placeae, and sensitivity of the placeae operation in patients with type III disbates, the decreased insufer instances produced by Ferstriff excess decreases
serum glaceae, plasma imusin, and hemoplobin A₂. These effects are independent of weight loss and persist with Re2nsit treatment.
Following Re2nsin treatment, LDL, HDL, and total cholestanol (total-C) increase,
athough total-CARD, and LDLA FOIL sected on otherage. The increase in the
total read of the control of the control of the
characteristic date to the increase in HDL and LDL cholestanol. Despite the
observed increase in total and LDL cholestanol. Apoli fraction levels are not
increased. Petients treated with Reznits and concomitant insufin exhibit an initial
reduction in triplycentiel levels. With the reduction in insufin doses that may occus
tolowing Reznith therapy, some attenuation of the triglyceride reduction may
occus.

OCCUI.

Pharmacokinstic estimators of systemic trogitazone exposure do not improve the prediction of pharmacocymamia response beyond that obtained based upon knowledge of the administrated does.

Rezufis has only been shown to exart its antihyperglycemic affect in the presence of insulis. Because Rezufis does not cirruntate insulin secretion, hypopycemia in patients treated with Rezufis atone is not to be expected. Because of this insulingendent machinism of action, Rezufis should not be used in patients with hypogycemia in patients with the dependent machinism of action, Rezufis should not be used in patients with hypergraphent machinism of action, Rezufis should not be used in patients with hypergraphents.

with insufe.

In one 6-month, double-blind, placebo-controlled study in insufin-treated type II diabetic patients receiving a mean of 75 (range 27-145) untitlyday of insufin with a mean baseline HbA₁₀ of 8.42 (range 7.04-12.68). Rezulin (200 of 600 mpday) to placebo was added in the insufin therapy, Investigation were instructed to reduce insufin doses only it two consecutive FSGs were 5:00 mpdt. Rezulin-freated patients showed a significant (p-0.0001) reduction in HbA₁₀ compared with patients with one-ordered placebox (see Table 2).

patients who received placebo (see Table 2). Thirty persent of petients treated with 200 ng Rezulin and 57% of patients treated with 500 ng Rezulin had an HbA₁; walve below 8% at the end of the study compared with 11% of placebo-treated patients. Accompanying this improvement of sylvemic control was a significant (p-0.0001) decrease in exogenous insulin design of 15% in the 200 ng Rezulin beatment group and 42% in the 600 ng Rezulin to teatment group on the 10% person of the 10% person person of the 10% person of the 10% person pe

TABLE 2. Mean Change From Baseline at 6 Months

	~	Trogitazone		
Parameter .	Placebo	200 mg	500 mg	
N	118	116	116	
HbA _{IP} %				
Mean Baseline (SE)	9.43 (0.10)	9.51 (0.10)	9.32 (0.11)	
Mean Change From Baseline (SE) ¹	-0.12 (0.10)	-0.84 (0.10)	-1.41 (0.10)	
Adjusted Mean Difference From Placebo	(SE)	-0.72 (0.14)*	-1.29 (0.14)*	
Percent Mean Change From Baseline	-1.3	-6.8	-15.1	
Insulin daily dosage, units				
Mean Baseline (SE)	75 (3.3)	73 (3.4)	71 (2.9)	
Mean Change From Baseline (SE)	1 (2.1)	-11 (2.1)	-29 (2.2)	
Adjusted Mean Difference From Placebo	o (SE) -	-12 (3.0)	-30 (3.0)*	
Percent Mean Change From Baseline	1	-15	-42	

p ≤0.0001

seres mean adjusted for investigator center and baseline

Hamoglobin A_{1C}




FIGURE 1

Placebo 200mg 2600mg

-5 -10 -15 -20 -25 -30 West 2426 Week 10712

A second 6-month, double-blind, placebo-controlled study in insulin-treated type II diabetics who previously were poorly controlled on oral agents receiving 30 to 150 units insulindry assessed the use of Rezulin in reducing exogenous insulin dosage while improving glycemic control as measured by capillary blood glycose. Patients treated with 200 mg (N-F5) and 400 mg (N-F6) Rezulin had their insulin doses decreased by 41% and 59%, respectively, compared to a reduction of insulin doses in the placeto group (N-F1) of 14% while maintaining or improving glycemic control. Forty-one percent of the patients in the 400 mg group decreased their insuff, injection frequency an average from 3 to 2 injections per day, insulin therapy was descentitued in 15% of platents in the 400 mg Rezulin group compared to 7% in the 200 mg group and 1.5% in the placebo group.

Rezulin™ (Troglizzone) Tablets

A greater than 50% reduction in insulin does was achieved by 51% of patients 200 mg and 70% on 400 mg once daily as compared to 17% on placebox. An extended open-label study of Rezulin (N+17), has followed insulin-vested by 8 lidables potents for up to groothe. Following 8 months of treatment w 400 mg of Rezulin, mean HM-N_C levels were decreased by 0.5% compared w beautiful or 11.5% z 2.0% (mean z 50). The mean insulin daily does decreased by 7.1% (42 mitsuliny) in these seventroen patients.

decreased by 71% (42 unbitdary) in these seventeen patients.

INDICATIONS AND USAGE

Rezulis is indicated by use in patients with type II diabetes currently on insulin berspy whose hyperglycentria is inadequately controlled (10th₂ >0.5%) despite insulin theory of over 50 units per day given as midglic lipscore.

Management of type II diabetes should include diet control. Caloric restriction, weight loss, and exercise are essential for the proper treatment of the diabete, patient. This is important not only in the primary treatment of type II diabetes, but in maintaining the efficacy of dry therapy. Prior to instation of health the target per control, and the proper treatment of the diabete of the dia

CONTRAINDICATIONS

Rezufin is contraindicated in patients with known hypersensitivity or allergy to Rezufin or any of its components.

PRECAUTIONS

General

General Because of its mechanism of action, Razulin is active only in the presence of insulin. Therefore, Razulin should not be used in type I diabetes or for the treatment of diabetic texto-actions; when the control texto-actions in North America (N=2510 patients), a total of 20 Razulin-1-sead optients were withdrawn tome treatment because of liver tumorion text chnormalities. Two of the 20 patients developed reversible jaumice. Both had fer biopsises which were constitutent with an inflorymentatic drug reaction (see ADVERSE REACTIONS, Laboratory Abnormalities).

AUVENSE REACTIONS, Laboratory Abnormalities).

Hypoglycemia: Patients receiving Rezulin in combination with insufin may be at risk for hypoglycemia and a reduction in the does of insufin may be necessary. Hypoglycemia has not been observed during the administration of Rezulin as monotherary and would not be expected beseed on the mechanism of action. Ovutation: in premenopausal anovutatory patients with insufin resistance, Rezulir bestment may result in resumption of ovutation. These patients may be at risk for pregnancy.

for pregnancy.

Hematologic: Across all clinical studies, hemoglobin declined by 3 to 4% in trogitazone-beated patients compared with 1 to 2% in those treated with placebo.

White blood cold courts also declined flightly in rogilatories treated with placebo.

White blood cold courts also declined flightly in rogilatories treated with placebo.

The placebo courts also declined flightly in rogilatories with the first burn see gipt weeks of the rays, Levels stabilized and remained unchanged for up to two
years of continuing therapy. These changes may be due to the distrional effects of increased plasma volume and have not been associated with any significant hematologic clinical effects (See ADVERSE REACTIONS, Laboratory Abnormatices).

Information for Patients

Information for Patients
Rezufia should be taken with meals. If the dose is missed at the usual meal, it may
be taken at the next meal if the dose is missed on one day, the dose should not
be doubted the following day.
It is important to adhere to distany instructions and to regularly have blood plucose
and phosystand hemoglobin tested. During periods of stress such as fews, trauma, insection, or surgery, insufin requirements may change and petients should
seek the advice of their physician.
When using combination therapy with insulin, the risks of hypophysemia, its symptoms and treatment, and conditions that predispose to its development should be
explained to patients and their family members.

explained to patients and their family members.

Drug interactions

Cholestyramine: Concomitant administration of cholestyramine with Rezulin reduces the absorption of trogitazone by approximately 70%; thus, coadministration of cholestyramine and Rezulin so not recommended. Acetaminophenic Coadministration of acetaminophenic Coadministration of acetaminophenic patients are continuophenic acetaminophenic Acetaminophenic Coadministration of the Acetaminophenic Coadministration of the Acetaminophenic Coadministration of the Acetaminophenic Coadministration of a moderate amount of abothel did not increase the risk of a cut by popplycemals in Rezulin-treated patients with type II diabetes melitics.

melitur.

Carcinogenesis, Mutagenesis, impairment of Fertility
Troglitazone was administered daily for 104 weeks to male rats at 100, 400, or 800 mg/kg and to female rats at 25, 50, or 200 mg/kg. Madmum plasms troglitazone AUC wales based on past of compound registering and past of the past of

ot patent compound. Troglizzone sus neither mitagenic in besteria nor classogenic in bone marrow of mice. Equivocal increases in chromesone obserations were observed in en in votor Chinese hamslet king coll assay, in mouse lymphoma cell gene mitations save results were equivocal when conducted with a microtion technique and negative with an egar plate technique. A liver unschieduled DNA synthesis assay in rate was negative.

was negative.

No adverse effects on fertility or reproduction were observed in male or female rate given 40, 200, or 1000 mg/kg daily prior to and throughout mating and gesta tion. AUC at these doses was estimated to be 2-to 8-told higher than the human

Pregnancy

Pregnancy
Pregnancy Category B. Tioglitazone was not terabgenic in rats given up to
2000 mg/kg or rabbles given up to 1000 mg/kg during organogenesis. Compared
to human exposure of 400 mg daily, estimated exposures based on AUC at these
doses were up to 8-loth higher in rats and up to 6-loth higher in rabbles. Body
weights of letures and offspring of rats given 2000 mg/kg during gestation were
decreased. Delayed postnatal development, attributed to decreased body weight,
was observed in offspring of rats given 40, 200, or 1000 mg/kg during late gestation and lactaion periods; no effects were observed in offspring of rats given 10 or
20 mg/kg.

20 mg/kg.

There are no adequate and well-controlled studies in pregnant women. Rezulin should not be used during pregnancy unless the potential benefit justifies the potential risk to the letus.

Because current information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenitial anomalies as well as increased necessal morbidity and mortially, most experts recommend that insutin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nursing Mothers

It is not known whether troglitazone is secreted in human milk. Troglitazone is secreted in the milk of lactating rats. Because many drugs are excreted in human milk, Rezulin should not be administered to a breast-teeding woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Rezulin™ (Troglitazone) Tablets

Geristric Use

Twenty-two percent of patients in clinical trials of Rezulin were 65 and over. No di-terance in effectiveness and eatily were observed between these patients and younger patients.

Use in Patients With Heart Failure

use at HELLERIES WILL HEALTH SELECTE
HEALT enterporant without microscopic changes has been observed in rodents at exposures exceeding 14 times the AUC of the 400 mg human dose. Serial echocardiographic evaluations in monkeys treated chronically at maximum achievable exposures (3-5 times the human exposure at the 400 mg dose) did not reveal changes in heart plans of human exposure at the 400 mg dose) did not reveal changes in heart plans of human exposure at the 400 mg dose) did not reveal changes in heart plans of human exposure at the 400 mg dose) in increase in existing output was observed. The methodology employed was able to detect a change of about 10% or more in left vermicular misss.

in animal studies, tropitazione treatment was associated with increases of 6th or 15th in pasma volume, in a study of 24 normal volumbers, an increase in plasma volume of 6th to 8th compared to placebo was observed totowing 6 weeks of tropitazione treatment.

troglazme trestment. No increased incidence of adverse events potentially related to volume expansion (eg. congestive heart takins) have been observed during controlled cfinical trials. However, patients with New York Heart Association (NYHA) Class III and IV cardiac status were not statisfed during direct atrials. Therefore, custion is advised during the administration of Rezulin to patients with NYHA Class III or IV cardiac status.

ADVERSE REACTIONS
In general, Rezulfu is well-blerated. Two patients in the clinical studies developed reversible jaunities with findings on liver biopey consistent with idiosynoratic drug reaction (See PRECAUTIONS, General).

reaction (See PRECAUTIONS, General).

The overall incidence and types of solvense reactions reported in glascobic controlled dirical trials for Reactive-treated patients and placebol-related patients at respect to the property of the prop

TABLE 3. North American Placebo-Controlled Clinical Studies: Adverse Events

Reported at a Frequency ≥ 5% of Rezulin-Treated Patients % of Patients				
	Placebo N = 492	Rezulin N = 1450		
Infection	22	18		
Headache	11	11		
Pain	14	10		
Accidental Injury	6	8		
Asthenia	5	6		
Dizzinesa	5	6		
Back Pain	4	6		
Nausoa	4	6		
Shinitis	7	5		
Diarrhea	6	5		
Urinary Tract Infection	6	5		
Peripheral Edema	5	5		
Pharyngitis	4	5		

Types of adverse events seen when Rezulin was used concomitantly with insulin (16-543) were similar to those during Rezulin monotherapy (N=1731), although hypodycemia occurred on insulin combination therapy (see PRECAUTIONS). Laboratory Abnormalities

Laboratory Abnormatilles Hematologic: Small decreases in hemoglobin, hematocrit, and neutrophil counts (within the normal range) were more common in Rezulin-treated than placebo-treated patients and may be related to lincreased plasma volume observed with Rezulin treatment. Hemoglobin decreases to below the normal range occurred in 5% of Rezulin-teated and 4% of placebo-treated patients. Lipids: Small changes in serum lipids have been observed (see CLINICAL PHARNACOLOGY Pharmacology) amics and Clinics Effects).

PHARMACOLOGY Pharmacodynamics and Clinical Ellects.

Serum Transamhaes Levels: During controlled clinical titlets.

Serum Transamhaes Levels: During controlled clinical titlets. 2.9% of Rezulintested patients had reversible elevations in AST or ALT greate than 3 times the upper limit of normal, compared with 0.9% of patients receiving placebo.

Hyperbilluriblemails P-125 types limit of normal, was found in 0.7% of Rezulintested patients compared with 1.7% of patients receiving placebo. In the population of patients treated with Rezulin, mean and median values to blatiuth, AST, ALT, askaline phosphatase, and GGT were decreased at the final visit compared with baseline, while values for LDH were increased slightly (see PRECAUTIONS, General, Hepatic).

DOSAGE AND ADMINISTRATION

Dosauce And Lathurster Nations. The current insulin dose should be continued upon initiation of Rezulin therapy. Rezulin therapy should be initiated at 200 mg once daily in patients on insulin therapy. For patients not responding adequately, the dose of Rezulin should be increased after approximately 2 to 4 weeks. The usual dose of Rezulin is 400 mg once daily. The maximum recommended daily dose is 600 mg, it is recommended that the insulin dose be decreased by 10% to 25% when tasting plasma glucose concentrations decrease to be set han 120 mg/di. In patients receiving concomitant insulin and Rezulin. Further adjustments should be individualized based on ghoose-lowering response. Rezulin should be taken with a mean

Patients With Renal Insufficiency
Dose adjustment in patients with renal insufficiency is not required (see CLINICAL PHARMACOLOGY, Pharmacokinetics and Drug Metabolism).

Patients With Hepatic Impairment

Rezulin should be used with caution in patients with hepatic disease (see CLINI-CAL PHARMACOLOGY, Pharmacokinetics and Drug Metabolism).

NOW SUPPLIED
Readin is available in 200 and 400 mg tablets as follows:
Routin is available in 200 and 400 mg tablets as follows:
200 mg Tablets, '480w, oval, non-cored, film-coated tablet with 'PD 352' debossed on one side, and '200' on the other, available in:

debossed on one side, and 200° on the oute N 0071-0352-15 Bottles of 30 N 0071-0352-23 Bottles of 90 N 0071-0352-40 (10 x 10 unit-dose bissers)

400 mg Tablets: Tan, oval, non-scored, film-coated tablet with "PD 353" debossed on one side, and "400" on the other, available in: N 0071-0353-15 Bottles of 30

N 0071-0353-23 Bottles of 90 N 0071-0353-40 (10 x 10 unit-dose blisters)

Store at controlled room temperature 20°C-25°C (68°F-77°F). Protect from moisture and humidity.

Caution: Federal law prohibits dispensing without prescription.

©1997, Warner-Lambert Co. January 1997

PARKE-DAVIS

Div of Warner-Lambert Co Morris Plains, NJ 07950 USA

Marketed by: PARKE-DAVIS Div of Warner-Lambert Co and SANKYO PARKE DAVIS reippany, NJ 07054 USA



EXHIBIT 2A

EXHIBIT 2A APPROVAL LETTER FOR PRELAY™ INCLUDING PACKAGE INSERT



Food and Drug Administration Rockville MD 20857

NDA 20-719

Sankyo U.S.A. Corporation Attn: David L. Woodward, Ph.D. Vice President, Development 780 Third Avenue, Suite 4700 New York, NY 10017

JAN 29 1997

Dear Dr. Woodward:

Please refer to your new drug application dated July 31, 1996, received August 1, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for PrelayTM (troglitazone) Tablets, 200 mg and 400 mg.

We acknowledge receipt of your submissions dated October 8 and 18, and December 17 and 20, 1996, and January 15 and 24 (2), 1997. The User Fee goal date for this application is August 1, 1997.

This new drug application provides for the use of Prelay Tablets in Type II diabetes patients whose hyperglycemia is inadequately controlled despite insulin therapy.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed marked-up draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed marked-up version of the draft physician labeling submitted by Parke-Davis to NDA 20-720 on January 29, 1997, (with the exception of trade name and company-specific items) and the draft carton and container labels submitted on January 22, 1997. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-719. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

We remind you of your Phase 4 commitment as specified in the Parke-Davis submission dated January 10, 1997, to conduct, in conjunction with Parke-Davis, a clinical study in NYHA Class III or IV patients to evaluate whether an increase in plasma volume, which may be observed in patients treated with troglitazone, leads to cardiac decompensation. This study will contain two treatment groups: troglitazone 600 mg/day vs. glyburide. A draft protocol, including the study length and number of patients to be studied, will be submitted to the FDA for approval within three months of the approval of this NDA.

The protocol, data, and final report should be submitted to your IND for this product and a copy of each cover letter sent to this NDA. In addition, we request under 21 CFR 314.81(b)(2)(vii) that you include in your annual report to this application, a status summary of the commitment. The status summary should include the number of patients entered, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments should be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to the Division of Metabolic and Endocrine Drug Products and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising, and Communications
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Michael F. Johnston, R.Ph., Consumer Safety Officer, at (301) 443-3490.

Sincerely yours,

James Bilstad, M.D.

Director

Office of Drug Evaluation II

Center for Drug Evaluation and Research

Enclosure

RezulinTM
(Troglitazone) Tublets

DESCRIPTION

RezulinTM (troglitazone) is an oral antihyperglycemic agent which acts primarily by decreasing insulin resistance. Rezulin is used in the management of type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes). It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconcogenesis. Troglitazone (±-5-[[4-[3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione) is not chemically or functionally related to either the sulfonylureas, the biguanides, or the α-glucosidase inhibitors. The molecule contains 2 chiral centers, with each of the 4 stereoisomers having similar pharmacologic effects. The structural formula is as shown:

1

$$CH_{3}$$

$$CH_{2}O$$

$$CH_{2}O$$

$$CH_{2}O$$

$$O$$

$$NH$$

Troglitazone is a white to yellowish crystalline compound; it may have a faint, characteristic odor. Troglitazone has a molecular formula of C₂₄H₂₇NO₅S and a molecular weight of 441.55 daltons. It is soluble in N,N-dimethylformamide or acetone; sparingly soluble in ethyl acetate; slightly soluble in acetonitrile, anhydrous ethanol, or ether; and practically insoluble in water.

Rezulin is available as 200- and 400-mg tablets for oral administration formulated with the following excipients: croscarmellose sodium, hydroxypropyl methylcellulose,

magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, povidone, purified water, silicon dioxide, titanium dioxide, and synthetic iron oxides.

CLINICAL PHARMACOLOGY

Mechanism of Action

Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin-dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Unlike sulfonylureas, troglitazone is not an insulin secretagogue.

In animal models of diabetes, troglitazone reduces the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states such as type II diabetes. Plasma lactate and ketone body formation are also decreased. The metabolic changes produced by troglitazone result from the increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of insulin resistance. Treatment with troglitazone did not affect pancreatic weight, islet number or glucagon content, but did increase regranulation of the pancreatic beta cells in rodent models of insulin resistance.

Since troglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin.

Pharmacokinetics and Drug Metabolism

Maximum plasma concentration (Cmax) and the area under plasma concentration-time curve (AUC) of troglitazone increase proportionally with increasing doses over the dose range of 200 to 600 mg/day (Table 1). Following daily drug administration, stendy-state plasma concentrations of troglitazone are reached within 3 to 5 days.

TABLE 1. Mean (±1 SD) Steady-State Pharmacokinetics of Troglitazone in 21 Normal Volunteers

Dosc (mg/day)	Cmax (µg/mL)	AUC(0-24) (μg-hr/mL)	CI√F* (mL/min)
200	0.90 (0.36)	7.4 (2.4)	500 (187)
400	1.61 (0.69)	13.4 (5.5)	601 (324)
600	2.82 (1.03)	22.1 (6.8)	496 (166)

^{*} CL/F = Apparent oral clearance.

Absorption: Troglitazone is absorbed rapidly following oral administration; the time for maximum plasma concentration (tmax) occurs within 2 to 3 hours. Food increases the extent of absorption by 30% to 85%; thus Rezulin should be taken with a meal to enhance systemic drug availability.

Distribution: Mean apparent volume of distribution (V/F) of troglitazone following multiple-dose administration ranges from 10.5 to 26.5 L/kg of body weight.

Troglitazone is extensively bound (>99%) to serum albumin. [14C]troglitazone partitions into red blood cells (~5% of whole blood radioactivity).

Mctabolism: In 6 healthy male volunteers given a single 400-mg dose of [14C]troglitazone after 14 days of treatment with 400-mg troglitazone tablets, the major metabolites found in the plasma were the sulfate conjugate (Metabolite 1), followed by the quinone metabolite (Metabolite 3). Only 3.1% of the dose was detected in the urine; this was primarily in the form of the glucuronide conjugate (Metabolite 2), which is present in negligible amounts in the plasma. In both normal volunteers and patients with

type II diabetes, steady-state levels of Metabolite 1 are 6 to 7 times that of troglitazone and Metabolite 3.

Troglitazone incubated with expressed human P450 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, and 3A4 in the presence and absence of known inhibitors of these enzymes showed no Metabolite 3 formation above levels in control samples. Incubation of Metabolite 3 with human liver microsomes suggests that it is not subject to further metabolism.

The inhibitory profile of troglitazone against the 7 major P450 isozymes was characterized using human liver microsomes. Troglitazone was found to inhibit 3A4, 2C9, and 2C19 by 40% to 67% at a concentration of 11 μ g/mL. Since the highest peak concentrations expected to be achieved on 600 mg once daily is in the range of 1 to 3 μ g/mL, inhibition may not be clinically important. The results of *in vivo* drug interaction studies tend to support this observation (see Drug Interactions); nevertheless, caution should be observed when Rezulin is used in combination with drugs known to be metabolized by one of these enzymes. The inhibitory characteristics of Metabolite 3 have not been investigated directly.

Excretion: Following oral administration of [14C]troglitazone, approximately 88% of the radioactivity is recovered in feces (85%) and urine (3%). Unchanged troglitazone is not recovered in urine following oral administration. Mean plasma climination half-life of troglitazone ranges from 16 to 34 hours.

Special Populations

Renal Insufficiency: In patients with various degrees of renal function, the apparent clearance of total and unbound troglitazone and the plasma elimination half-life of troglitazone, Metabolite 1, and Metabolite 3 do not correlate with creatinine clearance. Thus, dose adjustment in patients with renal dysfunction is not necessary (see DOSAGE AND ADMINISTRATION).

Hepatic Insufficiency: Troglitazone, Metabolite 1, and Metabolite 3 plasma concentrations in patients with chronic liver disease (Childs-Pugh Grade B or C) were increased by approximately 30%, 400% and 100%, respectively, compared to those in

healthy subjects without hepatic dysfunction. There was no change in plasma protein binding. No adverse events were noted in any group that were attributed to drug. Nevertheless, Rezulin should be used with caution in patients with hepatic disease.

Geriatrics: Steady-state pharmacokinetics of troglitazone, Metabolite 1, and Metabolite 3 in healthy clderly subjects are comparable to those seen in young adults.

Pediatrics: Pharmacokinetic data in the pediatric population are not available.

Gender: Plasma concentrations of troglitazone and its metabolites are similar in men and women.

Ethnicity: Pharmacokinetics of troglitazone and its metabolites are similar among various ethnic groups.

Pharmacodynamics and Clinical Effects

Clinical studies demonstrate that Rezulin improves insulin sensitivity in insulin resistant patients. Rezulin increases insulin-dependent glucose disposal, reduces hepatic gluconeogenesis, and enhances cellular responsiveness to insulin and thus, improves dysfunctional glucose homeostasis. In patients with type II diabetes, the decreased insulin resistance produced by Rezulin causes decreases in serum glucose, plasma insulin, and hemoglobin A_{IC}. These effects are independent of weight loss and persist with Rezulin treatment.

Following Rezulin treatment, LDL, HDL, and total cholesteroin crease total HDL and LDL/HDL ratios do not change. The increase in total cholesterol is due to the increase in HDL and LDL cholesterol. Despite the observed increase in total and LDL cholesterol, ApoB fraction levels are not increased. Patients treated with Rezulin and concomitant insulin exhibit an initial reduction in triglyceride levels. With the reduction in insulin doses that may occur following Rezulin therapy, some attenuation of the triglyceride reduction may occur.

Pharmacokinetic estimators of systemic troglitazone exposure do not improve the prediction of pharmacodynamic response beyond that obtained based upon knowledge of the administered dose.

6

Rezulin has only been shown to exert its antihyperglycemic effect in the presence of insulin. Because Rezulin does not stimulate insulin secretion, hypoglycemia in patients treated with Rezulin alone is not to be expected. Because of this insulin-dependent mechanism of action, Rezulin should not be used in patients with type I diabetes.

Clinical Studies

Two clinical studies were conducted to evaluate the effects of Rezulin on glycemic control and insulin dose in patients with type II diabetes who were being treated with insulin.

In one 6-month, double-blind, placebo-controlled study in insulin-treated type II diabetic patients receiving a mean of 73 (range 27-143) units/day of insulin with a mean baseline HbA_{1c} of 9.42 (range 7.04-12.48), Rezulin (200 or 600 mg/day) or placebo was added to the insulin therapy. Investigators were instructed to reduce insulin doses only if two consecutive FSGs were ≤ 100 mg/dL. Rezulin-treated patients showed a significant (p <0.0001) reduction in HbA_{1c} compared with patients who received placebo (see Table 2).

Thirty percent of patients treated with 200 mg Rezulin and 57% of patients treated with 600 mg Rezulin had an HbA_{tc} value below 8% at the end of the study compared with 11% of placebo-treated patients. Accompanying this improvement in glycemic control was a significant (p <0.0001) decrease in exogenous insulin dosage of 15% in the 200 mg Rezulin treatment group and 42% in the 600 mg Rezulin treatment group compared with 1% in the placebo group. HbA_{1c} values and insulin dose as a function of duration of Rezulin treatment are presented in Figures 1 and 2.

TABLE 2. Mean Change From Baseline at 6 Months

	Placebo			Troglitazone			
Parameter			20	0 mg	600	mg_	
N			116		116		
HbA _{ic} %						_	
Mean Baseline (SE) Buseline	9.43	(0.10)	9.51	(0.10)	9.32	(0.11)	
Adjusted Mean Change (SE)1	-0.12	(0.10)	-0.84	(0.10)	-1.41	(0.10)	
Adjusted Mean Difference from Placebo (SE)			-0.72	(0.14)*	-1.29	(0.14)*	
Percent Mean Change from Baseline		-1.3	•	-8.8	-1	5.1	
Insulin daily dosage, units						. •	
Mean Baseline (SE) Baseline	75	(3.3)	73	(3.4)	71	(2.9)	
Adjusted Mean Change (SE)	1	(2.1)	-11	(2.1)	-29	(2.2)	
Adjusted Mean Difference from Placebo (SE)		-	-12	(3.0)*	-30	(3.0)*	
Percent Mean Change from Baseline		1		-15	<u> </u>	42	


[•] $p \le 0.0001$

FIGURE 1


A second 6-month, double-blind, placebo-controlled study in insulin-treated type II diabetics who previously were poorly controlled on oral agents receiving 30 to 150 units insulin/day assessed the use of Rezulin in reducing exogenous insulin dosage while improving glycemic control as measured by capillary blood glucose.

Patients treated with 200-mg (N = 75) and 400-mg (N = 76) Rezulin had their insulin doses decreased by 41% and 58%, respectively, compared to a reduction of insulin dose in the placebo group (N = 71) of 14% while maintaining or improving glycemic control. Forty-one percent of the patients in the 400-mg group decreased their insulin injection frequency an average from 3 to 1 injections per day; 19% of patients receiving placebo decreased their injection frequency an average from 3 to 2 injections per day. Insulin therapy was discontinued in 15% of patients in the 400-mg Rezulin group compared to 7% in the 200-mg group and 1.5% in the placebo group.

^{&#}x27;Means were adjusted for baseline and investigator center



*p<0.0001 compared to placebo Means were adjusted for haseline and investigator conter FIGURE 1



°p<0.0001 cumpared to placebo Means were adjusted for baseline and investigator center

FIGURE 2

TO COLOR TO TO COMPANY OF THE TAREST AND THE TAREST

A greater than 50% reduction in insulin dose was achieved by 51% of patients on 200 mg and 70% on 400 mg once daily as compared to 17% on placebo.

An extended open-label study of Rezulin (n = 17), has followed insulin-treated type II diabetic patients for up to 9 months. Following 9 months of treatment with 400 mg of Rezulin, mean HbA_{1c} levels were decreased by 0.8% compared with baseline values of $11.8\% \pm 2.0\%$ (mean $\pm SD$). The mean insulin daily dose decreased by 71% (42 units/day) in these seventeen patients.

INDICATIONS AND USAGE

Rezulin is indicated for use in patients with type II diabetes currently on insulin therapy whose hyperglycemia is inadequately controlled (HbA_{1c}>8.5%) despite insulin therapy of over 30 units per day given as multiple injections.

Management of type II diabetes should include diet control. Caloric restriction, weight loss, and exercise are essential for the proper treatment of the diabetic patient. This is important not only in the primary treatment of type II diabetes, but in maintaining the efficacy of drug therapy. Prior to initiation of Rezulin therapy, secondary causes of poor glycemic control, e.g., infection or poor injection technique, should be investigated and treated.

CONTRAINDICATIONS

Rezulin is contraindicated in patients with known hypersensitivity or allergy to Rezulin or any of its components.

PRECAUTIONS

General

Because of its mechanism of action, Rezulin is active only in the presence of insulin. Therefore, Rezulin should not be used in type I diabetes or for the treatment of diabetic keto-acidosis.

Hepatic: During all clinical studies in North America (n=2510 patients), a total of 20 Rezulin-treated patients were withdrawn from treatment because of liver function test abnormalities. Two of the 20 patients developed reversible jaundice. Both had liver biopsies which were consistent with an idiosyncratic drug reaction (see ADVERSE REACTIONS, Laboratory Abnormalities).

Hypoglycemia: Patients receiving Rezulin in combination with insulin may be at risk for hypoglycemia and a reduction in the dose of insulin may be necessary. Hypoglycemia has not been observed during the administration of Rezulin as monotherapy and would not be expected based on the mechanism of action.

Ovulation: In premenopausal anovulatory patients with insulin resistance, Rezulin treatment may result in resumption of ovulation. These patients may be at risk for pregnancy.

Hematologic: Across all clinical studies, hemoglobin declined by 3 to 4 % in troglitazone-treated patients compared with 1 to 2 % in those treated with placebo. White blood cell counts also declined slightly in troglitazone treated patients compared to those treated with placebo. These changes occurred within the first four to eight weeks of therapy. Levels stabilized and remained unchanged for up to two years of continuing therapy. These changes may be due to the dilutional effects of increased plasma volume and have not been associated with any significant hematologic clinical effects (see ADVERSE REACTIONS, Laboratory Abnormalities).

Information for Patients

Rezulin should be taken with meals. If the dose is missed at the usual meal, it may be taken at the next meal. If the dose is missed on one day, the dose should not be doubled the following day.

It is important to adhere to dietary instructions and to regularly have blood glucose and glycosylated hemoglobin tested. During periods of stress such as fever, trauma, infection, or surgery, insulin requirements may change and patients should seek the advice of their physician.

When using combination therapy with insulin, the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and their family members.

Drug Interactions

Cholestyramine: Concomitant administration of cholestyramine with Rezulin reduces the absorption of troglitazone by approximately 70%; thus, coadministration of cholestyramine and Rezulin is not recommended.

Acctaminophen: Coadministration of acctaminophen and Rezulin does not alter the pharmacokinetics of either drug.

Warfarin: Rezulin has no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin therapy.

Sulfonylureas: Coadministration of Rezulin with glyburide does not appear to alter troglitazone or glyburide pharmacokinetics, but may further decrease fasting plasma glucose. There are insufficient data on the use of Rezulin with sulfonylureas to establish the efficacy of this combination.

Metformin: No information is available on the use of Rezulin with metformin.

Ethanol: A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in Rezulin-treated patients with type II diabetes mellitus.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Troglitazone was administered daily for 104 weeks to male rats at 100, 400, or 800 mg/kg and to female rats at 25, 50, or 200 mg/kg. Maximum plasma troglitazone AUC values based on parent compound represent exposures 12- and 47-fold higher for male and female rats, respectively, than human exposure of 400 mg daily. Troglitazone was not carcinogenic in male rats at any dose tested. In female rats, there was a statistically significant increase in sarcomatous tumors at the high dose (47-fold greater than estimated human exposure of parent compound). However, these findings are of unknown clinical relevance as this dose was associated with excessive mortality and is considered to have surpassed the maximum tolerated dose. No tumors of any type were increased in female rats at 25 and 50 mg/kg at exposures of 5- to 14-fold higher than in humans based on AUC of parent compound. In a 104-week study in mice given 50, 400, or 800 mg/kg, incidence of hemangiosarcoma was increased in females at 400 mg/kg and in both sexes at 800 mg/kg; incidence of hepatocellular carcinoma was increased in females at 800 mg/kg. The lowest dose with increased tumor incidence (400 mg/kg) was associated with AUC values of parent compound that were at least 16-fold higher than the human exposure. No tumors of any type were increased in mice at 50 mg/kg at exposures 2- to 4-fold higher than in humans based on AUC of parent compound.

Troglitazone was neither mutagenic in bacteria nor clastogenic in bone marrow of mice. Equivocal increases in chromosome aberrations were observed in an *in vitro* Chinese hamster lung cell assay. In mouse lymphoma cell gene mutations assays, results were equivocal when conducted with a microtiter technique and negative with an agar plate technique. A liver unscheduled DNA synthesis assay in rats was negative.

No adverse effects on fertility or reproduction were observed in male or female rats given 40, 200, or 1000 mg/kg daily prior to and throughout mating and gestation. AUC at these doses was estimated to be 2- to 8-fold higher than the human exposure.

Pregnancy

Pregnancy Category B. Troglitazone was not teratogenic in rats given up to 2000 mg/kg or rabbits given up to 1000 mg/kg during organogenesis. Compared to human exposure of 400 mg daily, estimated exposures based on AUC at these doses were up to 8-fold higher in rats and up to 6-fold higher in rabbits. Body weights of fetuses and offspring of rats given 2000 mg/kg during gestation were decreased. Delayed postnatal development, attributed to decreased body weight, was observed in offspring of rats given 40, 200, or 1000 mg/kg during late gestation and lactation periods; no effects were observed in offspring of rats given 10 or 20 mg/kg.

There are no adequate and well-controlled studies in pregnant women. Rezulin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Because current information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital anomalies as well as increased meanatal morbidity and mortality, most experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nursing Mothers

It is not known whether troglitazone is secreted in human milk. Troglitazone is secreted in the milk of lactating rats. Because many drugs are exercted in human milk, Rezulin should not be administered to a breast-feeding woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Twenty-two percent of patients in clinical trials of Rezulin were 65 and over. No differences in effectiveness and safety were observed between these patients and younger patients.

Use in Patients With Heart Failure

Heart enlargement without microscopic changes has been observed in rodents at exposures exceeding 14 times the AUC of the 400-mg human dose. Scrial echocardiographic evaluations in monkeys treated chronically at maximum achievable exposures (3-5 times the human exposure at the 400-mg dose) did not reveal changes in heart size or function. In a 2-year echocardiographic clinical study using 600 to 800 mg/day of Rezulin in patients with type II diabetes, no increase in left ventricular mass or decrease in cardiac output was observed. The methodology employed was able to detect a change of about 10% or more in left ventricular mass.

In animal studies, troglitazone treatment was associated with increases of 6% to 15% in plasma volume. In a study of 24 normal volunteers, an increase in plasma volume of 6% to 8% compared to placebo was observed following 6 weeks of troglitazone treatment.

No increased incidence of adverse events potentially related to volume expansion (e.g., congestive heart failure) have been observed during controlled clinical trials. However, patients with New York Heart Association (NYHA) Class III and IV cardiac status were not studied during clinical trials. Therefore, caution is advised during the administration of Rezulin to patients with NYHA Class III or IV cardiac status.

ADVERSE REACTIONS

In general, Rezulin is well-tolerated. The overall incidence and types of adverse reactions reported in placebo-controlled clinical trials for Rezulin-treated patients and placebo-treated patients are shown in Table 3. In patients treated with Rezulin in glyburide-

controlled studies (N=550) or uncontrolled studies (N=510), the safety profile of Rezulin appeared similar to that displayed in Table 3. The incidence of withdrawals during clinical trials was similar for patients treated with placebo or Rezulin (4%).

TABLE 3. North American Placebo-Controlled Clinical Studies: Adverse Events Reported at a Frequency ≥5% of Rezulin-Treated Patients

% of Patients

70 OT 1 ddcm3				
	Placebo N - 492	Rezulin N = 1450		
Infection	22	18		
Headache	11	11		
Pain	14	10		
Accidental Injury	6	8		
Asthenia	5	6		
Dizziness	5	. 6		
Back Pain	4	6		
Nausea	4	6		
Rhinitis	7	. 5		
Diarrhea	6	5		
Urinary Tract Infection	6	5		
Peripheral Edema	5	5		
Pharyngitis	4			

Types of adverse events seen when Rezulin was used concomitantly with insulin (N=543) were similar to those during Rezulin monotherapy (N=1731), although hypoglycemia occurred on insulin combination therapy (see PRECAUTIONS).

Laboratory Abnormalities

Hematologic: Small decreases in hemoglobin, hematocrit, and neutrophil counts (within the normal range) were more common in Rezulin-treated than placebo-treated patients and may be related to increased plasma volume observed with Rezulin treatment. Hemoglobin decreases to below the normal range occurred in 5% of Rezulin-treated and 4% of placebo-treated patients.

Version 7

Lipids: Small changes in serum lipids have been observed. See CLINICAL. PHARMACOLOGY, Pharmacodynamics and Clinical Effects.

Serum Transaminase Levels: During controlled clinical trials, 2.2% of Rezulin-treated patients had reversible elevations in AST or ALT greater than 3 times the upper limit of normal, compared with 0.6% of patients receiving placebo. Hyperbilirubinemia (>1.25 upper limit of normal) was found in 0.7% of Rezulin-treated patients compared with 1.7% of patients receiving placebo. In the population of patients treated with Rezulin, mean and median values for bilirubin, AST, ALT, alkaline phosphatase, and GGT were decreased at the final visit compared with baseline, while values for LDH were increased slightly.

DOSAGE AND ADMINISTRATION

The current insulin dose should be continued upon initiation of Rezulin therapy. Rezulin therapy should be initiated at 200 mg once daily in patients on insulin therapy. For patients not responding adequately, the dose of Rezulin should be increased after approximately 2 to 4 weeks. The usual dose of Rezulin is 400 mg once daily. The maximum recommended daily dose is 600 mg. It is recommended that the insulin dose be decreased by 10% to 25% when fasting plasma glucose concentrations decrease to less than 120 mg/dL in patients receiving concomitant insulin and Rezulin. Further adjustments should be individualized based on glucose-lowering response. Rezulin should be taken with a meal.

Patients With Renal Insufficiency

Dose adjustment in patients with renal insufficiency is not required (see CLINICAL PIIARMACOLOGY, Pharmacokinetics and Drug Metabolism).

Patients With Hepatic Impairment

Rezulin should be used with caution in patients with hepatic disease (see CLINICAL PHARMACOLOGY, Pharmacokinetics and Drug Metabolism).

HOW SUPPLIED

Rezulin is available in 200- and 400-mg tablets as follows:

200-mg Tablets: Yellow, oval, non-scored, film-coated tablet with PD 352 debossed on one side, and 200 on the other, available in:

N 0071-0352-15 Bottles of 30

N 0071-0352-23 Bottles of 90

N 0071-0352-40 (10×10 unit-dose blisters)

400-mg Tablets: Tan, oval, non-scored, film-coated tablet with PD 353 debossed on one side, and 400 imprinted on the other, available in:

N 0071-0353-15 Bottles of 30

N 0071-0353-23 Bottles of 90

N 0071-0353-40 (10 × 10 unit-dosc blisters)

Storage

Store at controlled room temperature, 20°C to 25°C (68°F-77°F). Protect from moisture and humidity.

Caution: Federal law prohibits dispensing without prescription.

©1997, Warner-Lambert Co.

January 1997

PARKE-DAVIS

Division of Warner-Lambert Co. Morris Plains, NJ 07950 USA

Marketed by:

PARKE-DAVIS

Div. of Warner-Lambert Co. and

SANKYO PARKE DAVIS

Parsippany, NJ 07054 USA

EXHIBIT 2B

EXHIBIT 2B APPROVAL LETTER FOR REZULIN™



Food and Drug Administration Rockville MD 20857

NDA 20-720

Parke-Davis Pharmaceutical Research
Division of Warner-Lambert Company
Attention: Irwin G. Martin, Ph.D.
Vice President/FDA Liaison, Worldwide Regulatory Affairs
P.O. Box 1047
Ann Arbor, MI 48106-1047

JAN 29 1997

Dear Dr. Martin:

Please refer to your new drug application dated July 31, 1996, received August 1, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for RezulinTM (troglitazone) Tablets, 200 mg and 400 mg.

We acknowledge receipt of your submissions dated August 15, 24, 27, and 29, September 5, 12, 16, and 24, October 1, 2, 4, 17, 18, and 28, November 1 (2), 5, 6, 15 (2), and 26, and December 4, 5 (2), 13, and 19, 1996, and January 3, 6, 10, 22, 21, 24, and 29, 1997. The User Fee goal date for this application is August 1, 1997.

This new drug application provides for the use of Rezulin Tablets in Type II diabetes patients whose hyperglycemia is inadequately controlled despite insulin therapy.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed marked-up draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed marked-up version of the draft physician labeling submitted on January 29, 1997, and the draft carton and container labels submitted on January 22, 1997. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-720. Approval of this submission by FDA is not required before the labeling is used.

NDA 20-720 Page 2

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

We remind you of your Phase 4 commitment dated January 10, 1997, to conduct a clinical study in NYHA Class III or IV patients to evaluate whether an increase in plasma volume, which may be observed in these patients treated with troglitazone, leads to cardiac decompensation. This study will contain two treatment groups: troglitazone 600 mg/day vs. glyburide. A draft protocol, including the study length and number of patients to be studied, will be submitted to the FDA for approval within three months of the approval of this NDA.

The protocol, data, and final report should be submitted to your IND for this product and a copy of each cover letter sent to this NDA. In addition, we request under 21 CFR 314.81(b)(2)(vii) that you include in your annual report to this application, a status summary of the commitment. The status summary should include the number of patients entered, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments should be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to the Division of Metabolic and Endocrine Drug Products and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising, and Communications
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug product when it is available.

NDA 20-720 Page 3

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Michael F. Johnston, R.Ph., Consumer Safety Officer, at (301) 443-3490.

Sincerely yours,

James Bilstad, M.D.

Director

Office of Drug Evaluation II

Center for Drug Evaluation and Research

Enclosure

EXHIBIT 3

EXHIBIT 3 RECORDED ASSIGNMENT

RECEIVED

NOV 28 1984

FRISHAUF, HOLTZ, GOODMAN & WOODWARD 261 MADISON AVENUE NEW YORK, NY 10016 CODEMAR & MUCHAMA, P.C.

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS HEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW. A DIGEST OF THE DOCUMENT HAS ALSO BEEN MADE AND APPEARS IN THE OFFICE'S RECORDS AS SHOWN:

ASSIGNOR: 001 YOSHIOKA, TAKAO

ASSIGNOR: 002 KITAZAWA, EIICHI

ASSIGNOR: 003 KURUMADA, TOMOYUKI

ASSIGNOR: 004 YAMAZAKI, MITSUO

ASSIGNOR: 005 HASEGAWA, KAZOU

DOC DATE: 08/24/84

DOC DATE: 08/24/84

RECORDATION DATE: 08/28/84 NUMBER OF PAGES 002 REEL/FRAME 4313/0986

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEF: 501 SANKYO COMPANY LIMITED 1-6, 3-CHOME NIHONBASHI HONCHO, CH UO-KU TOKYO JAPAN A CORP OF JAPAN

SERIAL NUMBER 6-644996 FILING DATE 08/28/84 PATENT NUMBER ISSUE DATE 00/00/00

TITLE OF INVENTION: THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

INVENTOR: 001 YOSHIOKA, TAKAO
INVENTOR: 002 KITAZAWA, EIICHI
INVENTOR: 003 KURUMADA, TOMOYUKI
INVENTOR: 004 YAMAZAKI, MITSUO
INVENTOR: 005 HASEGAWA, KAZOU

Attorney Docket____

In consideration of value received, I, having a residence and post office address as stated below next to my name, the sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are listed below) of an invention described in an application for United States patent entitled:

Thiazolidine derivatives, their preparation and compositions containing them

sell and assign to

SANKYO COMPANY LIMITED

a corporation of Japan having a business address at 1-6,3-chome, Nihonbashi Honcho, Chuo-ku, Tokyo, Japan

its successors, assigns or nominees, hereinafter referred to as "Assignee", my entire right, title and interest in and to said invention as disclosed, shown and described in said application for United States patent executed concurrently herewith;

and in and to all applications for patent and patents for said invention, in all countries of the world, including all divisions, reissues, continuations, substitutions and extensions thereof and all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property, including rights of priority, resulting from the filing of any of said applications; and I authorize and request any official whose duty it is to issue patents, to issue any patent on said invention or resulting therefrom to said Assignee, and I agree that on request and without further consideration, but at the expense of said Assignee, I will communicate to said Assignee or its representatives all facts known to me respecting said invention and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue, or other applications, make all rightful oaths and declarations, and generally do everything possible to aid said Assignee to obtain and enforce proper patent protection for said invention in all countries.

	INVENTOR: SIGNATURE on	d DATE	RESIDENCE AND POST OFFICE ADDRESS
1 1	0.9. 0 /1 1 1 1	Date: August 24, 1984	c/o Chemical Research Laborato- ries,Sankyo Company Limited,
	Type: Takao Yoshioka	Witness:	2-58,1-chome,Hiromachi,Shinagawa ku,Tokyo, Japan
202		Date: August 24, 1984	
	Type: Eiichi Kitazawa	Witness:	Same as above
203	Sign: Tonwyuhi Kurumada	Date: August 24, 1984	
	Type: .Tomoyuki Kurumada	Witness:	Same as above
204	Sign: Hitsus Yamazala	Date: August 24, 1984	c/o Biological Research Labora- tories,Sankyo Company Limited,
	Type: Mitsuo Yamazaki	Witness:	2-58,1-chome,Hiromachi, Shinagawa-ku,Tokyo,Japan

NOTE: TO BE DATED. WITNESS DESIRABLE. LEGALIZATION NOT REQUIRED.

RECORDING OFFICER: After recording, please return to:

FRISHAUF, HOLTZ, GOODMAN & WOGDWARD, P.C.

261 Madison Avenue New York, N. Y. 1001

(212) 972-1400

	INVENTOR: SIGNATURE OF	nd DATE	RESIDENCE AND POST OFFICE ADDRESS
205	Sign: Mara Idicogard	Date: August 24, 1984 Witness:	c/o Biological Research Labora- tories,Sankyo Company Limited,
2	Type: Kazuo Hasegawa	Williago.	2-58,1-chome,Hiromachi,Shinagawa
206	Sign:	Date:	
20	Туре:	Witness:	
77	Sign:	Date:	
207	Type:	Witness:	PAT
8	Sign:	Date:	RECO AUG 2
208	Type:	Witness:	TRACE TRACE
6	Sign:	Date:	RECORDED OF TRAILEMARK OF
509	Type:	Witness:	MARK OF 1984 PATENTS
	Sign:	Date:	ICE.
210	Type:	Witness:	

EXHIBIT 4

EXHIBIT 4 PATENT

United States Patent [19]

Yoshioka et al.

[11] Patent Number:

4,572,912

[45] Date of Patent:

Feb. 25, 1986

[54]	THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM					
[75]	Inventors:	Takao Yoshioka; Eiici Kitazawa; Tomoyuki Kurumada; Mitsuo Yamazaki; Kazou Hasegawa, all of Hiromachi, Japan				
[73]	Assignee:	Sankyo Company Limited, Tokyo, Japan				
[21]	Appl. No.:	644,996				
[22]	Filed:	Aug. 28, 1984				
[30]	Foreign	Application Priority Data				
Aug. 30, 1983 [JP] Japan 58-158375						
[52]	U.S. Cl					
[56]		References Cited				
U.S. PATENT DOCUMENTS						
		982 Kawamatsu				
Primary Examiner—Robert Gerstl Attorney, Agent, or Firm—Frishauf, Holtz, Goodman & Woodward						
[57]		ABSTRACT				

The compounds of formula (I):

(in which:

 R^1 and R^2 are the same or different and each represents hydrogen or C_1 – C_5 alkyl;

R³ represents hydrogen, an acyl group, a (C₁-C₆ alkoxy)carbonyl group or an aralkyloxycarbonyl group;

R⁴ and R⁵ are the same or different and each represents hydrogen, C₁-C₅ alkyl or C₁-C₅ alkoxy, or R⁴ and R⁵ together represent a C₁14 C₄ alkylenedioxy group; n is 1, 2 or 3;

W represents the -CH₂-, >CO or >CH-OR⁶ group (in which R⁶ represents any one of the atoms or groups defined for R³ and may be the same as or different from R³); and

Y and Z are the same or different and each represents oxygen or imino]

and pharmaceutically acceptable salts thereof have various valuable therapeutic effects on the blood system and may be prepared by a process which includes reacting a corresponding halopropionic acid derivative with thiourea.

39 Claims, No Drawings

THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

BACKGROUND OF THE INVENTION

The present invention relates to a series of new thiazolidine derivatives, which we have found to have a variety of valuable biological activities, coupled with an exceedingly low toxicity. The invention also provides processes for preparing the compounds and pharmaceutical compositions containing them.

A number of thiazolidine derivatives are disclosed in European Patent Publication No. 8203 which corresponds to U.S. Pat. No. 4,287,200 and in Chem. Pharm. Bull., 30,3580 (1982). Certain of the thiazolidine derivatives disclosed in these documents have the ability to lower blood lipid and blood sugar levels, although these compounds are a little toxic.

We have now discovered a series of new thiazolidine derivatives which likewise have the ability to lower blood lipid and blood sugar levels and, in addition, have a number of other valuable activities, but which have very low toxicity. In general, the compounds of the invention show blood lipid metabolism ameliorating activity. Specifically, the compounds have the ability to decrease the levels of blood lipid peroxides, blood triglycerides and blood cholesterol.

BRIEF SUMMARY OF THE INVENTION

The compounds of the present invention are compounds of formula (I):

(in which:

R¹ and R² are the same or different and each represents a hydrogen atom or a C₁-C₅ alkyl group;

R³ represents a hydrogen atom, a C₁-C6 aliphatic acyl group, an alicyclic acyl group, an aromatic acyl group, a heterocyclic acyl group, an araliphatic acyl group, a (C₁-C6 alkoxy)carbonyl group or an aralkyloxycarbonyl group;

R⁴ and R⁵ are the same or different and each represents a hydrogen atom, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a 55 C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3;

W represents the —CH₂—, >CO or >CH—OR⁶ group (in which R⁶ represents any one of the atoms or groups defined for R³ and may be the same as or 60 different from R³); and

Y and Z are the same or different and each represents an oxygen atom or an imino (=NH) group]

and pharmaceutically acceptable salts thereof.

The invention also provides a process for preparing 65 the compounds of the invention by:

(a) reacting a halopropionic acid derivative of formula (II):

$$\begin{array}{c|c}
R^{3} & & & (ID) \\
R^{3}O & & & \\
R^{3}O & & & \\
\end{array}$$

$$\begin{array}{c|c}
R^{1} & & & \\
CH_{2}-CH-A & & \\
X & & & \\
\end{array}$$

[in which:

R¹, R², R³, R⁴, R⁵, n and W are as defined above;

X represents a halogen atom; and

A represents a cyano group, a carboxy group, an alkoxycarbonyl group, a carbamoyl group or a group of formula $-COO(M)_m$, in which M represents a cation and m represents the reciprocal of the valency of the cation M] with thiourea, to give a compound of formula (III):

(in which R¹, R², R³, R⁴, R⁵, n, W and Y are as defined above) and then,

(b) if necessary, subjecting said compound to hydrolysis (which may be selective) to prepare said compound of formula (I),

(c) optionally, where W represents a >C=O group, reducing the compound produced in step (a) or step (b) to a compound where W represents a >CH—OH group,

(d) optionally, where W represents a >CH—OH group, acylating the compound to give a compound in which W represents a group of formula >CH—OR6' (in which R6' represents any of the groups defined for R6 but not the hydrogen atom), and

(e) if necessary, salifying the product.

The invention also provides a pharmaceutical composition for the treatment of hyperlipaemia or hyperglycaemia, which comprises at least one compound of the invention in admixture with a pharmaceutically acceptable carrier or diluent.

DETAILED DESCRIPTION OF INVENTION

The compounds of the invention, which are 5-[4-(chromanalkoxy)benzyl]thiazolidine derivatives, may be represented by the formulae (Ia), (Ib) and (Ic):

$$\begin{array}{c|c}
R^{4} & R^{5} & (Ia) \\
\hline
R^{3}O & R^{1} & CH_{2}CH - C=Y \\
\hline
R^{3}O & R^{2} & NH
\end{array}$$

$$\begin{array}{c|c}
R^4 & C & CH_2 & CH_$$

(in which R¹, R², R³, R⁴, R⁵, R⁶, n, Y and Z are as defined above) and include pharmaceutically accept- 20 able salts thereof.

In the compounds of the invention, where R¹ or R² represents an alkyl group, this may be a straight or branched chain alkyl group having from 1 to 5 carbon atoms and is preferably a primary or secondary alkyl 25 group, for example the methyl, ethyl, propyl, isopropyl. butyl, isobutyl, pentyl or isopentyl group.

Where R3, R6 or R6 represents an aliphatic acyl group, this preferably has from 1 to 6 carbon atoms and may include one or more carbon-carbon double or tri- 30 ple bonds. Examples of such groups include the formyl. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, hexanoyl, acryloyl, methacryloyl and crotonoyl groups. Where R3, R6 or R6 represents an alicyclic acyl group, it is preferably a cyclopentanecarbonyl, cyclohex- 35 anecarbonyl or cycloheptanecarbonyl group. Where R³, R⁶ or R⁶ represents an aromatic acyl group, the aromatic moiety thereof may optionally have one or more substituents (for example nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl or hydroxy 40 substituents); examples of such aromatic acyl groups include the benzoyl, p-nitrobenzoyl, m-fluorobenzoyl, o-chlorobenzoyl. p-aminobenzoyl. m-(dimethylamino)benzoyl, o-methoxybenzoyl, 3,4-dichlorobenzoyl, 3.5di-t-butyl-hydroxybenzoyl and 1-naphthoyl groups. 45 Where R3, R6 or R6 represents a heterocyclic acyl group, the heterocyclic moiety thereof preferably has one or more, preferably one, oxygen, sulfur or nitrogen hetero atoms and has from 4 to 7 ring atoms; examples of such heterocyclic acyl groups include the 2-furoyl, 50 3-thenoyl, 3-pyridinecarbonyl (nicotinoyl) and 4pyridinecarbonyl groups. Where R3, R6 or R6' represents an araliphatic acyl group, the aliphatic moiety thereof may optionally have one or more carbon-carbon double or triple bonds and the aryl moiety thereof 55 may optionally have one or more substituents (for example nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl or hydroxy substituents); examples of such araliphatic acyl groups include the phenylacetyl, pchlorophenylacetyl, phenylpropionyl and cinnamoyl 60 groups. Where R^3 , R^6 or R^6 represents a $(C_1-C_6$ alkoxy)carbonyl group, the alkyl moiety thereof may be any one of those alkyl groups as defined for R1 and R2, but is preferably a methyl or ethyl group, and the alkoxycarbonyl group represented by R3, R6 or R6 is therefore 65 preferably a methoxycarbonyl or ethoxycarbonyl group. Where R3, R6 or R6' represents an aralkyloxycarbonyl group, the aralkyl moiety thereof may be any one

of those included within the araliphatic acyl group represented by R3, Ro or Ro, but is preferably a benzovioxycarbonyl group.

Where R4 and R5 represent alkyl groups, they may be the same or different and may be straight or branched chain alkyl groups. They preferably have from 1 to 5 carbon atoms and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and isopentyl groups.

Where R4 and R5 represent alkoxy groups, these may be the same or different and may be straight or branched chain groups, preferably having from 1 to 4 carbon atoms. Examples include the methoxy, ethoxy, propoxy, isopropoxy and butoxy groups. Alternatively, R4 and R5 may together represent a C1-C4 alkylenedioxy group, more preferably a methylenedioxy or ethylenedioxy group.

Preferred classes of compounds of the present invention are as follows:

- (1) Compounds in which R3 represents a hydrogen atom, a C₁-C₆ aliphatic acyl group, an aromatic acyl group or a heterocyclic acyl group.
- (2) Compounds in which Y represents an oxygen atom; R1 and R2 are the same or different and each represents a hydrogen atom or a C1-C5 alkyl group; R3 represents a hydrogen atom, a C1-C6 aliphatic acyl group, an aromatic acyl group or a pyridinecarbonyl group; and R4 and R5 are the same or different and each represents a hydrogen atom, a C1-C5 alkyl group or a C1 or C2 alkoxy group.
- (3) Compounds as defined in (2) above. in which: R1, R2, R4 and R5 are the same or different and each represents a hydrogen atom or a C1-C5 alkyl group: n is 1 or 2; and W represents the -CH2- or >CO group.
- (4) Compounds as defined in (3) above, in which R³ represents a hydrogen atom, a C₁-C₅ aliphatic acylgroup, a benzoyl group, or a nicotinoyl group.
- (5) Compounds as defined in (4) above, in which: R1 and R4 are the same or different and each represents a C₁-C₅ alkyl group; R² and R⁵ are the same or different and each represents the hydrogen atom or the methyl group; and R3 represents a hydrogen atom or a C1-C4 aliphatic acyl group.
- (6) Compounds in which: W represents the -CH₂- or >CO group: Y and Z both represent oxygen atoms: n is I or 2; R1 and R4 are the same or different and each represents a C1-C4 alkyl group; R2 and R5 are the same or different and each represents the hydrogen atom or the methyl group; and R3 represents a hydrogen atom or a C1-C4 aliphatic acyl group.
- (7) Compounds as defined in (6) above, in which n is 1. (8) Compounds as defined in (6) or (7) above, in which

W represents the -CH₂- group.

Preferred compounds among the compounds of this invention are those wherein: R^{\dagger} is a C_1 - C_4 alkyl group. more preferably a methyl or isobutyl group, most preferably a methyl group; R2 is a hydrogen atom or a C₁-C₄ alkyl group, preferably a hydrogen atom, or a methyl or isopropyl group, more preferably a hydrogen atom or a methyl group, most preferably a methyl group; R3 is a hydrogen atom, a C1-C4 aliphatic acyl group, an aromatic acyl group or a pyridinecarbonyl group, preferably a hydrogen atom, or an acetyl, butyryl, benzoyl or nicotinoyl group, more preferably a hydrogen atom or an acetyl, butyryl or benzoyl group, most preferably a hydrogen atom or an acetyl group;

R4 is a hydrogen atom, a C1-C4 alkyl group or a C1 or C₂ alkoxy group, preferably a methyl, isopropyl, t-butyl or methoxy group, more preferably a methyl or t-butyl group, most preferably a methyl group; R5 is a hydrogen atom, a C₁-C₄ alkyl group or a C₁ or C₂ alkoxy 5 group, preferably a hydrogen atom, or a methyl or methoxy group, more preferably a hydrogen atom or a methyl group and most preferably a methyl group; n is I or 2, preferably I; Y is an oxygen atom; Z is an oxygen atom or an imino group, most preferably an oxygen 10 atom: and W is a -CH2- or > C=O group, preferably -CH₂-- group.

Specific examples of compounds of the present invention are given in the following list:

- 1. 5-[4-(6-hydroxy-2.5.7,8-tetramethylchroman-2-ylme- 15 35. 5-[4-(6-hydroxy-5,7-diisopropyl-2-methylchromanthoxy)benzyl]thiazolidine-2,4-dione
- 2. 5-[4-(6-hydroxy-2.5.7-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
- . 5-[4-(6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(2-ethyl-6-hydroxy-5.7,8-trimethylchroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione
- 6. 5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethox- 25 40. y)benzyl]thiazolidine-2,4-dione
- 7. 5-[4-(6-hydroxy-2,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-7-isopropyl-2-methylchroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione
- 9. 5-[4-(6-hydroxy-5,7-diisopropyl-2-methylchroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione
- 10. 5-[4-(6-hydroxy-2-methyl-7-propylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethylchroman-2-35 yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 12. 5-{4-[2-(6-hydroxy-2,5,7-trimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 14. 5-{4-[2-(6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
- 15. 5-{4-[2-(2-ethyl-6-hydroxy-5.7.8-trimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
- 16. 5-{4-[2-(6-hydroxy-5.7,8-trimethylchroman-2-yl)e- 45 thoxy]benzyl}thiazolidine-2,4-dione
- 5-{4-{2-(6-hydroxy-5,7-diisopropyl-2,8-dimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
- 5-{4-[2-(6-hydroxy-7-pentyl-2-propylchroman-2yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-7,8-dimethoxy-2,5-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 20. 5-[4-(6-hydroxy-7,8-dimethoxy-5-methylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(2-ethyl-6-hydroxy-7,8-dimethoxy-5-methyl-55 chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-2,5-dimethyl-7,8-methylenedioxychroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
- 23. 5-{4-[2-(6-hydroxy-7,8-dimethoxy-2,5-dimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 5-{4-[3-(6-hydroxy-2.5.7,8-tetramethylchroman-2yl)propoxy]benzyl}thiazolidine-2,4-dione
- 5-{4-[3-(7-t-butyl-6-hydroxychroman-2-yl)propoxy]benzyl}thiazolidine-2,4-dione
- 26. 5-[4-(6-hydroxychroman-2-ylmethoxy)benzyl]- 65 58. thiazolidine-2,4-dione
- 27. 5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

- 28. 5-[4-(6-hydroxy-5.7.8-trimethyl-2-propylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(7-t-butyl-6-hydroxy-2-isopropylchroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione
- 30. 5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
- 5-[4-(6-hydroxy-2-isobutyl-7-isopropylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
- 32. 5-[4-(6-hydroxy-5,7,8-trimethyl-2-pentylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
- 33. 5-[4-(6-hydroxy-2-isopentyl-5.7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-hydroxy-2.5.7.8-tetramethylchroman-2ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 36. 5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-1-one 37. 5-[4-(6hydroxy-2-methylchroman-2-ylmethoxy)benzyl]-2iminothiazolidin-4-one
- 5-[4-(2-ethyl-6-hydroxy-5.7,8-trimethylchroman-2ylmethoxy)benzyl]-2-iminothiazolidin-1-one
- 5-[4-(6-hydroxy-7,8-dimethoxy-2,5-dimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-vimethoxy)benzyl]-2-iminothiazolidin-4-one
- 5-[4-(2-ethyl-6-hydroxy-7,8-dimethoxy-5-methylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 30 42. 5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
 - 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)ethoxy]benzyl}-2-iminothiazlidin-4-one
 - 44. 5-{4-[2-(6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one
 - 5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2yl)ethoxy|benzyl}-2-iminothiazolidin-4-one
 - 5-{4-[2-(6-hydroxy-7,8-dimethoxy-2.5-dimethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one
 - 47. 5-{4-[2-(2-ethyl-6-hydroxy-7.8-dimethoxy-5-methylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one
 - 48. 5-{4-[2-(6-hydroxy-7.8-dimethoxy-5-methylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-1-one
 - 5-{4-[3-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)propoxy]benzyl}-2-iminothiazolidin-4-one
 - 50. 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2ylmethoxy)benzyl]-2,4-diiminothiazolidine
- 50 51 5-[4-(6-hydroxy-2,5,7-trimethylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 52. 5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 5-[4-(6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 5-[4-(7-t-butyl-6-hydroxychroman-2-ylmethoxy)benzyl]-2.4-diiminothiazolidine
 - 5-[4-(6-hydroxy-7,8-dimethoxy-2,5-dimethylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
- 60 56. 5-[4-(6-hydroxy-7,8-dimethoxy-5-methylchroman-2ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 5-[4-(2-ethyl-6-hydroxy-7,8-dimethoxy-5-methylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazoli-
- 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethylchroman-2yl)ethoxy]benzyl}-2,4-diiminothiazolidine
 - 5-{+[2-(7-t-butyl-6-hydroxy-2-methylchroman-2yl)ethoxy]benzyl}-2,4-diiminothiazolidine

- 5-{4-[2-(6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}-2.4-diiminothiazolidine
- 5-{4-[3-(6-hydroxy-7,8-dimethoxy-2.5-dimethylchroman-2-yl)propoxy]benzyl}-2,4-diiminothiazoli-
- 62. 5-[4-(6-acetoxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-benzoyloxy-2,5,7,8-tetramethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
- thoxy)benzyl]thiazolidine-2.4-dione
- 65. 5-[4-(6-acetoxy-2-methylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 66. 5-[4-(2-ethyl-6-isobutyryloxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 5-[4-(6-butyryloxy-2,5,7.8-tetramethylchroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione
- 68. 5-{4-[2-(6-m-fluorobenzoyloxy-2.5.7-trimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
- 69. 5-{4-[2-(6-acryloyloxy-7-t-butyl-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 5-{4-[2-(6-heptanoyloxy-2-methylchroman-2-yl)ethoxy[benzyl]thiazolidine-2,4-dione
- 5-{4-[2-(6-p-aminobenzoyloxy-2-ethyl-5.7,8-trime-25 thylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4dione
- 72. 5-{4-[2-(5,7,8-trimethyl-6-3'-thenoyloxychroman-2yl)ethoxy[benzyl]thiazolidine-2.4-dione
- 5-{4-[2-(6-2'-furoyloxy-5.7-diisopropyl-2.8-dime- 30 thylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4dione
- 5-{4-[2-(6-β-naphthoyloxy-7-pentyl-2-propylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione
- 75. 5-[4-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman- 35 2-ylmethoxy)benzyl]thiazolidine-2,4-dione
- 76. 5-{4-[6-(3,5-dichlorobenzoyloxy)-7,8-dimethoxy-5methylchroman-2-ylmethoxy]benzyl}thiazolidine-2.4-dione
- 77. 5-[4-(2-ethyl-7,8-dimethoxy-5-methyl-6-valeryloxy- 40 chroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
- 5-[4-(6-isonicotinoyloxy-2.5-dimethyl-7.8methylenedioxychroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
- 5-{4[2-(7,8-dimethoxy-2,5-dimethyl-6-p-nitrobenzoyloxychroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione
- 80. 5-{4-[3-(6-o-chlorobenzoyloxy-2,5.7,8-tetramethylchroman-2-yl)propyl]benzyl}thiazolidine-2,4-dione
- 81. 5-{4-[3-(7-t-butyl-6-m-dimethylaminobenzoyloxy-5methylchroman-2-yl)propoxy]benzyl}thiazolidine-2,4-dione
- 5-[4-(6-acetoxychroman-2-ylmethoxy)benzyl]-82. thiazolidine-2,4-dione
- 83. 5-[4-(6-acetoxy-2,7-dimethylchroman-2-ylmethoxy)benzyllthiazolidine-2,4-dione
- 84. 5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 85. 5-[4-(6-acetoxy-5,7-diisopropyl-2-methylchroman-2- 60 112 ylmethoxy)benzyl]-2-iminothiazolidin-1-one
- 5-{4-[7-t-butyl-6-(3,5-di-t-butyl-4-hydroxybenzoyloxy)-2-methylchroman-2-ylmethoxy]benzyl}-2iminothiazolidin-4-one
- 87. 5-[4-(6-acetoxy-2-methylchroman-2-ylmethoxy)ben- 65 zyl]-2-iminothiazolidin-4-one
- 88. 5-[4-(2-ethyl-5,7,8-trimethyl-6-phenylacetoxychroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

- 89. 5-[4-(6-cinnamoyloxy-7.8-dimethoxy-2.5-dimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 5-[4-(6-m-chlorobenzoyloxy-7,8-dimethoxy-5-90. methylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-tone
 - 91. 5-[4-(2-ethyl-7,8-dimethoxy-5-methyl-6-valeryloxychroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
- 64. 5-[4-(6-acetoxy-7-t-butyl-2-methylchroman-2-ylme- 10 92. 5-[4-(6-acetoxy-2.7-dimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-1-one
 - 5-{4-{2-(6-o-methoxybenzoyloxy-2.5.7,8-tetramethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one
 - 15 94. 5-{4-[2-(2-methyl-6-pivaloyloxychroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-1-one
 - 5-{4-[2-(7-t-butyl-2-methyl-6-propionyloxychroman-2-yl)ethoxy[benzyl]-2-iminothiazolidin-1-one
 - 5-{4-[2-(6-ethoxycarbonyloxy-7,8-dimethoxy-2,5-96. dimethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one
 - 97. 5-{4-[2-(6-p-chlorophenylacetoxy-2-ethyl-7,8-dimethoxy-5-methylchroman-2-yl)ethoxy]benzyl}-2iminothiazolidin-4-one
 - 5-{4-[2-(7,8-dimethoxy-5-methyl-6-3'-phenylpropionyloxychroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one
 - 5-{4-{3-(6-benzyloxycarbonyloxy-2.5.7.8-tetramethylchroman-2-yl)propoxylbenzyl}-2-iminothiazoli-
 - 100. 5-[4-(6-benzoyloxy-2.5.7,8-tetramethylchroman-2ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 5-[4-(6-cyclohexanecarbonyloxy-2.5.7-trimethylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 102. 5-[4-(6-acetoxy-7-t-butyl-2-methylchroman-2ylmethoxy)benzyl]-2.4-diiminothiazolidine
 - 5-[4-(6-acetoxy-2-methylchroman-2-ylmethoxy)-103. benzyl]-2,4-diiminothiazolidine
 - 5-[4-(6-acetoxy-7-t-butylchroman-2-ylmethoxy)-104. benzyl]-2.4-diiminothiazolidine
 - 105. 5-[4-(6-acetoxy-2.7-dimethylchroman-2-ylmethoxy)benzyl]-2.4-diiminothiazolidine
 - 5-[4-(6-acetoxy-7,8-dimethoxy-2,5-dimethylchroman-2-ylmethoxy)benzyl]-2.4-diiminothiazolidine
 - 107. 5-[4-(6-acetoxy-7,8-dimethoxy-5-methylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 5-[4-(6-acetoxy-2-ethyl-7,8-dimethoxy-5-methylchroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine
 - 109. 5-{4-[2-(6-methoxycarbonyloxy-2.5,7,8-tetramethylchroman-2-yl)ethoxy]benzyl}-2,4-diiminothiazolidine
 - 5-{4-[2-(7-t-butyl-6-cyclopentanecarbonyloxy-2methylchroman-2-yl)ethoxy]benzyl}-2,4-diiminothiazolidine
 - 5-{4-[2-(6-formyloxy-2-methylchroman-2-yl)e-111. thoxy]benzyl}-2,4-diiminothiazolidine
 - 5-{4-[3-(6-methacryloyloxy-7,8-dimethoxy-2,5dimethylchroman-2-yl)propoxy]benzyl}-2,4-diimino-
 - 5-[4-(6-hydroxy-2.5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 114. 5-[4-(4,6-dihydroxy-2,5,7,8-tetramethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione
 - 115. 5-[4-(6-hydroxy-2,5,7-trimethyl-4-oxochroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione

20

116. 5-[4-(7-t-butyl-6-hydroxy-2-methyl-Loxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

117. 5-[4-(7-t-butyl-4.6-dihydroxy-2-methylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2-methyl-t-oxochroman-2-ylme-5thoxy)benzyl]thiazolidine-2,t-dione

119. 5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethyl-4-oxochro-man-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

120. 5-[4-(2-ethyl-4,6-dihydroxy-5.7.8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

121. 5-[4-(6-hydroxy-5,7.8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

122. 5-[4-(6-hydroxy-2.7.8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

123. 5-[4-(6-hydroxy-7-isopropyl-2-methyl-4-oxochro- 15 man-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-5,7-diisopropyl-2-methyl-4-oxo-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 5-[4-(6-hydroxy-2-methyl-4-oxo-7-propylchroman-

2-ylmethoxy)benzyl]thiazolidine-2,4-diene

126. 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

127. 5-{4-[2-(4,6-dihydroxy-2,5,7,8-tetramethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

128. 5-{4-[2-(6-hydroxy-2,5,7-trimethyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

129. 5-{4-[2-(7-t-butyl-6-hydroxy-2-methyl-4-oxochro-man-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

130. 5-{4-[2-(7-t-butyl-4.6-dihydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

131. 5-{4-[2-(6-hydroxy-2-methyl-4-oxochroman-2-yl)e-thoxy]benzyl}thiazolidine-2,4-dione

132. 5-{4-[2-(2-ethyl-6-hydroxy-5,7,8-trimethyl-+oxo-chroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

133. 5-{4-[2-(6-hydroxy-5,7,8-trimethyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

134. 5-{4-[2-(6-hydroxy-5,7-diisopropyl-2.8-dimethyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

5-{4-[2-(6-hydroxy-4-oxo-7-pentyl-2-propylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

136. 5-[4-(6-hydroxy-7,8-dimethoxy-2,5-dimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

137. 5-[4-(6-hydroxy-7,8-dimethoxy-5-methyl-4-oxo-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

138. 5-[4-(2-ethyl-6-hydroxy-7,8-dimethoxy-5-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2,5-dimethyl-7,8-methylenedioxy-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

140. 5-{4-[2-(6-hydroxy-7,8-dimethoxy-2,5-dimethyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

141. 5-{4-[3-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochro-man-2-yl)propoxy]benzyl}thiazolidine-2,4-dione

142. 5-{4-{3-(7-t-butyl-6-hydroxy-4-oxochroman-2-yl)propoxy]benzyl}thiazolidine-2,4-dione

143. 5-[4-(6-hydroxy-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

144. 5-[4-(6-hydroxy-2,7-dimethyl-4-oxochroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

145. 5-[4-(6-hydroxy-5,7,8-trimethyl-4-oxo-2-propyl-65 174. chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione m

146. 5-[4-(7-t-butyl-6-hydroxy-2-isopropyl-4-oxochro-man-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

147. 5-[4-(2-butyl-6-hydroxy-5.7,8-trimethyl-4-oxochro-man-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

148. 5-[4-(6-hydroxy-2-isobutyl-5.7.8-trimethyl-1-oxo-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

149. 5-[4-(4.6-dihydroxy-2-isobutyl-5.7.3-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

150. 5-[4-(2-t-butyl)-6-hydroxy-5,7,8-trimethyl-4-oxo-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

151. 5-[4-(6-hydroxy-2-isobutyl-7-isopropyl-4-oxochro-man-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

152. 5-[4-(6-hydroxy-5.7-dimethyl-4-oxo-2-pentylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-5,7,8-trimethyl-2-pentyl-4-oxo-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 5-[4-(6-hydroxy-2-isopentyl-5,7,8-trimethyl-4-oxo-

chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione 155. 5-{4-[6-hydroxy-5,7,8-trimethyl-2-(2-methylbutyl)-4-xochroman-2-ylmethoxylbenzyl]thiazolidine-2,1

4-oxochroman-2-ylmethoxy]benzyl}thiazolidine-2.4-dione

156. 5-{4-[2-(2.2-dimethylpropyl)-6-hydroxy-5,7,8-trimethyl-4-oxochroman-2-ylmethoxy]benzyl} thiazolidine-2,4-dione

 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

158. 5-[4-(6-hydroxy-5,7-diisopropyl-2-methyl-toxo-chroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-tone

159. 5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

160. 5-[4-(6-hydroxy-2-methyl-toxochroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-tone

161. 5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethyl-4-oxochro-man-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5 162. 5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

163. 5-[4-(6-hydroxy-7,8-dimethoxy-2,5-dimethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazoli-din-4-one

164. 5-[4-(6-hydroxy-5,7,8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

165. 5-[4-(2-ethyl-6-hydroxy-7.8-dimethoxy-5-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazoli-din-4-one

166. 5-[4-(6-hydroxy-2,7-dimethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

167. 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethyl--oxochro-man-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

168. 5-{4-[2-(6-hydroxy-2-methyl-4-oxochroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

169. 5-{4-[2-(7-t-butyl-6-hydroxy-2-methyl-4-oxochro-man-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

170. 5-{4-[2-(6-hydroxy-7,8-dimethoxy-2,5-dimethyl-4-oxochroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

171. 5-{4-[2-(2-ethyl-6-hydroxy-7,8-dimethoxy-5-meth-yl-4-oxochroman-2-yl)ethoxy]benzyl}-2-imino-thiazolidin-4-one

60 172. 5-{4-[2-(6-hydroxy-7,8-dimethoxy-5-methyl-4-oxo-chroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

173. 5-{4-[3-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-yl)propoxy]benzyl}-2-iminothiazolidin-4-one

174. 5-[4-(6-hydroxy-2.5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine

175. 5-[4-(6-acetoxy-2.5,7.8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione 176. 5-[4-(6-acetoxy-+hydroxy-2.5.7.8-tetramethyl-chroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
177. 5-[4-(4.6-diacetoxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-acetoxy-4-benzoyloxy-2.5.7.8-tetramethyl-chroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione
 5-[4-(4-acetoxy-6-benzoyloxy-2.5.7.8-tetramethyl-

chroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

180. 5-[4-(4,6-dibenzoyloxy-2,5,7,8-tetramethylchro-man-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

181. 5-[4-(2-ethyl-4,6-diisobutyryloxy-5,7,8-trimethyl-chroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
 182. 5-[4-(4,6-dibutyryloxy-2,5,7,8-tetramethylchro-

man-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

183. 5-{4-[2-(6-m-fluorobenzoyloxy-1-heptanoyloxy-2.5,7-trimethylchroman-2-yl)ethoxy]benzyl}thiazoli-dine-2.4-dione

184. 5-{4-[2-(4.6-diacryloyloxy-7-t-butyl-2-methylchro-man-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

185. 5-{4-[2-(4-m-fluorobenzoyloxy-6-heptanoyloxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

186. 5-{4-[2-(5.7.8-trimethyl-4.6-bis{3-thenoxyloxy} chroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

187. 5-{4-[2-(4.6-bis{2-furoyloxy}-5,7-diisopropyl-2.8-dimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

188. 5-[4-(2.5.7,8-tetramethyl-4,6-dinicotinoyloxychroman-2-vlmethoxy)benzyl]thiazolidine-2.4-diene

189. 5-{4-[4,6-bis(3,5-dichlorobenzoyloxy)-7,8-dimethoxy-5-methylchroman-2-ylmethoxy]benzyl} thiazolidine-2,4-dione

190. 5-[4-(2-ethyl-7,8-dimethoxy-5-methyl-4,6-divaleryloxychroman-2-ylmethoxy)benzyl]thiazoli-dine-2.4-dione

191. 5-{4-[7-t-butyl-6-(3,5-di-t-butyl-4-hydroxyben-zoyloxy)-2-methyl-4-oxochroman-2-ylmethoxy]ben-zyl}thiazolidine-2,4-dione

192. 5-[4-(2-ethyl-5,7,8-trimethyl-4-oxo-6-phenylacetox- 40 ychroman-2-ylmethoxy)benzyl]thiazolidine-2.4-

193. 5-[4-(6-cinnamoyloxy-7.8-dimethoxy-2.5-dimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4dione

194. 5-[4-(6-m-chlorobenzoyloxy-7,8-dimethoxy-5-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazoli-dine-2,4-dione

195. 5-[4-(2-ethyl-7,8-dimethoxy-5-methyl-4-oxo-6-valeryloxychroman-2-ylmethoxy)benzyl]thiazoli-dine-2,4-dione

196. 5-{4-[2-(6-o-methoxybenzoyloxy-2,5.7.8-tet-ramethyl-4-oxochroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

197. 5-{4-[2-(2-methyl-4-oxo-6-pivaloyloxychroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

198. 5-{4-[2-(7-t-butyl-2-methyl-4-oxo-6-propionyloxy-chroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

199. 5-{4-[2-(6-ethoxycarbonyloxy-7,8-dimethoxy-2.5-60 dimethyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazoli-dine-2,4-dione

200. 5-{4-[2-(6-p-chlorophenylacetoxy-2-ethyl-7,8-dimethoxy-5-methyl-4-oxochroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

5-[4-{2-[7,8-dimethoxy-5-methyl-4-oxo-6-(3-phenylpropionyloxy)chroman-2-yl]ethoxy}benzyl]-thiazolidine-2,4-dione

202. 5-[4-(6-cyclohexanecarbonyloxy-2.5.7.8-tetrameth-yl-theoxochroman-2-ylmethoxy)benzyl]-2,4-diiminothiazolidine

203. 5-[4-(6-acetoxy-2.5.7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

204. 5-[4-(6-acetoxy-7-t-butyl-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

10 205. 5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

206. 5-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

207. 5-{4-[2-(6-acetoxy-7,8-dimethoxy-2,5-dimethyl-chroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

208. 5-{4-[2-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

Of the compounds listed above, preferred compounds are Compounds No. 1, 5, 6, 11, 13, 23, 27, 30, 34, 36, 38, 40, 42, 62, 63, 67, 75, 113, 116, 148, 157, 159, 162, 175, 205, 206, and 207. More preferred compounds are Compounds No. 1, 5, 13, 30, 62, 67, 113 and 116 and the most preferred compounds are Compounds No. 1 and 62.

Various of the compounds of the invention can exist in the form of tautomers. For example, those compounds of the invention in which Z represents an imino group and Y represents an oxygen atom can exist in the form of the tautomers (IV), (IVa) and (IVb):

45

$$R^4$$
 R^5
 (IVa)
 $($

$$\begin{array}{c}
R^4 \\
R^5 \\
R^{10} \\
R^2
\end{array}$$

$$\begin{array}{c}
R^1 \\
CH_2)_{\pi} O \longrightarrow CH_2 - CH_2 - CH_3 \\
NH$$

$$\begin{array}{c}
CH_2 - CH_3 - CH_3 \\
NH
\end{array}$$

Compounds in which both Y and Z represent imino groups can exist in the form of the tautomers (V), (Va) and (Vb):

compounds in which Y and Z both represent oxygen atoms can exist in the form of the tautomers (VI), (VIa) and (VIb):

effect upon various of the properties of the compounds, including their salt-forming ability, as discussed hereafter.

In addition, the compounds of the invention can exist in the form of various stereoisomers. For example, where W represents a > C=O or -CH₂- group, the carbon atoms at the 2-position of the chroman ring and the 5-position of the thiazolidine ring are both asymmetric. Furthermore, where W represents a > CH-OR⁶ group, the carbon atoms at the 2- and 4-positions of the chroman ring and at the 5-position of the thiazolidine ring are asymmetric. All of these thus give rise to the possibility of stereoisomers. All of the isomers are represented herein by a single formula, and the present invention envisages both mixtures of the isomers and the individual isomers, which may be separated from each other by conventional means.

The compounds of the present invention also include salts of compounds of the invention described above.

20 which may be salts with cations. Cations with which the compounds of the invention may form salts include: alkali metals, such as sodium or potassium; alkaline earth metals, such as calcium; and trivalent metals, such as aluminum.

It will, however, be appreciated that the particular nature of the salt employed is not critical to the present invention and any cations known in the art for forming salts of this type may equally be used in the present invention. The only constraint is that the cations should not, or should not to an unacceptable extent, increase the toxicity or reduce the activity of the resulting compound.

Because the compounds of the invention contain a number of salt-forming centres, mono- and di-salts may

For convenience, all of the tautomers are represented by a single formula, but the tautomeric nature of these compounds should be remembered, as it can have an

be formed. For example, because of the tautomerism described above in relation to the compounds of for-

mula (VI), there are two potential salt-forming reactive sites at the oxygen atom in the group -OR3 and the nitrogen atom at the 3-position of the thiazolidine ring.

PREPARATION OF NEW COMPOUNDS Step (a)

Compounds of the invention in which Z represents an imino group, that is to say compounds of formula (III):

$$\begin{array}{c|c}
R^{4} & & & & (III) \\
R^{3}O & & & & & \\
\end{array}$$

$$\begin{array}{c|c}
CH_{2}J_{\pi}-O & & & & \\
CH_{2}J_{\pi}-CH - C=Y \\
\vdots & & & \\
NH & & & \\
NH & & & \\
NH & & & \\
\end{array}$$

(in which R^1 - R^5 , n, W and Y are as defined above) may ²⁰ be prepared by reacting a compound of formula (II):

fin which R1-R5 and n are as defined above. A represents a cyano group, a carboxy group, an alkoxycarbonyl group, a carbamoyl group or a group of formula $-COO(M)_m$, in which M represents a cation and m is the reciprocal of its valency, and X represents a halogen 35 formula (VII):

include: alcohols, such as methanol, ethanol, propanol, butanol or ethylene glycol monomethyl ether; ethers, such as tetrahydrofuran or dioxane; ketones, such as acetone; dimethyl sulfoxide; sulfolane; or amides, such as dimethylformamide.

16

There is no particular limitation on the molar ratio of the compound of formula (II) to thiourea; however, we would normally prefer to use equimolar amounts of a molar excess of thiourea, preferably a slight molar ex-10 cess. In general, from 1 to 2 moles of thiourea per mole of the compound of formula (II) are preferred.

The various reaction conditions, such as the reaction temperature and time, will vary, depending upon the natures of the starting materials and the solvent; however, the reaction is normally effected at the reflux temperature of the solvent or at a temperature of from 80° to 150° C. for a period of from 1 to 20 hours.

The resulting compound of formula (III) may be the desired final product of the present invention, in which case it may be isolated from the reaction mixture by conventional means, as discussed hereafter. Alternatively, with or without isolation and/or purification, the compound of formula (III) may be subjected to one or both of steps (b) and (c), in any order, and, if desired. 25 step (c) may be followed by step (d). The product of any of these steps may be subjected to the salification reaction discussed in step (e).

Step (b)

In this step, the compound of formula (III), that is to say a compound of formula (I) in which Z represents an imino group, may be hydrolysed to give the corresponding compound of formula (I) in which Z represents an oxygen atom, that is to say a compound of

$$\begin{array}{c}
R^4 \\
R^3O
\end{array}$$

$$\begin{array}{c}
R^1 \\
(CH_2)_n - O
\end{array}$$

$$\begin{array}{c}
CH_2 - CH \\
S \\
NH
\end{array}$$

$$\begin{array}{c}
VIII \\
O
\end{array}$$

atom] with thiourea.

Where A represents a cyano group, the product is a compound in which Y represents an imino group; where A represents a carboxy, alkoxycarbonyl, carbamoyl or $-COO(M)_m$ group, the product is a compound where Y represents an oxygen atom.

In the above formula (II), where A represents an alkoxycarbonyl group, this is preferably a (C₁-C₆ alkoxy)carbonyl group, for example a methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl or butoxycarbonyl group. M preferably represents a 55 metal atom, such as a sodium, potassium, calcium or aluminum atom, or an ammonium group. X preferably represents a chlorine, bromine or iodine atom.

This reaction is preferably applied only to those compounds where W represents a $-CH_2-$ or >C=0 60 group, compounds in which W represents a >CH-OR6 group being prepared from the corresponding compound where W represents a >C=O group, as explained hereafter.

Reaction of the compound of formula (II) with thio- 65 urea is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect on the reaction. Suitable solvents

(in which R¹-R⁵, n, W and Y are as defined above).

The hydrolysis reaction is preferably carried out by heating the compound of formula (III) in a suitable 50 solvent with water and an organic acid (such as acetic acid) or a mineral acid (such as sulfuric acid or hydrochloric acid). The nature of the solvent is not critical to the invention, provided that it has no adverse effect upon the reaction; suitable solvents include: sulfolane; and alcohols, such as methanol, ethanol or ethylene glycol monomethyl ether.

The amount of acid used is preferably from 0.1 to 10 moles, more preferably from 0.2 to 3 moles, per mole of the compound of formula (III). The water or aqueous solvent is preferably employed in a large molar excess over the compound of formula (III).

Although not critical, the temperature employed for the reaction is preferably from 50° to 100° C. and the time required for the reaction is normally from 2 to 20

Where Y in the compound of formula (III) represents an imino group, the hydrolysis of the present step will normally likewise convert said imino group to an oxygen atom, the product being a compound in which both Y and Z are oxygen atoms. However, by careful control of the hydrolysis conditions, it is possible to prevent the hydrolysis reaction going to completion, in which case part of the product will be a compound in which Y 5 represents an imino group and Z represents an oxygen atom.

In addition to converting the imino group represented by Z to an oxygen atom, where R³ in the compound of formula (III) represents an acyl group, the 10 hydrolysis reaction may convert this to a hydrogen atom, although it is possible to maintain the acyl group represented by R³ intact, provided that appropriate reaction conditions are chosen, as is well-known in the art.

agent over the compound of formula (VII) may be desirable. In general, we prefer to employ from 1 to 2 moles of acylating agent per mole of compound of formula (VII).

The reaction conditions, such as the reaction temperature and reaction time, will vary, depending upon a number of factors, including the nature of the starting materials and solvent, but the reaction is generally carried out at a temperature of from 0° to 100° C. for a period of from several minutes to about 20 hours.

Step (c)

Compounds of formula (I) in which W represents a group of formula > CH—OH, that is to say compounds 15 of formula (Id):

$$\begin{array}{c}
R^{4} \\
R^{3}O
\end{array}$$

$$\begin{array}{c}
CH_{2} \\
CH_{2}
\end{array}$$

$$\begin{array}{c}
CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2}$$

$$\begin{array}{c}
CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2}$$

$$\begin{array}{c}
CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2} \\
CH_{2}$$

$$CH_{2} \\
CH_{2} \\
CH_{2} \\
CH_{2}$$

$$CH_{2} \\$$

Where the compound of formula (VII) is a compound in which R³ represents a hydrogen atom, this may be acylated to give a corresponding compound in which R³ represents one of the acyl groups defined above.

(in which R¹-R⁵, n, Y and Z are as defined above) may be prepared by reducing the corresponding compound in which W represents a group of formula > C=O, that is to say a compound of formula (Ib):

$$\begin{array}{c|c}
R^4 & \downarrow & \downarrow & \downarrow \\
R^3O & \downarrow & \downarrow$$

This acylation reaction may be carried out at any suitable stage in the reaction sequence and may, if desired, be carried out simultaneously with the acylation reaction of step (d), as described hereafter. Where, however, the acylation reaction is carried out separately from step (d), the conditions are preferably as follows:

The acylating agent is preferably an acid halide or an acid anhydride, or it may be an organic acid. such as an 45 aromatic carboxylic acid or an aliphatic carboxylic acid, in association with a dehydrating agent or dehydrating catalyst such as a mineral acid (e.g. hydrochloric acid or sulfuric acid) or an organic acid (e.g. p-toluenesulfonic acid).

The reaction is normally carried out in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect upon the reaction. Suitable solvents include: ethers, such as diethyl ether, tetrahydrofuran or dioxane; aromatic hydrocarbons, such as benzene or toluene; aliphatic hydrocarbons, such as hexane, cyclohexane or heptane; halogenated hydrocarbons, such as methylene chloride or chloroform; ketones, such as acetone or methyl ethyl ketone; amides, such as dimethylformamide or dimethylacetamide; organic bases, such as pyridine or triethylamine; sulfoxides, such as dimethyl sulfoxide; sulfones, such as sulfolane; or water; a single one of these solvents or a mixture of any two or more thereof may be employed.

The ratio of the amount of the compound of formula 65 (VII) in which R³ represents a hydrogen atom to the amount of acylating agent is not particularly critical, but the use of a slight molar excess of the acylating

(in which R1-R5, n. Y and Z are as defined above).

The reducing agent employed for this reaction is any one which is capable of reducing a ring carbonyl group to a > CH—OH group without affecting, or affecting to a substantial degree, the remainder of the molecule. Suitable reducing agents include borohydrides, such as sodium borohydride, or K-Selectride, especially sodium borohydride.

The reaction is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect upon the reaction. Suitable solvents include, for example: alcohols, such as methanol, ethanol, propanol, butanol or ethylene glycol monomethyl ether; and ethers, such as tetrahydrofuran or dioxane.

The molar ratio of the compound of formula (Ib) to the reducing agent is not critical, however we prefer to employ a molar excess of reducing agent, preferably from 1 to 20 moles of reducing agent (especially sodium borohydride) per mole of compound of formula (Ib).

The reaction conditions, particularly the reaction temperature and time, will vary depending upon a number of factors, especially the natures of the starting material, solvent and reducing agent. However, the reaction is normally carried out at a temperature of from 0° to 100° C. for a period of from 1 to about 20 hours.

Step (d)

Optionally, compounds of formula (I) in which W represents a group of formula >CH—OR° (in which R° represents any one of the groups defined for R° but 5 not the hydrogen atom), that is to say compounds of formula (Ie):

(in which R^1 - R^5 , R^6 , n. Y and Z are as defined above) may be prepared by acylating the corresponding compound of formula (Id), prepared as described in step (c). 20

The acylating agent is preferably an acid halide or acid anhydride, the parent acid of which will depend upon the acyl group R6 which is desired to be introduced into the compound.

The acylation reaction is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect upon the reaction. Examples of suitable solvents include: ethers, such as diethyl ether, tetrahydrofuran or dioxane; aromatic hydrocarbons, such as benzene, toluene or xylene; aliphatic hydrocarbons, such as hexane, cyclohexane or heptane; halogenated hydrocarbons, such as methylene chloride or chloroform; organic bases, such as pyridine or triethylamine; amides, such as dimethylformamide or dimethylacetamide; sulfoxides, such as dimethyl sulfoxide; and sulfones, such as sulfolane.

The ratio of the amount of compound of formula (Id) to the acylating agent is not particularly critical and we therefore prefer to employ a slight molar excess of acylating agent over compound (Id). In general, from 1 to 2 moles of acylating agent are employed per mole of 40 compound of formula (Id).

The reaction conditions, particularly reaction temperature and time, will vary depending upon a number of factors, especially the natures of the starting material, acylating agent and solvent, but we normally prefer to carry out the reaction at a temperature of from 0° to 100° C. for a period of from several minutes to about 20 hours.

Step (e)

The compounds of the invention, prepared as described in any of the above steps may be converted to their salts by conventional means, for example by reaction with a basic compound of an alkali metal (such as sodium or potassium), an alkaline earth metal (such as calcium) or a trivalent metal (such as aluminum). Preferred such compounds are sodium hydroxide, potassium hydroxide, sodium ethoxide and potassium t-butoxide.

It will be appreciated that the compounds produced 60 in all of the above steps can exist in various tautomeric forms, as illustrated in relation to compounds (IV), (V) and (VI).

The compounds prepared as described in any of the above steps may be separated after that step and, if 65 desired, purified by conventional means. Suitable isolation and purification steps include concentration of the reaction mixture by evaporating off the solvent under

reduced pressure, extraction with a suitable solvent, recrystallization, transfer into another solvent, chromatography and optical resolution. However, where two or more of the above steps are to be carried out, they may, if desired, be carried out without intermediate isolation or purification.

PREPARATION OF STARTING MATERIALS

The α-halocarboxylic acid derivatives of formula (II), which are the principal starting materials for preparing the compounds of the invention, are novel compounds and may be prepared by Methods A and B described below.

Method A

Compounds of formula (II) in which W represents a —CH₂— group may be prepared by the sequence of reactions illustrated in the following reaction scheme:

$$\begin{array}{c} R^4 \\ \\ HO \\ \\ R^2 \end{array}$$

(VIII)

(XI)

 R^4 R^5 O $(CH_2)_{\pi}OH$ (A2) (IX)

$$R^{7}O$$
 R^{1}
 $R^{7}O$
 R^{2}
 R^{3}
 R^{3}
 R^{3}
 R^{4}
 R^{5}
 R^{5}
 R^{5}
 $R^{7}O$
 R^{1}
 R^{2}
 R^{3}
 R^{3}
 R^{3}
 R^{3}
 R^{5}
 $R^{7}O$
 R^{1}
 R^{2}
 R^{3}
 R^{3}

$$R^4$$
 R^5
 CH_2
 R^3
 R^3

In the above formulae, R^1-R^5 , n, A and X are as defined above, p=(n-1); and R^7 represents a hydroxy-protecting group.

Step (A1)

The chroman carboxylic acid homologs (VIII), which are the starting materials for this Method, may be prepared as described, for example, in the Journal of the 5 American Oil Chemical Society, 51, 200 (1974).

These acids (VIII) are reduced with a reducing agent, such as lithium aluminum hydride or Vitride [sodium bis(2-methoxyethoxy)aluminum hydride], to give the corresponding chroman alcohol homolog (IX). This 10 reaction is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it does not interfere with the reaction. Suitable solvents include: ethers, such as diethyl ether, tetrahydrofuran or ethylene glycol dimethyl ether; aromatic hydrocarbons, such as benzene, toluene or xylene; and aliphatic hydrocarbons, such as hexane, heptane, cyclohexane, petroleum ether, ligroin or ethylcyclohexane.

The ratio of the amount of acid (VIII) to reducing agent is not particularly critical, but we generally prefer to use a slight molar excess of reducing agent. Preferably the amount of reducing agent is from 1 to 2 moles per mole of acid (VIII). The reaction conditions, particularly the reaction temperature and time, will vary depending upon a number of factors, such as the nature of the starting material, the reducing agent and the solvent, but the reaction is generally carried out at a temperature of from 10° to 100° C. for a period of from 10 minutes to 20 hours.

Alternatively, the chroman alcohol homolog (IX) 30 may be prepared by reacting a hydroquinone with a compound of formula (XII):

$$R^{1}$$
 (XII)

(in which n and R! are as defined above), e.g. a compound of formula (XIIa):

$$HO-CH_2-CH=C$$
 CH_2-OH
 $(XIIa)$

in the presence of aluminum chloride, as described in West German Pat. No. 3,010,504.

Step (A2)

The chroman alcohol homologs of formula (IX) obtained in step (A1) may be converted to the corresponding nitrophenoxyalkyl chroman compounds (X). However, before carrying out this reaction, we prefer that the phenolic hydroxy group should be protected by a 55 hydroxy-protecting group R⁷.

The nature of the hydroxy-protecting group is not critical and any such group commonly used in this type of reaction and compound may be employed. Suitable groups include: alkoxyalkyl groups, such as the methox-60 ymethyl group; aralkyl groups, such as the benzyl group; the 2-tetrahydropyranyl group; and acyl groups, such as the acetyl or benzoyl groups. The alkoxyalkyl groups are preferred. The reaction is normally effected by contacting a compound R⁷X (in which R⁷ is as defined above and X represents a halogen atom, preferably a chlorine atom), such as chloromethyl methyl ether or benzyl chloride, with the compound of formula (IX)

in the presence of a base such as an alkali metal or alkaline earth metal hydride (e.g. sodium hydride or calcium hydride) or an alkali metal alkoxide (e.g. sodium methoxide, sodium ethoxide or potassium t-butoxide). The reaction is normally carried out in the presence of a solvent, for example; an ether, such as diethyl ether, tetrahydrofuran or dioxane; an aromatic hydrocarbon, such as benzene, toluene or xylene; an aliphatic hydrocarbon, such as hexane or heptane; an amide, such as dimethylformamide or dimethylacetamide; a sulfoxide. such as dimethyl sulfoxide; or a sulfone, such as sulfolane. There is no particular limitation on the molar ratio of compound (IX) to the compound R7X, but we generally prefer to use a slight molar excess of the compound (IX), in order to reduce the risk of protecting the hydroxy group in the side chain at the 2-position. In general, we prefer to employ from 0.8 to 1 mole of the compound R7X per mole of the compound (IX). The reaction conditions, particularly the reaction temperature and time, may vary depending upon a number of factors, especially the nature of the starting material, the compound R⁷X and the solvent, but we normally prefer a reaction temperature of from 0° to 50° C, and a time of from several minutes to several tens of minutes.

The protected chroman alcohol produced by this reaction can, if desired, be isolated and purified, but it may be, and preferably is, converted to the nitrophenoxyalkylchroman compound of formula (X) without intermediate isolation.

Conversion to the compound of formula (X) is effected by reacting the protected compound (IX) with a 4-halonitrobenzene in the presence of a base, such as sodium hydride, in a solvent, such as dimethyl sulfoxide or dimethylformamide. The amount of 4-halonitrobenzene employed is preferably about 2 moles per mole of protected compound (IX). The reaction temperature is preferably from 30° to 100° C, and the time required for the reaction is usually from several minutes to several hours.

Step (A3)

The nitro compound of formula (X) thus obtained is reduced in this step to the corresponding amino compound of formula (XI). In the course of or before or after this reduction, the protecting group R⁷ may be allowed to remain as it is, removed or converted to another group' (particularly an acryl group, such as an acetyl or benzoyl group).

When deprotection of the compound (X) is desired. this can easily be achieved by reacting the compound (X) with a dilute aqueous acid (such as hydrochloric acid, sulfuric acid or nitric acid) to hydrolyse the protecting group. The reaction is normally carried out in the presence of a solvent, for example: an alcohol, such as methanol, ethanol or propanol; an ether, such as tetrahydrofuran or dioxane; a ketone, such as acetone or methyl ethyl ketone; an organic acid, such as acetic acid or propionic acid; dimethyl sulfoxide; dimethylformamide; or water. Of these, water or an organic acid is preferred. The amount of acid used for hydrolysis is preferably from 0.01 to 5 moles, more preferably from 0.01 to I mole, per mole of the compound (X). We prefer to carry out the reaction in the presence of a large molar excess of water or of acetic acid as the solvent. The reaction temperature is preferably from ambient temperature to 100° C. and the time required for the reaction is normally from several minutes to about 20 hours.

If it is desired to convert the protecting group R7 to another group, particularly an acyl group, this may be achieved by acylation of the deprotected compound obtained as described above. The acylating agent may be an acid halide, such as acetyl chloride or benzoyl 5 chloride, or an acid anhydride, such as acetic anhydride. This reaction is preferably carried out in the presence of an organic amine (such as pyridine or triethylamine) or in the presence of an inorganic base (for example an alkali metal hydroxide, such as sodium hy- 10 droxide or potassium hydroxide, or an alkali metal carbonate or bicarbonate, such as sodium carbonate, potassium carbonate or sodium bicarbonate). The acylating reaction is preferably carried out in the presence of a solvent, for example: an aliphatic hydrocarbon, such as 15 hexane, cyclohexane, heptane, ligroin or ethylcyclohexane; an aromatic hydrocarbon, such as benzene, toluene or xylene; an organic amine, such as pyridine or triethylamine; a ketone, such as acetone or methyl ethyl ketone; an amide, such as dimethylformamide; a sulfoxide, 20 such as dimethyl sulfoxide; or water. The ratio of the amount of deprotected compound (X) to acylating agent is not particularly critical, however, a slight molar excess of acylating agent is usually preferred, for example from 1 to 1.5 moles of acylating agent per mole 25 of deprotected compound (X). Where an organic amine is employed as the acid-binding agent, it may be employed in any amount from 1 mole to a large molar excess per mole of the compound of formula (X). Where an inorganic base is employed as the acid-bind- 30 ing agent, it is preferably employed in an amount of from 1 to 10 moles per mole of the compound of formula (X). The reaction conditions, particularly the reaction temperature and time, may vary depending upon a number of factors, particularly the natures of the start- 35 ing material and solvent employed, but the reaction is preferably effected at a temperature of from 0° to 100° C. for a period of from several minutes to 20 hours.

The nitro compound of formula (X) (which may optionally have been subjected to any of the processes 40 described above) is then reduced to the amino compound of formula (XI). The reduction may be a catalytic reduction process employing hydrogen or reduction with a metal (such as zinc or iron) and an acid (which may be a mineral acid such as hydrochloric acid 45 or sulfuric acid or an organic acid such as acetic acid). Preferably a catalytic reduction process is employed. The catalyst employed for this catalytic reduction is preferably palladium-on-carbon, Raney nickel or platinum oxide, of which palladium-on-carbon is particu- 50 which W represents a >C=O group, that is comlarly preferred. The hydrogen pressure is preferably from 1 to 100 atmospheres (1.01 to 101 bars), more preferably from 1 to 6 atmospheres (1.01 to 6.06 bars). The reaction is preferably effected in the presence of a solvent, the nature of which is not critical, provided 55 that it has no adverse effect upon the reaction. Suitable solvents include: alcohols, such as methanol or ethanol; aromatic hydrocarbons, such as benzene or toluene; ethers, such as tetrahydrofuran; organic acids, such as acetic acid; water; or mixtures of any two or more 60 thereof. The reaction conditions, particularly the reaction temperature and time, may vary depending upon a number of factors, particularly the nature of the starting material, the method employed for reduction and the solvent, but the reaction is normally effected at a tem- 65 perature from ambient to 50° C. and the period required for the reaction is generally from several minutes to about 20 hours.

Step (A4)

The 2-(4-aminophenoxyalkyl)chroman derivative of formula (XI), prepared as described in step (A3) above, is diazotized and then subjected to a Meerwein arylation, to give the desired a-halocarboxylic acid compound of formula (IIa). The two reactions are preferably effected sequentially in the same reaction system and under essentially the same conditions.

The diazotization reaction comprises reacting the amino compound of formula (IX) with a nitrite (such as sodium nitrite) in the presence of an acid, such as hydrochloric acid or hydrobromic acid.

The Meerwein arylation reaction comprises reacting the resulting diazonium compound with acrylic acid, an acrylic acid ester (such as methyl acrylate or ethyl acrylate) or another acrylic acid derivative (such as acrylonitrile or acrylamide) in the presence of a catalytic amount of a cuprous compound (which may be a salt. such as cuprous chloride, or another cuprous compound such as cuprous oxide). The acrylic acid esters are preferred and the preferred cuprous compound is

The reactions are preferably effected in the presence of a solvent, the nature of which is not critical, provided that it does not interfere with the reactions. Suitable solvents include: alcohols, such as methanol or ethanol; ketones, such as acetone or methyl ethyl ketone; water: or a mixture of any two or more thereof. The molar ratio of the amino compound of formula (XI) to the acrylic acid or derivative thereof is preferably from 1:1 to 1:15, more preferably from 1:5 to 1:10. The molar ratio of the amino compound (XI) to the cuprous compound is preferably from 1:0.01 to 1:1, more preferably from 1:0.03 to 1:0.3. The reaction conditions, particularly the reaction temperature and time, may vary depending upon a number of factors, especially the natures of the starting materials and the solvent employed. but the reaction is normally carried out at a temperature from ambient temperature to 100° C., preferably from 30° to 60° C., and the period required for the reaction is normally from about 20 minutes to about 20 hours, more preferably from 30 minutes to 2 hours.

Method B

α-Halocarboxylic acid derivatives of formula (II) in pounds of formula (IIb), may be prepared as illustrated in the following reaction scheme:

$$\begin{array}{c|c}
R^{3} & O & R^{1} \\
R^{3}O & R^{2} & O & (CH_{2})_{n} - O & NH_{2} & (B3)
\end{array}$$

$$R^{3}$$
 R^{3}
 R^{3

In the above formulae, R^1-R^5 , n, A and X are as defined above. The reaction sequence comprises the following steps:

Step (B1)

The acetophenone derivative of formula (XIII) 30 which is one of the starting materials for this step may be prepared, for example, as described in Chem. Berichte, 95, 1413. The other starting materials, the pnitrophenoxyalkyl alkyl ketones of formula (XIV), may be prepared, for example, as described in J. Med. Chem., 21, 386 (1978) and J. Am. Chem. Soc., 99, 7653 (1977).

In this step, the compounds (XIII) or (XIV) are reacted together in the presence of a secondary amine, as described, for example, in Japanese Patent Application Kokai No. 19670/77.

The reaction is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect upon the reaction. Suitable solvents include: aliphatic and aromatic hydrocarbons, such as petroleum ether, benzene, toluene, xylene, hexane and cyclohexane; halogenated aliphatic and aromatic hydrocarbons, such as carbon tetrachloride, methylene chloride, chloroform, chlorobenzene and dichlorobenzene; ethers, such as diethyl ether, tetrahydrofuran and dioxane; amides, such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone; alcohols, such as methanol, ethanol and ethylene glycol monomethyl ether; esters, such as ethyl acetate; nitriles, such as acetonitrile; and sulfoxides, such as dimethyl sulfoxide.

The secondary amine employed in this reaction is preferably a compound of formula R^9 —NH— R^{10} , in which R^9 and R^{10} may be the same or different and each represents an alkyl group or R^9 and R^{10} , together with the nitrogen atom to which they are attached, represent 60 a nitrogen-containing heterocyclic ring system. Examples of such secondary amines include diethylamine, dimethylamine, N-methylpiperazine, pyrrolidine, piperidine or morpholine, of which pyrrolidine is particularly preferred.

The molar ratio of the compound of formula (XIII) to the compound of formula (XIV) is not particularly critical, but, to avoid waste, roughly equimolar amounts of the two compounds are used. In general, the amount of secondary amine is preferably from 0.05 to 1.5 moles, more preferably from 0.1 to 1 mole, per mole of the compound of formula (XIII) or (XIV).

The reaction conditions, particularly reaction temperature and time, may vary depending upon a number of factors, especially the nature of the starting materials and of the solvent, but, in general, we prefer to carry out the reaction at a temperature of from -30° C, to +150° C, more preferably from 10° to 120° C, for a period of from 30 minutes to 3 days.

Step (B2)

In this step, the nitro compound of formula (XV) prepared as in step (B1) is reduced to the corresponding amino compound of formula (XVI). This reaction is precisely the same as step (A3) of Method A, employing the same reaction conditions and reagents.

Step (B3)

In this step, the amino compound of formula (XVI), obtained as described in step (B2), is diazotized and then subjected to a Meerwein arylation, to give the desired α-halocarboxylic acid derivative of formula (IIb). These reactions are precisely the same as those described in step (A4) of Method A and may be carried out employing the same reagents and reaction conditions.

If desired, the corresponding α -halocarboxylic acid derivative of formula (II) in which W represents a >CH—OH or >CH—OR6 group may be prepared following essentially the same procedures as described in steps (c) and (d) of the process of the present invention; it is, however, much preferred that, instead, the compound of formula (IIb) should be employed as the starting material in the process of the invention and that steps (c) and optionally (d) should be carried out, if desired, as part of the process of the invention.

The compounds of formulae (IIa) and (IIb) prepared as described above in Methods (A) and (B) can, if desired, be converted to various of their hydrolysis products or may be transesterified or converted to salts, for example such metal salts as the sodium, potassium, calcium or aluminum salts. Alternatively, they can be converted from metal salts or from compounds having free hydroxyphenyl groups or free carboxy groups to derivatives thereof, for example as follows:

Compounds in which R3 represents a hydrogen atom and A represents a carboxy group can be prepared by hydrolysis of the corresponding compound of formula (II) in which, for example, R3 represents an acyl group and A represents an alkoxycarbonyl group. This reaction is preferably effected in the presence of a base, for example: an inorganic base, such as an alkali metal carbonate (e.g. sodium carbonate or potassium carbonate) of an alkali metal hydroxide (e.g. sodium hydroxide or potassium hydroxide); or an organic base, such as an alkali metal alkoxide (e.g. sodium methoxide, sodium ethoxide or potassium t-butoxide). The reaction is preferably effected in the presence of a solvent, the nature of which is not critical, provided that it has no adverse effect upon the reaction. Suitable solvents include: lower alcohols, such as methanol or ethanol; ethers, 65 such as tetrahydrofuran or dioxane; water; or mixtures of any two or more thereof.

The molar ratio of the compound of formula (II) to the base is preferably from 1:1 to 1:5, more preferably

from 1:2 to 1:3. Although the reaction conditions, particularly the reaction temperature and time, may vary depending upon a number of factors, particularly the natures of the starting material, base and solvent employed, the reaction is generally carried out at a temperature of from -10° C. to $+30^{\circ}$ C., more preferably from 0° to 10° C, and the reaction time is generally from several minutes to several tens of hours.

The compound of formula (II) in which R³ represents a hydrogen atom and A represents an alkoxycarbonyl 10 group can be prepared by solvolysis of the corresponding compound in which R3 represents an acyl group and A represents an alkoxycarbonyl group. This is carried out in the presence of a base, preferably an alkali metal alkoxide, such as sodium methoxide, sodium ethoxide or 15 potassium t-butoxide. The reaction is preferably effected in the presence of a solvent, for example: an alcohol, such as methanol, ethanol, propanol, isopropanol or t-butanol; an ether, such as tetrahydrofuran or dioxane; or a mixture of any two or more thereof. If the 20 alkoxycarbonyl group represented by A in the starting material is to be kept intact, it is preferred that the alkali metal alkoxide should be the alkoxide corresponding to this alkoxycarbonyl group and that the solvent should be an alcohol, which likewise corresponds to the alk- 25 oxycarbonyl group. However, the alkoxycarbonyl group in the starting material may, if desired, be converted into any other alkoxycarbonyl group by suitable choice of the alkali metal alkoxide and the alcohol sol-

The molar ratio of the compound of formula (II) to the base is preferably from 1:1 to 1:3, more preferably from 1:1 to 1:2. The reaction conditions, especially the reaction temperature and reaction time, may vary, depending upon a number of factors, particularly the na- 35 tures of the starting materials, bases and solvents employed, but the reaction is preferably carried out at a temperature of from -10° C. to $+30^{\circ}$ C., more preferably from 0° to 10° C., for a period of from several minutes to several tens of hours.

Compounds of formula (II) in which R3 represents an acyl group and A represents a carboxy group may be prepared by hydrolysis of the corresponding compound of formula (II) in which R3 represents an acyl group and A represents an alkoxycarbonyl group. In this case, the 45 14. hydrolysis is effected in the presence of an inorganic base (for example an alkali metal carbonate, such as sodium carbonate or potassium carbonate, or an alkali metal hydroxide, such as sodium hydroxide or potassium hydroxide) or in the presence of another base such 50 as an alkali metal alkoxide (for example sodium methoxide, sodium ethoxide or potassium t-butoxide). This reaction is preferably effected in the presence of a solvent, for example: a lower alcohol, such as methanol or ethanol; an ether, such as tetrahydrofuran or dioxane; 55 water; or a mixture of any two or more thereof. The molar ratio of the compound of formula (II) to the base is preferably from 1:1 to 1:5, more preferably from 1:1 to 1:2. The reaction conditions, particularly the reaction ber of factors, especially the natures of the starting materials, bases and solvents employed, but the reaction is normally effected at a temperature of from -10° C. to +30° C., more preferably from 0° to 10° C. for a period of from several minutes to several tens of hours.

In the a-halocarboxylic acid compounds of formula II), the carbon atom at the 2-position of the chroman ring and that carbon atom to which the group A and the atom X are both attached are both asymmetric and accordingly give rise to stereoisomers, all of which are represented herein by a single formula. However, of course, the isomers may, if desired, be separated by conventional means and the present invention envisages the use of both individual isomers and mixtures thereof.

The a-halocarboxylic acid compounds of formula (II) have also been observed to lower the level of blood lipid peroxides and, in addition, have the effect of lowering blood triglycerides and blood cholesterol. They can therefore be expected to be useful as antihyperlipemic agents.

Of the compounds of formula (II) which exhibit the therapeutic effects mentioned above and which also form part of the present invention, preferred compounds are those listed below:

- 2-chloro-3-[4-(6-hydroxy-2.5,7.8-tetramethylchroman-2-ylmethoxy)phenyl]propionic acid
- 3-[4-(6-acetoxy-2,5.7.8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionic acid
- 3. Ethyl 2-chloro-3-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]propionate
- 4. Ethyl 3-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2ylmethoxy)phenyl]-2-chloropropionate
- Ethyl 3-[4-(6-benzoylozy-2.5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate
- 6. 3-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylmethoxy)phenyl]-2-chloropropionic acid
- 7. Ethyl 3-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2ylmethoxy)phenyl]-2-chloropropionate
- 8. Ethyl 3-[4-(6-acetoxy-7-t-butyl-2-methylchroman-2ylmethoxy)phenyl]-2-chloropropionate
- 2-chloro-3-[4-(6-hydroxy-2-methylchroman-2-ylmethoxy)phenyl]propionic acid
- Ethyl 3-[4-(6-acetoxy-2-methylchroman-2-ylmethoxy)phenyl]-2-chloropropionate
- 2-chloro-3-[4-(6-hydroxy-7,8-dimethoxy-2.5-dimethylchroman-2-ylmethoxy)phenyl]propionic acid
- 3-{4-[2-(6-acetoxy-7.8-dimethoxy-5-methylchroman-2-yl)ethoxy]phenyl}-2-chloropropionic acid
- 13. Ethyl 2-bromo-3-[4-(2-ethyl-6-hydroxy-7,8-dimethoxy-5-methylchroman-2-ylmethoxy)phenyl]pro-
- 2-chloro-3-[4-(6-hydroxy-2,7-dimethylchroman-2ylmethoxy)phenyl]propionic acid
- 15. Ethyl 2-chloro-3-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)phenyl]propionate
- 16. Ethyl 3-[4-(6-acetoxy-2,7-dimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate
- Ammonium 2-chloro-3-{4-{2-(2-ethyl-6-hydroxy-5.7-diisopropylchroman-2-yl)ethoxy]phenyl}propionate
- 18. 3-{4-[6-(3.5-di-t-butyl-4-hydroxybenzoyloxy)-5.7diisopropyl-2-methylchroman-2-ylmethoxy]phenyl}-2-chloropropionic acid
- 19. Sodium 2-chloro-3-{4-[3-(8-ethyl-5,7-diisopentyl-6p-methylbenzoyloxy-2-propylchroman-2-yl)propoxy]phenyl}propionate
- temperature and time, may vary depending upon a num- 60 20. Potassium 2-chloro-3-{4-[2-(5,7-dibutyl-6-cyclohexanecarbonyloxy-2-isopropyl-8-propylchroman-2yl)ethoxy]phenyl}propionate
 - 21. Aluminum tris{3-[4-(2-butyl-6-2'-furoyloxy-7-isopentyl-5.8-dimethylchroman-2-ylmethoxy)phenyl]-2chloropropionate}
 - 2-chloro-3-{4-[2-(2-isopentyl-5,7-dimethyl-6phenylacetoxychroman-2-yl)ethoxy]phenyl}propionamide

10

35

23. Ethyl 3-[4-(6-acetoxy-2-ethyl-5.7,8-trimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate

Ethyl 3-[4-(6-acetoxy-2-isobutyl-5,7,8-trimethyl-chroman-2-ylmethoxy)phenyl]-2-chloropropionate
 2-chloro-3-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxo-chroman-2-ylmethoxy)phenyl]propionic acid

- 26. 3-[4-(6-acetoxy-2.5.7.3-tetramethyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionic acid
- 27. Ethyl 2-chloro-3-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)phenyl]propionate
- 28. Ethyl 3-[4-(6-acetoxy-2.5.7,8-tetramethyl-4-oxo-chroman-2-ylmethoxy)phenyl]-2-chloropropionate
- Ethyl 3-[4-(6-benzoyloxy-2.5.7.8-tetramethyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate
 3-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-15]
- 2-ylmethoxy)phenyl]-2-chloropropionic acid 31. Ethyl 3-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxo-
- chroman-2-ylmethoxy)phenyl]-2-chloropropionate
 32. Ethyl 3-[4-(6-acetoxy-7-t-butyl-2-methyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate
- 2-chloro-3-[4-(6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)phenyl]propionic acid
- Ethyl 3-[4-(6-acetoxy-2-methyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate
- 2-chloro-3-[4-(6-hydroxy-7,8-dimethoxy-2,5-25 dimethyl-4-oxochroman-2-ylmethoxy)phenyl]propionic acid
- 3-{4-[2-(6-acetoxy-7,8-dimethoxy-5-methyl-1-oxochroman-2-yl)ethoxy]phenyl}-2-chloropropionic acid
- Ethyl 2-bromo-3-[4-(2-ethyl-6-hydroxy-7.8-dimethoxy-5-methyl-4-oxochroman-2-ylmethoxy)phenyl]propionate
- 2-chloro-3-[4-(6-hydroxy-2,7-dimethyl-4-oxochroman-2-ylmethoxy)phenyl]propionic acid
- Ethyl 2-chloro-3-[4-(6-hydroxy-2,7-dimethyl-1-oxochroman-2-ylmethoxy)phenyl]propionate
- 40. Ethyl 3-[4-(6-acetoxy-2,7-dimethyl-1-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate
- 41. Ammonium 2-chloro-3-{4-[2-(2-ethyl-6-hydroxy- 40 5,7-diisopropyl-4-oxochroman-2-yl)ethoxy]phenyl} propionate
- 42. 2-chloro-3-{4-[6-(3.5-di-t-butyl-4-hydroxyben-zoyloxy)-5.7-diisopropyl-2-methyl-4-oxochroman-2-ylmethoxy]phenyl}propionic acid
- Sodium 2-chloro-3-{4-[3-(8-ethyl-5,7-diisopentyl-6p-methylbenzoyloxy-4-oxo-2-propylchroman-2yl)propoxy]phenyl}propionate
- 44. Potassium 2-chloro-3-{4-[2-(5,7-dibutyl-6-cyclohex-anecarbonyloxy-2-isopropyl-4-oxo-8-propylchroman-2-yl)ethoxy]phenyl}propionate
- 45. Aluminum tris{3-[4-(2-butyl-6-2'-furoyloxy-7-iso-pentyl-5,8-dimethyl-4-oxochroman-2-ylmethoxy)-phenyl]-2-chloropropionate}
- 46. 2-chloro-3-{4-[2-(2-isopentyl-5,7-dimethyl-4-oxo-6-55 phenylacetoxychroman-2-yl)ethoxy]phenyl}propionamide
- 47. 2-chloro-3-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethyl-4-oxochroman-2-ylmethoxy)phenyl]propionic acid
 The compounds of the invention have been shown to 60 have a very strong ability to lower the level of lipid peroxides, as demonstrated by the test against rat liver microsomal lipid peroxidation described in Biochem. Biophys. Res. Commun., 95, 734 (1980). In addition, in experiments using alloxan-induced hyperlipaemic mice, 65 the compounds have demonstrated the ability to lower blood lipid peroxide, triglyceride and cholesterol levels.

Moreover, the compounds of the invention are less

toxic than many known compounds to experimental animals such as rats, as assessed by tests in which the appetite, body weight and hepatic enlargement are checked.

Accordingly, it is considered that the compounds of the present invention will be useful for the therapeutic treatment of human hyperlipaemia, diabetes and complications thereof, especially diabetes mellitus. The compounds of the invention may be administered orally, for example in the form of tablets, capsules, powders or granules, or parenterally, for example by injection or in the form of a suppository. The recommended dosage will, of course, vary depending upon the age and body weight of the patient as well as the nature and severity of the disease. However, for an adult human patient, a daily dose of from 50 mg to 5 g (which may be administered in a single dose or in divided doses) is recommended in the treatment of hyperlipaemia, diabetes mellitus and complications thereof.

The following Examples illustrate the preparation of various of the compounds of the present invention, whilst the subsequent Test Examples illustrate the valuable biological properties of these compounds. Preparation of various of the starting materials employed in the Examples is illustrated in the subsequent Preparations.

In the nuclear magnetic resonance spectra reported in the Examples and Preparations, the abbreviation "D" means that the signal disappeared upon the addition of heavy water (D₂O), and the abbreviation "nd" means that precise identification of the signal was not possible because of overlap by other signals or the absorption of the solvent.

EXAMPLE 1

(a)

5-[4-(6-Hydroxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

A mixture of 9.6 g of ethyl 3-[4-(6-acetoxy-2,5.7,8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chioropropionate, 1.8 g of thiourea and 11 ml of sulfolane was reacted for 80 minutes under a nitrogen stream at 115°-120° C. Subsequently, a mixture of 90 ml of acetic acid. 30 ml of concentrated hydrochloric acid and 15 ml of water was added to this, and the resulting mixture was further heated for 12 hours at 85°-90° C. 27 g of sodium bicarbonate were added to this reaction mixture, and, once evolution of carbon dioxide had ceased. the solvent was distilled off. A 10:1 by volume mixture of benzene and ethyl acetate was added to the residue, and the crude product was washed with a mixture of equal volumes of a saturated aqueous solution of sodium bicarbonate and water. The white powder produced was removed by filtration and washed again with water. It was then recrystallized from acetone to give 2.2 g of 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one, 205°-207° C.

Nuclear Magnetic Resonance Spectrum (heptadeuterated dimethylformamide + D₂O) δ ppm: 1.37 (3H. singlet); about 2 (2H, multiplet); 2.02 (3H. singlet); 2.14 (6H. singlet); 2.3–3.1 (solvent absorption); 3.42 (1H. doublet of doublets, J=15 & 4.5 Hz); 4.60 (1H. doublet of doublets, J=9 & 4.5 Hz); 6.93 (2H. doublet, J=9 Hz); 7.23 (2H. doublet, J=9 Hz).

(b)

5-[4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

The organic solution produced by removing the 5 white powder in step (a) above was washed with water and dried over anhydrous sodium sulfate. The solvent was then distilled off. The resulting crude product was purified by column chromatography through silica gel eluted with a mixture of benzene and ethyl acetate first 10 in a volume ratio of 10:1 and then in a volume ratio of 10:1.4. 3.4 g of the desired 5-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, melting at 184*-186* C., were obtained from the fractions eluted with the latter mixture.

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone) δ ppm: 1.39 (3H. singlet); about 2 (2H. multiplet); 2.02 (3H. singlet); 2.09 (3H. singlet); 2.13 (3H. singlet); 2.63 (2H. broad triplet, J=6 Hz); 3.07 (1H. doublet of doublets, J=15 & 9 Hz); 3.41 (1H. doublet of doublets, J=15 & 4.5 Hz); 3.97 (2H. AB Type, J=9 Hz); 4.70 (1H. doublet of doublets, J=9 & 4.5 Hz); 6.90 (2H. doublet, J=9 Hz); 7.21 (2H. doublet, J=9 Hz).

EXAMPLE 2

5-[4-(6-Hydroxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

3.1 g of 5-[4-(6-hydroxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one [prepared as described in Example 1(a)] were added to a mixture of 45 ml of acetic acid. 15 ml of concentrated hydrochloric acid and 8 ml of water, and the mixture was reacted for 12 hours at 85°-90° C. It was then processed and purified in a similar manner to Example 1(a), giving 2.5 g of 5-[4-(6-hydroxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione. whose melting point and nuclear magnetic resonance spectrum were consistent with those of the product of Example 1(b).

EXAMPLE 3

(a) Benzene mono adduct of 5-[4-(6-acetoxy-2.5,7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

0.725 g of 5-[4-(6-hydroxy-2,5,7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione was dissolved in 4 ml of benzene; 400 mg of dry pyridine were added; 0.2 g of acetic anhydride was added dropwise under a nitrogen stream at 5°-10° C.; and the mixture was reacted for 2 days at room temperature. The resulting white crystals were separated by filtration, washed with benzene and vacuum-dried for 30 minutes at 90° C., giving 0.74 g of the benzene mono adduct of 55 5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione. This substance was liquefied at 98°-100° C., solidified and again liquefied at 176°-178° C.

Nuclear Magnetic Resonance Spectrum (CDCl₃) & 60 ppm: 1.42 (3H, singlet); 1.98 (3H, singlet); about 2 (2H, multiplet); 2.03 (3H, singlet); 2.09 (3H, singlet); 2.31 (3H, singlet); 2.63 (2H, broad triplet, J = 6 Hz); 3.03 (1H, doublet of doublets, J=15 & 9 Hz); 3.42 (1H, doublet of doublets, J=15 & 4.5 Hz); 3.84 and 3.98 (2H, AB Type, 65 J=9 Hz); 4.45 (1H, doublet of doublets, J=9 & 4.5 Hz); 6.87 (2H, doublet, J=9 Hz); 7.15 (2H, doublet, J=9 Hz); 7.38 (6H, singlet); 8-8.5 (1H, broad singlet).

Elemental Analysis: Calculated for C₂₆H₂₉NO₆S.C₆H₆: C, 68.45%, H, 6.28%, N, 2.50%, S, 5.70%. Found: C, 68.54%, H, 6.13%, N, 2.51%, S, 5.87%.

(b)

5-[4-(6-Acetoxy-2,5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione

In order that the desired free 5-[4-(6-acetoxy-2.5.7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione could be obtained. 730 mg of the benzene mono adduct obtained as described in step (a) above were dissolved in 5 ml of acetone; the solvent was distilled off; the residue was solidified by adding water; and the white amorphous powder produced was vacuum-dried in a dessicator in the presence of phosphorus pentoxide, to give 0.61 g of the title compound, softening at about 90° C.

Elemental Analysis: Calculated for C₂₆H₂₉NO₆S: C, 64.60%, H, 6.06%, N, 2.90%, S, 6.62%. Found: C, 64.34%, H, 6.15%, N, 2.84%, S, 6.55%.

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone) δ ppm: 1.41 (3H, singlet); 1.97 (3H, singlet); 1.98 (3H, singlet); about 2 (2H, nd); 2.04 (3H, singlet); 2.27 (3H, singlet); 2.67 (2H, broad triplet, J=6 Hz); 3.07 (1H, doublet of doublets, J=15 & 9 Hz); 3.42 (1H, doublet of doublets, J=15 & 4.5 Hz); 4.00 (2H, AB Type, J=9 Hz); 4.71 (1H, doublet of doublets, J=9 & 4.5 Hz); 6.91 (2H, doublet, J=9 Hz); 7.21 (2H, doublet, J=9 Hz).

EXAMPLE 4

5-[4-(6-Acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

The procedure described in Example 1(a) was repeated, except that 490 mg of ethyl 3-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate, 100 mg of thiourea and 2 ml of sulfolane were heated at 110°-120° C. for 5 hours. The product was then treated as described in Example 1(a), except that the crude product (in the form of crystals) was washed with ethyl acetate, to give the title compound, softening at 228°-236° C.

Mass spectrum (m/e): 468 (M+).

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide+CDCl₃) δ ppm: 1.92 (3H, singlet); 1.93 (3H, singlet); 2.02 (3H, singlet); 1.63-2.17 (2H, nd); 2.30 (3H, singlet); 2.57-3.97 (4H, nd); 4.0-4.37 (3H, nd); 4.53 (1H, doublet of doublets. J=9 & 4 Hz); 6.93 (2H, doublet, J=9 Hz); 7.19 (2H, doublet, J=9 Hz); 8.5-9.0 (2H, broad singlet, D).

EXAMPLE 5

(a)

5-[4-(6-Acetoxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

The reactions described in Example 1(a) were repeated, except that 1.5 g of ethyl 3-[4-(6-acetoxy-2.7-dimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate, 300 mg of thiourea and 2 ml of sulfolane were heated at 120° C. for 2 hours. The reaction mixture was then purified by adding diethyl ether to the reaction mixture, and distilling off the solvent to leave a residue. This residue was purified by column chromatography through silica gel eluted first with a 9:1 by volume mixture of benzene and ethyl acetate, to give the title compound.

Rf value: 0.41 (thin layer chromatography, silica gel, developing solvent: 4:1 by volume mixture of benzene and ethyl acetate).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 5 ppm: 1.42 (3H. singlet); 1.65-2.4 (2H. multiplet); 2.10 (3H. singlet); 2.28 (3H. singlet); 2.73 (2H. broad triplet, J=6 Hz); 3.0-3.6 (2H. multiplet); 3.93 (2H. AB Type, J=9 Hz); 4.50 (1H. doublet of doublets, J=9 & 4.5 Hz); 6.70 (1H. singlet); 6.73 (1H. singlet); 6.85 (2H. doublet, J=9 Hz); 7.15 (2H. doublet, J=9 Hz); 8.7-9.0 (1H. broad singlet, D).

(b)

5-[4-(6-Acetoxy-2.7-dimethylchroman-2-ylmethoxy)-benzyl]-2-iminothiazolidin-4-one

The silica gel chromatography column described in Example 5(a) was then eluted with a 1:4 by volume mixture of benzene and tetrahydrofuran, to give the title compound as a solid softening at 170°-175° C.

Rf value: 0.57 (thin layer chromatography, silica gel, developing solvent: 1:4 by volume mixture of benzene and tetrahyrofuran).

Mass spectrum (m/e): 454 (M $^{+}$).

Nuclear Magnetic Resonance Spectrum (heptadeuterated dimethylformamide) δ ppm: 1.39 (3H, singlet); 1.7-2.2 (2H, multiplet); 2.03 (3H, singlet); 2.27 (3H, singlet); 2.6-3.0 (3H, nd); 3.0-4.0 (1H, broad singlet, D); 3.42 (1H, doublet of doublets, J=15 & 4.5 Hz); 4.02 (2H, singlet); 4.53 (1H, doublet of doublets, J=9 & 4.5 Hz); 6.65 (1H, singlet); 6.79 (1H, singlet); 6.95 (2H, doublet, J=9 Hz); 7.21 (2H, doublet, J=9 Hz); 8.4-9.0 (1H, broad singlet, D).

EXAMPLE 6

5-{4-[2-(6-Acetoxy-7-t-butyl-2-methylchroman-2-yl)e-thoxy]benzyl}-2-iminothiazolidin-4-one

The procedure described in Example 1(a) was repeated, except that 266 mg of ethyl 3-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)ethoxy]phenyl}-2-chloropropionate, 50 mg of thiourea and 4 ml of sulfolane were heated at 110°-120° C. for 4.5 hours. The product was treated as described in Example 1(a) except that the crude product was purified by column chromatography through silica gel eluted with a 1:1 by volume 45 mixture of benzene and ethyl acetate, to give the title compound, melting at 175°-178° C.

Mass spectrum (m/e): $510 (M^+)$.

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) δ ppm: 1.24 (9H, singlet); 1.31 (3H, singlet); 1.82 (2H, broad triplet, J=7 Hz); 2.03 (2H, broad triplet, J=7 Hz); 2.25 (3H, singlet); 2.68 (2H, triplet, J=7 Hz); 2.87 (1H, doublet of doublets, J=14 & 9 Hz); 3.30 (1H, doublet of doublets, J=14 & 4 Hz); 4.13 (2H, triplet, J=7 Hz); 4.51 (1H, 55 doublet of doublets, J=9 & 4 Hz); 6.68 (1H, singlet); 6.75 (1H, singlet); 6.87 (2H, doublet, J=9 Hz); 7.15 (2H, doublet, J=9 Hz); 8.67 (1H, broad singlet, D); 8.88 (1H, broad singlet, D).

EXAMPLE 7

5-{4-[2-(6-Acetoxy-7,8-dimethoxy-2,5-dimethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one

The procedure described in Example 1(a) was repeated, except that 558 mg of ethyl 3-{4-[2-(6-acetoxy-657,8-dimethoxy-2,5-dimethylchroman-2-yl)ethoxy]-phenyl}-2-chloropropionate, 100 mg of thiourea and 12 ml of sulfolane were heated at 110°-115° C. for 3.5

34

hours. The product was subsequently treated as described in Example 1(a), except that the crude product, in the form of an oil, was purified by column chromatography through silica gel, eluted with a 20:1 by volume mixture of ethyl acetate and methanol, to give the title compound, softening at 103*-110* C.

Mass spectrum (m/e): 528 (M+).

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone) δ ppm: 1.39 (3H, singlet); 1.94 (3H, singlet); 1.8-2.15 (4H, nd); 2.23 (3H, singlet); 2.63 (2H, broad triplet, J=6 Hz); 2.83 (1H, doublet of doublets, J=15 & 9 Hz); 3.42 (1H, doublet of doublets, J=15 & 5 Hz); 3.77 (3H, singlet); 3.78 (3H, singlet); 4.21 (2H, broad triplet, J=6 Hz); 4.45 (1H, doublet of doublets, J=9 & 5 Hz); 6.87 (2H, doublet, J=9 Hz); 7.19 (2H, doublet, J=9 Hz); 7.7-8.2 (1H, broad singlet, D).

EXAMPLE 8

20 5-{4-[2-(6-Hydroxy-2.5,7,8-tetramethylchroman-2-yl)e-thoxy]benzyl}thiazolidine-2,4-dione

1.6 g of ethyl 3-{4-[2-(6-acetoxy-2.5.7,8-tetramethyl-chroman-2-yl)ethoxy]phenyl}-2-chloropropionate, 300 mg of thiourea and 2 ml of sulfolane were heated at 110°-115° C. for 3 hours under a nitrogen stream. A mixture of 4 ml of water, 2 ml of ethylene glycol monomethyl ether and 1 ml of concentrated hydrochloric acid was then added and the whole mixture was heated at 95°-97° C. for 4.5 hours. The mixture was then treated as described in Example 1(a), except that the crude product, in the form of an oil, was purified by column chromatography through silica gel, eluted with a 10:1 by volume mixture of benzene and ethyl acetate, 35 to give the title compound, melting at 152°-154° C.

Mass spectrum (m/e): 455 (M $^{\pm}$).

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone) δ ppm: 1.34 (3H, singlet); 1.87 (2H, broad triplet, J=7 Hz); 2.03 (3H, singlet); 2.07 (3H, singlet); 2.14 (3H, singlet); 2.0 (2H, nd); 2.64 (2H, broad triplet, J=7 Hz); 3.07 (1H, doublet of doublets, J=15 & 9 Hz); 3.41 (1H, doublet of doublets, J=15 & 4.5 Hz); 4.0–4.4 (3H, multiplet); 4.70 (1H, doublet of doublets, J=9 & 4.5 Hz); 6.95 (2H, doublet, J=9 Hz); 7.20 (2H, doublet, J=9 Hz).

EXAMPLE 9

(a)

5-{4-[2-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)e-thoxy]benzyl}thiazolidine-2,4-dione

The procedure described in Example 1(a) was repeated, except that 13.5 g of ethyl 2-chloro-3-{4-[2-(6hydroxy-2.5.7,8-tetramethylchroman-2-yl)ethoxy]phenyl}propionate, 4.4 g of thiourea and 20 ml of sulfolane were reacted for 14 hours at 110° C. The crude product was dissolved in ethyl acetate and the solution was washed with water and dried over anhydrous sodium sulfate. The solvent was then distilled off under reduced pressure and the resulting residue was purified by column chromatography through silica gel. This was first eluted with a 4:1 by volume mixture of benzene and ethyl acetate, and from these fractions were obtained the desired 5-{4-[2-(6-hydroxy-2.5.7.8-tetramethylchroman-2-yl)ethoxy[benzyl]thiazolidine-2.4-dione. whose melting point and nuclear magnetic resonance spectra agreed with those of the product of Example 8.

(b)

5-{4-[2-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)ethoxy|benzyl}-2-iminothiazolidin-1-one

The column described in Example 9(a) above was 5 then eluted with a 1:1 by volume mixture of benzene and tetrahydrofuran, and from the resulting fractions were obtained the desired 5-{4-[2-(6-hydroxy-2.5.7,8tetramethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-1-one, melting at 175°-180° C.

Mass spectrum (m/e): 454 (M-).

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) 8 ppm: 1.28 (3H. singlet); 1.6-2.2 (13H, nd); 2.2-3.2 (2H, nd); 2.80 (1H, doublet of doublets. J = 15 & 9 Hz; 3.1-3.5 (1H. nd); 15 3.9-4.3 (2H. multiplet); 5.5 (1H. doublet of doublets. J=9 & 4.5 Hz); 6.82 (2H. doublet, J=9 Hz); 7.15 (2H. doublet, J=9 Hz); 7.37 (1H. singlet, D); 8.67 (1H. broad singlet, D); 8.89 (1H, broad singlet, D).

EXAMPLE 10

5-[4-(6-Hydroxy-5.7.8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

290 mg of 5-[4-(6-acetoxy-5,7,8-trimethylchroman-2ylmethoxy)benzyl]-2-iminothiazolidin-4-one (prepared 25 as described in Example 4) were added to a mixture of 3 ml of concentrated hydrochloric acid, 1.5 ml of water and 5 ml of ethylene glycol monomethyl ether, and the mixture was heated under reflux for 3.5 hours. The reaction mixture was then processed and purified as 30 adeuterated dimethyl sulfoxide) δ ppm: 1.30 (9H, sindescribed in Example 1(a), and the crude product, in the form of an oil, was subjected to column chromatography through silica gel. The title compound, melting at 158°-159° C., was obtained from the fractions eluted with a 4:1 by volume mixture of benzene and ethyl 35 4.11 (2H, broad triplet, J=7 Hz); 4.85 (1H, doublet of acetate.

Mass spectrum (m/e): $427 (M \pm)$.

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) 8 ppm: 1.99 (3H. singlet); 2.04 (3H, singlet); 2.06 (3H, singlet); 1.5-2.25 (2H, 40 nd); 2.25-2.87 (2H, nd); 2.87-3.5 (2H, nd); 3.97-4.34 (3H, nd); 4.87 (1H, doublet of doublets, J=9 & 4 Hz); 6.98 (2H, doublet, J=9 Hz); 7.20 (2H, doublet, J=9Hz); 7.44 (1H, broad singlet, D); 11.3-12.3 (1H, broad singlet, D).

EXAMPLE II

5-[4-(6-Hydroxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

170 mg of 5-[4-(6-acetoxy-2,7-dimethylchroman-2-50 ylmethoxy)benzyl]-2-iminothiazolidin-4-one (prepared as described in Example 5) were added to a mixture of 0.2 ml of 2N hydrochloric acid and 2 ml of ethylene glycol monomethyl ether, and the mixture was reacted at 95°-97° C. for 6 hours. It was then processed and 55 purified as described in Example 1(a), except that the crude product, in the form of an oil, was subjected to column chromatography through silica gel, eluted with a 9:1 by volume mixture of benzene and ethyl acetate, to give the title compound.

Rf value: 0.36 (thin layer chromatography, silica gel, developing solvent: 4:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 413 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 65 ppm: 1.42 (3H, singlet); 1.78 (1H, doublet of doublets, J = 15 & 7 Hz); 2.07 (1H. doublet of doublets, J = 15 & 7Hz); 2.17 (3H, singlet); 2.68 (2H, broad triplet, J = 7 Hz);

3.06 (1H, doublet of doublets, J = 15 & 9 Hz); 3.46 (1H, doublet of doublets, J=15 & 4.5 Hz); 3.88 (2H, AB Type, J=9 Hz); 4. \longleftrightarrow .6 (2H, multiplet), changing after adding D2O to 4.47 (1H, doublet of doublets, J=9 & 4.5 Hz); 6.50 (1H, singlet); 6.62 (1H, singlet); 6.87 (2H, doublet, J=9 Hz); 7.15 (2H, doublet, J=9 Hz); 8.4-8.6 (1H, broad singlet, D).

EXAMPLE 12

5-{4-(2-(7-t-Butyl-6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

75 mg of 5-{4-{2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one (prepared as described in Example 6) were added to a mixture of 0.5 ml of concentrated hydrochloric acid, 2 ml of water and 2 ml of ethylene glycol monomethyl ether, and the mixture was heated under reflux for 4 hours. The mixture was then processed and purified by the 20 procedures described in Example 1(a), except that the crude product, in the form of an oil, was purified by column chromatography through silica gel. eluted with a 5:1 by volume mixture of benzene and ethyl acetate, to give the title compound.

Rf value: 0.21 (thin layer chromatography, silica gel. developing solvent: 5:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 469 (M^{-}).

Nuclear Magnetic Resonance Spectrum (hexglet); 1.32 (3H, singlet); 1.77 (2H, broad triplet, J=7Hz); 1.99 (2H. broad triplet, J=7 Hz); 2.60 (2H. broad triplet, J = 7 Hz); 3.03 (1H, doublet of doublets, J = 15 & 9 Hz); 3.29 (1H. doublet of doublets, J = 15 & 4.5 Hz); doublets, J=9 & 4.5 Hz); 6.48 (1H. singlet); 6.51 (1H. singlet); 6.89 (2H, doublet, J=9 Hz); 7.16 (2H, doublet, J=9 Hz); 8.63 (1H, broad singlet. D); 11.3-12.7 (1H, broad singlet, D).

EXAMPLE 13

5-{4-[2-(6-Hydroxy-7,8-dimethoxy-2.5-dimethylchroman-2-yl)ethoxy]-benzyl}thiazolidine-2.4-dione

560 mg of 5-{4-[2-(6-acetoxy-7,8-dimethoxy-2.5dimethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin-1-one (prepared as described in Example 7) were added to a mixture of 7 ml of concentrated hydrochloric acid, 2.5 ml of water and 10 ml of ethylene glycol monomethyl ether, and the mixture was heated under reflux for 13 hours. The reaction mixture was then processed and purified as described in Example 1(a), except that the crude product, in the form of an oil, was purified by column chromatography through silica gel eluted with a 9:1 by volume mixture of chloroform and ethyl acetate, to give the title compound.

Rf value: 0.15 (thin layer chromatography, silica gel. developing solvent: 9:1 by volume mixture of chloroform and ethyl acetate).

Mass spectrum (m/e): 487 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.39 (3H, singlet); 1.90 (2H, broad triplet, J=6Hz); 2.10 (3H, singlet); 2.15 (2H, broad triplet, J=6 Hz); 2.62 (2H, broad triplet, J=6 Hz); 3.09 (1H, doublet of doublets, J=15 & 9 Hz); 3.45 (1H. doublet of doublets. J = 15 & 5 Hz); 3.85 (3H, singlet); 3.95 (3H, singlet); 4.20 (2H, broad triplet, J=6 Hz); 4.49 (1H, doublet of doublets, J=9 & 5 Hz); 5.40 (1H, singlet, D); 6.87 (2H,

doublet, J=9 Hz); 7.16 (2H, doublet, J=9 Hz); 3.1-8.4 (1H, broad singlet, D).

EXAMPLE 14

5-{4-{2-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)e- 5 thoxy]benzyl}thiazolidine-2,4-dione

The reaction described in Example 13 was repeated, except that 5-{4-[2-(6-hydroxy-2.5.7,8-tetramethylchroman-2-yl)ethoxy]benzyl}-2-iminothiazolidin—one (prepared as described in Example 9) was used as the starting material. This was subsequently treated as described in Example 1(a) and then separated and purified as in Example 8, to give the title compound, whose melting point and mass and nuclear magnetic resonance spectra agreed with those of the product of Example 8.

EXAMPLES 15-18

The procedure described in Example 3 was repeated, except that the acetic anhydride was replaced by the appropriate acylating agent identified hereafter and, in Example 18, a different thiazolidine derivative was used, to give the following compounds:

EXAMPLE 15

5-[4-(6-butyryloxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, using butyryl chloride

Melting at: 147°-150° C.

Mass spectrum (m/e): 511 (M-).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.06 (3H, triplet, J=6 Hz); 1.65-2.2 (13H, multiplet); 2.45-2.75 (4H, multiplet).

EXAMPLE 16

5-[4-(6-benzoyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, from benzoic anhydride.

Rf value: 0.53 (thin layer chromatography, silica gel, developing solvent: 4.1 by volume mixture of benzene 40 and ethyl acetate).

Mass spectrum (m/e): 545 (M÷).

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) δ ppm: 7.45-7.85 (3H, multiplet); 8.05-8.3 (2H, multiplet).

EXAMPLE 17

5-[4-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione, from nicotinoyl chloride hydrochloride

Melting at: 196°-198° C.

Mass spectrum (m/e): 546 (M-).

Nuclear Magnetic Resonance Spectrum (CDCl₃) 8 silica gel, eluted with a 5:1 by volume mixture of and ethyl acetate, to give the title compound, plet); 8.7–9.1 (1H, multiplet); 9.4–9.6 (1H, multiplet).

EXAMPLE 18

5-{4-[2-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione, from nicotinoyl chloride hydrochloride and 5-{4-[2-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione (prepared as described in Example 14)

Rf value: 0.45 (thin layer chromatography, silica gel, 65 developing solvent: 1:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 560 (M+).

Nuclear Magnetic Resonance Spectrum (heptadeuterated dimethylformamide) δ ppm: 7.6–7.85 (1H, multiplet); 8.5–8.7 (1H, multiplet); 8.9–9.1 (1H, multiplet); 9.35–9.5 (1H, multiplet).

In the nuclear magnetic resonance spectra reported in the above Examples 15-18, only those signals are reported which are characteristic of the 6-acyloxy part of the compound prepared.

EXAMPLE 19

5-[4-(2-Ethyl-6-hydroxy-5.7,8-trimethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

2.4 g of ethyl 3-[4-(6-acetoxy-2-ethyl-5,7,8-trimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate, 494
mg of thiourea and 3 ml of sulfolane were heated under
a nitrogen stream for 4.5 hours at 100°-110° C. At the
end of this time, 3 ml of ethylene glycol monomethyl
ether. 3 ml of water and 1 ml of concentrated hydrochloric acid were added and the resulting mixture was
heated for a further 3.5 hours at 96°-98° C. The reaction
mixture was then processed as described in Example
1(a) and the resulting crude product, in the form of an
oil, was purified by column chromatography, eluted
with a 10:1 by volume mixture of benzene and ethyl
acetate, to give the title compound.

Rf value: 0.29 (thin layer chromatography, silica gel, developing solvent: 4:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 455 (M-).

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) δ ppm: 0.90 (3H. triplet. J=6 Hz); 1.5-2.1 (4H, nd); 1.99 (3H. singlet); 2.01 (3H. singlet); 2.05 (3H. singlet); 2.4-2.7 (2H. multiplet);
2.8-3.7 (2H. nd); 3.94 (2H. singlet); 4.84 (1H. doublet of doublets. J=9 & 4.5 Hz); 6.90 (2H. doublet. J=9 Hz);
7.15 (2H. doublet, J=9 Hz); 7.40 (1H. broad singlet, D).

EXAMPLE 20

5-[4-(6-Hydroxy-2-isobutyl-5,7.8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

1.99 g of ethyl 3-[4-(6-acetoxy-2-isobutyl-5,7.8-trime-thylchroman-2-ylmethoxy)phenyl]-2-chloropropionate.

0.42 g of thiourea and 2.1 g of sulfolane were reacted under a nitrogen stream at 125°-150° C. for 3.5 hours. At the end of this time, 15 ml of ethylene glycol monomethyl ether, 4 ml of water and 2 ml of concentrated hydrochloric acid were added and the mixture was reacted for a further 3.5 hours at 96°-98° C. The reaction mixture was then treated as described in Example 1(a) and the resulting crude product, in the form of an oil, was purified by column chromatography through silica gel, eluted with a 5:1 by volume mixture of hexane 55 and ethyl acetate, to give the title compound.

Rf value: 0.30 (thin layer chromatography, silica gel, developing solvent: 4:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 483 (M \div).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 0.96 (3H, doublet, J=6 Hz); 1.01 (3H, doublet, J=6 Hz); 1.71 (2H, doublet, J=6 Hz); 1.8-2.3 (3H, nd); 2.10 (6H, singlet); 2.16 (3H, singlet); 2.61 (2H, triplet, J=6 Hz); 3.02 (1H, doublet of doublets, J=9 & 15 Hz); 3.43 (1H, doublet of doublets, J=4 & 15 Hz); 3.92 (2H, singlet); 4.33 (1H, singlet); 4.43 (1H, doublet of doublets, J=4 & 9 Hz); 6.85 (2H, doublet, J=9 Hz); 7.13 (2H, doublet, J=9 Hz); 8.4-9.0 (1H, broad).

EXAMPLE 21

Monosodium salt of 5-[4-(6-hydroxy-2,5.7.8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione

101 mg of 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione were suspended in 0.5 ml of 99.5% ethanol. 4.33 ml of a 0.0526N ethanolic solution of sodium hydroxide were then added to the suspension and the mixture was stirred at room temperature for 1 hour. The crystals obtained by evaporating off the solvent under reduced pressure were dried by heating them under reduced pressure at 60° C. for 3 hours in the presence of phosphorus pentoxide. to give the title compound, melting at 15 203°-208° C. (with decomposition).

Nucelar Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) δ ppm: 1.30 (3H. singlet); 1.66–2.10 (2H. multiplet); 1.96 (3H. singlet); 2.03 (3H. singlet); 2.05 (3H. singlet); 2.35–2.80 (3H. multiplet); 3.15–3.35 (1H. multiplet); 3.92 (2H. broad singlet); 4.09 (1H. doublet of doublets, J=4.5 & 11.5 Hz); 6.85 (2H. doublet, J=9 Hz); 7.10 (2H. doublet, J=9 Hz); 7.42 (1H. broad singlet, D).

Elemental analysis: Calculated for C₂₄H₂₆NO₅. ²⁵ SNa.H₂O: C. 59.86%; H. 5.86%; N. 2.91%; S. 6.66%; Na. 4.77%. Found: C, 59.78%; H. 5.54%; N, 2.84%; S, 6.37%; Na. 5.04%.

EXAMPLE 22

5-[4-(6-Hydroxy-2.5,7.8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

A mixture of 1.3 g of ethyl 3-[4-(6-acetoxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)phenyl]-2chloropropionate (prepared as described in Preparation 45), 0.4 g of thiourea and 2 g of sulfolane was heated at 120°-130° C. for 4 hours under a nitrogen stream. Then 15 ml of ethylene glycol monomethyl ether, 4 ml of water and 2 ml of concentrated hydrochloric acid were 40 added, in that order, to the reaction mixture, and heating was continued, but at 70°-90° C., for a further 2.5 days. Water was then added to the reaction mixture, after which it was extracted with benzene. The extract was washed with water and dried over anhydrous so-45 dium sulfate. Benzene was distilled off from the extract. The residue was subjected to silica gel column chromatography, eluted with a 5:3 by volume mixture of hexane and ethyl acetate, to yield 5-[4-(6-hydroxy-2,5,7,8tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione. Its softening point was 79°-83°

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.50 (3H, singlet); 2.11 (3H, singlet); 2.22 (3H, singlet); 2.56 (3H, singlet); 2.66 (1H, doublet, J=15 Hz); 3.05 (1H, doublet, J=15 Hz); 3.05 (1H, doublet of doublets, J=9 & 15 Hz); 3.42 (1H, doublet of doublets, J=4 & 15 Hz); 3.95 (1H, doublet, J=10 Hz); 4.07 (1H, doublet, J=10 Hz); 4.46 (1H, doublet of doublets, J=4 & 9 Hz); 4.5-5.2 (1H, broad singlet); 6.84 (2H, doublet, J=9 Hz); 7.13 (2H, doublet, J=9 Hz).

EXAMPLE 23

5-[4-(4,6-Dihydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

450 mg of sodium borohydride were added to a mixture of 278 mg of 5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-

dione (prepared as described in Example 22) and 9 ml of methanol, and the resulting mixture was stirred at room temperature for 2 hours. Then, a 1% w/v aqueous solution of acetic acid was added to the reaction mixture, and the mixture was neutralized with an aqueous solution of potassium carbonate and extracted with ethyl acetate. The ethyl acetate solution was washed with water and dried over anhydrous sodium sulfate. Ethyl acetate was distilled off from the mixture under reduced pressure, and the resulting residue was subjected to silica gel column chromatography, eluted with a 5:3 by volume mixture of hexane and ethyl acetate, to yield 5-[4-(4.6-dihydroxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione. Its melting point was 102°-118° C.

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone and D_2O) $\hat{0}$ ppm: 1.52 (3H. singlet); 2.01 (3H. singlet); 2.13 (3H. singlet); 2.29 (3H. singlet); 1.9–2.5 (1H. nd); 2.9–3.6 (2H. multiplet); 4.03 (2H. singlet); 3.9–4.5 (1H. nd); 4.6–5.1 (2H. multiplet); 6.7–7.4 (4H. nd).

EXAMPLE 24

5-[4-(7-t-Butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

In a similar manner to Example 22, a mixture of 291 mg of ethyl 3-[4-(6-acetoxy-7-t-butyl-2-methyl-1-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate (prepared as described in Preparation 49), 64 mg of thiourea and 1 ml of sulfolane was heated. 5 ml of ethylene glycol monomethyl ether, I ml of concentrated hydrochloric acid and 2 ml of water were added, and the resulting mixture was further heated under reflux for 6 hours. Ethyl acetate was then added to the reaction mixture, and the resulting solution was washed with water and dried over anhydrous sodium sulfate. The ethyl acetate was removed by evaporation under reduced pressure, and the resulting residue was subjected to silica gel column chromatography, eluted with a 5:1 by volume mixture of benzene and ethyl acetate, to give 143 mg of the desired 5-[4-(7-t-butyl-6-hydroxy-2methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione.

Softening point: 95°-107° C.

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone) δ ppm: 1.40 (9H, singlet); 1.48 (3H, singlet); 2.65 (1H, doublet, J=16.5 Hz); 3.05 (1H, doublet, J=16.5 Hz); 3.08 (1H, doublet of doublets. J=9 & 14 Hz); 3.42 (1H, doublet or doublets. J=4.5 & 14 Hz); 4.14 (2H, singlet); 4.74 (1H, doublet of doublets. J=4.5 & 9 Hz); 6.83 (1H, singlet); 6.92 (2H, doublet, J=9 Hz); 7.23 (1H, singlet); 7.24 (2H, doublet, J=9 Hz); 7.50–9.40 (1H, broad, D).

EXAMPLE 25

5-[4-(6-Acetoxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

A mixture of 2.0 g of ethyl 3-[4-(6-acetoxy-2.5.7,8-tet-60 ramethyl-4-oxochroman-2-ylmethoxy)phenyl]-2chloropropionate (prepared as described in Preparation 45), 0.62 g of thiourea, and 3.1 g of sulfolane was heated at 120°-125° C. for 7 hours under a nitrogen stream. The reaction mixture was extracted with benzene and then 65 the benzene was distilled off from the extract. Water was then added to the residue and the oily layer was separated. The oily layer was subjected to silica gel column chromatography [successively with an eluent of (1) a 2:1 by volume mixture of n-hexane and ethyl acetate, (2) ethyl acetate, and (3) a 1:1 by volume mixture of ethyl acetate and ethanol] to yield 5-[4-(6-acetoxy-2.5.7,8-tetramethyl-toxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-tone in a yield of 0.74 g. This was further purified by recrystallization from ethyl acetate, to give the purified title compound melting at was 218*-222* C.

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide \div D₂O) δ ppm: 1.43 (3H, 10 singlet); 2.04 (6H, singlet); 2.32 (3H, singlet); 2.35 (3H, singlet); 2.4–3.5 (4H, nd); 4.13 (2H, singlet); 4.56 (1H, doublet of doublets, J=4 & 9 Hz); 6.85 (2H, doublet, J=9 Hz); 7.14 (2H, doublet, J=9 Hz).

TEST EXAMPLE 1

Effect on hyperlipidaemia

The test animals were 8 weeks old male mice. These animals were fasted for 18 hours, after which 75 mg/kg $_{20}$ of alloxan was injected into the tail vein of each animal. Each of the test compounds was administered orally at a dose of 100 mg/kg body weight 30 minutes before and 24 and 30 hours after administration of the alloxan. Blood was collected from an incision in the cervical $_{25}$ region 48 hours after administration of the alloxan. The amount collected was 100 or 200 μ l. The blood was diluted 10 or 20 times with a physiological saline solution and centrifuged (3,000 rpm, 10 minutes) to determine the lipid content.

Lipid peroxide was determined at TBA (thiobarbituric acid)—reacting substance according to Yagi's method [K. Yagi: Biochem. Med., 15, 212-216 (1976)]. Measurements of cholesterol and triglyceride were made according to the enzyme method. A Determiner 35 TC (a registered trade mark of Kyowa Medix) kit was used for the measurement of cholesterol and Triglyceride Measuring Agent (GPO-p-chlorophenol color developing method) (Wako Jyunyaku) kit was used for triglyceride.

As a control, the procedure was repeated, except that no test compound was administered.

The test compounds were as follows:

Compound A:

5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (a compound of the invention);

Compound B:

5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazoli-dine-2.4-dione (a prior art compound).

The results are shown in the following Table:

TABLE 1

agent	No. of animals	lipid peroxide (nmol/ml)	triglyceride (mg/dl)	cholesterol (mg/dl)
Control	10	36.8 ± 6.9	636 ± 128	81.3 ± 4.7
Compound A	10	16.8 ± 1.5	270 ± 33	59.6 ± 1.4
Compound B	10	(P < 0.02) 29.9 ± 5.2 (NS)	(P < 0.02) 586 = 127 (NS)	(P < 0.01) 72.5 ± 5.6 (NS)

NS = not significant.

As shown in Table 1, Compound A of this invention 65 significantly inhibited lipid peroxide, triglyceride and cholesterol, but the comparative compound did not exhibit such an inhibitory action.

TEST EXAMPLE 2

Effect On Blood Sugar

The test animals employed were male mice of the C₅₇BL/6J-Ob/Ob strain aged about 4 months. The animals were employed in groups of 4 for each test.

Compound A and the same prior art Compound B as was used in Test Example 1 were mixed at a level of 0.2% by weight with a powder feed (MM-1, Funabashi Farm) and given freely to the mice for 2 weeks, during which time water was also freely available. At the end of the experiment, blood was collected from a vein in the tail and the blood sugar level was determined by the glucose oxidase method. A control group was treated similarly, except that the active compounds were omitted.

With the blood sugar level of the control set arbitrarily at 100, the blood sugar level of Compound A was 57 and that of Compound B was 56, indicating an excellent ability to reduce blood sugar levels.

PREPARATION I

6-(Methoxymethoxy)-2.5.7.8-tetramethylchroman-2ylmethanoi

16.1 g of 6-hydroxy-2.5,7,8-tetramethylchroman-2ylmethanol were dissolved in 70 ml of dry dimethylformamide. 3.0 g of a 50% w/w suspension of sodium hydride in oil (which had been washed with cyclohexane 3 times) were added gradually to the resulting solution at 5°-10° C., with stirring and under a nitrogen stream. The mixture was reacted for I hour at room temperature, and then the solution was ice-cooled to 3°-5° C., and 5.5 g of chloromethyl methyl ether dissolved in 40 ml of dry benzene were added dropwise. After the whole of this had been added, the solution was reacted for 1 hour at room temperature. The reaction mixture was then poured into ice-water and extracted with cyclohexane. The extract was washed four times with a 5% w/v aqueous solution of sodium hydroxide, and then with water. It was then dried and the solvent was distilled off under reduced pressure, giving the desired 6-(methoxymethoxy)-2,5.7.8-tetramethylchroman-2-ylmethanol. On thin layer chromatography, the Rf value was 0.45 [silica gel; developing solvent:benzene:ethyl acetate=4:1 by volume].

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.21 (3H, singlet); 1.6–2.0 (3H, multiplet); 2.07 (3H, singlet); 2.15 (3H, singlet); 2.19 (3H, singlet); 2.6 (2H, broad triplet, J=9 Hz); 3.60 (3H, singlet); 3.63 (2H, singlet); 4.85 (2H, singlet).

PREPARATION 2

6-(Methoxymethoxy)-2,5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman

6 g of a 50% w/w suspension of sodium hydride in oil were placed in a reaction container and washed with cyclohexane. 100 ml of dry dimethyl sulfoxide and then 19.0 g of 6-(methoxymethoxy)-2,5,7,8-tetramethylchroman-2-ylmethanol dissolved in 20 ml of dry benzene were added, and the mixture was reacted for 20 minutes under a nitrogen stream at 60° C. Small portions of p-chloronitrobenzene (totalling 21.6 g) were added to 65 this solution whilst cooling with water to 30° C., and then the reaction was continued for 1 hour at 60° C. The reaction mixture was then poured into ice-water and extracted with ethyl acetate. The extract was washed

with water, and dried over anhydrous sodium sulfate. The solvent was distilled off, leaving a reddish brown crude oil. This oil was subjected to silica gel column chromatography, eluted first with a 1:1 by volume mixture of benzene and cyclohexane and then with benzene 5 alone. A light yellowish oil, the desired 6-(methoxymethoxy)-2.5.7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman, was obtained from the portion eluted with benzene. Rf value on thin layer chromatography: 0.12 [silica gel; developing solvent:benzene].

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.41 (3H, singlet); about 2 (2H, multiplet); 2.05 (3H, singlet); 2.14 (3H, singlet); 2.18 (3H, singlet); 2.6 (2H, broad triplet, J=9 Hz); 3.60 (3H, singlet); 3.95 and 15 4.09 (2H, AB type, J=9 Hz); 4.86 (2H, singlet); 6.96 (2H. doublet, J=9 Hz); 8.19 (2H. doublet, J=9 Hz).

PREPARATION 3

6-Hydroxy-2.5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman

32.8 g of 6-(methoxymethoxy)-2,5.7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman were dissolved in 300 ml of acetic acid containing 5.3 g of a 10% w/w aque- 25 thylchroman, melting at 138*-140° C. ous solution of sulfuric acid, and the mixture was heated for 10 minutes at 60° C. The reaction mixture was cooled and then poured into a mixture of 420 g of sodium bicarbonate and 1 kg of ice and extracted with ethyl acetate. The extract was washed with water and 30 dried over anhydrous sodium sulfate. The solvent was distilled off from the extract, leaving a light yellowish powder, the desired 6-hydroxy-2,5,7,8-tetramethyl-2-(4nitrophenoxymethyl)chroman, melting at 114°-116° C.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 35 ppm: 1.41 (3H, singlet); about 2 (2H, multiplet); 2.06 (3H, singlet); 2.10 (3H, singlet); 2.15 (3H, singlet); 2.6 (2H, broad triplet, J=6 Hz); 4.05 (2H, AB Type, J=9Hz); 4.25 (1H, broad singlet); 6.96 (2H, doublet, J=9Hz); 8.16 (2H, doublet, J=9 Hz).

PREPARATION 4

6-Acetoxy-2.5.7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman

20.4 g of 6-hydroxy-2.5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman were dissolved in 60 ml of pyridine, and, while stirring, 30 ml of acetic anhydride were added dropwise at 10° C. The mixture was gradu-1 hour at 30° C. The reaction mixture was cooled and then poured into ice-water and extracted with a 1:1 by volume mixture of benzene and cyclohexane. The extract was washed well with a 2% w/v aqueous solution was dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure, giving the desired 6-acetoxy-2,5,7,8-tetramethyl-2-(4nitrophenoxymethyl)chroman. Rf value on thin layer chromatography: 0.64 [silica gel; developing solvent; benzene and ethyl acetate = 10:1 by volume]

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.41 (3H, singlet); 1.98 (3H, singlet); about 2 (2H, multiplet); 2.02 (3H, singlet); 2.05 (3H, singlet); 2.31 65 (3H, singlet); 2.6 (2H, broad triplet, J=6 Hz); 3.98 and 4.10 (2H, AB Type, J=9 Hz); 6.97 (2H, doublet, J=9Hz); 8.20 (2H, doublet, J=9 Hz).

PREPARATION 5

6-Acetoxy-2-(4-aminophenoxymethyl)-2,5,7,8-tetramethylchroman

24.3 g of 6-acetoxy-2.5.7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman were dissolved in a mixture of 200 ml of methanol and 20 ml of benzene and reacted for 3 hours under a hydrogen pressure of 45-55 lb/sq. inch (3.1-3.8 bars), using Pearl's hydrogen adding apparatus, in the presence of 7 g of 10% w/w palladium-oncarbon. The palladium-on-carbon was removed by filtration from the reaction mixture and washed with a mixture of 600 ml of acetone and 60 ml of concentrated hydrochloric acid. The filtrate and the washings were combined and the mixture was neutralized with sodium bicarbonate. The solvent was then distilled off, and the crude crystals obtained were dissolved in ethyl acetate. The ethyl acetate solution was washed with water and dried over anhydrous sodium sulfate. The ethyl acetate was then distilled from the extract, and the crude substance obtained was washed with a 1:1 by volume mixture of benzene and cyclohexane, giving the desired 6-acetoxy-2-(4-aminophenoxymethyl)-2.5,7,8-tetrame-

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.42 (3H, singlet); about 2 (2H, multiplet); 2.00 (3H, singlet); 2.04 (3H, singlet); 2.10 (3H, singlet); 2.31 (3H. singlet): 2.6 (2H. broad triplet. J = 6 Hz): 3.37 (2H. broad singlet); 3.80 and 3.95 (2H. AB Type. J=9 Hz); 6.62 (2H. doublet, J=9 Hz); 6.78 (2H. doublet, J=9Hz).

PREPARATION 6

Ethyl

3-[4-(6-acetoxy-2,5,7.8-tetramethylchroman-2-yimethoxy)phenyl]-2-chloropropionate

17.5 g of 6-acetoxy-2-(4-aminophenoxymethyl)-2,5.7,8-tetramethylchroman were dissolved in a mixture of 130 ml of acetone and 30 ml of water, and 13 ml of concentrated hydrochloric acid, followed by 4.3 g of sodium nitrite dissolved in 8.5 ml of water, were added dropwise, with ice-cooling, to the product. 37.3 ml of ethyl acrylate were added dropwise, and then 680 mg of cuprous oxide were added gradually to the product. whilst keeping its temperature at 40°-43° C. Generation of nitrogen terminated after about 30 minutes. Benzene was then added to the reaction mixture (which consisted of 2 layers) to extract the organic layer. The ally restored to room temperature and then reacted for 50 benzene extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. The solvent was then distilled off from the extract. The dark brownish oil thus obtained was subjected to silica gel column chromatography, eluted of hydrochloric acid and then with water, after which it 55 with a 1:1 by volume mixture of benzene and cyclohexane and then the proportion of benzene was progressively increased until it was eluted with benzene alone. 3-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-Ethyl ylmethoxy)phenyl]-2-chloropropionate was obtained from the fractions eluted with a 2:1 by volume mixture of benzene and cyclohexane and with benzene alone. Rf value on thin layer chromatography: 0.39 [silica gel; developing solvent:benzene:ethyl acetate = 20:1 by volume].

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.23 (3H, triplet, J = 7.5 Hz); 1.42 (3H, singlet); 1.98 (3H, singlet); about 2 (2H, multiplet); 2.04 (3H, singlet); 2.09 (3H, singlet); 2.31 (3H, singlet); 2.6 (2H, broad triplet, J=6 Hz); 3.05 (1H. doublet or doublets, J=15 & 7.5 Hz); 3.31 (1H. doublet or doublets, J=15 & 7.5 Hz); 3.83 and 3.99 (2H. AB Type, J=9 Hz); 4.18 (2H. quartet, J=7.5 Hz); 4.38 (1H. triplet, J=7.5 Hz); 6.85 (2H. doublet, J=9 Hz); 7.14 (2H. doublet, J=9 5 Hz).

PREPARATION 7

3-[4-(6-Acetoxy-2.5,7.8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionic acid

0.16 g of ethyl 3-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate was dissolved in a mixture of 1.5 ml of 99.5% ethanol and 0.2 ml of tetrahydrofuran. 265 mg of a 9.55% w/w aqueous solution of sodium hydroxide were added dropwise. under a nitrogen stream at 0°-4° C., to the resulting mixture. The mixture was then reacted for a further 20 hours at 0°-5° C., after which it was neutralized, whilst ice-cooling, by adding 0.68 g of a 10% w/w aqueous solution of hydrochloric acid. The solvent was then distilled off under reduced pressure. The separated light reddish oil was further extracted with chloroform, and the chloroform extract was washed with water and dried over anhydrous sodium sulfate. The crude product obtained by distilling off the chloroform under reduced pressure was subjected to column chromatography through silica gel and the desired 3-[4-(6-acetoxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)phenyl]-2chloropropionic acid was obtained from the fractions eluted with a 20:1 by volume mixture of benzene and 99.5% ethanol. Rf value on thin layer chromatography: 0.6 (tailing) [silica gel; developing solvent; benzene:99.5% ethanol=4:1 by volumel.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.42 (3H, singlet); 1.98 (3H, singlet); about 2 (2H, multiplet); 2.03 (3H, singlet); 2.09 (3H, singlet); 2.32 (3H, singlet); 2.6 (2H, broad triplet, J=6 Hz); 3.2 (2H, multiplet); 3.85 and 4.00 (2H, AB Type, J=9 Hz); 4.4 (1H, multiplet); 6.86 (2H, doublet, J=9 Hz); about 7 (1H, broad singlet); 7.15 (2H, doublet, J=9 Hz).

PREPARATION 8

2-Chloro-3-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]propionic acid

0.48 g of ethyl 3-[4-(6-acetoxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate was dissolved in a mixture of 5 ml of 99.5% ethanol and 2 ml of tetrahydrofuran. To this was added dropwise, under a nitrogen stream at 8°-10° C., a solution prepared by 50 dissolving 133 mg of sodium hydroxide in 1 ml of 99.5% ethanol. When the whole of the solution had been added, the mixture was reacted for a further 18 hours at 0°-5° C., after which it was neutralized by adding to it dropwise a solution prepared by dissolving 0.37 g of 55 concentrated hydrochloric acid in 1 ml of 99.5% ethanol. The solvent was then distilled off from the mixture under reduced pressure. The pale reddish oil thus separated was extracted with chloroform, and the chloroform extract was washed with water and then dried 60 over anhydrous sodium sulfate. The crude product obtained by distilling the chloroform off under reduced pressure was subjected to silica gel column chromatography, and the desired 2-chloro-3-[4-(6-hydroxy-2.5.7,8tetramethylchroman-2-ylmethoxy)phenyl]propionic acid was obtained from the fractions eluted with a 10:1 by volume mixture of benzene and ethyl acetate. Rf value on thin layer chromatography: 0.4 (tailing) [silica

gel; developing solvent; benzene:99.5% ethanol = 6:1 by volume]. Melting point 148*-149* C.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δppm: 1.40 (3H, singlet); about 2 (2H, multiplet); 2.10 (6H, singlet); 2.15 (3H, singlet); 2.6 (2H, broad triplet, J=6 Hz); 3.05 (1H, doublet of doublets, J=15 & 7.5 Hz); 3.83 and 3.98 (2H, AB type, J=9 Hz); 4.40 (1H, triplet, J=7.5 Hz); about 6 (2H, broad singlet); 6.85 (2H, doublet, J=9 Hz); 7.14 (2H, doublet, J=9 Hz).

PREPARATION 9

Ethyl

2-chloro-3-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]propionate

0.48 g of ethyl 3-[4-(6-acetoxy-2.5.7.8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate was dissolved in a mixture of 3 ml of absolute ethanol and 2 ml of dry tetrahydrofuran. An ethanolic solution of sodium ethoxide (prepared by dissolving 49.0 mg sodium in 2 ml of absolute ethanol) was added dropwise, under a nitrogen stream at 10°-13° C., to the resulting solution. The mixture was then reacted for 21 hours at 0°-5° C., after which 0.22 g of concentrated hydrochloric acid dissolved in 99.5% ethanol was added dropwise, with ice-cooling. The solvent was then distilled off from the reaction mixture under reduced pressure: the separated light reddish oil was extracted with chloroform; and the extract was washed with water and then dried over anhydrous sodium sulfate. The crude product obtained by distilling the chloroform off from the extract under reduced pressure was subjected to silica gel column chromatography, and the desired 2-chloro-3-[4-(6-hydroxy-2.5.7,8-tetramethylchroman-2-ylmethoxy)phenyl]propionate was obtained from the fractions eluted with benzene. Rf value on thin layer chromatography: 0.60 [silica gel: developing solvent: benzene:ethyl acetate = 10:1 by volume].

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.23 (3H. triplet. J=7.5 Hz); 1.40 (3H. singlet); about 2 (2H. multiplet); 2.10 (6H. singlet); 2.15 (3H. singlet); 2.6 (2H. broad triplet, J=6 Hz); 3.05 (1H. doublet of doublets, J=15 & 7.5 Hz); 3.30 (1H. doublet of doublets, J=15 & 7.5 Hz); 3.83 and 3.95 (2H. AB Type. J=9 Hz); 4.16 (2H. quartet, J=7.5 Hz); 4.18 (1H. singlet); 4.36 (1H. triplet, J=7.5 Hz); 6.85 (2H. doublet, J=9 Hz), 7.13 (2H. doublet, J=9 Hz).

In the following Preparations 10-38, only those parts of the signals of the nuclear magnetic resonance spectra which are relevant to the compounds prepared are reported.

PREPARATIONS 10-16

The procedure described in Preparation 3 was repeated, but using the appropriate chroman starting material, to prepare the following compounds:

PREPARATION 10

6-hydroxy-5,7,8-trimethyl-2-(4-nitrophenoxymethyl)chroman

Melting at: 167.5°-169° C.

Mass spectrum (m/e): 343 (M+).

Rf value: 0.60 (thin layer chromatography, silica gel, developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 4.23 (1H, singlet, D); 7.05 (2H, doublet, J=9 Hz); 8.23 (2H, doublet, J=9 Hz).

PREPARATION 11

6-hydroxy-2.7-dimethyl-2-(4-nitrophenoxymethyl)chroman

Rf value: 0.45 (thin layer chromatography, silica gel, developing solvent: 10:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 329 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 4.03 (1H. singlet, D); 6.95 (2H. doublet, J=9 Hz); 15 8.20 (2H. doublet, J=9 Hz).

PREPARATION 12

7-t-butyl-6-hydroxy-2-methyl-2-[2-(4-nitrophenoxy)ethyl]chroman

Rf value: 0.71 (thin layer chromatography, silica gel, developing solvent: 5:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 385 (M $^+$).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 4.34 (1H, singlet. D); 6.97 (2H, doublet. J=9 Hz); 8.21 (2H, doublet. J=9 Hz).

PREPARATION 13

6-hydroxy-7,8-dimethoxy-2,5-dimethyl-2-[2-(4-nitrophenoxy)ethyl]chroman

Melting at: 119°-121° C.

Mass spectrum (m/e): 403 (M+).

Rf value: 0.49 (thin layer chromatography, silica gel, developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ⁴⁰ ppm: 5.43 (1H, singlet, D); 6.99 (2H, doublet, J=9 Hz); 8.23 (2H, doublet, J=9 Hz).

PREPARATION 14

6-hydroxy-2,5,7,8-tetramethyl-2-[2-(4-nitrophenoxy)e-thyl]chroman

Rf value: 0.33 (thin layer chromatography, silica gel, developing solvent, 10:1 by volume mixture of benzene 50 and ethyl acetate).

Mass spectrum (m/e): 371 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 4.21 (1H, singlet, D); 6.95 (2H, doublet, J=9 Hz); 8.20 (2H, doublet, J=9 Hz).

PREPARATION 15

2-ethyl-6-hydroxy-5,7,8-trimethyl-2-(4-nitrophenoxymethyl)chroman

Rf value: 0.42 (thin layer chromatography, silica gel, developing solvent: 20:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 371 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 4.20 (1H, singlet, D); 6.98 (2H, doublet, J=9 Hz); 8.18 (2H, doublet, J=9 Hz).

PREPARATION 16

6-hydroxy-2-isobutyl-5,7,8-trimethyl-2-(4-nitrophenoxymethyl)chroman

Rf value: 0.42 (thin layer chromatography, silica gel, developing solvent: 20:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): $399 (M^{\pm})$.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 4.22 (1H, singlet, D); 6.98 (2H, doublet, J=9 Hz);
 8.18 (2H, doublet, J=9 Hz).

PREPARATIONS 17-23

Using the corresponding 6-hydroxy compounds prepared as described in Preparations 10-16 above, the procedure of Preparation 4 was repeated, to give the following 6-acetoxy compounds:

PREPARATION 17

6-acetoxy-5,7,8-trimethyl-2-(4-nitrophenoxymethyl)chroman

Melting at: 132*-134* C.

Rf value: 0.66 (thin layer chromatography, silica gel, developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 385 (M \pm).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.31 (3H. singlet); 7.05 (2H. doublet, J=9 Hz); 8.23 (2H, doublet, J=9 Hz).

PREPARATION 18

35 6-acetoxy-2,7-dimethyl-2-(4-nitrophenoxymethyl)chroman

Rf value: 0.45 (thin layer chromatography, silica gel. developing solvent: 20:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 371 (M +).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.23 (3H, singlet); 6.95 (2H, doublet, J=9 Hz): 8.20 (2H, doublet, J=9 Hz).

PREPARATION 19

6-acetoxy-7-t-butyl-2-methyl-2-[2-(4-nitrophenoxy)e-thyl]chroman

Rf value: 0.21 (thin layer chromatography, silica gel, developing solvent: 50:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 427 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.29 (3H, singlet); 6.95 (2H, doublet, J=9 Hz); 8.21 (2H, doublet, J=9 Hz).

PREPARATION 20

6-acetoxy-7,8-dimethoxy-2.5-dimethyl-2-[2-(4-nitrophenoxy)ethyl]chroman

Rf value: 0.45 (thin layer chromatography, silica gel, developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 445 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.33 (3H, singlet); 6.99 (2H, doublet, J=9 Hz); 8.23 (2H, doublet, J=9 Hz).

PREPARATION 21

6-acetoxy-2.5.7.8-tetramethyl-2-[2-(4-nitrophenoxy)ethyllchroman

Rf value: 0.38 (thin layer chromatography, silica gel, developing solvent: 10:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 413 (M \pm).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 10 ppm: 2.31 (3H. singlet); 6.95 (2H. doublet, J=9 Hz); 8.20 (2H, doublet, J=9 Hz).

PREPARATION 22

thyl)chroman

Rf value: 0.44 (thin layer chromatography, silica gel. developing solvent: 4:1 by volume mixture of cyclohexane and ethyl acetate).

Mass spectrum (m/e): 413 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl3) δ ppm: 2.31 (3H. singlet); 6.98 (2H. doublet, J=9 Hz); 8.20 (2H, doublet, J=9 Hz).

PREPARATION 23

6-acetoxy-2-isobutyl-5.7.8-trimethyl-2-(4-nitrophenoxymethyl)chroman

Rf value: 0.41 (thin layer chromatography, silica gel. 30 developing solvent: 4:1 by volume mixture of cyclohexane and ethyl acetate).

Mass spectrum (m/e): $441 (M \pm)$.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.32 (3H, singlet); 6.98 (2H, doublet, J=9 Hz); 35 ppm: 3.28 (2H, singlet, D); 6.61 (2H, doublet, J=9 Hz); 8.17 (2H, doublet, J=9 Hz).

PREPARATIONS 24-30

Following the procedure described in Preparation 5. 40 but using the appropriate nitrophenoxy compounds prepared as described in Preparations 17-23, the following compounds were prepared:

PREPARATION 24

6-acetoxy-2-(4-aminophenoxymethyl)-5,7,8-trimethylchroman

Melting at 162.5°-164.5° C.

Rf value: 0.11 (thin layer chromatography, silica gel. 50 developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 355 (M=).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 3.37 (2H, singlet, D); 6.65 (2H, doublet, J=9 Hz); 55 6.85 (2H, doublet, J=9 Hz).

PREPARATION 25

6-acetoxy-2-(4-aminophenoxymethyl)-2,7-dimethylchroman

Rf value: 0.52 (thin layer chromatography, silica gel, developing solvent: 1:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 341 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 3.30 (2H, singlet, D); 6.60 (2H, doublet, J=9 Hz); 6.76 (2H, doublet, J=9 Hz).

PREPARATION 26

6-acetoxy-2-[2-(4-aminophenoxy)ethyl]-7-t-butyl-2methylchroman

Rf value: 0.15 (thin layer chromatography, silica gel. developing solvent: 5:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 397 (M-).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.97-3.53 (2H. broad singlet, D); 6.63 (2H, doublet. J=9 Hz); 6.77 (2H. doublet. J=9 Hz).

PREPARATION 27

6-acetoxy-2-ethyl-5.7.8-trimethyl-2-(4-nitrophenoxyme- 15 6-acetoxy-2-[2-(4-aminophenoxy)ethyl]-7,8-dimethoxy-2.5-dimethylchroman

> Rf value: 0.43 (thin layer chromatography, silica gel. developing solvent: 1:1 by volume mixture of benzene 20 and ethyl acetate).

Mass spectrum (m/e): 415 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 3.23 (2H. broad singlet, D); 6.61 (2H. doublet, J=9 Hz); 6.77 (2H, doublet, J=9 Hz).

PREPARATION 28

6-acetoxy-2-[2-(4-aminophenoxy)ethyl]-2,5,7,8-tetramethylchroman

Rf value: 0.14 (thin layer chromatography, silica gel, developing solvent: 10:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 383 (M $^{\pm}$).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 6.75 (2H, doublet, J = 9 Hz).

PREPARATION 29

6-acetoxy-2-(4-aminophenoxymethyl)-2-ethyl-5,7.8trimethylchroman

Melting at: 123°-124° C.

Rf value: 0.09 (thin layer chromatography, silica gel, developing solvent: 5:1 by volume mixture of cyclohex-45 ane and ethyl acetate).

Mass spectrum (m/e): 383 (M=).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.8-3.5 (2H, broad singlet, D); 6.59 (2H, doublet, J=9 Hz); 6.76 (2H, doublet, J=9 Hz).

PREPARATION 30

6-acetoxy-2-(4-aminophenoxymethyl)-2-isobutyl-5,7,8trimethylchroman

Melting at: 137°-138° C.

Rf value: 0.11 (thin layer chromatography, silica gel. developing solvent: 4:1 by volume mixture of cyclohexane and ethyl acetate).

Mass spectrum (m/e): 411 ($M \div$).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.7-3.4 (2H, broad singlet, D); 6.61 (2H, doublet, J=9 Hz); 6.77 (2H, doublet, J=9 Hz).

PREPARATIONS 31-38

Following the procedure described in Preparation 6. but using the appropriate starting materials prepared as described in Preparations 24-30 and 41, the following compounds were prepared:

PREPARATION 31

ethvi

3-[4-(6-acetoxy-5,7,8-trimethylchroman-2-yl-methoxy)phenyl]-2-chloropropionate

Rf value: 0.70 (thin layer chromatography, silica gel. developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 474 (M $^{\pm}$).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 10 ppm: 2.7 (2H, doublet of doublets, J = 10 & 5 Hz); 3.13 (1H. doublet of doublets, J=15 & 7.5 Hz); 3.30 (1H. doublet of doublets, J=15 & 7.5 Hz); 4.05-4.46 (6H, multiplet).

PREPARATION 32

ethyl

2-chloro-3-{4-[2-(6-hydroxy-2.5.7.8-tetramethylchroman-2-yl)ethoxy]phenyl}propionate

Rf value: 0.42 (thin layer chromatography, silica gel, developing solvent: 20:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 460 (M+).

ppm: 2.6 (2H, broad triplet, J=6 Hz); 3.11 (1H, doublet of doublets, J=15 & 7.5 Hz); 3.27 (1H, doublet of doublets, J = 15 & 7.5 Hz; 4.05-4.5 (6H, multiplet).

PREPARATION 33

ethyl

3-[4-(6-acetoxy-2.7-dimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate

Rf value: 0.45 (thin layer chromatography, silica gel, developing solvent: 20:1 by volume mixture of benzene 35 and ethyl acetate).

Mass spectrum (m/e): $460 (M^{+})$.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.7 (2H, broad triplet, J=6 Hz); 3.12 (1H, doublet of doublets, J=15 & 7.5 Hz); 3.27 (1H, doublet of dou-40 blets, J=15 & 7.5 Hz); 3.90-4.45 (5H, multiplet). blets, J = 15 & 7.5 Hz); 3.8-4.45 (5H, multiplet).

PREPARATION 34

ethyl

3-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)ethoxy]phenyl}-2-chloropropionate

Rf value: 0.53 (thin layer chromatography, silica gel, developing solvent: 10:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 516 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.7 (2H, broad triplet, J=6 Hz); 3.11 (1H, doublet of doublets, J = 15 & 7.5 Hz); 3.27 (1H, doublet of doublets, J=15 & 7.5 Hz); 4.03-4.50 (5H, multiplet).

PREPARATION 35

3-{4-[2-(6-acetoxy-7,8-dimethoxy-2.5-dimethylchroman-2-yl)ethoxy]phenyl}-2-chloropropionate

Rf value: 0.45 (thin layer chromatography, silica gel. developing solvent: 9:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 534 (M $^{+}$).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 65 ppm: 2.6 (2H, broad triplet, J=6 Hz); 3.10 (1H, doublet of doublets, J=15 & 7.5 Hz); 3.27 (1H, doublet of doublets, J = 15 & 7.5 Hz; 4.07-4.46 (5H, multiplet).

PREPARATION 36

ethvi

3-{4-[2-(6-acetoxy-2.5.7.8-tetramethylchroman-2-yl)ethoxy]phenyl}-2-chloropropionate

Rf value: 0.39 (thin layer chromatography, silica gel. developing solvent: 20:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 502 (M-).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.6 (2H, broad triplet, J=6 Hz); 3.06 (1H, doublet of doublets, J = 15 & 7.5 Hz); 3.32 (1H. doublet of doublets, J = 15 & 7.5 Hz; 4.05-4.45 (5H, multiplet).

PREPARATION 37

ethyl

3-[4-(6-acetoxy-2-ethyl-5,7,8-trimethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate

Rf value: 0.33 (thin layer chromatography, silica gel. developing solvent: 100:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): $502 (M^{+})$.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ Nuclear Magnetic Resonance Spectrum (CDCl₃) δ 25 ppm: 2.6 (2H, broad triplet, J=6 Hz); 3.05 (1H, doublet of doublets, J = 15 & 7.5 Hz); 3.30 (1H, doublet of doublets, J = 15 & 7.5 Hz); 3.90-4.45 (5H. multiplet).

PREPARATION 38

3-[4-(6-acetoxy-2-isobutyl-5,7.8-trimethylchroman-2ylmethoxy)phenyl]-2-chloropropionate

Rf value: 0.44 (thin layer chromatography, silica gel. developing solvent: 100:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 530 (M+).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 2.6 (2H, broad triplet, J=7 Hz); 3.05 (1H, doublet of doublets, J=15 & 7.5 Hz); 3.30 (1H, doublet of dou-

PREPARATION 39

2-(6-Benzyloxy-2,5,7,8-tetramethylchroman-2-yl)ethanol

Following the procedure described in Preparation 1, 2-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)ethanol was reacted with benzyl bromide and treated and purified to give the title compound.

Rf value: 0.31 (thin layer chromatography, silica gel. developing solvent: 10:1 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 340 (M $^+$).

Spectrum Nuclear Magnetic Resonance 55 (CDCl₃+D₂O) δ ppm: 1.31 (3H, singlet): 1.67-2.37 (4H, multiplet); 2.10 (3H, singlet); 2.17 (3H, singlet); 2.23 (3H, singlet); 2.65 (2H, broad triplet, J = 6 Hz); 3.90 (2H, triplet, J=6 Hz); 4.72 (2H, singlet); 7.3-7.65 (5H, multiplet).

PREPARATION 40

6-Benzyloxy-2,5,7,8-tetramethyl-2-[2-(4-nitrophenoxy)ethyl]chroman

2-(6-Benzyloxy-2,5,7,8-tetramethylchroman-2-yl)ethanol (prepared as described in Preparation 39) was reacted with p-chloronitrobenzene and the reaction mixture was treated and purified as described in Preparation 2, to give the title compound.

53

Rf value: 0.43 (thin layer chromatography, silica gel, developing solvent: benzene).

Mass spectrum (m/e): 461 (M-).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.37 (3H, singlet); 1.90 (2H, triplet, J=6 Hz); 2.11 5 (3H, singlet); 2.18 (3H, singlet); 2.24 (3H, singlet); 2.0-2.3 (2H, nd); 2.66 (2H, triplet, J=6 Hz); 4.32 (2H, triplet, J=6 Hz); 4.73 (2H, singlet); 6.94 (2H, doublet, J=9 Hz); 7.3-7.65 (5H, multiplet); 8.20 (2H, doublet, J=9 Hz).

PREPARATION 41

2-[2-(4-Aminophenoxy)ethyl]-6-hydroxy-2.5.7.8-tetramethylchroman

6-Benzyloxy-2,5,7.8-tetramethyl-2-[2-(4-nitrophenox-y)ethyl]chroman (prepared as described in Preparation 40) was catalytically reduced and then the reaction mixture was processed as described in Preparation 5. The resulting crude product was purified by silica gel column chromatography and the title compound was 20 obtained from the fractions eluted with a 4:1 by volume mixture of benzene and ethyl acetate.

Rf value: 0.36 (thin layer chromatography, silica gel, developing solvent: 3:2 by volume mixture of benzene and ethyl acetate).

Mass spectrum (m/e): 341 (M-).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.32 (3H, singlet); 1.87 (2H, triplet, J=6 Hz); 2.10 (6H, singlet); 2.15 (3H, singlet); 2.0-2.3 (nd); 2.64 (2H, broad triplet, J=6 Hz); 3.2-4.1 (2H, broad singlet); 4.12 ³⁰ (3H, triplet, J=6 Hz); 6.60 (2H, doublet, J=9 Hz); 6.75 (2H, doublet, J=9 Hz).

PREPARATION 42

6-Hydroxy-2,5,7.8-tetramethyl-2-(4-nitrophenoxymethyl)chroman-4-one

A mixture of 3.9 g of 2,5-dihydroxy-3,4,6-trimethylacetophenone, 3.9 g of 4-nitrophenoxyacetone, 2.0 g of pyrrolidine and 15 g of toluene was left standing at 40 room temperature for 2 days. Dilute hydrochloric acid was then added to the reaction mixture and the mixture was extracted with diethyl ether. The remaining aqueous layer was again extracted with ethyl acetate and the ethyl acetate extract was added to the ethereal extract. 45 The resulting mixture was dried over anhydrous sodium sulfate. The solvent was distilled off from the mixture. Hexane was added to the resulting residue, and the crystals thus precipitated were collected by filtration. The crystals were subjected to silica gel column chromatography, eluted with a 5:1 by volume mixture of hexane and ethyl acetate, and then recrystallized from ethyl acetate, to yield 6-hydroxy-2,5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman-4-one. Its melting point was 199°-204° C.

Nuclear Magnetic Resonance Spectrum (hexadeuterated dimethyl sulfoxide) δ ppm: 1.43 (3H, singlet); 2.01 (3H, singlet); 2.14 (3H, singlet); 2.46 (3H, singlet); 2.67 (1H, doublet, J=16 Hz); 3.03 (1H, doublet, J=16 Hz); 4.31 (2H, singlet); 7.19 (2H, doublet, J=9 Hz); 7.92 (1H, singlet); 8.21 (2H, doublet, J=9 Hz).

PREPARATION 43

6-Acetoxy-2.5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman-4-one

A mixture of 17.7 g of 5-acetoxy-2-hydroxy-3,4,6-trimethylacetophenone. 14.6 g of 4-nitrophenoxyacetone, 7.5 g of pyrrolidine and 60 ml of benzene was left

54

standing at room temperature for one day, and then the mixture was refluxed for 7 hours using a water separator. At the end of this time, water and ethyl acetate were added to the reaction mixture and the organic layer was separated. It was then dried over anhydrous sodium sulfate. The solvent was distilled off and the resulting residue was subjected to silica gel column chromatography, eluted with a 2:1 by volume mixture of hexane and ethyl acetate, to yield 6-acetoxy-2,5,7,8-tetramethyl-2-(4-nitrophenoxymethyl)chroman—one.

Rf value: 0.17 (thin layer chromatography, silica gel, developing solvent: hexane:ethyl acetate=3:1 by volume).

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.56 (3H. singlet); 2.10 (6H. singlet); 2.36 (3H. singlet); 2.43 (3H. singlet); 2.70 (1H. doublet, J=15 Hz); 3.06 (1H. doublet, J=15 Hz); 4.11 (1H. doublet, J=10 Hz); 4.24 (1H. doublet, J=10 Hz); 6.98 (2H. doublet, J=9 Hz); 8.20 (2H. doublet, J=9 Hz).

PREPARATION 44

6-Acetoxy-2-(4-aminophenoxymethyl)-2.5.7,8-tetrame-thylchroman-4-one

Hydrogen gas was passed for 2 hours through a mixture of 3.6 g of 6-acetoxy-2,5,7.8-tetramethyl-2-(4-nitrophenoxymethyl)chroman-4-one. 1 g of 10% w/w palladium-on-carbon and 100 ml of methanol at room temperature under atmospheric pressure. The catalyst was then removed by filtration and the filtrate was condensed by evaporation under reduced pressure. The residue was subjected to silica gel column chromatography, eluted with a 2:1 by volume mixture of hexane and ethyl acetate, and the resulting crude product was recrystallized from acetone, to yield 6-acetoxy-2-(4-aminophenoxymethyl)-2,5,7,8-tetramethylchroman-4-one. Its melting point was 177°-178° C.

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.49 (3H, singlet); 2.09 (3H, singlet); 2.12 (3H, singlet); 2.33 (3H, singlet); 2.42 (3H, singlet); 2.65 (1H, doublet, J=15 Hz); 3.07 (1H, doublet, J=15 Hz); 3.2-3.6 (2H, broad singlet); 3.91 (1H, doublet, J=10 Hz); 4.06 (1H, doublet, J=10 Hz); 6.60 (2H, doublet, J=9 Hz); 6.75 (2H, doublet, J=9 Hz).

PREPARATION 45

Ethyl

3-[4-(6-acetoxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate

3 ml of concentrated hydrochloric acid and then an aqueous solution of 700 mg of sodium nitrite in 1.1 ml of water were added dropwise to a mixture of 2.1 g of 6-acetoxy-2-(4-aminophenoxymethyl)-2,5.7,8-tetramethylchroman-4-one and 26 ml of acetone, whilst cooling with ice. The mixture was stirred for 30 minutes at the same temperature. 7 g of ethyl acrylate were then added, after which cuprous oxide was added gradually, while keeping the reaction temperature at 30°-35° C. The reaction mixture was then stirred for I hour at room temperature. Water and benzene were added to the reaction mixture. The benzene layer was separated, washed with water and dried over anhydrous sodium sulfate. Benzene was distilled off and the residue was subjected to silica gel column chromatography, eluted with a 3:1 by volume mixture of hexane and ethyl acetate, to yield ethyl 3-[4-(6-acetoxy-2.5.7,8-tetramethyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropion-

Rf value: 0.21 (thin layer chromatography, silica gel. developing solvent: hexane:ethyl acetate=3:1 by vol-

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.24 (3H, triplet, J=7 Hz); 1.51 (3H, singlet); 2.10⁻⁵ (3H, singlet); 2.12 (3H, singlet); 2.34 (3H, singlet); 2.43 (3H. singlet); 2.67 (1H, doublet, J=15 Hz); 3.07 (1H. doublet of doublets, J=7.5 & 15 Hz); 3.10 (1H, doublet. J=15 Hz); 3.32 (1H. doublet of doublets, J=7.5 & 15 $_{10}$ Hz); 4.06 (2H. singlet); 4.18 (2H, quartet, J=7 Hz); 3.9-4.5 (1H. nd); 6.84 (2H. doublet, J=9 Hz); 7.15 (2H. doublet, J=9 Hz).

PREPARATION 46

7-t-Butyl-6-hydroxy-2-methyl-2-(4-nitrophenoxymethyl)chroman-1-one

In a similar manner to Preparation 42, a mixture of 2.0 g of 4-t-butyl-2.5-dihydroxyacetophenone, 1.9 g of 4nitrophenoxyacetone, 1.0 g of pyrrolidine and 10 ml of benzene was allowed to stand at room temperature for 2 days. To the reaction mixture was then added 10% w/w hydrochloric acid, and the crude product was extracted with ethyl acetate. The organic extract was 25 dried over anhydrous sodium sulfate, and the residue obtained by removing the solvent was subjected to silica gel column chromatography, eluted with a 10:1 by volume mixture of benzene and ethyl acetate. The resulting crude crystals were washed with cyclohexane to 30 give the desired 7-t-butyl-6-hydroxy-2-methyl-2-(4nitrophenoxymethyl)chroman-4-one.

Melting point: 205°-209° C.

Nuclear Magnetic Resonance Spectrum (hex- 35 adeuterated acetone) δ ppm: 1.39 (3H, singlet); 1.53 (9H. singlet); 2.70 (1H, doublet, J = 16.5 Hz); 3.05 (1H, doublet, J = 16.5 Hz); 4.37 (2H, singlet); 6.80 (1H, singlet); 7.18 (2H, doublet, J = 10 Hz); 7.22 (1H, singlet); 8.22 (2H, doublet, J = 10 Hz); 8.31 (1H, singlet, D).

PREPARATION 47

6-Acetoxy-7-t-butyl-2-methyl-2-(4-nitrophenoxymethyl)chroman-4-one

A mixture of 1.7 g of 7-t-butyl-6-hydroxy-2-methyl-2-(4-nitrophenoxymethyl)chroman-4-one. I ml of acetic anhydride and 10 ml of pyridine was allowed to stand at room temperature for 1 day. The reaction mixture was then poured into ice-water and stirred for 2 hours, and 50 added to the reaction mixture, and the organic layer the crude substance was extracted with benzene. The organic solution was washed successively with 3N hydrochloric acid, water, a saturated aqueous solution of sodium bicarbonate and water, and dried over anhydrous sodium sulfate. The solvent was evaporated off 55 under reduced pressure, and the crude product thus obtained was recrystallized from a 10:1 by volume mixture of benzene and ethyl acetate, to give the desired 6-acetoxy-7-t-butyl-2-methyl-2-(4-nitrophenoxymethyl)chroman-4-one.

Melting point: 82°-84° C.

Nuclear Magnetic Resonance Spectrum (hexadeuterated acetone) δ ppm: 1.33 (9H, singlet); 1.57 (3H, singlet); 2.33 (3H, singlet); 2.82 (1H, doublet, 65 J=16.5 Hz); 3.13 (1H, doublet, J=16.5 Hz); 4.42 (2H, singlet); 6.93 (1H, singlet); 7.25 (2H, doublet, J=9 Hz); 7.44 (1H, singlet); 8.22 (2H, doublet, J=9 Hz).

PREPARATION 48

6-Acetoxy-2-(4-aminophenoxymethyl)-7-t-butyl-2methylchroman-4-one

In a similar manner to Preparation 44, 0.9 g of 6acetoxy-7-t-butyl-2-methyl-2-(4-nitrophenoxymethyl)chroman-t-one was dissolved in 20 ml of acetic acid, and catalytic hydrogenation was performed for 5.5 hours with a hydrogen pressure of 45-55 lb/sq. inch (3.1-3.8 bars), using Pearl's apparatus, in the presence of 0.4 g of 10% w/w palladium-on-carbon. The palladiumon-carbon was removed by filtration from the reaction mixture and washed with acetic acid. The filtrate and the washings were combined, and the mixture was poured into ice-water, neutralized with sodium carbonate, and extracted with benzene. The benzene extract was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was subjected to silica gel column chromatography, eluted with a 5:1 by volume mixture of benzene and ethyl acetate, to give the desired 6-acetoxy-2-(4aminophenoxymethyl)-7-t-butyl-2-methylchroman-4-one.

Rf value: 0.24 (thin layer chromatography, silica gel, developing solvent: benzene:ethyl acetate = 5:1 by vol-

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.35 (9H, singlet); 1.52 (3H, singlet); 2.30 (3H, singlet); 2.67 (1H. doublet, J = 16.5 Hz); 3.07 (1H, doublet, J = 16.5 Hz); 3.20-3.60 (2H. broad. D); 3.92 (1H. doublet, J = 10.5 Hz); 4.07 (1H. doublet, J = 10.5 Hz); 6.58 (2H. doublet, J = 10 Hz); 6.75 (2H. doublet, J = 10Hz); 6.98 (1H, singlet); 7.49 (1H, singlet).

PREPARATION 49

Ethyl

3-[4-(6-acetoxy-7-t-butyl-2-methyl-4-oxochroman-2ylmethoxy)phenyl]-2-chloropropionate

In a similar manner to Preparation 45, to a mixture of 0.42 g of 6-acetoxy-2-(4-aminophenoxymethyl)-7-tbutyl-2-methylchroman-4-one and 5 ml of acetone were added dropwise, whilst cooling with ice, 0.2 ml of concentrated hydrochloric acid and then a solution of 0.09 g of sodium nitrite in 0.5 ml of water. 1.1 g of ethyl acrylate were then added dropwise, after which 16 mg of cuprous oxide were added gradually to the mixture. whilst keeping its temperature at 40°-43° C. Evolution of nitrogen ceased after about 30 minutes. Benzene was was separated. The resulting benzene extract was washed with water and dried over anhydrous sodium sulfate. The residue after evaporation of the benzene was subjected to silica gel column chromatography, eluted with a 20:1 by volume mixture of benzene and ethyl acetate, to give the desired ethyl 3-[4-(6-acetoxy-7-t-butyl-2-methyl-4-oxochroman-2-ylmethoxy)phenyl]-2-chloropropionate.

Rf value: 0.61 (thin layer chromatography, silica gel, 60 developing solvent: benzene:ethyl acetate = 5:1 by vol-

Nuclear Magnetic Resonance Spectrum (CDCl₃) δ ppm: 1.25 (3H, triplet, J = 7 Hz); 1.35 (9H, singlet); 1.55 (3H, singlet); 2.32 (3H, singlet); 2.70 (1H, doublet, J = 16.5 Hz); 2.95-3.50 (3H, multiplet); 3.90-4.50 (5H, multiplet); 6.87 (2H. doublet, J=9 Hz); 7.00 (1H, singlet); 7.17 (2H. doublet, J=9 Hz); 7.50 (1H. singlet).

We claim:

1. Compounds of formula (I):

in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group:

R³ represents hydrogen: C₁-C₀ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O. S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ ₂₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3;

W represents the —CH₂—, >CO or >CH—OR° group (in which R° represents any one of the atoms 30 or groups defined for R³ and may be the same as or different from R³); and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

2. Compounds as claimed in claim 1. in which; R^3 represents hydrogen, a C_1 - C_0 aliphatic acyl group, one of said aromatic acyl groups or one of said heterocyclic acyl groups.

3. Compounds as claimed in claim 1, in which: Y 40 represents an oxygen atom; R^1 and R^2 are the same or different and each represents hydrogen or a C_1 - C_5 alkyl group; R^3 represents hydrogen, a C_1 - C_6 aliphatic acyl group, one of said aromatic acyl groups or a pyridine-carbonyl group; and R^4 and R^5 are the same or different 45 and each represents hydrogen, a C_1 - C_5 alkyl group or a C_1 or C_2 alkoxy group.

4. Compounds as claimed in claim 3, in which: R^1 , R^2 , R^4 and R^5 are the same or different and each represents hydrogen or a C_1 – C_5 alkyl group; n is 1 or 2; and W 50 represents the — CH_2 — or >CO group.

5. Compounds as claimed in claim 4, in which R^3 represents a hydrogen atom, a C_1 - C_5 aliphatic acyl group, or the benzoyl or nicotinoyl group.

6. Compounds as claimed in claim 5, in which: R¹ and 55 R⁴ are the same or different and each represents a C₁-C₅ alkyl group; R² and R⁵ are the same or different and each represents the hydrogen atom or the methyl group; and R³ represents hydrogen or a C₁-C₄ aliphatic acyl group.

7. Compounds as claimed in claim 1, in which: W represents the $-CH_2-$ or >CO group; Y and Z both represent oxygen atoms; n is 1 or 2; R^1 and R^4 are the same or different and each represents a C_1-C_4 alkyl group; R^2 and R^5 are the same or different and each 65 represents the hydrogen atom or the methyl group; and R^3 represents hydrogen or a C_1-C_4 aliphatic acyl group.

8. Compounds as claimed in claim 7, in which n is 1.

 Compounds as claimed in claim 7 or claim 8, in which W represents the —CH₂— group.

10. Compounds as claimed in claim 1, selected from the group consisting of:

5-[4-(6-hydroxy-2.5.7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(2-ethyl-6-hydroxy-5,7.8-trimethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-5.7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-{4-[2-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2yl)ethoxy]benzyl}thiazolidine-2,4-dione

5-{4-[2-(6-hydroxy-7.8-dimethoxy-2,5-dimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(2-ethyl-6-hydroxy-5.7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-acetoxy-2.5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-benzoyloxy-2.5,7,8-tetramethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-butyryloxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(2.5,7,8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2-isobutyl-5.7.8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4dione

5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-2-isobutyl-5.7.8-trimethyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-acetoxy-2.5,7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)e-thoxy]benzyl}-2-iminothiazolidin-4-one

5-{4-[2-(6-acetoxy-7,8-dimethoxy-2,5-dimethylchro-man-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one and pharmaceutically acceptable salts thereof.

11. The compound as claimed in claim 1.

5-[4-(6-hydroxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione and pharmaceutically acceptable salts thereof.

12. The compound as claimed in claim 1.

5-[4-(2-ethyl-6-hydroxy-5.7.8-trimethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

13. The compound as claimed in claim 1.

5-{4-(2-(7-t-butyl-6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione and pharmaceutically salts thereof.

14. The compound as claimed in claim 1.

5-[4-(6-hydroxy-2-isobutyl-5,7.8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 10 pharmaceutically acceptable salts thereof. atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₀ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3; and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

20. Compounds of formula (Ib):

15. The compound as claimed in claim 1.

5-[4-(6-acetoxy-2.5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

16. The compound as claimed in claim 1,

5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

17. The compound as claimed in claim 1,

5-[4-(6-hydroxy-2,5.7,8-tetramethyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

18. The compound as claimed in claim 1,

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

19. Compounds of formula (la):

in which:

 R^1 and R^2 are the same or different and each represents hydrogen or a C_1 - C_5 alkyl group;

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino: naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group:

n is 1, 2 or 3; and

(Ia)

$$\begin{array}{c|c}
R^4 & CH_2 - CH & C=Y \\
R^3O & R^2 & NH
\end{array}$$

in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group;

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

21. Compounds of formula (Ic):

cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substitutents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, 65 halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero

in which:

 R^1 and R^2 are the same or different and each represents hydrogen or a C_1 - C_5 alkyl group:

R³ represents hydrogen: C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy,

61

62

halogen, nitro, amino and $di(C_1-C_4)$ alkyl)amino: naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O. S or N hetero atoms; phenyl(C_2-C_3)aliphatic acyl; cinnamoyl; (C_1-C_0 alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3;

R° represents any one of the atoms or groups defined for R³ and may be the same as or different from R³;

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmateutically acceptable salts thereof.

22. Compounds as claimed in claim 1 or claim 19, which are salts with cations.

23. Compounds as claimed in claim 1 or claim 19, in the form of the sodium salt.

24. A pharmaceutical composition for the treatment of hyperlipaemia or hyperglycaemia, which comprises at least one active compound in admixture with a pharmaceutically acceptable carrier or diluent, wherein said active compound is selected from compounds of formula (I):

$$R^{3}O$$
 R^{2}
 W
 $(CH_{2})_{n}-O$
 $CH_{2}-CH$
 $C=Y$
 NH
 Z

in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group:

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a ⁵⁰ C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3:

W represents the —CH₂—, >CO or >CH—OR⁶ group (in which R⁶ represents any one of the atoms or groups defined for R³ and may be the same as or 55 different from R³); and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

25. Compositions as claimed in claim 24, in which: R³ 60 represents hydrogen, a C₁-C₆ aliphatic acyl group, one of said aromatic acyl groups or one of said heterocyclic acyl groups.

26. Compositions as claimed in claim 24, in which: Y represents an oxygen atom; R¹ and R² are the same or 65 different and each represents hydrogen or a C₁-C₅ alkyl group; R³ represents hydrogen, a C₁-C₆ aliphatic acyl group, one of said aromatic acyl groups or a

pyridinecarbonyl group; and R^4 and R^5 are the same or different and each represents hydrogen, a C_1 - C_5 alkyl group or a C_1 or C_2 alkoxy group.

27. Compositions as claimed in claim 26, in which: R^1 , R^2 , R^4 and R^5 are the same or different and each represents hydrogen or a C_1 – C_5 alkyl group; n is 1 or 2; and W represents the — CH_2 — or >CO group.

28. Compositions as claimed in claim 27, in which R^3 represents a hydrogen atom, a C_1 - C_5 aliphatic acyl

group, or the benzoyl or nicotinoyl group.

29. Compositions as claimed in claim 28, in which: R¹ and R⁴ are the same or different and each represents a C₁-C₅ alkyl group; R² and R⁵ are the same or different and each represents the hydrogen atom or the methyl group; and R³ represents hydrogen or a C₁-C₄ aliphatic acyl group.

30. Compositions as claimed in claim 24, in which: W represents the $-CH_2-$ or >CO group; Y and Z both represent oxygen atoms; n is 1 or 2; R^1 and R^4 are the same or different and each represents a C_1-C_4 alkyl group; R^2 and R^5 are the same or different and each represents the hydrogen atom or the methyl group; and R^3 represents hydrogen or a C_1-C_4 aliphatic acyl group.

31. Compositions as claimed in claim 30, in which n is

32. Compositions as claimed in claim 30 or claim 17, in which W represents the —CH₂— group.

33. Compositions as claimed in claim 24, wherein said active compound is selected from the group consisting of:

5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione

5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-{4-[2-(6-hydroxy-2.5,7,8-tetramethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

5-{4-[2-(6-hydroxy-7,8-dimethoxy-2.5-dimethylchroman-2-yl)ethoxy]benzyl}thiazolidine-2.4-dione

5-[4-(6-hydroxy-2.7-dimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(7-t-butyl-6-hydroxy-2-methylchroman-2-ylme-thoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-2,7-dimethylchroman-2-ylmethoxy)-benzyl]-2-iminothiazolidin-4-one

5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-benzoyloxy-2,5,7,8-tetramethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-butyryloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(2.5.7,8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2.5,7,8-tetramethyl-4-oxochroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

10

5-[4-(7-t-butyl-6-hydroxy-2-methyl-t-oxochroman-2-ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-hydroxy-2-isobutyl-5.7,8-trimethyl-1-0xochroman-2-ylmethoxy)benzyl]thiazolidine-2.4dione

5-[4-(6-hydroxy-2.5.7.8-tetramethyl-4-oxochroman-2ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethyl-1-oxochroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one

5-[4-(6-acetoxy-2.5,7,8-tetramethyl-4-oxochroman-2ylmethoxy)benzyl]thiazolidine-2.4-dione

5-[4-(6-acetoxy-5,7,8-trimethylchroman-2-ylmethox-15 y)benzyl]-2-iminothiazolidin-4-one

5-{4-[2-(6-acetoxy-7-t-butyl-2-methylchroman-2-yl)e-thoxy|benzyl}-2-iminothiazolidin-4-one

5-{4-[2-(6-actoxy-7,8-dimethoxy-2,5-dimethylchro-man-2-yl)ethoxy]benzyl}-2-iminothiazolidin-4-one 20 and pharmaceutically acceptable salts thereof.

34. Compositions as claimed in claim 24, wherein said

 R^1 and R^2 are the same or different and each represents hydrogen or a C_1 - C_5 alkyl group:

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O. S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3; and

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

36. Compositions as claimed in claim 24, in which said active compound is selected from compounds of formula (Ib):

$$\begin{array}{c|c}
R^4 & C & CH_2 - CH & C = Y \\
R^{3}O & R^{2} & NH & Z
\end{array}$$

active compound is selected from the group consisting of:

5-[4-(6-hydroxy-2,5.7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(2-ethyl-6-hydroxy-5,7,8-trimethylchroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

5-{4-[2-(7-t-butyl-6-hydroxy-2-methylchroman-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione

5-[4-(6-hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylme-thoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-butyryloxy-2,5.7.8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(6-hydroxy-2,5,7,8-tetramethyl-4-oxochroman-2ylmethoxy)benzyl]thiazolidine-2,4-dione

5-[4-(7-t-butyl-6-hydroxy-2-methyl-4-oxochroman-2- 50 ylmethoxy)benzyl]thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

35. Compositions as claimed in claim 24, in which said active compound is selected from compounds of formula (1a):

in which:

in which:

R¹ and R² are the same or different and each represents hydrogen or a C₁-C₅ alkyl group:

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O. S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represent hydrogen, a C₁-C₅ alkyl group or a C₁-C₅ alkoxy group, or R⁴ and R⁵ together represent a C₁-C₄ alkylenedioxy group;

n is 1, 2 or 3;

and

Y and Z are the same or different and each represents the oxygen atom or the amino group:

and pharmaceutically acceptable salts thereof.

37. Compositions as claimed in claim 24, in which

$$\begin{array}{c}
R^4 \\
R^3O
\end{array}$$

$$\begin{array}{c}
R^1 \\
(CH_2)_n - O
\end{array}$$

$$\begin{array}{c}
CH_2 - CH \\
S \\
NH
\end{array}$$

$$\begin{array}{c}
C = Y \\
NH
\end{array}$$

said active compound is selected from compounds of formula (Ic):

in which:

 R^1 and R^2 are the same or different and each represents hydrogen or a C_1 - C_5 alkyl group;

R³ represents hydrogen; C₁-C₆ aliphatic acyl; (C₅-C₇ cycloalkane)carbonyl; benzoyl, benzoyl substituted with one to three substituents selected from the group of C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, halogen, nitro, amino and di(C₁-C₄ alkyl)amino; naphthoyl; 4-7 membered heterocyclic acyl wherein heterocyclic moiety has O, S or N hetero atoms; phenyl(C₂-C₃)aliphatic acyl; cinnamoyl; (C₁-C₆ alkoxy)carbonyl; or benzoyloxycarbonyl;

R⁴ and R⁵ are the same or different and each represents hydrogen, a C₁-C₅ alkyl group or a C₁-C₅

alkoxy group, or R^4 and R^5 together represent a C_1 - C_4 alkylenedioxy group;

n is 1, 2 or 3;

(Ic)

R6 represents any one of the atoms or groups defined for R3 and may be the same as or different from R3;

Y and Z are the same or different and each represents the oxygen atom or the imino group; and pharmaceutically acceptable salts thereof.

38. Compositions as claimed in claim 24 or claim 35, wherein said active compound is in the form of a salt with a cation.

39. Compositions as claimed in claim 24 or claim 35, wherein said active compound is in the form of the sodium salt.

30

35

40

45

50

55

60

65

EXHIBIT 5

EXHIBIT 5 CERTIFICATE OF CORRECTION

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. :

4,572,912

PAGE 1 OF 2.

: February 25, 1986

INVENTOR(S): Takao YOSHIOKA et al

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the title page of the patent:

Under the heading of "References Cited", change the name of the inventor of the second listed reference to --Kawamatsu--.

Insert a third reference as follows:

--4,287,200

9/1981 Kawamatsu--.

In the Abstract:

The left-hand column, line 8, change ${}^{\circ}C_{1}14C_{4}{}^{\circ}$ to ·-c₁-c₄--.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. :

4,572,912

PAGE 2 OF 2.

DATED

February 25, 1986

INVENTOR(S):

Takao YOSHIOKA et al

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 19, equation (Ie), appearing at lines 10 - 15, change the "W" in the second segment of equation to

Column 62 (Claim 32), line 27, change "claim 30 or claim 17" to --claim 30 or claim 31--.

Signed and Sealed this

Twentieth Day of January, 1987

Am

Attesting Officer

DONALD ! QUIGG

Commissioner of Patents and Trademarks

EXHIBIT 6

EXHIBIT 6 MAINTENANCE FEE PAYMENT RECEIPTS



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D. C. 20231

PAYOR NUMBER 001933

RECEIVED

APR 28 1989

FRISHAUF, HOLTZ, GOODMAN & HOODHARD, P.C.

600 THIRD AVENUE - 30TH FLOOR NEW YORK, NY 10016 FRISHAUF, HOLTZ, GOODMAN & WOODWARD, P.C. DATE HAILED 04/25/89

069714

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will concer in column 10, "status" below.

If a maintenance fee payment is defective, the reason is indicated by code in column 10, "status" below. An explanation of the codes appears on the reverse of the Maintenance Fee Statement. TIMELY CORRECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(k) and (l).

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

ITH NBR	PATENT NUMBER		FEE AMOUNT	SUR CHARGE	SERIAL NUMBER	PATENT DATE	FILE Date		SML ENT	STAT
1	4,547,513	173	450		06/679,466	10/15/85	12/07/84	04	ΝО	PAID
2	4,550,143	173	450		06/616,601	10/29/85	06/01/84	04	ИÜ	PAID
3	4+550+145	173	450		06/559,381	10/29/85	12/08/83	0.4	NO	PAID
9	4.550.134	173	450		06/644,784	10/29/85	08/27/84	04	ИO	PAID
5	4,572,912	173	450		06/644,996	02/25/86	08/28/84	04	ИО	PAID

If the "status" column for a patent number listed above does not indicate "PAID" a code or an asterisk (*) will appear in the "status" column. Where an asterisk (*) appears, the codes are set out below by the related item number. An explanation of the codes indicated in the "status" column and as set out below by the related item number appears on the reverse of the maintenance fee statement.

ITH ATTY DKT
NBR NUMBER
1 84874
2 84364
3

DIRECT THE RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE \$65.65 COMMISSIONER OF PATENTS AND TRADEMARKS, BOX M. FEE, WASHINGTON, DC 202346



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D. C. 20231 Address:

PAYOR NUMBER 001933

FRISHAUF, HOLTZ, GOODMAN &

WOODWARD, P.C.

600 THIRD AVENUE - 30TH FLOOR

NEW YORK, NY 10016

9200

DATE MAILED 03/22/93

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will appear in column 10, "status" below.

If a maintenance fee payment is defective, the reason is indicated by code in column 10, "status" below. An explanation of the codes appears on the reverse of the Maintenance Fee Statement. TIMELY COR-RECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(k) and (I).

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

ITM NBR			FEE AMOUNT	SUR CHARGE	SERIAL NUMBER	PATENT DATE				
1	4,572,912	184	1870		06/644,996	02/25/86	08/28/84	08	NO	PAID

If the "status" column for a patent number listed above does not indicate "PAID" a code or an asterisk (*) will appear in the "status" column. Where an asterisk (*) appears, the codes are set out below by the related item number. An explanation of the codes indicated in the "status" column and as set out below by the related item number appears on the reverse of the maintenance fee statement.


> ITM NBR

ATTY DKT NUMBER -

84566~HV

DIRECT THE RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE TO: COMMISSIONER OF PATENTS AND TRADEMARKS, BOX M. FEE, WASHINGTON, DC 20231 EXHIBIT 7

EXHIBIT 7 IND SUBMISSION LETTER



1425 BROAD STREET CLIFTON, NEW JERSEY 07013-4221 (201) 777-2800

January 30, 1989 Ref. No. 19-91

Department of Health and Human Services Food and Drug Administration 5600 Fishers Lane Rockville, Maryland 20857

Attention: Solomon Sobel, M.D. - Director

Division of Metabolism and Endocrine Drug Products

Dear Dr. Sobel:

Submitted herewith in triplicate is an initial IND application provided on behalf of Sankyo Company Ltd., Tokyo, Japan. This IND contains information on Sankyo research compound CS-045, an oral hypoglycemic agent.

Also provided with this letter, is a letter dated January 4, 1989 from Dr. Akira Ogiso, Director, Research Planning Department of Sankyo Company, Ltd. authorizing Oxford Research International Corp. as the agent and representative to the FDA on behalf of Sankyo Company Ltd. for this IND.

Provided within this IND is a clinical protocol entitled, "Mechanism of Action Studies on CS-045, A New Oral Hypoglycemic Agent in Patients with Non-Insulin Dependent Diabetes Mellitus". This study will be conducted by Dr. Jerrold M. Olefsky, University of California, San Diego School of Medicine.

Please do not hesitate to contact me if you have any questions concerning the IND.

Thank you for your cooperation.

Sincerely,

William M. Troetel, Ph.D. Senior Vice President

WEST COAST OFFICE (213) 670-5300

MIDWEST OFFICE (515) 472-1833

The 2. Tunte

TELEX: 170942 OXFRD FAX: (201) 777-9847



SANKYO CO., LTD.

Cable: DIASTASE TORTO Telex: 724838 DIASTASE Tel: (03) 562-0411 Fax: (03) 561-5409

No. 7-12, Ginza 2-chome, Chuo-ku,
Tokyo 104, Japan.

January 4, 1989

Department of Health and Human Services U.S. Food and Drug Administration 5600 Fishers Lane Rockville, Maryland 20857, USA

Attention: Solomon Sobel, M.D., Director
Division of Metabolic and Endocrine Drug Products

Dear Dr. Sobel:

This letter will serve to inform you that Dr. William M. Troetel, Senior Vice President, Oxford Research International Corp., 1425 Broad Street, Clifton, New Jersey 07013, USA, has been named our agent and representative in the United States for filing of an Investigational New Drug Application for CS-045, a novel oral hypoglycemic, and subsequent clinical studies.

This letter authorizes Dr. Troetel and Oxford Research to act on behalf of Sankyo Company, Ltd. to submit filings to FDA and to receive responses from FDA on our behalf. They may also from time to time, request meetings with various divisions within FDA to discuss matters pertinent to research interests of the Sankyo Company, Ltd.

Please feel free to contact me if there are any questions concerning this matter.

Thank you for your cooperation.

Sincerely,

Akira Ogiso, Ph.D.

Director

Research Planning Department

cc: William M. Troetel, Ph.D.
 Oxford Research International Corp.

DEPARTMENT OF HEALTH AND HUMAN SERVICES form Approved: OM8 No. 0910-0014 Expiration Date: November 30, 1987. PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION NOTE: No drug may be shipped or clinical INVESTIGATIONAL NEW DRUG APPLICATION (IND) investigation begun until an IND for that investigation is in effect (21 CFR 312.40). (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) Part 312) I. NAME OF SPONSOR 2. DATE OF SUBMISSION Sankyo Co., Ltd. January 30, 1989 3. ADDRESS (Number, Street, City, State and Zip Code) 4. TELEPHONE NUMBER (Include Area Code) 7-12, 2-Chome, Ginza Chuo-ku Tokyo 104, Japan D11-813-562-0411 5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) 6. IND NUMBER (If previously assigned) CS-045 7. INDICATION(S) (Covered by this submission) Oral hypoglycemic agent 8. PHASE (S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: PHASE 1 OTHER ☐ PHASE 2 ☐ PHASE 3 (Specify) 9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314). DRUG MASTER FILES (21 CFR 314.420). AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. 10. IND submissions should be consecutively numbered. The initial IND should be numbered SERIAL NUMBER: "Serial Number: 000." The next submission (i.e., amendment, report, or correspondence) should be numbered "Serial Number: 001." Subsequent submissions should be numbered $\sigma \sigma \sigma$ consecutively in the order in which they are submitted. 11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply) ☑ INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND) PROTOCOL AMENDMENT(S): INFORMATION AMENDMENT(S): IND SAFETY REPORT(S): ☐ NEW PROTOCOL CHEMISTRY/MICROBIOLOGY ☐ INITIAL WRITTEN REPORT ☐ PHARMACOLOGY/TOXICOLOGY ☐ CHANGE IN PROTOCOL FOLLOW-UP TO A WRITTEN REPORT CLINICAL INEW INVESTIGATOR RESPONSE TO FDA REQUEST FOR INFORMATION ANNUAL REPORT RESPONSE TO CLINICAL HOLD ☐ GENERAL CORRESPONDENCE REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN. OTHER INACTIVATED, TERMINATED OR DISCONTINUED (Specify) Refer to the designated CFR citations before checking any of the following: ☐ TREATMENT IND 21 CFR 312.35(b) ☐ TREATMENT PROTOCOL 21 CFR 312.35(a) ☐ CHARGE REQUESTMOTIFICATION 21 CFR 312.7(d) FOR FDA USE ONLY CDR/DBIND/DGD RECEIPT STAMP DDR RECEIPT STAMP IND NUMBER ASSIGNED: DIVISION ASSIGNMENT:

RM FDA 1571 (8/87)

PREVIOUS EDITION IS OBSOLETE.

	12. CONTENTS OF APPLICATION								
	This application contains the following items: (check all that apply)								
į	[A 1. Form FDA 1571 [21 CFR 312.23 (a) (1)]								
6	1 2. Table of contents [21 CFR 312.23 (a) (2)]								
	[3. Introductory statement [21 CFR 312.23 (a) (3)]								
	및 4. General investigational plan [21 CFR 312.23 (a) (3)]								
	☐ 5. Investigator's brochure [21 CFR 312.23 (a) (5)]								
1	6. Protocol(s) [21 CFR 312.23 (a) (6)]								
ı	ু a. Study protocol(s) [21 CFR 312.23 (a) (6)]								
1	」 b. Investigator data [21 CFR 312.23 (a) (6)(iii)(b)] or completed Form(s) FDA 1572								
	(c. Facilities data (21 CFR 312.23 (a) (6)(iii)(b)) or completed Form(s) FDA 1572								
1	d. Institutional Review Board data [21 CFR 312.23 (a) (6)(iii)(b)] or completed Form(s) FDA 1572								
1	7. Chemistry, manufacturing, and control data [21 CFR 312.23 (a) (7)]								
	a. Environmental assessment or claim for exclusion [21 CFR 312.23 (a) (7)(iv)(e)]								
1	의 8. Pharmacology and toxicology data [21 CFR 312.23 (a) (8)]								
1	9. Previous human experience [21 CFR 312.23 (a) (9)]								
	☐ 10. Additional information [21 CFR 312.23 (a) (10)]								
I	13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION?								
ı	IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION? 🛭 YES 👚 🗆 NO								
ì	IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.								
L	A CONTRACTOR AND A COSTING OF THE OBLIGATIONS TRANSFERRED.								
	14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS								
l	Stanley B. Garbus, M.D. Oxford Research International Corp.								
l	1425 Broad Street								
r	Clifton, N.J. 07013 Tel: 201 777-2800 15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRING.								
	THE DRUG								
l	Akira Ogiso, Ph.D.; Director, Research Planning Department Hiroyoshi Horikoshi, D.V.M., Ph.D., Chief Researcher, Biological								
(Research Labs. Sankyo Co., Ltd. Tokyo, Japan								
	lagree not to begin clinical investigations until 30 days after FDA's receipt of the IND or on earlier notification								
	by FDA. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements								
	set forth in 21 Crk Part 36 will be responsible for the initial and continuing review and approval of each of the								
ı	studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.								
H	16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED 17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED								
	REPRESENTATIVE REPRESENTATIVE								
Ľ	Senior Vice President								
	8. ADDRESS (Number, Street, City, State and Zip Code) Oxford Research International Corp (Include Area Code) 20. DATE								
-	1425 Broad Street Tel:201-777-2800								
É	Clifton, N.J. 07013 Fax:201-777-9847								
. (WARNING: A willfully false statement is a criminal offense USC Title 18, Sec. 1001.)								

EXHIBIT 8

EXHIBIT 8 IND ACKNOWLEDGEMENT LETTER

Public Health Service

me por

Food and Dray Administration Rockyine IND SUCSY

IND 32,703

NOU-14-1994 12:46 FROM

FFR -9 1989

Sankyo Co., Ltd. Attention: William M. Troetel, Ph.D. 7-12, 2-Chome, Ginza Chuo-ku Tokyo 104, Japan

Dear Sir/Macain:

We are pleased to acknowledge receipt of your Investigational New Drug Application (IND) submitted under section 505(1) of the Federal Pood, Drug, and Cosmetic Act. Please note the following identifying data:

SANKYO U.S.A. CORP.

THD number assigned: 32,703

Sponsor: Sankyo Co., Ltd.

Name of Drug: CS-045

Date of Submission: January 30, 1989

Date of Receipt: February 7, 1989

IT IS UNDERSTOOD THAT STUDIES IN BUILDING WILL HOP BE INITIATED UNTIL 30 DAYS AFTER THE DATE OF RECEIPT SHOWN ABOVE. If, within the 30 day period, we notify you of serious deficiencies that require correction before human studies can begin or that would require restriction of human studies until correction, it is understood that you will continue to withhold or restrict such studies until you are notified that the material you have submitted to correct the deficiencies is satisfactory.

You are responsible for compliance with the Pederal Food, Drug and Counstic Act and Regulations. This responsibility includes the immediate reporting of any alarming adverse reservois in either animal or human studies, and submission of progress reports at intervals not to exceed one year.

.32,703

Page 2

s sponsor of the clinical study proposed under this IND, you are now free to utain supplies of the investigational drug.

lease forward all future communications concerning this IND in TRIPLICATE, DENTIFIED WITH THIS IND NUMBER and addressed as follows:

Pood and Drug Administration
Center for Drug Evaluation and Research, HFD-510
Attention: DOJUMENT CONTROL ROOM 14803
5000 Fishers Lane
Rockville, Maryland 20857

:nould you have any questions concerning this IND, please cull me at $301)\ 443-\ 3510$.

mostilister

Consumer Safety Officer

Division of Metabolism and Enducrine

Drug Products

Binderely yours,

Center for Drug Evaluation and Research

EXHIBIT 9

.

EXHIBIT 9 OCTOBER 12, 1990 IND TRANSFER LETTER

SANKYO U.S.A. CORPORATION

780 THIRD AVENUE, SUITE 2301 **NEW YORK, N.Y. 10017**

October 12, 1990

Solomon Sobel, M.D. Director, Division of Metabolic and Endocrine Drug Products/HFD-510 Attn: Document Control Room 14B-03 Office of Drug Research and Review II National Center for Drugs and Biologics Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 USA

IND 32,703 Re: CS-045 Tablets Serial/Amendment #008

Dear Dr. Sobel:

This is to advise you that effective October 12, 1990, Sankyo U.S.A. Corporation will be the sponsor for the Investigational New Drug Application, IND #32,703, relating to the oral hypoglycemic agent, CS-045 Tablets. This IND is-being transferred from Sankyo Co. Ltd., Tokyo, as stated in the enclosed letter addressed to you, dated October 5, 1990, from Sankyo Co. Ltd. Tokyo, as well as in the letter, dated October 9, 1990, from Oxford Research International Corporation.

Sankyo U.S.A. Corporation accepts the responsibility for this IND and agrees to comply with all applicable FDA regulations. Enclosed is a completed and signed Form 1571.

In this regard, we are also enclosing the curriculum vitae of the staff of Sankyo U.S.A. Corporation who will be responsible for monitoring the conduct and progress of further CS-045 clinical investigations as well as for the review and evaluation of information relevant to the safety of this compound.

We also acknowledge that a request was made by you, in a letter dated May 19, 1989, for additional data prior to the initiation of further studies. We will now compile data towards satisfying this request, but we believe that a meeting would be helpful to clarify some of the issues.

Dr. Solomon Sobel October 12, 1990 Page 2

After compiling data, we will submit these to you and formulate questions we wish to pursue; at that time, we will request a date for a meeting.

Thank you for your kind assistance in this matter.

sincerely,

Par G. Goding.

Paul G. Gooding, M.B., B.S. Director, Clinical Research for Sankyo U.S.A. Corporation

PGG/ye

Enclosures:

Submitted in triplicate.

Letter, Sankyo Co. Ltd. (Tokyo) to FDA dated October 5, 1990 Letter, Sankyo U.S.A. Corporation to FDA dated

October 12, 1990 1571 Form (Original and 2 copies)

Letter, Oxford Research International Corporation

to FDA dated October 9, 1990

EXHIBIT 10A

EXHIBIT 10A APRIL 26, 1991 IND TRANSFER LETTER

SANKYO U.S.A. CORPORATION

780 THIRD AVENUE, SUITE 2301 NEW YORK, N.Y. 10017

April 26, 1991

Solomon Sobel, M.D.
Director, Division of Metabolic and Endocrine
Drug Products/HFD-510
Attn: Document Control Room 14B-03
Office of Drug Research and Review II
National Center for Drugs and Biologics
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857, USA

Re: IND #32,703 CS-045 Tablets Amendment 012

Dear Dr. Sobel:

This is to advise you that effective April 26, 1991, Sankyo U.S.A. Corporation will transfer the Investigational New Drug Application, IND #32,703, relating to the oral hypoglycemic agent CS-045 Tablets, and all amendments thereto except:

- (1) Section 7(a), Chemistry, Manufacturing and Controls (Drug Substance), Vol. 1, pages 214 to and including 407 of the original application
- (2) Stability of CS-045 (Drug Substance) included in the 1990 Annual Report, Section III, pages 6-19 inclusive, submitted to the FDA on April 16, 1990 (IND #32,703, Amendment 006)
- (3) items/comments 1 and 2 of the Chemistry, Manufacturing and Controls (Drug Substance) section contained in our November 20, 1990 submission to the FDA (IND #32,703, Amendment 009)
- to: Parke-Davis Pharmaceutical Research Division Warner-Lambert Company 2800 Plymouth Road Ann Arbor, Michigan 48106-1047

Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, as the new sponsor, will confirm acceptance of responsibility for this IND and will formally agree to comply with all applicable F.D.A. Regulations, via letter, in the immediate future.

Solomon Sobel, M.D. April 26, 1991 Page 2

Please address all future communications relating to this IND to Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, at the address noted above, for the attention of:

Irwin G. Martin, Ph.D. Director, Worldwide Regulatory Affairs Tel: (313) 996-7756

FAX: (313) 996-7890

IND #32,703 was initially submitted to the F.D.A. on January 30, 1989, by Oxford Research International Corporation, acting as agent and representative to the F.D.A. on behalf of Sankyo Co., Ltd., Tokyo, Japan. Subsequently, on October 12, 1990, IND #32,703 was formally transferred to Sankyo U.S.A. Corporation, New York, N.Y. (Amendment 008).

Parke-Davis Pharmaceutical Division, Warner-Lambert Company has been made aware that:

- 1. A request was made from HFD-510, in a letter dated May 19, 1989, for additional data prior to the initiation of further studies.
- 2. A partial answer to the questions raised was submitted on November 20, 1990 (Amendment 009), however, certain clinical pharmacokinetic concerns were not addressed in this submission.

Sankyo Co. Ltd., Tokyo, Japan has separately filed a Type I Drug Master File (DMF #9047) and a Type II Drug Master File (DMF #9048) relating to the Chemistry and Manufacturing Controls section for the new drug substance, and has provided authorization for Parke-Davis Pharmaceutical Division, Warner-Lambert Company, to incorporate the information contained in these D.M.F.'s into their IND by cross reference.

Please add this information to the subject file.

Solomon Sobel, M.D. April 26, 1991
Page 3

Thank you for your kind assistance in this matter.

Sincerely,

Paul 4. Gooding.

Paul G. Gooding, M.B., B.S. Vice President, Medical for Sankyo U.S.A. Corporation

PGG/ye

Submitted in triplicate

cc: Dr. Irwin G. Martin, Ph.D.
Director, Worldwide Regulatory Affairs
Parke-Davis, Warner Lambert

EXHIBIT 10B

EXHIBIT 10B MAY 13, 1991 IND TRANSFER LETTER

PARKE-DAVIS

Pharmaceutical Research Division Warner-Lamber Company

May 13, 1991

IND 32,703 Serial No. 013 CS-045 (CI-991)

Re: <u>Transference of IND</u>

Solomon Sobel, M.D.
Director
Division of Metabolism and Endocrine Drug
Products (HFD-510)
Document Control Room 14B-03
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Dear Dr. Sobel:

Please be advised that effective immediately, sponsorship of IND 32,703 is transferred from Sankyo U.S.A. Corporation to Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company. A copy of the transfer letter from Sankyo is attached.

Parke-Davis assumes full responsibility for all matters relating to this IND except for drug substance manufacturing. We have received a complete copy of the IND from Sankyo Company, Ltd except for drug substance manufacturing information. Sankyo U.S.A. Corporation has opened a Type I Drug Master File (DMF #9047) and a Type II Drug Master File (DMF #9048) for drug substance updates and communication. Parke-Davis hereby commits to amending this IND with notification of any changes or updates to the drug substance information relevant to this IND as contained in the Sankyo DMFs #9047 and #9048. All communications concerning the drug substance should, therefore, be directed to Sankyo U.S.A. Corporation via DMFs #9047 and #9048.

CS-045 is also known by the Parke-Davis code name of CI-991. Future correspondence to IND 32,703 will refer to CI-991 exclusively.

Enclosed is a summary of the training and experience of the Parke-Davis medical monitor, Rebecca Norris, M.D.

Only one clinical study has been conducted under IND 32,703. Dr. Jerrold Olefsky has been notified of the change in the IND sponsors. His clinical study report is being finalized and will be submitted to the IND by Parke-Davis when it is completed.

Solomon Sobel, M.D. IND 32,073 May 13, 1991 Page 2

We commit to amend the IND within 60 days to cover any changes resulting from new ownership, and to provide for subsequent changes by amendment in accord with IND regulations.

Please address all communications concerning this IND to the undersigned.

Sincerely,

Irwin G. Martin, Ph.D. Senior Director

Worldwide Regulatory Affairs

Telephone 313\996-7756 Fax 313\996-7890

IGM/rt43091

Attachment

EXHIBIT 11A

EXHIBIT 11A NDA SUBMISSION LETTER FOR PRELAY™

SANKYO U.S.A. CORPORATION

780 THIRD AVENUE, SUITE 1700 'NEW YORK, N.Y. 10017

July 31, 1996

NDA 20-719
Ref. No. 1
Vol 1.1
Prelay™ (troglitazone) Tablets

Re: Original New Drug Application User Fee I.D. No. 3008

Food and Drug Administration Document and Records Section 12420 Parklawn Drive Rockville, Maryland 20852

Dear Sir/Madam:

Pursuant to § 505(b)(1) of the FDC Act, enclosed is a new drug application (20-719) for PrelayTM (troglitazone) Tablets. This NDA provides evidence for the use of troglitazone as an adjunct to diet in the treatment of Type II diabetes in patients who are inadequately controlled by insulin therapy.

The NDA number 20-719 was preassigned to this application on March 20, 1996.

As required under the Prescription Drug User Fee Act of 1992, 50% of the 1996 application fee (\$102,000.00) has been sent to the Food and Drug Administration in care of Mellon Bank, Philadelphia, Pennsylvania on July 10, 1996. A User Fee Cover Sheet, Form FDA 3397, follows this cover letter.

The primary data in support of this NDA were developed by Sankyo U.S.A. Corporation and the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company under IND 32,703. Other data were generated by Sankyo Co., Ltd., Japan and GlaxoWellcome Ltd., U.K.

Please include by cross-reference the complete contents of NDA 20-720 for Rezulin™ (troglitazone) Tablets, which is submitted by Parke-Davis concurrently with this NDA. Permission to cross reference the Parke-Davis NDA has been granted to Sankyo U.S.A. Corporation, and a copy of the Parke-Davis letter providing this permission is attached to this letter. Please also include in this NDA by cross reference the presubmission and any subsequent amendments to NDA 20-720. Sankyo U.S.A. Corporation has been provided with a complete copy of NDA 20-720.

Food and Drug Administration NDA 20-719 July 31, 1996 Page 2

As noted on the attached 356h, only Item 4.c.i., Labels and Labeling, and Item 13, Patent Information and Request for Exclusivity, are provided herein. The content of the labels and labeling are identical to that of Rezulin except that the brand name has been changed to Prelay and the NDC numbers will differ.

Reference to all Drug Master Files made in NDA 20-720 are also made herein. Copies of letters from all DMF holders (referenced in NDA 20-720) allowing the FDA to refer to these DMFs on behalf of Sankyo U.S.A. Corporation are located following this cover letter.

Sankyo U.S.A. Corporation is a wholly owned subsidiary of Sankyo Co., Ltd. By contractual agreement with Warner-Lambert, Sankyo U.S.A. Corporation has future rights to market troglitazone under our own brand name. We, therefore, are submitting this NDA to provide this for future marketing potential. Prior to marketing, we commit to supplement this NDA with any changes in Item 3 to provide for a Sankyo U.S.A. Corporation market-image tablet. In addition, the NDC numbers will be assigned in the future for these tablets.

Due to the significant therapeutic advance provided by troglitazone to insulin-taking patients with Type II diabetes, we feel a priority review for this new drug is appropriate.

If you need additional information or have any questions regarding this submission, please contact me at 212/753-3172 (FAX 212/308-2491).

Sincerely,

David L. Woodward, Ph.D. Vice President, Development

NDA Copies "Blue" Archive

"Tan" Medical

"Red" Chemistry

"Maroon" Field (San Juan and Newark)

"Orange" Biopharmaceutics

"Yellow" Pharmacology

"Green" Biometrics

DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG FOR HUMAN USE OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations, 314)

Form Approved: OMB No. 0910-0001 Expiration Date: Jure 30, 1992 See OMB Statement on Page 3.

FOR	FOA USE ONLY
DATE RECEIVED	DATE FLED
DIVISION ASSIGNED	NDA/ANDA NO. ASS.

NOTE: No application may be filed unles	s a completed	application form has l	been receive	ed (21 CFR Part 314).		
NAME OF APPLICANT Sankyo U.S.A. Corporation						
ADDRESS (Number, Street, City, State and Zip Code) Suite 1700			TELEPHONE NO. (Include Area Code)			
780 Third Avenue		(212) 7:	53-3172			
New York, N.Y. 10017			NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER (If previously issued)			
			20-719			
	DRUG PI	RODUCT				
ESTABLISHED NAME (e.g., USP/USAN) troglitazone	PROPRIETARY NAM Prelay tm	AE (if any)				
CI-991; CS-045; GR92132X; PD137070	CI-991; CS-045; GR92132X; PD137070 (±-5-[[4-[3,4-dihydro			o-6-hydroxy-2,5,7,8-tetramethyl-2H-1- hoxy]phenyl]methyl]-2,4-thiazolidinedione)		
SAGE FORM Fablets	ROUTE O	TE OF ADMINISTRATION STRENGTH(S)				
PROPOSED INDICATIONS FOR USE						
Type II diabetes		(1		·		
LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPRINT 314). AND DRUG MASTER FILES (21 CFR 314.420) RENDA 20-720 IND 32,703; 49-782 (NIH); 44,609 (K. Osei DMF 9047, 9048 (Sankyo Co., Ltd.) DMF 721, 4164, 9314, 1016, 1466, 2880, 19	, MD, Ohio	o St. Univ.)	W DRUG OF	R ANTIBIOTIC APPLICATIONS (21 CFR		
		ON APPLICATION	-	:		
TY	PE OF APPLICA	ATION (Check one)				
THIS SUBMISSION IS A FULL APPLICATION (21 CFR 31)	4.50)□ THIS \$	SUBMISSION IS AN A	BBREVIATE	D APPLICATION (ANDA) (21 CFR 314.55		
IF AN ANDA, IDENTIFY THE APPRO	VED DRUG PR	ODUCT THAT IS THE	BASIS FOR	THE SUBMISSION		
NAME OF DRUG	HOLDER OF APPRO	OVED APPL	ICATION			
STA	TUS OF APPLI	CATION (Check one)				
PRESUBMISSION AN AMA		A PENDING APPLICA BMISSION	TION	SUPPLEMENTAL APPLICATION		
PROPOS	ED MARKETIN	IG STATUS (Check of	ne).			
APPLICATION FOR A PRESCRIPTION DRUG PRODUCT (I) FORM FDA 356h (12/91)	Rxj	☐ APPLICATION	FOR AN O	VER - THE - COUNTER PRODUCT (OTC)		

	CONTENTS OF APPLICATION
This	application contains the following items: (Check all that apply)
	1. Index
	2. Summary (21 CFR 314.50(c))
	3. Chemistry, manufacturing, and control section (21 CFR 314.50(d)(1))
	4. a. Samples (21 CFR 314.50(e)(1)) (Submit only upon FDA's request)
	b. Methods Validation Package (21 CFR 314.50(e)(2)(i))
	c. Labeling (21 CFR 314.50(e)(2)(ii))
x	i. draft labeling (4 copies)
	ii. final printed labeling (12 copies)
	5. Nonclinical pharmacology and toxicology section (21 CFR 314.50(d)(2))
	6. Human pharmacokinetics and bioavailability section (21 CFR 314.50(d)(3))
	7. Microbiology section (21 CFR 314.50(d)(4))
	8. Clinical data section (21 CFR 314.50(d)(5))
	9. Safety update report (21 CFR 314.50(d)(5)(vi)(b))
	10. Statistical section (21 CFR 314.50(d)(6))
	11. Case report tabulations (21 CFR 314.50(f)(1))
	12. Case reports forms (21 CFR 314.50(f)(1))
х	13. Patent information on any patent which claims the drug (21 U.S.C. 355(b) or (c))
	14. A patent certification with respect to any patent which claims the drug (21 U.S.C. 355(b)(2) or (j)(2)(A))
x	15. OTHER (Specify) NDA 20-720 is included herein by cross-reference
prece subm with	se to update this application with new safety information about the drug that may reasonably affect the statement of contraindications, warnings, sutions, or adverse reactions in the draft labeling. I agree to submit these safety update reports as follows: (1) 4 months after the initial sission, (2) following receipt of an approvable letter and (3) at other times as requested by FDA. If this application is approved, I agree to comply all laws and regulations that apply to approved applications, including the following: 1. Good manufacturing practice regulations in 21 CFR 210 and 211.

3. In the case of a prescription drug product, prescription drug advertising regulations in 21 CFR 202.

4. Regulations on making changes in application in 21 CFR 314.70, 314.71, and 314.72.

5. Regulations on reports in 21 CFR 314.80 and 314.81.

6. Local, state and Federal environmental impact laws.

If this application applies to a drug product that FDA has proposed for scheduling under the controlled substances Act I agree not to market the product until the Drug Enforcement Administration makes a final scheduling decision.

NAME OF RESPONSIBLE OFFICIAL OR AGENT David L. Woodward, Ph.D. Vice-President, Development Sankyo U.S.A. Corporation

SIGNATURE OF RESPONSIBLE OFFICIAL OR AGENT

DATE

July 31, 1996

JRESS (Street, City, State, Zip Code) 780 Third Avenue (Suite 1700) New York, N.Y. 10017

TELEPHONE NO. (Include Area Code) (212) 753-3172

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)

FORM FDA 356h(12/91)

EXHIBIT 11B

A STATE OF THE STA

EXHIBIT 11B NDA SUBMISSION LETTER FOR REZULIN™

Ann Arbor, MI 48105

2800 Plymouth Road Phone: (313) 996-7756 Fac unde: (313) 998-2856



Irwin G. Martin, Ph.D. Vice President, FDA Liaison Worldwide Regulatory Affairs

July 31, 1996

NDA 20-720 Ref. No. 1 Vol 1.1 - 1.334 Rezulin™ (troglitazone) Tablets

Re: Original New Drug Application User Fee I.D. No. 2566

Food and Drug Administration Document and Records Section 12420 Parklawn Drive Rockville, Maryland 20852

Dear Sir/Madam:

Pursuant to § 505(b)(1) of the FDC Act, enclosed is a new drug application (20-720) for Rezulin™ (troglitazone) Tablets. This NDA provides evidence for the use of troglitazone as an adjunct to diet in the treatment of Type II diabetes in patients who are inadequately controlled by insulin therapy.

The NDA number 20-720 was preassigned to this application on March 20, 1996. A presubmission of the rodent carcinogenicity study reports was made to this NDA on March 27, 1996 and received by the Division of Metabolism and Endocrine Drug Products on March 28, 1996. These reports, therefore, are not included in this submission.

As required under the Prescription Drug User Fee Act of 1992, 50% of the 1996 application fee (\$102,000.00) has been sent to the Food and Drug Administration in care of Mellon Bank, Philadelphia, Pennsylvania on July 10, 1996. A User Fee Cover Sheet, Form FDA 3397, follows this cover letter (Attachment A).

In a letter from Dr. Sobel of the Division of Metabolism and Endocrine Drug Products on June 3, 1996 (IND 32,703), the trade name Rezulin™ was deemed acceptable.

The data contained in this NDA were developed by Parke-Davis under IND 32,703 as well as by our development partners Sankyo Co., Ltd. (Japan) and GlaxoWellcome Ltd. (U.K.). Sankyo U.S.A. Corporation conducted one study under IND 32,703 which is also contained in this NDA.

Food and Drug Administration NDA 20-720 July 31, 1996 Page 2

Reference is made to the letter of July 26, 1996 from Dr. Sobel, Division Director of the Division of Metabolic and Endocrine Drug Products (IND 32,703; Attachment B). As noted in Dr. Sobel's letter, the Division has waived the need for Case Report Tabulations from the clinical studies conducted by Sankyo Co., Ltd. and GlaxoWellcome, Ltd. The requirement for Case Report Forms (CRFs) from patients who withdrew from these studies due to an adverse event has also been waived, although the CRFs from patients in the GlaxoWellcome studies who withdrew due to a serious adverse event have been provided. CRFs from subjects in these trials who died have been provided.

Permission is hereby granted to Sankyo U.S.A. Corporation to include by cross reference the complete contents of this NDA, including the presubmission and any subsequent amendments to this pending NDA, in support of their application for Prelay[™] (troglitazone) Tablets, NDA 20-719, which is submitted concurrently with this NDA.

Troglitazone is the first member of the thiazolidinediones class of compounds. It is an oral antihyperglycemic compound which acts primarily by treating insulin resistance. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Mechanism of action studies differentiate it from other oral antidiabetic compounds. This NDA contains clinical safety data on 3816 patients and volunteers, including 228 for over one year. Two studies of six-months duration provide evidence of efficacy in the insulin-taking Type II diabetes population. A total of 401 patients in this population have been treated with troglitazone.

Parke-Davis has met with the Division of Metabolism and Endocrine Drug Products concerning troglitazone on numerous occasions during its development. Meetings which were held to discuss the treatment of Type II diabetic patients on insulin are summarized below. Summaries of and minutes from all meetings with the agency concerning troglitazone are provided in Attachment C to this cover letter.

1) An End-of-Phase 2 meeting for insulin-taking Type II diabetic patients was held on August 2, 1995. At this meeting we provided an overview of our proposed clinical program in insulin-taking Type II diabetes patients. During subsequent conversations with the agency, it was agreed that the protocols for clinical studies 991-040 and 991-068, if successfully conducted, could provide an approvable NDA for use of troglitazone in this patient population. The final reports for these studies are enclosed with this NDA. [An End-of-Phase 2 meeting on the broader Type II diabetes indication and preclinical issues was held on August 9, 1994.]

Food and Drug Administration NDA 20-720 July 31, 1996 Page 3

2) A pre-NDA meeting was held on January 4, 1996. An overview of the enclosed NDA was provided at this meeting and a number of agreements were reached.

Patent and exclusivity information and the Generic Drug Enforcement Act certification are located in Item 13 and are contained in Volume 1.1 of this NDA. Please refer to the attached Form FDA 356h and NDA Index which detail the complete contents of this NDA.

Pursuant to 21 CFR 314.440, a complete copy of the Chemistry, Manufacturing and Controls section of this NDA has been sent to the FDA District Office in Newark, New Jersey. In addition, a complete copy of this section has been sent to the San Juan, Puerto Rico District Office since the drug product is manufactured at our Vega Baja, Puerto Rico facility. The drug substance is manufactured by Sankyo Co., Ltd. in Japan.

Copies of all DMF letters referenced in this NDA are located in Item 3 as well as provided immediately following this cover letter (Attachment D).

Due to the significant therapeutic advance provided by troglitazone to insulin-taking patients with Type II diabetes, we feel a priority review for this exciting new drug is appropriate.

If you need additional information or have any questions regarding this application, please contact Ms. Mary Taylor at 313/996-5000 or the undersigned. Dr. Sean Brennan may be contacted for issues related to Chemistry, Manufacturing or Controls at 313/996-7596 (FAX 313/996-7890).

Sincerely,

Irwin G. Martin, Ph.D.

IM\rm t:\nda\20-720\073196.001

Enclosures Attachments A - D Food and Drug Administration NDA 20-720 July 31, 1996 Page 4

NDA Copies

"Blue" Archive	Vol 1.1 - 1.334
"Red" Chemistry and Labeling	Vol 1.1 - 1.23
"Yellow" Pharmacology	Vol 1.1 - 1.2, 1.24 - 1.82
"Orange" Biopharmaceutics	Vol 1.1 - 1.2, 1.83 - 1.136
"Tan" Medical	Vol 1.1 - 1.2, 1.137 - 1.215
"Green" Biometrics	Vol 1.1 - 1.2, 1.216 - 1.229
"Maroon" Field (North Brunswick)	Vol 1.3 - 1.22
Mrs. Regina Brown	
"Maroon" Field (San Juan)	Vol 1.3 - 1.22

Mr. Samuel Jones/Mr. Richard Dent

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE

FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG FOR HUMAN USE OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations, 314)

Expiration Date: June 30, 1992 See OMB Statement on Page 3.						
FOR FDA	USE ONLY					
DATE RECEIVED	DATE FILED					
DIVISION ASSIGNED	NDA/ANDA NO. ASS.					

NOTE: No application may be filed unless	a completed	application form has t	een receive	ed (21 CFR Part 314).	
NAME OF APPLICANT			DATE OF	SUBMISSION	
Parke-Davis Pharmaceutical Research			July 31	1996	
Division of Warner-Lambert Company					
ADDRESS (Number, Street, City, State and Zip Code)			TELEPHO	NE NO. (Include Area Code)	
2800 Plymouth Road, P.O. Box 1047 Ann Arbor, MI 48106-1047			313/996	5-7756	
Am Abot, Mr. 40100 1017			NEW DRU	IG OR ANTIBIOTIC APPLICATION	
			NUMBER	(If previously issued)	
			20-720		
	DRUG PI	RODUCT	20 .20		
			IF tit one		
ESTABLISHED NAME (e.g., USP/USAN) troglitazone		PROPRIETARY NAM Rezulin™	it (if any)		
Hoghtazone	CHEMICA				
CODE NAME (if any)	(±-5-[[4	4-[3,4-dihydro-6-	hydroxy	-2,5,7,8-tetramethyl-2H-1-	
CI-991; CS-045; GR92132X; PD137070	benzop	yran-2-yl)metho	oxy]phenyl]methyl]-2,4-thiazolidinedione)		
DOSAGE FORM	ROUTE O	F ADMINISTRATION		STRENGTH(S)	
	0==1			200 mg, 400 mg	
Alets	Oral			200 mg, 400 mg	
PROPOSED INDICATIONS FOR USE					
Type II diabetes					
LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPL	ICATIONS (2	1 CFR Part 312), NEV	V DRUG OR	ANTIBIOTIC APPLICATIONS (21 CFR Part	
314), AND DRUG MASTER FILES (21 CFR 314.420) REFERR	ED TO IN THI	S APPLICATION:		•	
IND 32,703					
DMF 9047, 9048 (Sankyo Co., Ltd.)					
DMF 721, 4164, 9314, 1016, 1466, 2880, 193	33, 1941,	6684			
ini	FORMATION	ON APPLICATION			
TYP	E OF APPLICA	ATION (Check one)			
THIS SUBMISSION IS A FULL APPLICATION (21 CFR 314	.50)□ THIS S	SUBMISSION IS AN A	BBREVIATE	D APPLICATION (ANDA) (21 CFR 314.55)	
IF AN ANDA, IDENTIFY THE APPROV					
	-	HOLDER OF APPRO			
NAME OF DRUG					
STAT	US OF APPLI	CATION (Check one)			
☐ PRESUBMISSION ☐ AN AME	NDMENT TO	A PENDING APPLICA	TION	☐ SUPPLEMENTAL APPLICATION	
ORIGINAL APPLICATION	☐ RESU	BMISSION			
PROPOSI	ED MARKETIN	NG STATUS (Check or	ne).		
APPLICATION FOR A PRESCRIPTION DRUG PRODUCT IF	Rx)	☐ APPLICATION	FOR AN	OVER - THE - COUNTER PRODUCT (OTC)	
FORM FDA 356h (12/91)					

	CONTENTS OF APPLICATION
— – Thia	application contains the following items: (Check all that apply)
X	1. Index
X	2. Summary (21 CFR 314.50(c))
x	3. Chemistry, manufacturing, and control section (21 CFR 314.50(d)(1))
	4. a. Samples (21 CFR 314.50(e)(1)) (Submit only upon FDA's request)
x	b. Methods Validation Package (21 CFR 314.50(e)(2)(i))
	c. Labeling (21 CFR 314.50(e)(2)(ii))
х	i. draft labeling (4 copies)
	ii. final printed labeling (12 copies)
х	5. Nonclinical pharmacology and toxicology section (21 CFR 314.50(d)(2))
х	6. Human pharmacokinetics and bioavailability section (21 CFR 314.50(d)(3))
	7. Microbiology section (21 CFR 314.50(d)(4))
х	8. Clinical data section (21 CFR 314.50(d)(5))
	9. Safety update report (21 CFR 314.50(d)(5)(vi)(b))
x	10. Statistical section (21 CFR 314.50(d)(6))
X	11. Case report tabulations (21 CFR 314.50(f)(1))
x	12. Case reports forms (21 CFR 314.50(f)(1))
x	13. Patent information on any patent which claims the drug (21 U.S.C. 355(b) or (c))
	14. A patent certification with respect to any patent which claims the drug (21 U.S.C. 355(b)(2) or (j)(2)(A))
	15. OTHER (Specify)
l agr	ee to update this application with new safety information about the drug that may reasonably affect the statement of contraindications,

warnings, precautions, or adverse reactions in the draft labeling. I agree to submit these safety update reports as follows: (1) 4 months after initial submission, (2) following receipt of an approvable letter and (3) at other times as requested by FDA. If this application is approved, I agree to comply with all laws and regulations that apply to approved applications, including the following:

1. Good manufacturing practice regulations in 21 CFR 210 and 211.

2. Labeling regulations in 21 CFR 201.

3. In the case of a prescription drug product, prescription drug advertising regulations in 21 CFR 202.

4. Regulations on making changes in application in 21 CFR 314.70, 314.71, and 314.72.

5. Regulations on reports in 21 CFR 314.80 and 314.81.

6. Local, state and Federal environmental impact laws.

If this application applies to a drug product that FDA has proposed for scheduling under the controlled substances Act I agree not to market the product until the Drug Enforcement Administration makes a final scheduling decision.

NAME OF RESPONSIBLE OFFICIAL OR AGENT

Irwin G. Martin, Ph.D.

Vice President, FDA Liaison

Worldwide Regulatory Affairs

ADDRESS (Street, City, State, Zip Code)

00 Plymouth Road, P.O. Box 1047

Ann Arbor, MI 48106-1047

SIGNATURE OF RESPONSIBLE OFFICIAL OR AGENT

TELEPHONE NO. (Include Area Code)

313/996-7756

WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)

FORM FDA 356h(12/91)

EXHIBIT 12

EXHIBIT 12 IND LOG

IND/ND	A/DMF	#: 32,703	IND	Doc Type:	FDA CORRE	SPONDENCE	12/17/96 Page 1
			•	Sub	Гуре:	IND	
-: CI#: -			991	Sub	Date:	1/30/89	
Generic			7 7 12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Ann	Date:		
202	27-1		era to the terms of the terms	- 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	Age years of	V	
Product	Name:		oglitazone Tablet		SERVICE NUMBER	17. 15. 17. 16.	
The state of the s	1924 1924 1934		TOPPEN THE T			er van de Heren er in de. Kommente forske kan her	AND THE PERSON NAMED IN
Barcode	Ser/	AND THE PARTY OF T	RE/ Contents/R	Report Title/	Report No.		
		To:	Contents/n				
	24	From:					
1			Agree 2				
B04163		Wed, Jan 04,	1989 Letter RE:	Authorization t	o Submit Filin	gs to FDA	
·新·	-	S. Sobel, MD					
製造され							
B04163		Mon Jan 30	1989 Letter RF:	Transferring M	onitoring of C	linical Investigation	<u>et Ski - Ebok</u>
\$6.363	650	S. Sobel, MD	1394 S	7. 6556	089-1868 -		
	Angelden. Lange			id on diskiry Lagrandi Silida			
	_	10 E . 10 P. 10 P. 10 P. 10 P.		Test Test		THE REPORT OF THE PERSON OF TH	
B04163	0	Mon, Jan 30,	1989 Initial IND	A STATE OF		TO THE FOREST AND THE SECTION OF THE	. यहाः सुरक्षका स्थान । । । । । । । । । । । । । । । । । । ।
	Sec. 14.	Although the state of	17. 24. On 18. Care				
B04171		Thu, Feb 09,	1989 Letter from	FDA			
		W. Troetel					
	1	J. Weber					
B04171	1		1989 Protocol A	mendment (Ne	w Investigato	rs)	
an ar	11.50		33.74		7.7/10/2		
B04171	2	Mon Sen 18	1989 Letter RE:	New Subinves			
		S. Sobel, MD		4.4	6 a		
-76							
		PERSONAL CHARGES AND A SECOND AS A SECOND		and the second			
B04171	3	Wed, Oct 18,	1989 Protocol A	menament (Ch	ange in Protoc	:01) 	are a transmission and a second and a
					Mary Nation		
	***	SOUTH STATES	and the state of				
B04171	4		1990 Letter RE:	Increase Dosin	g Period	. Take the state of the state of the state of	San 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
		S. Sobel, MD		ti de dina			
		1725.5.Clark*+3.2*					
B04171	5		1990 Letter RE:	Lower of Plasn	na Glucose Le	vels	1
	2003	S. Sobel, MD		75 (- 3)			
					1.特殊。		
B04171	6	Mon Apr 16	1990 Annual Rej	nort		- 1 1 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	THE STATE OF STATE OF
	1 2	Wiori, Apr 16,	1030 Aillidai Nej	,	(14) (14),		
					Angel		
B04171	7		1990 Letter RE:	Updated Sumn	nary and Clinic	cal Data Information	**************************************
		S. Sobel, MD					
4	1 2			 5 (8) 		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

IND/NDA/DMF	#: 32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	12/17/96	Page 2
				Type:	IND	377.7	
SCI#:		1 5/4 2 ==	Sub	Date:	1/30/89		
	No.	77: "					
Generic:	4	estas met missis		r Date:	₹/ \$-, -, -, - , - , - , - , - , - , - , -		
Product Name:		zone Tablets				4.4	15. 6 300.00
A CONTRACT	- Alberta Control				DAMPED AND THE TOP	Carried Contract	
Barcode Ser/	Date	RE/	port Title/	Report No.	1		4年2月19日
Ref#	To:	Contents/Rep	ort No./				- Pr- 1
	From:			***			
D04171 el	Fri, Oct 12, 1990	Letter RE: Tr	enefer of IN	D Soonsorshi	n	· · · · · · · · · · · · · · · · · · ·	
B04171 8	S. Sobel, MD	Letter NE. 11	arisici oi iiv	er inds		. 4 +	`
	J. 300ci, WD	3					
	महरूष । विकास			A Tool .	HARELON CO	4	
B04171 9	Tue, Nov 20, 1990	Letter RE: Re	sponse to F	DA Request	for Information	Maria Maria	
	S. Sobel, MD				STATE OF THE STATE		t de la companya de Na parte de la companya de la compa
	17 Mg - Wall 1987 - 28 4 28						
B04172 10	Tue, Apr 23, 1991		emistry/Mic] .
ななか 子 人 () ()	S. Sobel, MD		13.	100000			
	1 47 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		<u> 4</u>	基件等符合。		विभिन्निक्षान्त्र ।	
B04172 11	Wed, Apr 24, 1991	Annual Repo	n.	T. A. Str. A. H.	2000年度 1965年度11日第1	WT1.	
	Washington Committee and the	de de la					
B04172 12	Fri, Apr 26, 1991	Letter RE: Tr	ansfer of IN	ID		m Territoria de la como	
	S. Sobel, MD		44.00		The North		
		4-1-					
B04173 13	Mon, May 13, 1991	Letter RE: Tr	ansference	of IND			
(S. Sobel, MD	8120 V 1817				**************************************	X 14 / 1 / 1 / 1
	I. Martin				e Marites	100	
	78-870m - 1-28-28-28-28-28-28-28-28-28-28-28-28-28-		3	O A T		A. Salar	* 98, 4, 30, 24, 31, 31, 31, 31, 31, 31, 31, 31, 31, 31
B04173	Mon, May 20, 1991	Memo RE: I	ype I DMF S	1047 1047	**************************************	SANGER CONTRACTOR	
A 15-1	I. Martin	The Contract					
	E. Nakajima, Ph.D.						
B04173	Mon, May 20, 1991	Memo RE: T	ype II DMF	9047			
	I. Martin						
	E. Nakajima, Ph.D.					學學學學	
B04173	Tue, May 21, 1991		DA Meetino	<u> </u>	The state of the s	· · · · · · · · · · · · · · · · · · ·	
3.00	140, 1114, 21, 100						
			W				
<u> </u>	10500 水水花枝木		100				
B04173 14	 	Letter RE: In	formation A	mendment (Inemistry)		19, 17,6
	S. Sobel, MD						
	I. Martin, Ph.D.						
B04173 15	Fri, Jun 07, 1991	Letter RE: In	formation A	mendment (Clinical) to IND 32,70	3 for CI-991	tablets
	S. Sobel, MD.		- 129.0				
	I. Martin, Ph.D.	7. 6.	_	新热力的 。			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

IND/ND	A/DMF	#: 32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	12/17/96 Page 3
A		1.00		Sub	Type:	IND	
CI#:		99	1 3	Sub	Date:	. 1/30/8	9
	3-1-1		<u>- 1 () () () () () () () () () (</u>	Ann	r Date:		
Generic					entered light	30 1 3 2 1 2 2 2 2 3 2 3 2 3 2 3 2 3 2 3 2	
Product	Name:	The state of the s	zone Tablets	te Militaria, Tur	17 to 2 mil. +7,4	Programme & Commence	
(0) N		- in a single particular of	اسم شا درست		and remains that is	人名 在2.288群人	
factor	- 244		RE/	Report Title/	neport No.		
	2 pla (4)	From:					
199						***	
B04173		Wed, Jun 12, 1991	Memo RE:	June 3, 1991	Meeting Min	utes	
		L. Spivey					
	ا ا	L.E. Weissberger	J.,		(Asia)	· · · · · · · · · · · · · · · · · · ·	
B04173	16	Thu, Jun 13, 1991	Response to	FDA RE: Re	equest for Inf	ormation	
	13.88	S.Sobel, MD					
		I. Martin, Ph.D.					
B04173	17	Thu, Jun 20, 1991	Letter RE: C	Seneral Corre	spondence	1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
\$\$\$ \$\cdot\cdot\cdot\cdot\cdot\cdot\cdot\cdot	.4.3.3	S. Sobel, MD		食料渗出		Section Section	
		I. Martin					
B04173	18	Thu, Jul 18, 1991	Letter RF: I	nformation A	mendment (C	linical)	* *\$\$*\\$\$\$\$\$\\\$\\\$\\\$\\\$\\\$\\\$\\\$\\\$\\\$\\\$\\
(1) 173	70, 20,	S. Sobel, MD	366	Maria Com	400		SHAME AND AND
		I. Martin					
the Late	20 V	V ERT OF BERNELLEY			(4)多分别之一	TENE TOWN TRAFF.	
B04174	19	Wed, Jul 31, 1991	IB Opdate	STANKE IN	578 3 60 20	STATE OF THE PARTY	
(4)		-				40	
		ALINAMAN SAME NAME OF SAME					
B04174	20	Wed, Sep 04, 1991	Protocol An	nendment (No	ew Investigat	ors)	
	34.				4.0		March 1
		FOXY SHALL CHIEF, TO					4
B04175	21	Fri, Sep 06, 199	Information	Amendment	(Pharmacolo	gy/Toxicology)	Trongs of the Control
		Par St. Brasil Co.					
B04176	22	Tue, Oct 01, 199	Protocol An	nendments (N		itors)	
	177.2						
數數	714.77	English State					
B04176	1 1	Wed, Oct 02, 199		RE: Sponsors			
age of a	, c ; ; ; ; ;	I. Martin					Angles of State of the State of
		S. Sobel					
B04176	23	Fri, Nov 01, 199	l etter RF- I	nformation Δ	mendment		<u>्रा १५४ में में (चित्रः स्</u>
S		FII, NOV 01, 199	Letter RE: I	nformation A	mendment (C	CLinical)	
in the second		S. Sobel, MD					
		I. Martin					
B04176	24	Thu, Dec 12, 199	Information	Amendment	(Clinical)	<u>and a grant of the grant of the contract of t</u>	13. (3.) * (3.5.) * (
204170 204170		1110, Dec 12, 133	" .				
			1 .	* * <u>.</u>	W		

IND/NDA	A/DMF	#: 32,703	IND	Doc Type:	FDA CORRI	ESPONDENCE	12/17/96 Page 4
	. :	The State of the S	S. 9	Sub	Type:	IND	· · · · · · · · · · · · · · · · · · ·
STCI#:	-4-7-	等的 数据	991	Sub	Date:	1/30/89	· · · · · · · · · · · · · · · · · · ·
			- 3 - 3	Арг	r Date:	-	
Generic:			on the state of the		party providing		
Product I	Name:		litazone Tablet		**************		
	ers resili	Territoria de la composición		Report Title/		The Parkets	
Barcode 3S	28.4	Date To:	Contents/R	eport No./	neport No.		
		From:		Light of			
				ر در			
				1.		(C)	n
B04176	25	Wed, Jan 08, 19	92 Protocol A	mendment (No	ew investigate	ors/Change in Protoco	<u>"</u>
			\dashv . \vdots				
			- A				
B04176	26	Wed, Jan 08, 19	92 Information	n Amendment	(Pharmacolog	y/Toxicology)	
	1.5.	to the second straight, and	المراد والمعالمة أأسي				
B04176	27	Fri, Jan 17, 19	92 Letter RE:		mendment (C	hemistry) and Protoco	ol Amendment (New
	77.15		Investigato	or) - 3.443 - c	* (45.64) To	thouse although it as we	The region of the state of the
		S. Sobel					
		I. Martin			建 以4.10.		
B04176	28	Mon, Jan 27, 19			ew Investigate	or)	ACCUSAGE OF PROCESSION AND CONTRACTOR OF THE CONTRACTOR AND CONTRA
	4-11						
	44	ATTENDED TO FILE VENT MANY					
B04176		Wed, Feb 12, 19		Information A	mendment		
	10.4	S. Sobel		104			Contract Contract
	11	I. Martin					
B04176	30	Mon, Mar 16, 19	992 Letter RE:	Information A	mendment (P	harmacology/Toxicolo	ogy)
	2012		24.7	-736	+//4		Representation of the second
B04177	31	Fri, Mar 27, 19	992 Letter RE:	Information A	mendment	5. 256 erizesin 8. 22 zu 24. 22. 22. 22. 2	
30	1 0 1 1 2 2 2 2	S. Sobel	经额外。		1000	1998年的新兴区	
		I. Martin					
DO4170	1 22	Tue, Apr 21, 19	BOOL ottor BE	Information A	mendments		337 4 COMMON OF THE STREET
B04178	32	S. Sobel	a a a a a a a a a a a a a a a a a a a	Windshielder Z	DETERMINED IN INC.	VIOLET PHONES	
		I. Martin					
gentler, "~(KRONTON GRAN		一类中心的一类概念的意思。	
B04178	33	Tue, Apr 28, 19	-17:5-	port		wer is to the action	
3.28 . Sec.		1774 J. 149, M. W. 1814	Section 1		新兴学生12.00 .00.		which the transfer of the second
B04178	34	Fri, May 15, 1	992 Informatio	n Amendmen	ts (Pharmacol	ogy/Toxicology)	
		Marie III - Jane Tribert					
B04178	35	1		mendment (N			
	.						

IND/ND/	A/DMF#	#: 32,703	IND	Doc Type:	: FDA CORRE	ESPONDENCE	12/17/96	Page 5
	•	no and ore		. Sul	ьТуре:	IND	:	
CI#:			991		b Date:	1/30)/89 🚕 👙	
Generic:			<u>rija ang Bibalija.</u>	Ap.	pr Date:		10.00	
			Projection -		· Links State (Section 1997)	473		
Product	Name:		oglitazone Tabl	ers responsible to the	STANGEN OF			
arcode S	er/	Date	# RE/	Report Title/	Report No.	第一个第一名	A STATE OF THE STA	
P A	ef# 👺	ro.	Contents/	Report No./	**************************************			
	3	From:						
				night and force				
B04178	36	Mon. Jun 01.	1992 Letter RE	: General Corre	espondence		<u> </u>	
		S. Sobel	1 4 5 7 . 3		The section of			
		I. Martin	4 £ 5 1 · · ·	海绵 痛		4.5		
B04178	37	Eri lun 05		Amendments (New Investigat	tors/Change in Pi	rotocol)	<u> </u>
504176	3,	111, 0011 00,	Constitution of					
	1.4		表表は					
다. (1981년) PO4179		Tue lue 00	1992 Informati	on Amendmen	t (Clinical)	. Pagina in		<u> </u>
B04178	30 - 32	Tue, Jun 03,	in the	With the second		- 1802V:		Maria Sapar A 3
	37.							Service Allegan
	76 ¹	Sales and the		General Corr	ocnondonco		for sufficient of the	() · · · · · · · · · · · · · · · · · · ·
B04178	39	S. Sobel	1992 Letter RE	General Com	espondence	. 15		ta Brigaria
	100	I. Martin			· 25 44			
		MORE SHIPPING	. Rosenia de la constanta de l		(Dharmanala	· · · · · · · · · · · · · · · · · · ·	以代表的 的。	State of Carlot
B04178	40	Tue, Jun 16,	1992 Informati	on Amenamen	t (Pharmacolog	y/roxicology)		
				in Contract			0.22	
	1 1	EN MARKEN MARKET MARK	1000		4 3 5 9 4 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	MC	****	
804178	41	Tue, Aug 04, S. Sobel	1992 Letter RE	:: Information /	Amenament: C	NIC		A Contact Contact
	Aller 1	I. Martin		fa.	1464			
		ESCHOLOGICAL TO	W. W. Co. St. Co.			AN PROMISE		and Court of the C
B04178	42	Thu, Aug 27,	1992 Informat	ion Amenamen	it (Pharmacolog	gy/ i oxicology/	general grant	器有证明性的证
理·特拉·								
		HANDE TO CHAMPION						
B04178		Tue, Sep 29,	1992 Letter Ru	=: Information /	Amenament (P	harmacology/Tox	(icology)	
Elements .		· 医自己的物体。由190						
B04179	44	Mon, Oct 12,	1992 Informat	ion Amendmer		gy/I oxicology)	A 1745 2.15 3.5	general en skilliger en de
A. 10 10 10 10 10 10 10 10 10 10 10 10 10	141.5	College by the state of the			<u>्रिक्षित्र श्रीकृति</u>			
B04179		Tue, Oct 27,	1992 FDA Let	ter RE: Refer to	ND 32,703	(g)		
1	3,7	- 357 A V 44 1			19 E. S. L.	319.55.5		
B04179	45	Tue, Nov 24,	1992 Informat	ion Amendmer	nt (Pharmacolo	gy/Toxicology)		
	ال فيرجد	I	F					

/DMF#:	32,703		Doc Type: FDA CORRE		12/17/96	
		<i>र</i> भें से १ के <u></u>	SubType:	IND	<u> </u>	
		991	Sub Date:	1/30/89		-13 •
e vez		Section of the section of	Annr Date			40
		man bander one of the			(1) · (2) · (2) · (3) · (3) · (4) ·	
lame:	T See See	roglitazone Tablets	The state of the s			. : •
				<u>, para di Para di Para di Para di Para di</u> Ny INSEE di Para		—
						77
**************************************	42.7	A Contents/Nepo				
Fro	m: 🚁 🔏		and the state of t			•
				F 15 15 15 15 15 15 15 15 15 15 15 15 15	•••	•
46 We	d, Nov 25,	1992 Protocol Amen	ndment (New Protocol)			<u> </u>
						٠.
					*	:
				<u> </u>	<u> </u>	٠,٠
4/ 11	ie, Dec Ut,	1332 FTO LOCUL AMERI	James Contract Contract			
						1
						<u> </u>
		1992 General Corres	spondence			زلــ
· · · · · · · · · · · · · · · · · · ·						
्र-हुँ <mark>।. १</mark>						
49 M			ndment (Change in Proto	col)		
23.5		544.48.24			A 4 电温温管	
						الألم ع و
	-X-70043030	4000 FD 4 L - + DF	Commont Population To	Control of Children		<u> </u>
		1993 FDA Letter RE	: Comment negarding 10	Sicology Studies		761
A Laborator	and the same					
50 M	on, Jan 18	1993 Protocol Amen	ndment (New Investigato	rs/Change in Protoco))	12
	and the second second second second	757777				
			ndment (New Protocol)	The straight to the straight of the	1 X 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
1		42.00				
	the war you was	RESIDENCE IN CONTRACTOR			<u> </u>	—j [°]
	ed, Jan 20		ndment (New Protocol)	The state of the s	A SCHOOL SECTION	
	13.88 AS / 4 A					
				ors)		
- 3.5					7.	1
						, r
100			spondence		- STATES	
		3 2 Contract		. (4 1.4	1237	
						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		1005 7 10 10 10 10 10 10 10 10 10 10 10 10 10	+377 (A) (A)			
55 T	ue, Feb 16	, 1993 General Corres	spondence			}
		14.9 0 4				
S.	Sobel ards/Martin					
	Iame:	To: To: From:	Jame: Troglitazone Tablets From: 46 Wed, Nov 25, 1992 Protocol Amer 47 Tue, Dec 01, 1992 Protocol Amer 48 Fri, Dec 11, 1992 General Corres S. Sobel I. Martin 49 Mon, Dec 28, 1992 Protocol Amer Thu, Jan 07, 1993 FDA Letter RE I. Martin S. Sobel 50 Mon, Jan 18, 1993 Protocol Amer 51 Mon, Jan 18, 1993 Protocol Amer 52 Wed, Jan 20, 1993 Protocol Amer 53 Tue, Feb 02, 1993 Protocol Amer 54 Tue, Feb 02, 1993 Protocol Amer 55 Sobel 56 Tue, Feb 02, 1993 Protocol Amer	SubType: 991 Sub Date: Appr Date: Appr Date: From: 46 Wed, Nov 25, 1992 Protocol Amendment (New Protocol) 47 Tue, Dec 01, 1992 Protocol Amendment (New Protocol) 48 Fri, Dec 11, 1992 General Correspondence S. Sobel I. Martin 49 Mon, Dec 28, 1992 Protocol Amendment (Change in Protocol) Thu, Jan 07, 1993 FDA Letter RE: Comment Regarding Total (New Investigator) I. Martin 5. Sobel 50 Mon, Jan 18, 1993 Protocol Amendment (New Investigator) 51 Mon, Jan 18, 1993 Protocol Amendment (New Protocol) 52 Wed, Jan 20, 1993 Protocol Amendment (New Protocol) 53 Tue, Feb 02, 1993 Protocol Amendment (New Investigator) 54 Tue, Feb 02, 1993 General Correspondence S. Sobel I. Martin	SubType: IND 991 Sub Date: 1/30/89 Appr Date	SubType: IND 991 Sub Date: 1/30/89 Appr Date: 1/30/89 If Date: 1/30/89 REPS: Report Title, Report No. 1/3 From: 46 Wed, Nov 25, 1992 Protocol Amendment (New Protocol) 47 Tue, Dec 01, 1992 Protocol Amendment (New Protocol) 48 Fri, Dec 11, 1992 General Correspondence 5. Sobel

IND/ND	A/DMF	# : 32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	_ 12/17/96	Page 7
de.	- 1	-6-24-5-	· · · · · · · · · · · · · · · · · · ·	Sub	Type:	IND		
CI#:			991	Sub	Date:	1/30/8	39 🥯 🔆	
Generic			· · · · · · · · · · · · · · · · · · ·	Арр	r Date:		7.00	
Product		SALTO	glitazone Tabl	ets	<u>-€.≱. ₹. 1999 (197</u>	<u> </u>		
					Harrist Chamber	Name and American		
arcode S	Ser/	Date - CA			Report No.		18 34 A 35 Y	以
The state of the s	Ref# 🖺	To:	Contents/	Report No./				
		From:	ر المواقع المو المواقع المواقع المواق					
								* *
B04181	56	Mon, Feb 22, 1	993 Protocol	Amendment (Ch	nange in Proto	col)		
							orizantija Odina kaja na s	* .
				مِنْدِي مِنْ يَا مُنْ يَا الْمُ				
B04181	57	Wed, Feb 24, 1	993 Protocol	Amendment (Ne	w Investigate	ors)	195 to 118 to 1	34.73.7
		range, same that have						
B04181		Fri, Feb 26, 1	993 FDA/P-D	Meeting Minute	s (23-Feb-93) 	fair .	
		Ann Hards	- X					
		्र ^{क्} रिक्ट सन्दर्भ ग्रीति होते । अ			A TOTAL CONTRACTOR			
B04181	58	Mon, Mar 01, 1	993 Protocol	Amendment (Cl	nange in Proto	ocol)	o fak ett kokskerite	5 (186 J.S.) 1
					eren de la companya d			
4.7		CARLO CONTRACTOR				Mark On the	成的第 年基	建筑数 位于
B04181	59	Wed, Mar 03, 1	993 Protocol	Amendment (No	ew Investigat	ori Catalogiska (1907) si		
1.0					7700		20	
CALCON.		TAL MARKEN		A		(2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1		
B04181	60	Mon, Mar 15, 1	Protocol	Amenament (N	ew investigat	ors)	ne de la companya de	(2) 12 March 18
		Tue, Mar 16, 1	00314	Aug DAIR DAIR				AND THE CONTROL
B04181	01	Tue, Mar 16,	1993 Williams	DI FDA/F-D WE	sting	. 10 S. C.		
804181	62	Thu, Mar 25, 1		w Manufacturin	og and Contro	<u> Makanan Kabupaten dan Merinabahan</u> Merina	ak (C. Bethley)	<u>्रम्भित्री</u> <u>िहिन्ती</u>
004101	02	111u, IVIai 25,	1995 Chemisu		General Control			
B04181	63	Fri Mar 26		Correspondence	i i gefr _e a et a dir _e .	<u>reach a faireach aire ann a</u>	tion of a transfer	
504101 5035 4	1 00 4 7 C 3	711, 14181 20,	3.77					(1) (A) (1)
B04181	64		1993 Protocol	Amendment (N	ew Investigat	ors)	2560, # 1 JF - 3	1.19%
Was a s	(2. 45° c)	,	1 1 1 1 1	in the				
B04181	65	Mon, Apr 05,	1993 Letter RI	: Closing FDA	Master File 5	3.11146	·	
	3 6 5 4		0.00			to 1.7		
					*			

IND/NDA	V/DMF	#: 32,703	IND	Doc Type:	FDA COF	RRESPONDE	NCE	12/17/96	Page 8	· .
4		4.48	ej Selesi	Subi	ype:	IND		સુરેલા _ક ર		
€ Cl#:	<u>.</u>	99	1146	Súb	Date:	· [1/30/89	200	- K. S. S.	73 75
	- 1		<u>್ಯಾಟ್ಟ್ಟ್ :</u>	Ann	Date:					
Generic:					Date.		10 10 10 10 10 10 10 10 10 10 10 10 10 1		特色	
Product I	Vame:		zone Tablet		50.70 D B			ing die		dağur.
	il en de la	Color St. St. Colors (Colors	B. W. W. T. 19.	THE STATE OF THE S		والرابية موايرات		33000	ACT I	1825
Barcode S	er/ 🎅 ef#	Date	RE/	Report Title/	Report No				第二次	
		From:			الشدوطن الأول المارية					
							(موفر حائي ١٠٠)	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		21%
								7		• • •
B04181		Wed, Apr 07, 1993	FDA Letter	·						
		I. Martin				-		•		
3.00		S. Sobel				• • •				
B04181	66			mendment (Ne	w Investig	ator)				
	.,				Kan d	· · · · · · · · · · · · · · · · · · ·				1.5
					#1245					
B04181	67	Thu, Apr 15, 1990		rrespondence			7.00	process per special party		
	7-3	S. Sobel			na.			表表的 大部		
		I. Martin								-5_3 - 7.
B04181	68	Tue, Apr 20, 199	Protocol A	mendments (N	ew Investi	gator & Chai	nge in Proto	col)	and and	
BU4101	ંદ્ર ઢ.સ્	Tue, Apr 20, 1993	129 1 A		Mires :	gutor a Grid				
					17.					
	6.7 30.2	10.70 m 10.44.2000.200			41-6		() Makes			
B05726	69	Tue, May 04, 1993 S. Sobel	Hesponse	to FDA Reques	t for infor	nation		(A.	*500°	
		I. Martin						- 4.0	1.2	
4.5		TANK MARKET TO								
B05726	70	Wed, May 05, 199	Informatio	n Amendment	(Pharmaco	logy/Toxicol	ogy)	710 Y 7		20
		S. Sobel					. y			
		I. Martin						4 14	Court	
B05726	71	Fri, May 07, 199		mendment (Ch	ange in Pr	otocol)	and taken it comment to the events.			
15.22										
		Harry Market at 14 and	J		1.0					
B05726	72		IND Safety	/ Report/Initial	Written Re	port				Ţ.
600	1142						, Y. W. 1989	4	明數內定	· \$35.
B05726	73	Mon, May 17, 199		Minutes of 26	-Apr-Meet	ing	, washing to .		<u> 222</u> . 19 . 1 . 12	<u></u>
(Santa 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		S. Sobel				21 34	4.34	Section 1		
		I. Martin			64 X					
Sporzac	3/4 (C)	39 14 11 10 100		FDA Mosting	(26-Apr-9	31		ં તેવી ફર્મી કેન્દ્ર ૧૧૯ કે	Arti trigin	**************************************
B05726	<u> </u>	Tue, May 18, 199	Sivilliutes 0	I I DA Weeting	(20-Api-9			1 3 to		
					200				A A W	
國際自然		<u> </u>			7 3 5 5	47.			-11	
B05726	74	<u></u>	3 Letter RE:	Information A	mendment	(Pharmacolo	gy/Toxicolo	gy & Clinic	al)	
2.0		S. Sobel	4.4			*		14		
X.		I. Martin	J :-	, - 1		•				
200		and the same time		•						

: IND/ND	A/DMF#	#: 32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	12/17/96 Page 9
			i de la companya da	Sub1	Гуре:	IND]
CI#:			991	Sub	Date:	1/30/89	40-7-12
Generic:			Two Tax Section 1	Appr	Date:		1.00
			reserve :		and the second		
Product			roglitazone Tablet		nat with 7		
		Date V		Report Title/	7.41 - 121 - 121 - 121	ignor No.	
	24	To:	Contents/R	eport No./			
		From:			ing flow of		
					•	•	
B05726	75	Wed. May 26.	1993 Letter RE:	General Corres	pondence		
<u>000720</u> ℃	1	,,			<u> </u>		
							* (1)
B05726	76	Tue. Jun 01.	1993 Protocol A	mendment (Ne	w Investigat	ors/Change in Protoc	ol)
		100,000.00.					
ite:							
B05727	77	Tue Jun 08	1993 Information	n Amendment	(Pharmacolo	gy/Toxicology & Clin	cal)
A		700,001100					
						•	
B05921	78	Fri Jun 18	1993 Protocol A	mendment (Ch	anges in Pro	tocol)	
200021	Juliana.	111, 0011 10	394 t 2 M			1.0	
B05921	79	Fri Jun 25	, 1993 IND Safety	Report: Initial	Written Rep	<u>ार सम्बद्धाः १८० च्या ५५४</u> ort	A CONTRACTOR OF THE CONTRACTOR
	20.00	, , , , , , , , , , , , , , , , , , , ,					
				4.0	200		
B05921	80		, 1993 Annual Re	port		Control of the Contro	
		· · · · · · · · · · · · · · · · · · ·	25 7.0	77.03		AND THE RESERVE TO TH	
1	C . 2			1			
B05921	81	Wed, Jun 30	, 1993 IND Safety				
	122			* 227			
B05921	1 1	Wed, Jul 07	, 1993 FDA Lette	r RE: Submiss	ion dated 4	May-93	
	C PARTY		484 H		10 m		
		F7 0 1 111 83					
B05921	82			mendment (Ch	nange in Prot	ocol & New Investig	ators)
第 表示。							
B05921	83	Fri, Jul 09	, 1993 Informatio	n Amendment	(Clinical)		
\$ 73.2 ·	er er er			- 0 			
		en en en digentage	To be made	i i i i i i i i i i i i i i i i i i i			
B05921	84			n Amendment	(Pharmacolo	gy/Toxicology & Clir	ical)
	1.5		- 7			-	
٠,	× •	* *** * * * * * * * * * * * * * * * *	A 3 4 A A				•

IND/ND/	A/DMF#	# : 32,703	IND	Doc Type:	FDA C	ORRESP	ONDENCE		12/17/96	Page 10
	٠.			SubT	ype:	11	1D		.: *	
CI#:	· 1123		991	Sub	Date:	<u> </u>	1/	30/89	name of the second	
					Dotos		i	 -		
Generic:				Appr	Date:	<u></u>				
Product	Name:		roglitazone Tablet						1	
			Account to the control of				اد ماه او در ادر ادر ادر ادر ادر ادر ادر ادر ادر	*1924*	- ಮುಂದೆವರು - ಆಗಾರ್ಚ್ ನಟ್ಟು	and some control of the control of t
	erl l	Date 7 - A L	RE/	Report Title/	Report	No.				
H			Contents/R	eport No./			**************************************	i d	7.5800 -2447	
	ا" ،	From:			• .			•		•
					•		- :			•
B06146	85	Mon, Jul 19,	1993 IND Safety	Report: Initial	Written	Report		_		
46.0					·		··.			
artination of the second of th	e -				÷.					
DOGG 40	l oct	[13 kg/ker] 3 kg			·		· ·		• •	
B06146	86	Mon, Jul 19,	1993 General Co	rrespondence						
	30 A.							# <u>} </u>		
14 D. D.	is a	75 10 10 10 10 10 10 10 10 10 10 10 10 10					4.2 44.	* Y		
B06146	87	Tue, Jul 27,	1993 Information	Amendment (Clinical)				
	. := -									
	_ :. [4			e e e					
B06146	88		1993 Information		Pharma	cology/T	oxicology	& Clinic	al)	
								法		
	3.5%. 3.5%.							25.3		
B06146	89		1993 Response t	o FDA Reques	t for In	ormation	<u> </u>	Tracklage at .	4 (C) 61 (1998) (40 87)	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
7/35	(*************************************	111, 7129 107	19.00		2560	#1818 P		12	* W. * * * * * * * * * * * * * * * * * *	
		- 11 TO 12 TO 15 T		Donom 10 Do	Pana		Contract Con	k, 124.		
B06146	90	Fri, Aug 13,	1993 IND Safety	Report: 10 Da	y nepo	it Marketyke	record spars	TANK!		
-										
2.7		CONTRACTOR			ALC:		文 技能的公	200		
B06146	91	Mon, Aug 16,	1993 Information	Amendment	Clinica) 51/2/2017	a Silabeas	en stut	TP 888 5 5 5 1	The second secon
							Awa to se			
		1、加工工艺学校基础						10 P		
B06146			, 1993 IND Safety							
			La activi	TIMES.					1. V. P. B. S. S. V. 2. M. S.	
	1.48 3			(18)						
B06146	93	Wed Aug 25	, 1993 Information	n Amendment:	Clinica		4			1
	1 	S. Sobel				F-1	7.7.	3 7		"我们是我们送了 "
	1.1	I. Martin			v	1.35 44.11 - 1.5	, , , , , , , , , , , , , , , , , , ,	0		
085*2	्रो ^{. ।}		1003 Information		(Clinian	n				
B06146	93	vvea, Aug 25,	, 1993 Information	Sign of Condition in	Cirilo	•				
						(* je - 72.				
2.2	: (1)		Line of Spirit Fred Spirit			<u> </u>				
B06146	94		, 1993 Protocol A	mendments: (Change	in Protoc	ol pasta		\$0345 K 4	
	***	S. Sobel			- 30	 • .		*		
រក់ខ្លែធំ ក		I. Martin					• • • • • • • • • • • • • • • • • • • •			
1		124	Section 1995						, , ,	

IND/NDA	//DMF#:	32,703	IND	Doc Type: Fl	_		12/17/96 Pa	geii
	· · · · · · · · · · · · · · · · · · ·		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	SubTyp	e: [IN	1D		<u> </u>
Cl#:			991	Sub Da	te:	1/30/89		
Generic:		<u> </u>	<u>তিম ক্রিছেল</u> ে (এইগ্রুগ্রুগ	Appr D	A	<u>, * </u>		
		东 岛门	المراجعين معالمة المعالمة					
Product N	lame:		Troglitazone Table		ଖର୍ମ୍ୟ ପ୍ରଥମ ଅନ୍ତର୍ଶ କଥି	B. A.N. Colon Material		
			Marine Marine Service and Assessment	たかはないなれるなどから	and a second		Water half	r Files in
arcode S	er/ Da ef# To	****		Report Title/ Re	port No.		error	
	Fro							
	rit.							
्रि १३			A Company					
806284			, 1993 IND Safety	Report: Initial W	ritten Report			
	· -	Sobel						
	1.	Martin						
306284			, 1993 Informatio	n Amendments: P	harmacology/	Toxicology		
Mary 1	s.	Sobel		为社会教	经数据 2000			
	1000	Martin						
306284), 1993 Protocol A	mendment: New	Protocol	AND THE RESERVE	P- V	
40.49		Sobel	468.5	的数据的 多数数			and the	up e
	38 J. I	Martin						
006304		tales to the	5, 1993 General C	orrespondence	286 S- 40 - 458	en en Die Williams (1997)	# [25.47] 15 [25.27] A.	
306284		Sobel	, 1993 delleral C	Sirespondence	TOTAL CONTRACTOR		AND THE STATE OF T	
	22 min 3	Martin						
	503 July 3	AL MICHELL SHE						等。特别特别
306284			I, 1993 Protocol A	mendments: New	Investigator/	Change in Protoci	oi Carresander de	
	82823-C	Sobel Martin		37 2 3 24 X		.	***	
11.25		THE WORLD						144
306378	100 T	hu, Oct 21	I, 1993 Informatio	n Amendments: P	harmacology-	Toxicology/Clinic	al	endelegen ize
	9673334	Sobel						
.	100000000000000000000000000000000000000	Martin						
306378			7, 1993 Protocol A	mendments: Nev	v Protocol/Ch	ange in Protocol		
Act Ship	.″,⊹∵, S.	Sobel						
	245 22° - 51	vin Martin						
306378		ue, Nov O	2, 1993 Minutes	Control of Section 200	egistates of the second	and the state of t	**************************************	***************************************
1		Sobel						
	120 3 3 4 2 5	Martin						
306378		ed Nov O	3, 1993 Protocol A	Amendment: Char	nge in Protoco	<u> 15-04-2006533</u> H	reasonable to a real real	15475 A. 15 A.
1000.0 10% 8 15 77 1		Sobel	132602	AND STREET	100mm (1)			
	397 T 10 H	Martin						
1000000		GRADIORA Esi Nov Ol	5, 1993 General C	orresonadeses: A	Minutes of No.	vember 2 1992 f	Meeting	False 1 24 (c. 1.1.)
306378		Sobel	JANA CAR	The supridence. N	Washington in the second	7. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.		Sec.
		Martin						
	(3/1) 3/10 14	New year of the first of the first			BENDER EX			
B06378			0, 1993 Information	on Amendments: F	harm/Tox/Cli	nical		<u>ا الراب الشا</u>
. 45 * .:				1 TO 16 TO 1	7 × 3 7 3 1		2.3.5 (5)	
	` - ' · ' - '	Sobel Martin						

IND/NDA/	DMF#	: 32,703	IND	Doc Type:	FDA C	CORRE	SPONDENCE	12/17/96	Page 12
5.02			ing the second second	Sub	ype:	".	IND	(4)	
#CI#: ** ***	E 3	77 - 14 A	991 清景寺	Šub	Date:		1/30/89	Bridge .	ing Nggan dan man
A 10			ALFRED TO SERVICE SERVICE	ار از این از مرکزی این از	Data		Tan I family Tan	213-224	
Generic:		L	Metars of the later	- Carlotte	Date:		X		
Product Na	me:		roglitazone Tablets					14.15	
And the same of the	e de la compa	e at several expension and the	AND DESCRIPTION OF THE PARTY OF	_ 12027A + 140 A	مة دور وراجة الكرية	1437 ** 53		Greek taken all	eren er
Barcode Ser	22 1	"大学","大学"	A REPORT		Report	No.			
Ref	\$ \frac{1}{2} \frac{1}{2}	A	Contents/Re	hore wo:\ ~3					is
		rom:		्राप्त के जिल्हा संस्थान					
			-					Y	
B06378	105	Fri, Nov 19,	1993 Protocol Am	nendment: Ne	w Inve	stigator			
18402	- ; [S. Sobel			3		w martin		100
	[. Martin		الله أو الله الله الله الله الله الله الله الل	s				- (
B06511	1	Mon Nov 22		eference resp	onse to	FDA R	equest for Informat	ion on 7/7/	93
1500311 1500311		. Martin	3 4 50 45 4 15		in the second		神道以一种道道	المراجع المام والأ	
		S. Sobel							
		स्त र १ जर व्यक्तिकार					国际公司 产生产品		
B06511			1993 FDA letter F	Request for In	tormati	on	· · · · · · · · · · · · · · · · · · ·	, Kenne of the co	` E
	.	. Martin			```				
	: E	S. Sobel প্ৰক্ৰি	And the second s						
B06511	106	Mon, Nov 22,	1993 CMC Amen	dment: Drug	Substai	nce Ana	lytical Method Upd	ate	
NOW SERVICE		S. Sobel							
		D. Furlano							
B06511	107	Wed. Dec 01.	, 1993 IND Safety	Report: Follo	w-up to	o a Writ	ten Report	(1125) Black & W. W.	
	22	S. Sobel	0.00						
		I. Martin							
DOCE 11		Eri Dog 02	, 1993 Response to	EDA Reques	t for In	formati	nn		
	108	S. Sobel	, 1993 nesponse to	Mark Control				200	
	6 P. I	I. Martin			T. Alva			100	
		A STATE OF THE SECOND						2,25,25,26	
B06511	22.00		, 1993 Information	Amendment:	Pharm	acology	// I oxicology		18 18 58 58 58 58 58 58 58 58 58 58 58 58 58
4.	(2) PAY 1	S. Sobel			30.	3			
	Ç.,	I. Martin			42.1				
B06511	110	Mon, Dec 13	, 1993 Information	Amendment:	Chem	istry, N	lanufacturing and C	ontrols	7 #8 0 20 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	33. T. F1	S. Sobel							
		D. Furlano			102.				
B06511	111			Amendment	Chem	nistry (C	MF Update Notifica	ition)	
		S. Sobel				Y			
		D. Furlano							
POSE11		Tuo Dog 28	, 1993 Information	Amendment	Clinica	al	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)		25 C. S.
B06511	112	S. Sobel	, 1330 moniation	A Section of the	C. 44 (9); 1				
		A. Hards							
	95 YI	and the same and the					"是不是不是不是不是不是不是不是不是不是不是不是不是不是不是不是不是不是不是不		rest in the second
B06551	113		, 1994 IND Safety	Report: Initia	ı Writt	en Repo	ort Valoria (j. 1882. i 18	6.15 N.	14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
		S. Sobel							
	- ,	I. Martin				11.		-	
			* ·····				•		

IND/ND	A/DMF#:	32,703		IND	Doc Type:	FDA CO	DRRESP	ONDENCE	12/17/96	Page 13
Tarat.			. :		Sub	Гуре:	IN	D		
CI#:	5 9	F-5 3	991	Ne Steel	Sub	Date:	·.	1/30/89	- 35, 12	
100		47、沙岸	- Y-144.	 						
Generic				Print Committee	App	Date:	.3· └	9 40 V 10 3 . T		
Product	Name:		Troglitaz	one Table	ets					
2.5					Called Winds And			1970 TO 125 8976		
Barcode	Ser/∵ ∉Da	ite 🔆 🧎	7.5	RE/	Report Title/	Report I	Vo.			40 m
	Ref# To		34.	Contents/I	Report No./					
The state of the s	Fre	om:				7	•			
100	1					:•[*			5.3	
B06551	114 10	/od_lan_13	1994	Protocol A	Amendments: N	lew Prot	ocol/Cha	nge in Protocol	• ·•• • · · · · · · · · · · · · · · · ·	
B00331		Sobel	2, 1334	110100017	STO .					
2.4		Martin			4					_ 3
									*	···········
B06551			7, 1994	Informatio	n Amendments	: Clinical	<u> </u>			43.74.11.11
		Sobel						المرابعة ال المرابعة المرابعة ال		
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Martin	200 0000000000							
B06551					n Amendment:	Pharma	cology/To	oxicology		
r Thinks		Sobel								
1 (1) (1) 1 (1) (2)	I.	Martin				E.	ser Kons			
DOCEE4	* * * A		1004	<u> </u>	to FDA Reques	t for lofe	rmation	The Land Control of the Control of t	tin e lina iso	
B06551	117	Sobel	1, 1994	nesponse	to FDA neques		Jimation Jan	-5		
	15 Tak 183	Martin			新加州的		- C 			
建工	Sales Sales	SEVEN SIC			大台湾	NEAR A		一种企业和企业等等	公司的政治	
B06551	118	Fri, Mar 04	4, 1994	Information	on Amendments	: Pharm	acology/	Toxicology	ADT ANTENNA	Stead Ser and Section Con-
	24 24 25	. Sobel				100				
		Martin	2014 TENERO					199		
B06551					y Report: Follo	w-up to	a Writte	n Report		
		. Sobel			45 478	33. 70			y	
	1.	Martin		7 125				* 170		
DOCE TA		AND MARK			Amendments:	Change i	n Protoco	<u>i i kata kata kata kata kata kata kata k</u>	A CONTRACTOR OF THE CONTRACTOR	3.20 (3.
B06551		. Sobel	1, 1334	A COLUCIO	Amendments.	Solver .	11.10toc	ACCOMPANY	Natives th	
	45	Martin								
		A 44 500 10 10 10	· mer hallere					4 14 3		
B06551	 		2, 1994	IND Safet	ty Report: Follo	w-up to	a Writte	n Report	\$2.298 + 18.5 - 18.	e contract of the contract of
		. Sobel					, f			
		Martin	AND AND STATE			\$ 26.7\\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	(4/A)			
B06551	122				on Amendment	s: Clinic	al			
1000	; s	. Sobel		8. 46.5	405	$\hat{t}\hat{F}$	114			
		Martin					-	10000000000000000000000000000000000000		
B06551	12214	(ad May O	<u> 100</u> 4	Informati	on Amendment	Chemis	stry (DM	F Update Notifica	ntion)	· <u>· ···</u>
1 6000		. Sobel	7, 1334	224 5 7 19	ST Americanient	. J	2.17 (2.14)		A. 30 - 1 -	
1.7.15	:	. Furlano					#.* #			
	Sale of the	y 5 9 11 45 5				14. July 1		<u>in jaitinaka</u>		
B06551	125 T			4		: CMC L	Jpdate -	Specifications an	d Tests for	Bulk Drug
* 14.1.	<u></u>	Sabal	· '6' [32]	Substanc	:e			70 to 11 to	1	•
v	· · · · · · · · · · · · · · · · · · ·	. Sobel		 		1.				
	P	. Furlano	47 7 79 4	<u>l</u>						

IND/NDA/DM	F#: 32,703	IND	Doc Type:	FDA CORRE	SPONDENCE	12/17/96 Page 14
Anna .			SubT	ype:	IND	
Erci#:	99	1	~~ Sub	Date:	1/30/89	Marie Carlotte Control of the Contro
		<u> </u>				
Generic:		Ange 10 - 20 4 11	Appr	Date:		
Product Name	Troglita	zone Tablets				
The same		BLIT INCINSTAN	The state of the Carl	Control of		
Barcode Ser/	Date	RE/ → NO TR	eport Title/	Report No.		
Ref#	To:	Contents/Rep	ort No./			
	From:		7 00 5			
and the second						
B06993 124	4 Thu, May 12, 1994	Information A	mendments	: Pharmacolog	av/Toxicology/Clinic	al .
300993 12-	S. Sobel			×		
	I. Martin					
30 L	engly of place the wife			87 S. 2-1		
B06993	Tue, May 17, 1994	Letter from S	ankyo: Reg	arding move to	new headquarters	The sign of the state of the st
	I. Martin	1.2	a (1) (1) (1) (2) (4) (4) (4) (4) (4)			
	A. Itoh					
B06993 120	6 Wed, May 18, 1994		endment: Cl	nange in Proto	col	
V 30 -	S. Sobel	8 0 1 3 3 3				
	I. Martin		7 m 1			
5 00000 100	7 Tue, May 31, 1994	I Conoral Corr	oonondonoo:	Peguest for	End-of-Phase 2 Mag	ting
B06993 12	7 Tue, May 31, 1994	General Com	espondence.	nequest for the	IIU-UI-Filase 2 Iviee	Cing Constitution of the C
Mary Mary	S. Sobel		7			
	TO THE PROPERTY OF THE PARTY OF			3.49.53	C. The Ballion of	
B07017 12	8 Wed, Jun 01, 1994	Information /	Amendments	: Pharmacolo	gy/Toxicology/Clinic	al
	S. Sobel			200		
100 Mil. 11	M. Taylor					
B07055	Mon, Jun 20, 1994		FDA: Regar	ding Research	Reports	· ·
	∄I. Martin					
	S. Sobel		A			
	A COMPANY		200			
B07055 12		Information /	Amenament:	Pharmacolog	y/ i oxicology	
	S. Sobel					
	I. Martin				Water Commencer	
B07055 13	0 Thu, Jul 07, 1994	Protocol Am	endment: Ne	w Protocol		
多种的人	_. S. Sobel					
	I. Martin					
B07055 13	1 Thu. Jul 07, 199	Information	Amendment:	Chemistry, N	Manufacturing and (Controls
	S. Sobel	3:3:3		18. 2014		
	D. Furlano					
	STATE OF THE STATE					
B07055	Thu, Jul 14, 1994	HUrug Export	Application	Service Services	eli e la Calaba	
	M. Limoli					
	I. Martin		1			
B07055 13		4 Annual Repo	ort		=	
	S. Sobel					
	I. Martin			1.70		
	77844	*				

T IND/NDA/I	DMF#	: [32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	12/17/96 Pag	je 15
4		n waster		Sub	Туре:	IND		
Ci#:		99	<u> </u>	Sub	Date:	1/30/89	[14 14 14 15 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
		100 100 100 100 100 100 100 100 100 100	,	Δος	r Date:			
Generic:	4				Date.			سوائق
Product Na	mė:	Troglita						
Control of the control	القائدة المسترد 2-ورات			MELIGIAA 1977 DLMANGALI, 12		(1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	West-Plans	:
Barcode Ser	/ >5D # = }_	ate Towns	RE/ Contents/	Report Title/ Report No./	Heport No.			
1		rom:					*	
			4. A					• • •
						-		
B07055	133	Fri, Jul 22, 1994	Protocol A	Amendment: N	lew Protocol			
		S. Sobel						· · ·
	با .	. Martin क्षेत्रकार सम्बद्धाः						
B07102		Wed, Jul 27, 1994	Information	n Amendment	s: Pharmaco	logy/Toxicology		
	3.3	S. Sobel		(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)				
	泰里	. Martin						
B07203	135 1	Mon, Aug 08, 1994	Protocol A	Amendments:	Change in Pro	otocol		
RATES NO.	9	S. Sobel						
		. Martin	J					
B07203		Tue, Aug 09, 1994		dum of End-of-	Phase 2 Mee	ting		
	_	Parke-Davis					信息蒙蒙部:	
		J. Short						
B07203		Tue, Aug 23, 199			: Letter of A	uthorization	The state of the s	
- E. S.		S. Sobel		84 A.				
		. Martin			XII			
B07203	1371	Ned, Aug 24, 199	Protocol	Amendment: N	New Protocol	The second of the second of the second	AND A STATE OF THE PARTY OF THE	Street Its Color of Control of
200		S. Sobel	2002	WP HEAT			4928	Garage S
		. Martin						
207202		Fri, Aug 26, 199	1 Protocol	Amendment:	lew Protocol			<u> </u>
B07203	138	S. Sobel	# F1010C017	Amendment.	13 M (48 /	AND THE REAL PROPERTY.	7.36 A C C C C C C C C C C C C C C C C C C	
	Y ∴ 🥍 –	. Martin						
		No. 14 Care Sales		- FDA A	al Panast		THE PARTY OF	
B07203		Tue, Aug 30, 199	4 Letter fro	m FDA: Annu	ai neport	and against the section of the secti	h	
	1.43	. Martin S. Sobel						
	() () () () () () () () () ()	· · · · · · · · · · · · · · · · · · ·		46.14.			100000000000000000000000000000000000000	
B07203			4 General C	Correspondence	e: End-of-Pha	se 2 Meeting Minute	is The second section of the second	
	- 1	S. Sobel						
羅於 一	ارد <u>ن</u> ا	l. Martin					Hart Street	
B07203	140	Fri, Sep 09, 199	4 Protocol	Amendment: N	lew Investiga	tor		
	1 1	S. Sobel	\downarrow					
		l. Martin						
B07203	141	Wed, Sep 21, 199	4 Protocol	Amendments:	New Protoco	/New Investigator		
		S. Sobel						
	, ;:	I. Martin	J∴		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			7

IND/ND/	A/DMF	#: 32,703	IND	Doc Type:	FDA CORRE	SPONDENCE	12/17/96 P	age 16
		i Tarihin	eren eren eren eren eren eren eren eren	SubT	уре:	IND		
; € CI#:			991 #6970	Sub I	Date:	1/30/89		
1				<u> </u>				
Generic:			and the first team.	Appr	Date:	<u> </u>		
Product I			oglitazone Tablets				39,544	. प्रदर्श
	_		Market State of the State of th	žiu ki taru sičivi i i su i taru te		್ರಾಕ್ಷ್ಮ್ ಪ್ರತೀಚಿಸುತ್ತದೆ. ಪ್ರತಿಕ್ರಿಸ್ಟ್ ಪ್ರತಿಕ್ರಿಸಿದ್ದಾರೆ. ಆಗಿದ್ದೇವರ ಮುಳ್ಳಾಗಿ ಪ್ರವೀತ ಪ್ರಕ್ರಿಸಿದ್ದಾರೆ.	2 14258 - 13 14 . Orași Antonio	
		Date 🔥 🤰	RE/	Report Title/				
R	lef#	To:	Contents/Re	port No./ ~				
		From:			•	•		• •
B07203	142	Fri, Sep 30,	1994 Protocol Am	nendment: Ne	w Investigate	or		
		S. Sobel, M.D.	4.5.	357		* 6		
		I. Martin			(0)	(i)		*
D07000	· · ·	Tue 000 04	1004 Pospones to	EDA Roquest	for Informat	ion	estitu (* 3	·
B07203	ا مدر	J. Short	1994 Response to	TOA nequest	ioi miloimai	ion Table 1,18 a.f. N		
		I. Martin		4.4				- بادو د المحادي
		Andrew Williams			1.0		", B. K.	
B07203	143	Tue, Oct 04,	1994 Information	Amendment:	Chemistry, N	fanufacturing and Co	ntrols	
		S. Sobel, M.D.			- 4.			
	7	D. Furlano						
B07203		Tue, Oct 25,	1994 Letter from	FDA			*	
		I. Martin	62.1828		CASA	34.5		
	46 N 6	C.M. Limoli						
D07202	3 (F/A)		1994 Protocol An	andment: No	w Protocol		A. T. March Street	1.5
B07203	140 300 A	S. Sobel	1994 FIGUCUI AII	nendment. Ne	AND STATE OF			
		I. Martin						
	7.0	The second second	530		# 4 Av 10			
B07203			1994 General Cor	rrespondence:	Suspended	Enrollment	e a promotor de la company	(A)
		S. Sobel						
		I. Martin						
B07203			1994 Protocol An	nendment: Ne	w Protocol			, č.
1.25					7.9			
B07203	144	Thu Nov 17	1994 Information	Amendment:	Clinical	30 (41) 37 3 38 38 10 72 44		
\$3.45 % S	9% 3	S. Sobel	543.14°	rt Gilding	130	A STATE OF THE STATE OF THE	STATE OF THE STATE	18.5
		I. Martin		SACA .	Taken a			
美养物		THE PERSON			**************************************			
B07258	149		1994 General Co	rrespondence:	52-Week M	onkey Study Summa	ry 	
		S.Sobel						ا معالی است. ماران
	المراجعة ا	I. Martin					Harrist Commence	· · · · · · · · · · · · · · · · · · ·
B07258	148			Amendment:	Chemistry (DMF Update Notifica	tion)	
343	ą <u>– 16</u>	S. Sobel						
		D. Furlano		A. Control				
B07258	150	Thu, Dec 08,	1994 Protocol Ar	nendment: Ch	nange in Prot	ocol		
-	<u> </u>	S. Sobel			Ĭ.			
		I. Martin			***			*
		4.	<u></u>		-		7 7	

IND/NE	A/DMF	#: 32,703	IND	Doc Type: FDA C	ORRESPON	DENCE	12/17/96	Page 17	
			,	SubType:	IND				- · · * }
CI#:		99	1]	Sub Date:	ا و فيس	1/30/89	Sanda Sanda		13
精力		्रद्रीय क्षेत्रीय क्षे <u>त्रीय क्षाप्रकार</u> - राज्यस्य क्षाप्रकार		Appr Date:					
Generic	10.00		· · · · · · · · · · · · · · · · · · ·	- Approving					
Product	Name:		zone Tablets		· · · · · · · · · · · · · · · · · · ·		A Park		
	Page 1	E JET IN THE STATE .	1130 Och 5	ia lastronom falko Santillitaralen 24	4			57.4.5	
Barcode	0.44	The state of the s	RE/ Re Contents/Repo	port Title/ Report	No.				
		To: From:							
					: ₁ ; .		-		• .
					•	* * * * * * * * * * * * * * * * * * * *	÷.		
B07258	151	Thu, Dec 22, 1994	IND Safety Re	port: Initial Writte	n Report	<u> </u>			_],
		S. Sobel						, ,	* .
	۱ ا	I. Martin			. i				
B07258		Thu, Jan 05, 1995	Protocol Ame	ndments: New Pro	tocol/General	Corresponder	nce		_]:
1.3		S. Sobel							
3000 m		I. Martin							
B07258	153	Fri, Jan 06, 1995		mendment: CMC					
	() () () () () () () ()	S. Sobel	4.3					The second	
		D. Furlano							3.
B07258	154	Mon, Jan 16, 1995		ndment: General C	orrespondenc	e	اللك كه داير فاطبيوف ا	· · · · · · · · · · · · · · · · · · ·	一),
in the second		S. Sobel			in the second	A Commence of the Commence of			
		I. Martin							
B07424	155	Tue, Jan 31, 1995	Protocol Ame	ndment: New Prot	ocol/New Inv	estinators/Cha	nge in Prot	<u>a substitution</u> ncol	
007424		S. Sobel	Frotocol Aine					**************************************	
		I. Martin							
22.0	450	**************************************			otal IDME III	data Natificat	ioal		
B07424	156	Mon, Feb 06, 1995 S. Sobel	Information A	menament: Chemi	Stry (DIVIE OF	Juale Notificat	1011)	7 (A)	
		D. Furlano					W.		(14)
104		ATTACK TO BE SENTERED			经验				
B07424	157		Protocol Ame	ndment: New Prot	ocol		i bira i bira	Contraction	
		S. Sobel	13.42						
		I. Martin						域的影響	142
B07496	158	= 51.04.4005		ndment: New Inve	stigators	2018 - 5018 28 20 50	er med aconta	# 1 × 1 × 1 × 1	125 125 125
		S. Sobel							
		I. Martin							
B07496		Tue, Feb 28, 1995					`		
10 S. Z.		I. Martin							
		S. Sobel							
B07496	159	Wed, Mar 01, 1995	IND Safety R	eport: Initial Writte	n Report		v		
		S. Sobel	J2 15 1						<u> </u>
		I. Martin							
B07496	160	Fri Mar 03 1995	Protocol Ame	endment: New Prot	181		<u>- 현실, 기구 : 한국</u>	<u> </u>	
B07490		S. Sobel	100000 74Me			4 4 5 1 5			7
		I. Martin							er sa i Lagragia
21. 11.		1. M.	· ·		:				

(ND/ND/	A/DMF#:	32,703	IND Doc Type:	FDA CORRESPOND	ENCE	12/17/96 Page 18
2.0		٠,	SubTy	rpe: IND		·
CI#:	HARIO I	99	1] 소약 출시를 👉 Sub D	ate:	1/30/89	A CONTRACTOR OF THE PARTY OF TH
- N. 1. 1.					· • ·	
Generic:			Appr	Date: 19 AUCT	1	
Product	Name:	Troglita:	zone Tablets			
		The state of the	transfer of the second	go desir bela degree	A 10 3 A	
Barcode S			RE/ Report Title/ F	Réport No.		
H	lef# To		Contents/Report No./			
	Fr	om:		· · ·	••,	
B07496	161 7	uo Mar 07 1995	Protocol Amendment: Ch	ange in Protocol		
B07490		Sobel	Trotocor Amendment: On			
200	· -	Martin			4	
1	- L	Company (All output				
B07609			Information Amendments:	Pharmacology/Tox	cology/Clinica	al
	3/4.25/X }	. Sobel				
		Martin अयुक्त के अक्षर के प्राप्त				
B07604	163 V		Protocol Amendments: Ne	w Investigators/Cha	ange in Protoc	ol
\$ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		. Sobel	er Samer Santine		10 to 10 to	
	字 [I.	Martin				
1007040	5, N. C	30 20 10 100 100 E	Protocol Amendment: Nev	w protocol. Now low	neticators Cl	nance in Protocol
B07646		ved, Apr 12, 1995 . Sobel	A A Market Commence of the Com	v protocor, reev inv	estigators, Ci	Chables Control
	高麗 八十一	Martin				
18.0	250 2 200	2011年2012年20日20年20日20日 2011年2012年20日20日20日20日20日20日20日20日20日20日20日20日20日2	SHEET SHOW		建筑建筑	
B07604	165		Protocol Amendment, New	/ Protocol	**************************************	
		. Sobel				
	200 mars 200 mars 201	Martin				
TOWNS TO ALL			Protocol Amendment: Cha			į,
					2.4	
		ngs and designation		popo in Protopol		
B07604		non, Apr 24, 1995 . Sobel	Protocol Amendment: Ch	narige in Protocol		
	2350 x 3	Martin				
		and the second second second second second				
B07677			Information Amendment:	Chemistry, Manufa	cturing and Co	ontrols
建 建70-13		. Sobel				
	S S	. Brennan				
B07677	168W	/ed, May 03, 1995	General Correspondence	- <u>.51. 6-L.</u>		
	S			Si Cara		
	35 - I.	Martin				
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	n Spins	and the second of the second o	Day of the FDA Massins	Baller De	4 38	
B07677			Request for FDA Meeting		, 1,35	
		. Sobel				
	rican i Li	Martin				
807677	0 1		General Correspondence		7.00	
	·	1r. J. Short				
	· · · · · · · · · · · · · · · · · · ·	1. Taylor				
; ••		A MANUAL TANKS		· · · · · · · · · · · · · · · · · · ·	. '}'	·¥.,

IND/NDA	VDMF	#: 32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	12/17/96 Pa	ge 19
5.55	· ·			Sub	Type:	IND	_]	
erci#:	1+ / 3	े इस्	991	Sut	Date:	1/30/8	9	
					والمناز والمراجعة			
Generic:			and the second		or Date:			
Product I	Vame:	- Na	roglitazone Table			·-··		
CENTRAL TO THE				a ta di kang Kalabatan Kang Kanggaran Ka		ing a sing a Sing a sing a	<u>a da a da a da</u> Adalah dan darah	-
Barcode S	er/ 💥	Date ::	RE/ Contents/l	Report Title/	Report No.			1
		والمرقاء المراجا	Contentar	teport teo.,				
		From:						
		* 1		10		<i>y</i>	· · · · · · · · · · · · · · · · · · ·	• ,//
	170	Wed, Jun 07,	1995 New Prote	ocol: 991-057	<u>'-001</u>			
		S. Sobel			*			
200 mg		I. Martin						
	172	Thu, Jun 15,	, 1995 Informatio	n Amendment	s: Pharmcolo	gy/Toxicology & Cli	nical	
B. 120. 2. 14	2. 14	S. Sobel		11.10				
		I. Martin						
B10131	171	Mon Jun 19	1995 RR 744-0	0178, 745-02	254, 764-023	08, 764-02345		
25000 P		S. Sobel	V 40			-62		
		I. Martin					*	
D10104	1 70	C-1 (v1.07	100EIND Safet	y Poport				
B10134	173	S. Sobel	, 1995 IND Safet	y nepuri	Appar and the			1,3,4,4
		I. Martin			The second			
		大学 一大小学を		"我们是我们的	· · · · · · · · · · · · · · · · · · ·			
B10134	174		, 1995 Annual Re	eport	e tomania de la Socia	Problem Problems	10089 A-030 E-643E-7	
		S. Sobel I. Martin			Code .			
		PARTICULAR STORY		A STATE OF THE STA	16	ALCOHOLDS AND THE		
B10134	175		, 1995 IND Safet	y Report	Table She was a second of the	TO THE ACT OF THE MEDICAL PROPERTY.	estated on Symphylic of	ig Skuden berauv
10 A		S. Sobel			- 1 × 1			
		I. Martin		A STATE OF THE PARTY OF THE PAR				
B10134	176		, 1995 IND Safet					
	12.53.44 1.53.44	S. Sobel			**			
	全学 方法:	I. Martin						
B10320	177	Mon, Aug 14	, 1995 Submissi	on of 30 Resea	rch Reports	<u> </u>	<u> </u>	
45 14 64 7 74		S. Sobel				(1) (4) (2) (3) (4)		19 July 10 1
		I. Martin						
B10298	170		, 1995 New Inve	estinators		<u> </u>	San	
1510230	170	S. Sobel	3.5	origotore	The state of the s	17200		
		I. Martin						
	. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	2 3 2 4 5 200 mg		2201 001 069	& Amondmon	<u> 1. 0。 - 対決の活動</u> + 1		
B10298	179	S. Sobel	, 1995 New Prot	0001 331-008	& Amendmen	1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		
		I. Martin						
		Andry Agendage						
B10298	180		, 1995 New Inve	stigators	the state of the state of	. W		
		S. Sobel		*				
		I. Martin			3		· ·	

IND/NDA	/DMF	#: 32,703	IND	Doc Ty	ype: FDA COR		NCE	12/17/96	Page 20
ils.		<u> </u>	erina. An isali esta		SubType:	IND		Y	<u>.</u>
CI#:			991		Sub Date:	£.	1/30/89	a Water water	
Generic:					Appr Date:			N. 44.	
			Series Consultation		· Alexander at the				
Product I	lame:		Froglitazone Tablet	is			. Line graph S		
			RE	Report T	ttle/ Report No		**************************************	ng this hope for a	克尼蒙罗沙 拉
R	ef#	To:	Contents/R	eport No.	1				
6 1 X 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3	From:			(1)	•			
						· ·	•		4.
	1		400clas - Dog						
B10298	181		, 1995 New Proto	COI					
\$5°.	• * (* (*)	S. Sobel I. Martin						*	
	1,	1. IVIAI (III		<u> </u>					<u> </u>
B10298	182		, 1995 New Proto	col			(ab 5.7.)	<i></i>	·
	er se.	S. Sobel		*					
		I. Martin					(4)(图)		
B10521	183		, 1995 IND Safety	Report					
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		S. Sobel	1,5,5						
	TE.	I. Martin	1.3						
B10521	185		, 1995 IND Safety	Report	•		•	*	
		S. Sobel	<i>N</i> 8		1,30,32,43				
		l. Martin					注注数 。	运搬货	
B10521		Thu Sen 14	l, 1995 New Inves	tigators	· · · · · · · · · · · · · · · · · · ·	all of the second	gering page angger	CHARLES CO.	The second of th
6.0321		S. Sobel	200 St. 12				4.77	25.94.23	A THE HEAT
)		I. Martin			38 W 12				
944 - 1 S	4.00	The Condition	1005 ND Coton	. Poport					
B10521		S. Sobel	I, 1995 IND Safet	A CAR		16.0	60 40 00 40	3 3 3 6 Y	1920
		I. Martin						Warren.	
		To be well all the	CALCOLA SALVE		77.49			* ***	第12章 经营业
B10521	187		5, 1995 IND Safet	y Report	. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	12 1.0 63 (1.06.23			er () Printe (V wet
		S. Sobel							
		I. Martin	A STATE OF THE STA	4					
B10521	188		2, 1995 Response	to FDA R	equest for Inforr	mation	n in 200 last	and the state of the	
		S. Sobel							
		I. Martin	Salah Maria				建筑设置		
B10521	189		5, 1995 IND Safet	y Update					
	· · · · · · · · · · · · · · · · · · ·	S. Sobel							the state of the s
		I. Martin							
B10521	190	Wed, Sep 2	7, 1995 IND Safet	y Report:	Initial Written F	Report			
2.5	,	S. Sobel							
	_	I. Martin							
D10531	101	Man Oct O	2, 1995 IND Safet	y Report	Follow-Up to a	Written Ren	<u>ng twate nj</u> ort		3 4
B10521	191	S. Sobel	z, 1999inu Salet	y neport:	TOROW-OP TO a	: stricten nep	<u></u>	ja , "V. ,i	
		I. Martin		1					
					9	6	\$ Y 7	*	

IND/NDA	\/DMF	#: 32,703	IND	Doc Type:	FDA COF	RESPON	DENCE	12/17/96	Page 21
			0.00	Sub	Туре:	IND			*
CI#:	***	781	991	Sub	Date:	.sr [1/30/89	121 (35 . Puls .	The Secretary Secretary
Service Control		3	331)				9 (1997)		
Generic:	,			App	r Date:	<u> </u>			
Product N	Vame:		Troglitazone Tablet	s				1200	
			ender the road		2 m	1.2.64.	Timuralian d		
Barcode . S	er/ 💸	Date 💮	RE/			7.第一年	18. 19. 1		
R	ef#	To:	Contents/R	eport No./ 📜		in the life			कर्म (१९ <mark>०५</mark> स्ट्रिक्ट)
		From:							•
D10531	102	Mad Oat O	4, 1995 Information	Amendment	Pharmaco	logy/Tox		<u> </u>	
B10521	192	S. Sobel	4, 1995 110111181101	Amendment	· · · ·	nogy, rox	- F -		
		I. Martin			*				
	•							<u> </u>	
B10726	193		4, 1995 Information	Amendment:	Pharmaco	logy/Tox	* *************************************		
		S. Sobel			adorran Adorran				
		I. Martin							
	194		7, 1995 IND Safety	Report: Initia	l Written R	eport			
	1,500	S. Sobel	. 3. 2. 27.	at y V				() j-1	
1	1.3.	I. Martin							7.3.737
D40040	405	T . O-4.2	4 1005 Canada Ca	eroonondonoo	() (Siz. **	<u>, i</u>	1 182 115 116	7,2	· · · · · · · · · · · · · · · · · · ·
B10842	195	S. Sobel	4, 1995 General Co	respondence	<u> </u>	·		79) 1 - Le-1 (
		I. Martin		AWARE TO WA	A Stant				
		tinger and in		1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		44 3			
B10842	196	Tue, Oct 2	4, 1995 General Co	rrespondence:	Pre-NDA	Meeting R	equest	Tam Salukaya k	Name of the Control o
16.1.2.10	. 4	S. Sobel			la v			1.22	
	4	102495.196		37747	7.46			* 4****	
B10842	197		4, 1995 IND Safety	Report: Initia	l Written F	leport			
		S. Sobel	14.4	d.				18:5	
		I. Martin					* ***		14.43 4
2.0040		POSSET COMESSION	0, 1995 Protocol A	mondmonts:	Change in I		a rich	The state of the s	tuna megantana. H
B10842	198	S. Sobel	U, 1995 Protocor A	Tel Sel	Change III	1010001	NE STATE OF		2000 2000 22
		I. Martin							
	4 N . 4 3	Sec. 20 - 1 28 200 - 1	Harry Harry	生人。		A. 9.	计算规则处理	55年	
B10842	199		2, 1995 Information	n Amendment:	Pharmac	ology/Tox		5, # . T. (),	
		S. Sobel							
		I. Martin	· WAS SEE			Transfer die			
B10842	200		2, 1995 Informatio	n Amendment	s: Clinical				
		S. Sobel	1.45		4.4.4.4			销售货业	
		I. Martin							3 48
D11010	201		8, 1995 Informatio	n Amendment	Pharmac	ology/Toy	<u> </u>	<u> Andrewski</u>	· · · · · · · · · · · · · · · · · · ·
B11010	201	S. Sobel	o, 1999illoillatto	Amendment		097/102		- 14 E	
生演 医毛		I. Martin				i i s			
		ii. iviai tiii				<u> </u>			
B10992	202	Thu, Nov 0	9, 1995 IND Safety	Report: Initia	al Written I	Report		4 **	142
4.		S. Sobel							
E VAN		I. Martin		\$ (· · ·			aya. Ayar Ta		

. IND/ND	A/DMF#	32,703	IND	Doc Type:	FDA CORR	ESPONDENCE	12/17/96 Page 22
-				Sub	Туре:	IND]
Ci#:		17. 3.X	991	Sub	Date:	1/30/89	
Generic:			gy the state of the state of	App	r.Date:		
	1.00		3	مه و المهني رواسه	and the second	- 1	
Product			roglitazone Tablet		BLECO TOLER	न्या । क्षेत्रक <mark>भागा भागा</mark> है।	
Barcode (S			RE/				
Barcode 1	Sef# T	7	Contents/R	eport No./	Support 140.		
		rom:				W.	
				*			
24.000	1 0001	ri N- 00	1005	- Ad	CMC	.* :	
B10992		. Sobel	1995 Information	n Amenument	CIVIC		
		. Brennan					
	_	S. 11 12.	:			- x-	
B10992			1995 General Co	orrespondence	: Proposal to	r Trade Name	
	: . 	. Sobel Martin					
	₹ : €	THEFT A THE AM					
B10992	206	Tue, Nov 21,	1995 Protocol A	mendments:	New Protocol	<u> </u>	
		. Sobel		3 Z .			
	[]	Martin					
B10992	207		1995 IND Safety	Report: Follo	ow-Up to a W	ritten Report	
	S	. Sobel		Santa J.			
		Martin				200mm,为有关的	
B10992	208 V	Ved, Nov 22,	1995 IND Safety	y Report: Folk	ow-Up No. 2	to a Written Report	
		. Sobel	79.05.7				
	ESTATION BARRY	. Martin			<i>9</i> 45		
B10992		Tue. Nov 28.	1995 IND Safety	Report: Follo	ow-Up to a W	ritten Report	
		. Sobel	10 To		Cate Co	SECTION CONTRACTOR	
	7.3	Martin					
B10992	1 1-	Tue Nov 28	1995 FDA's Rep		基据现在15mm 1.5°	-Self-transfer of the self-transfer of the	7
PURE TO THE	المساسات	Martin	000000				
		3. Troendle					
B10992	210	Fri Doc 01	, 1995 Protocol A	mendments:	New Protoco	<u>.::///.234</u>	(A) The Control of th
B10332		S. Sobel	3405 S		Philair 1886		
	₹ 3 ~~⊢	Martin					
7.0000		Configuration of the Configuration	, 1995 Protocol A		Now Protoco	<u> </u>	
B10992		S. Sobel	, 1995 Protocol A	amenoments.	New Fioloco		
4.7	1-	. Martin					
	٠ ٢	2. L. W				la su (Ta - 2 C)	
B11677	<u> </u>		, 1995 Informatio	n Amendment	s. Pharmaco	logy/Tox & Clinical	
	-	S. Sobel . Martin		* -			
	24, 285	Literature States			Y		57%益性,在多十九年
B11677	<u> </u>		, 1995 Information	n Amendment	ts: Clinical		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
(n;	·	S. Sobel				- M-1	
	<u> </u>	. Martin		* -		*	

IND/NDA	V/DMF#	#: 32,703	IND	Doc Ty	pe: FDA CO		DENCE	12/17/96	Page 23
ing.	-	<u></u>		8	SubType:	IND			
CI#:	.:	- M. 25 [991		Sub Date:		1/30/89		in the second
Generic:					Appr Date:		· · · · · · · · · · · · · · · · · · ·	1	a de la companya de La companya de la companya de l
100 mg			iaaaaa Tab		a grading of the second	الله ادار	•		
Product I	vame:	N. 30 1815 1	litazone Tab		a Walataco i	A Company of the con-	· 40.155.154.254.		
arcode S	orl S	Date (Salar		to the believe in the	de/ Report N	رى يى، ئاۋىدىنى ئىسى			
				/Report No./					
	- = -	From:							
						0			
011044	214	Thu, Dec 21, 19	QE Protocol	Amendment	s: New Proto	col and Ger	neral Correspo	ndence	· · · · · · · · · · · · · · · · · · ·
311844	<u> </u>	S. Sobel	33,71010001	Amendment	_ 14 , ·	cor and oc.	iciai concept		
	· · · }	l. Martin			n de la companya de La companya de la co				. *
\$. N. 4-1		T. D. 01 10	05 0	Carrando	non Monk IS	C and ICE		<u></u>	· · · · · ·
311844		Thu, Dec 21, 19 S. Sobel	95 General	Corresponde	NEW TOOK IS	S and ISE		3.0% of \$5.00.	
	* 1. A.	I. Martin		8 2 3 3 3 4 3					
	ું કું દક્ષ્યુ ા	37-457 3447 112/4 67 1			No. of the last of			TO CHESTON	वित्र मुस्कित्र
311844	<u> </u>		95 Protocol	Amendment	s: New Proto	COI	1 (N)	·	in the factor of the contract
	1. 1.	S. Sobel I. Martin							t it is the
		1 (m)		3.46					
11844		Thu, Dec 28, 19	95 Protocol	Amendment	s: New Inves	tigators	- 4 - 15 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	TUSAL A MAY	1,14
	3,783	S. Sobel							
	2.34 St . A	I. Martin	3						
311844	218	Fri, Jan 12, 19	96 General	Corresponde	nce	80, 777 9 9 19 10 A	STREET,	constant	And the Kerney day of the
		S. Sobel						- # T	
	, l	I. Martin			18.78				
B12336	219	Mon, Jan 15, 19		tion Amendm	ent: Clinical,	Pharmacol	ogy/Toxicolog)Y	2 (7 - 10 and 1 Go + 10co
	2.00	S. Sobel							
	38 4 5 5 5 X	I. Martin							
312569		Mon, Jan 22, 19		Amendmen	t: Change in F	Protocol		ğ	
		S. Sobel							
		1. Martin							
312569	221	Mon, Jan 22, 19	96 IND Saf	ety Report:	Initial Written	Report			
		S. Sobel	No. of the last		STATE OF				
		I. Martin							
312569	222	Wed, Jan 24, 19	96 Protoco	i Amendmen	t: Change in I	Protocol	ATTRICATED (A. 97)	<u>(4. 45.1828) (1) (5.21)</u>	THE PERSON OF THE
		S. Sobel		14.76° 5 12°					
		I. Martin							
312569	223	Fri, Jan 26, 19	96 IND Saf	ety Report:	Follow-up to a	Written Re	eport	N Garage Contract	
in the		S. Sobel		16.133					-25
	14.4 2.4 %	I. Martin							
B12569	324	Tue, Jan 30, 19		tion Amendo	nents: Pharma	cology/To	<u>ളുടെ പ്രൂക്ക് (</u> cicology	48 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	the state of
18/2 7	4	S. Sobel	200 miloima	Section Control	7 7 7 7				27.
		I. Martin							
at the	ا عاد	sa barring s			***	•			

IND/N	DA/DMF	#: 32,703	IND	Doc Type:	: FDA CORRE	SPONDENCE	12/17/96	Page 24
			. : · ·	Sul	ьТуре:	IND		4 <u></u>
Ci#:		△ 99	1 35	Su	b Date:	1/30/89	Section 1	- 84. 1J.
Generic				An	pr Date:	,		
Carlo delle la		-		ئ <u>نٽ:</u> ⊢		1		
	t Name:		zone Tablets		7.1	A TANKAL ALAMA	3	
3.6			weeks 11.				1.68 5 1.10	
Barcode	Ref#	Date S.	Contents/Rep		Report No.			
	:	From:	y .	· · *		6		*
							٠.	4.3
			1.47 ·		· · · · · · · · · · · · · · · · · · ·	• • • • • • • • • • • • • • • • • • • •	<u> </u>	
B12569	225		Protocol Am	endment: I	New Protocol			
	• -	S. Sobel	ļ					144
		I. Martin					• • • • • • • • • • • • • • • • • • • •	
B12569	226	Wed, Jan 31, 1996	IND Safety F	leport: Init	ial Written Rep	ort		
Ž.		S. Sobel						16 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
437.45 127.45		I. Martin						
B12569	227		Information A	Amendmen	t: Clinical].
		S. Sobel		,				
	• :	I. Martin						
B12569	228	Mon, Feb 05, 1996	General Corr	espondence	e: Pre-NDA Me		1.5 1.1 1.1	· · · · · · · · · · · · · · · · · · ·
7 5/2-1	223	S. Sobel			garan Au			
	\$ 0 G	I. Martin						
B12569		Tue, Feb 06, 1996		Report: Init	ial Written Ren	ort	STATE OF SHIPS	1 Tel bysty Sentilly
B12303	225	S. Sobel	We salety i	Sala Silas			FALL STATE	
		I. Martin			MARKS.			
		PLATE OF PROPERTY OF					ANNEASS:	
B13013	230		Information	Amenamen	ts: Clinical and	Pharmacology/Toxi	Cology	
141		S. Sobel					3 miles	1.00
200		CONTRACTOR CONTRACTOR						
B12569	232	Wed, Feb 14, 1996	Protocol Am	endment:	Change in Prote	ocol	Hidar Parking Car	
		S. Sobel						
		I. Martin						
B12569	231	Wed, Feb 14, 1996	Response to	FDA Requ	est for Informat	tion		
		S. Sobel						
		I. Martin						
B13015	233	Wed, Feb 21, 1996		Amendmen	ts: Pharmacol	ogy/Toxicology		
21649 1787		S. Sobel				建筑 。 下来		
		I. Martin						
B13015	234	Wed, Feb 21, 1996	Protocol Am	endment:	Change in Prot	ocol	V* , , , ,	
160		S. Sobel						
	*	I. Martin] - :	e≅				
B13015		Wed, Feb 21, 1996	General Cor	respondenc	e: Request for	Meeting	***	
237		S. Sobel	Jueneral Con)	o. nequest for	Mooting 195	11 57 -	
		I. Martin	1					
15		\$ 10 P \$	_		·			* • • •

IND/NDA/	DMF#:	32,703	IND C	oc Type:	FDA CO	DRRESPONDEN	CE	12/17/96	Page 25
			•	SubT	Гуре:	IND			
-:	· · · · · · ·	99	<u>1</u>	Sub	Date:	14.50	1/30/89	11 144	
- Fit					27.4	3			
্রি Generic:			7 7 Table 10	Appi	Date:				
Product N	ame:	Troglita	one Tablets						
Singles			gen have jar (i. Grandsauthund d					\$1.425 \$41.50	
Barcode Se	r/∵∃Da f# ३°–	te 🔞 📜	RE/ Reports/Report	ort Title/	Report I	No.			
	f# To		- Contentantepo						
2 46		om: Prifite 1998.	, · · · · · · ·						, ,
	,							····································	
B13015		hu, Feb 22, 1996	National Institu	te of Heal	th's Follo	w-up Correspon	dence		
	· ½ —	Whitcomb						•	
		Elder-Leak, NIH		- <u>-</u>	<u> </u>				
B13015	236 T	ue, Feb 27, 1996	Information A	mendment	: Clinica	1			
	— احدور .)	Sobel						で基準した	
		Martin		* 1.5					
B13015		ue, Feb 27, 1996	Information Ar	nendment:	Pharma	cology/Toxicolo	gy		
	s.	Sobel							
	். * ட	Martin	ļ						
B13015		on, Mar 04, 1996	Desk Copy	<u></u>					
1200	Α.	. Jordan							
		Martin			To the	A SECTION AND THE		在第一次 在第一次	
B13015		on, Mar 04, 1996			THE COME SERVE	**************************************	. ST AUGUSTAN		2000
) Distribution	252					MARVE	
) i l.	Martin			218				
B13015	238 T	ue, Mar 12, 1996	IND Safety Re	port: Follo	w-up to	a written report		A COMPANY AND A PROPERTY	
3.00		Sobel			/1. / P (*)	***********		42.25	
	1.	Martin					7	We see	
B13015	230 IV	/ed, Mar 13, 1996	Protocol Amer	dments: (Changes	in Protocol. Nev	v Investiga	tor	2-2-1-1-1-2
13013		Sobel	25.000	4 60 M			(1-2-1- 4)	发生产生	
	7 S	Martin							
B13827	240 7	hu, Mar 21, 1996	Information A	nendments	Pharm	acology/Toxicol	ogy and C	inical	TO SERVICE STATES
D13027		Sobel .		nendment.			r : wiles		
	1.5	Martin							
	Page Selection	245C-3 4-C15-4C35-75			227		Mily Mile (HA	THE POPULAR	
B14043	-200K I	Fri, Mar 22, 1996	FDA's reply to	Seriai No.	237				
	<i>→</i> —	Martin . Troendle					14.54		* 1
		ele de la company			1,13		<u> </u>	<u>َ رَا</u> فَقَرِيْنِي	<u> </u>
B14043		Tue, Mar 26, 1996	Information A	mendment:	Clinica	l seks sama sagases s		Jiri Ac .	
	*	. Sobel Martin			San				
ing the same		N 12 / 22 / 10 / 10 125 125 125	1					<u> </u>	
B14043		led, Mar 27, 1996						1 1 2	7,11,4%,4%
	: <u> </u> S	. Sobel				*			

. IND/ND/	A/DMF	#: 32,703	IND	Doc Type:	FDA C	ORRESPO	NDENCE	12/17/96 Page 26
- T				Sub	Гуре:	IND		
CI#:			991 352-35	Sub	Date:		1/30/89	uteralization of the
			Contract Con	Ann	Data			
Carence:			يعاشا حساني البادية لوهايط	Арр	Date.	- 113		
Product I	Name:		roglitazone Tablets					
A STATE OF THE STA	ا الله الله الله الله الله الله الله ال		Carried State of the Control of the		i sinat ayar.	<u>.</u> د د چر برده		Le marks - market of the
Barcode S		Date	RE/ N-1	Report Title/	Report	No.		
H	ef#	To:	Contents/Re	port No./	a i	A Wall		
	37.	From:						
					9			
B14043	242	Mon. Apr 01,	1996 General Cor	respondence:	Pre-ND	A Meeting	Information	
感答 :		S. Sobel	1,74				• • •	•:
		I. Martin						· · · · · · · · · · · · · · · · · · ·
		- 1 14 Jan		<u> </u>	.5	0		
B14043	-		1996 General Cor	respondence	lant.	* * *	- · · · · · · · · · · · · · · · · · · ·	
	- E - C	S. Sobel						
	120	I. Martin						
B14043			1996 Protocol An	nendment: Cl	hange in	Protocol, I	New Investigato	rs
1. 6.10	, ,	S. Sobel	1	- (- 3			
		I. Martin						
D1 4040			1006IND Safatu	Ponort: Follo	W-UD to	a Written	Report	
B14043		S. Sobel	1996 IND Safety	neport. Follo	Cost i	a willen	teport	to elikarran
		I. Martin						
		18.82-1-1-0-1-1-1-2558# 1 8.			No.			
B14043	247	Wed, Apr 10,	1996 Protocol An	nendment: N	ew Prote	ocol	E STATE OF VACCOU	
	197	S. Sobel						
		I. Martin						
B14034	248		1996 IND Safety	Report: Follo	w-up to	a Written	Report	age of the control of
			7.48		244	icalian.		
		I. Martin		914				
	A A	STATE STATE		37.24 S. 1971		A SAMO		
B14043	249		, 1996 Protocol Ar	nendments: I	New Pro	tocol, Char	nge in Procol, Ni	ew investigators
	N. S.	S. Sobel						
		I. Martin						
B14732	250	Tue, Apr 23,	, 1996 Response t	o FDA Reques	st for Inf	ormation		
	13.432	S. Sobel			ĸŹŶĞĖ,			
	10.24	I. Martin				a de la companya de l		
D14722	251	Tue May 14	, 1996 IND Safety	Penort: Follo	NA-UO TO	a Written	Report	<u>ିର୍ଦ୍ଦର ଅନ୍ତିଶିକ୍ତିକ ପ୍ରେଟିକର୍ଡ</u>
B14732	251	S. Sobel	, 1990 IND Salety	Report. Folio	W-up to	a written	neport	
		I. Martin				7		
	17	r r gran jetaje s						
B14732	252	Tue, May 28	, 1996 Protocol Ar	nendment: C	hange ir	Protocol,	New Investigate	ors
		S. Sobel				Őğ.		
		I. Martin				, stage		
B14732	253		, 1996 IND Safety	Report: Follo	w-up N	o. 2 to a W	ritten Report	
2017	1 200	S. Sobel		1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		#83	See See	
	4	I. Martin			10	**		
				. •	*		• ;	

IND/ND		#: 32,703	IND Doc Type: FDA CORRESPONDENCE 12/17/96 Page 27
HADNED	A/DIVIII 7	7. 32,700	SubType: IND
<u></u> \$CI#: ···	·.	99	1 Sub Date: 1/30/89
Sq.			Appr Date:
Generic:	· /: ''		
Product	Name:	Troglita	zone Tablets
arcode S	er/		RE/ Report Title/ Report No.
F		To:	Contents/Report No./
	, i	From:	
	•		
314732	254	Thu, May 30, 1996	Protocol Amendment, New Protocol, New Investigators
, tra		S. Sobel	
		I. Martin	
314732		Mon, Jun 03, 1996	FDA's Reply
**************************************		I. Martin	
	4.7	S. Sobel	
314732	255	Mon. Jun 17, 1996	Protocol Amendment: New Protocol
		S. Sobel	
		I. Martin	
314732	256	Mon. Jun 24, 1996	General Correspondence
*****		S. Sobel	
		I. Martin	
314732	257	Fri Jun 28 1996	Protocol Amendment: New Protocol
204		S. Sobel	
	44	I. Martin	
320038	259	Wed, Jul 10, 1990	
120030		S. Sobel	
		I. Martin	
B20038		- Thu Jul 11 1996	General Correspondence
520030 Valoria		S. Sobel	
		I. Martin	
B20038	261	Thu Jul 11 199	6 General Correspondence: Meeting Minutes
		S. Sobel	
	11.8 4.8 21.8 4.8	I. Martin	
B20038	1 100	Fri, Jul 26, 199	
	<u> </u>	I. Martin	
以 为		S. Sobel] - 이 40대에 맞았다. 이 대학생님, 20대의 이웃으로 다
B20038	262	Mon. Jul 29, 199	6 Protocol Amendment: New Protocol
B20036	1 202	S. Sobel	
		I. Martin	
B20038	263	Mon Aug 26 199	6 IND Safety Report: Initial Written Report
-4	203	S. Sobel	Salety reports and the
		1	

IND/NDA	/DMF	#: 32,703	IND	Doc Type:	FDA CORRE	SPONDENCE	12/17/96 Page 28
		•	•	Sub	Гуре:	IND	
€CI#:		<i>y</i> S 9:	91	Sub	Date:	1/30/89	
1					S.	111 22	
Generic:				App	r Date:	1 2 2 2 2 2	
Product N	lame:		azone Tablets		271 101 112		
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	i i i		ega e eg <u>a al</u> Ber e egalaret				aranga dalamangan kalanda dalam dala
Barcode S		Date	RE/ :: !! Contents/Re	Report Title/	Report No.		
		The second of th	Contentante	port ito.,			
444		From:	•				
WAR.			•		200		
B20038	264	Thu, Aug 29, 199	6 Protocol Am	nendment: No	ew Protocol, C	hange in Protocol	
		S. Sobel					
		I. Martin					
B20038	265	Tue, Sep 10, 199	6 IND Safety	Report: Follo	w-up to a writ	ten report	
The Late		S. Sobel					
		I. Martin					
B22145	266	Fri, Sep 13, 199	6 Protocol An	nendment: N	ew Protocol	W WA SINGS IN VIA	
~~~		S. Sobel			A Salar Carlo		
		M. Taylor					
B22145	267	Mon, Sep 16, 199	GIND Safety	Report: Follo	w-up to a Wri	tten Report	No. 1 of any section 1
1022143 4-55/4-16-16-16-16-16-16-16-16-16-16-16-16-16-	207	S. Sobel	3.30 )	rioporti i ono	See as let		
	+.4	M. Tyler					
		NEW TOTAL STATE			AND THE		
B22145	# 29%Abc33	Thu, Sep 19, 199	6 Clinical Rev	iew	742 425	78.57.78.67.22.67.4	
		Mary E. Taylor Gloria Troendle	$\dashv$ . The $d$				
		AND HAVE ALL HAVE TO CAU		\$2 <b>93</b> , (\$157)			
B22145	268	Fri, Sep 27, 199	6 General Cor	respondence:	Literature	acom econos avados	
		S. Sobel	$\dashv$				
		M. Tayler					
B22145	269	Tue, Oct 01, 199	6 Protocol An	nendments: (	Change in Prot	ocols, New Investig	ators.
		S. Sobel					
		M. Taylor					
B22145	270	Fri, Oct 18, 199	6 Protocol An	nendment: N	ew Investigato	ors, Change in Proto	col
4000		S. Sobel	79.2			<b>第4位数据</b>	
		M. Taylor					
B22526	271	Wed, Oct 30, 199		nendment: N	ew Protocol	The standing of the standing	88 8 JUL 24 8 4 JUL 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25
25 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	S. Sobel	3.7°.		200 Mar 1 1 1 1 1	200 TOP 1-40-	
		M. Taylor					
P22520	370	Fri, Nov 01, 199	SIND Safat	Undate: Foll	OW-UD to a MA	itten Report	RESET FREETING 1
B22526	272	S. Sobel	Solind Safety	Opuate, 1011	ুৰ্ণ হৈ	itteri neport	
		M. Taylor	$\dashv$				
						一位 经营	
B22526	273	Wed, Nov 06, 199	6 Protocol Ar	mendment: N	lew'Investigate	ors Recognition As	
		S. Sobel	** *** *5	*			
		M. Taylor					

. IND/ND/	A/DMF#:	32,703	IND	Doc Type:	FDA CORRESPO	NDENCE	12/17/96	Page 29
			which is a second	Sub	Type: IND		]	The state of the s
			991	Sub	Date: 🗁 💛 😉	1/30/89	. Paris	eis Manie Hai
Generic			Name of the Control	Арр	r Date:	C. Maria . maria .		
Product	Name:	Tr	oglitazone Table		Application of the second of t			
No. of Participant					PERMITTER PROPERTY.	TO ARTHUR MANAGEMENT		
	er/ Da lef# To	TO DETAIL	RE/ Contents/l		Report No.			
	a fin	m:						
B22526		ri, Nov 15,	1996 IND Safet	y Report: Seco	and Follow-up to an	Initial Written	Report	
- 174	., °., ̀, s.	Sobel	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
	75 JAC 4032	Taylor						
B22526				Amendment: N	ew Investigators			
	S.	Sobel						
	M.	Taylor						
B22526	276 M	n, Nov 25,	1996 General C	orrespondence	: Draft Protocol for	Review		
	- ;;; S. M.	Sobel Taylor						

EXHIBIT 13

## EXHIBIT 13 NDA LOG

IND/NDA/DN	MF#: 20-720	NDA	Doc Type:	•		NCE	12/17/96	Page 1
<u> </u>			SubT	<del></del>	NDA		<u>-</u>	
CI#:	9	91	Sub		<u> </u>	7/31/96		
Generic				Date:	<u> </u>			
Product Nam	re: Troglit	azone						error and a little
		الأواد المقالية فيمي	Land Control of the c	W 1987 L 1987	satisfy the second	च्यास्य सम्बद्ध	The same	
arcode Ser/	⊁ Date	RE/	Report Title/	Report No.				
Ref#	To:	Contents/I	Report No./				·#2 3	
	From:	-0-				71		
								· · · · · · · · · · · · · · · · · · ·
314151	0 Wed, Mar 27, 199	6 Presubmis	ssion NDA		· ·	: : : : : : : : : : : : : : : : : :		
	S. Sobel		4			1 .0	17.	1.0
	I. Martin	7				10	Si.	
3.4741	Thu, Apr 04, 199	- Bro cubmi	ission Receipt	• • •	<u> </u>	<u> </u>	· · · · · · · · · · · · · · · · · · ·	
314741	I. Martin	Op 16-SUDITI	A Might No St. No.			1 6 g 5 g 25 g 25		
	E. Galliers							
<b>第</b> 第一个	** A KOT - SI 7 194		Problem Port State	की है है इस दिस्ती । • • • • • • • • • • • • • • • • • • •			**************************************	
314741	0 Wed, May 01, 199	6 Desk Cop	y of Presubmiss	ION NUA		19.	11,2 +	• 17-
	J. Webber	_		1				
	i. iviaitiii			al and	e je ^{st te} r te jes	1 1		<u> </u>
314741	Tue, Jul 16, 199		eeting Minutes			94 T St. 18	1. 81.	
	Central Labeling Co	<u>의</u> : : : : : : : : : : : : : : : : : : :						
	I. Martin							
314741	Wed, Jul 31, 199		y Action Packag	je				
	E. Galliers, FDA			で、公舗				
	M. Taylor							
314741	Wed, Jul 31, 199		udy Information	See 19 November 2 Village 22	· · · · · · · · · · · · · · · · · · ·	2. C. C. V. Date 3. C. C.	Commence of the Commence of th	
**************************************	G. Turner, FDA		CONTRACTOR	LINE COLUMN LANGUE TORN	4.20% F	1144	K T	orthograph (#35
4.5	M. Taylor		•	HAPT.	, A& ( .	4.4		
320352	1 Wed, Jul 31, 199		lew Drug Applic	ation	74.45.4.42.4.4	(*C*44,831,636,7508)	Tagliana (1914)	\$403554 \$ \$ 15000 \$180.17 5,00
650002	FDA	\$ 17 Sept			£440.44	<b>可以的非常</b>		Mark St.
	I. Martin					Virginia de la compansión de la compansi		
	Carl A Col 100		an of Electronic	न भेरते केट्रीकेट <b>D</b> oto		નું <del>કે જો હાઇ</del> ક	1. 2. " "	\$\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
820973	O Thu, Aug 01, 199 D. Marticello, Ph.D		on or Electronic	Data	375.2	4.20	A CANON	ng ar mining lang.
	M. Taylor	$\mathcal{L}_{\hat{a}}$						
	ीं - वार्ष्ट्रास्त्राच्या व वर्ष्ट्रास्त्रा						\$\$\$\$\frac{1}{2}\$	
B20973	Mon, Aug 05, 199	6 Acknowle	edgement of ND	A submissi	ion.	<del></del>	ne spilariti	
	I. Martin	$\dashv$ ,					Çer.	
	E. Galliers					- સ્ટ્રેક્સફ્રેફ્ટિં _ક	<u> </u>	
B20973	Mon, Aug 12, 199	Copy of	Summary Volum	e of the N	DA.	• • • • • • • • • • • • • • • • • • • •	1 X 20 + 1	
	A. Itoh						·생() . 수 항공	
	M. Taylor	J.;						
B21244	2 Thu, Aug 15, 199	6 Request	for Information.					
	S. Sobel	10 -		7 / 7 / 7 / 7 7 / 7 / 78				
	M. Taylor	7 . :						٠.

IND/NDA	V/DMF	#: 20-720	NDA	Doc Type:	FDA CORRE	SPONDENCE	12/17/96 Pag	e 2
**************************************	: :		•	SubTy	pe:	NDA		
*CI#:		14 23	991	Şub D	ate: 🕌	7/31/96		:
Generic:				Appr I	Date:			
1	<b>34.</b> 19			100000				
Product I		1967 St. 1964 St. 1975 A. 1984	glitazone	· · · · · · · · · · · · · · · · · · ·	.533 -333 -	reconstruction in the second	100	
			Thursday 2		<u> </u>		tale.	
rcode S	er/ 🐣	Date	機RE/ 点音・	Report Title/ R	eport No.	<b>国际</b> 一个人		
R	et#		Contents/R	eport No.		ورورا والأوارات فلسهة الرهو ووسياقال		4
		From:				•		
				* (X)   0	. ()			
21244		Thu. Aug 22. 1	996 Copy of C	ase Report Forms	<u>.                                    </u>			
3-/7		S. Sobel						
β1. 136-11.	- 1	I. Martin					00	
		1 4 Y 2						·
21785			996 Request fo	r Case Report Fo	orms		22 x 2 3 "	<del></del>
25		G. Turner					to the	
		I. Martin						
21244		Thu, Aug 22, 1		linutes		- m - 13 - 13 - 13 - 13 - 13 - 13 - 13 -		·
		Central Labeling						
		I. Martin				/		
<u> </u>	1948			- 5	<del>Vija de se e</del>			· · · · · ·
21244	4	Tue, Aug 27, 1	996 NDA Revie	w Status	en :			
ر المراجع الماجعة المراجع المراجع المراجعة		S. Sobel						
		I. Martin						
21244	20 V	Wed Aug 28 1		or Case Report Fo	orms - Addi	ional Information	ASPELLED A LAND OF PARTY AND A PRINTER TO	
6 24 X	3 / <b>3</b> 4 / 35	G. Turner	<b>公共</b>			NEW PLANS AS A DE		Table Sec
		I. Martin		- 4064			M in	
		LINE COLUMN TO SERVICE				CONTRACTOR WILL	erest as deca	4.
321244	5	Thu, Aug 29, 1	200	and the second of the second o	Add Co. Co. Co.	THE PART OF THE PART NAME OF STREET	encounty in a constant of the constant	de la la la calactera
	(C) (C) (C) (C)			To compare	S. S. E. Grant Broken Sec. 5 15		i An Cas	
energy)	**	I. Martin					***	
21244	<u>8€35-35</u> 6	Thu, Sep 05, 1			entern marin	- 19 San 19	10 ma	1 to 1-5 to 11-5 to 1
	E ZESTE S	S. Sobel	Fast of F.	1000年8月			SAZ VOICE	10.10
		I. Martin						3. 1
		2 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2			14.		等例。15 台灣·	
21244				nicity Reports fo	r Troglitazo	ne		
F. A.		Charles E. Roth		<b>发导。通过14</b>				
		C.T. Viswanath						[東管東]
** 10 175 · .	7	Thu Sen 12		is made to our p	ending ND/		100 A 2 A 2 A 2 A 2 A 2 A 2 A 2 A 2 A 2 A	
in 12.	<u> </u>	S. Sobel		35. gh. 100 f				•
	r ,- )	I. Martin						
		A 10 A 10 A 10 A 10			. 1111			ý.
321244	8	Mon, Sep 16, 1	996 Response	to FDA Request	for Informa	tion		
		S. Sobel						· .
		I. Martin	3.0		<i>}</i>			
21244	1	Tue Sep 17	1996 Priority Re	view.			A Start Comment	
21244	1 1 1 32 3	Irwin G. Martin	330 Friority Re	SVIGVV	<u></u>	<u> </u>	Arthur Congress	* **
		Solomon Sobel						٠.
. " \		COORDION SOREI	1 .	100				

	F#:  20-720	NDA  Doc	Type:  FDA COR		12/17/96	. ugo u
era'.			SubType:	NDA		
CI#:	. 99	91	Sub Date:	7/31/96	.:	*
Generic:		<del></del>	Appr Date:			
dellenc.			App. Jato.			
Product Name	**				J	
W. 194	ale <u>indi</u> en <mark>1825 en 1888. En 1888 en 1888. Ben en en europe en 1888 en 1888.</mark>		14 °		21 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	
Barcode Ser/	Date	RE/ Report	Title/ Report No.			
Ref#		Contents/Report N	0.7			ត្រូវក្មី ្គី ដើមទំនឹង ។ ទី
	From:	·(i)		*		
			• • •	• , .	. O	
9	Tue, Sep 24, 1996	6 Electronic Data Se	ets			
	S. Sobel			:		
	. Martin	J ⊕		-0		
B22334 10	Tue, Oct 01, 199	6Letter of Authoriz	ation			÷
1 de 2	S. Sobel					
	S. Brennan					
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				- 1.21 - 1.21	Section 1994
B22334 11	Wed, Oct 02, 199	6 Request for Addit	onal Information			
	S. Sobel	-				
	I. Martin		<u> </u>			
B22334	Wed, Oct 02, 199	6 Desk Copy				<u> </u>
2.4	M. Fossler				P. 6	
	M. Taylor					
B22334 12		6 Minor Amendmen				
	S. Sobel	<b>使于</b> 例是为你。		群的人的主义是		的外的
	S. Brennan				10.45	
B22334 (		6 Desk Copy of Tw			AC STARK CARRESTS	25 CON 34 14 CHOM & 147 55 VI
	H. Rhee	ACTOR CONTROL		SUNCY WATER	SACARETY	179 37 <b>15</b> 723
4	M. Taylor					
	3 3 - 4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1				N. 4. 22.4.3	
B22334		6 Meeting with Drs	. Bilstad and Sobel	I SKO JE, WEI INTROLIE	: <1.50.45\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$	
	Distribution					400
	W. Merino					
B22334	Wed, Oct 09, 199	6 Deficiencies in th	e Environmental A	ssessments of 20-720	and 20-719	 
	Irwin G. Martin					
Maria de la companya	Solomon Sobel					
B22363 1:		6 Requested Study	Reports			
	S. Sobel				, , , , , , , , , , , , , , , , , , ,	***
A A CONTRACTOR						
	I. Martin					
	,, ,	6 Undated Informat	ion			
	Fri, Oct 18, 199	6 Updated Informat	ion			
	,, ,	6 Updated Informat				
B22364 14	Fri, Oct 18, 199 S Sobel I Martin					
B22364 14	Fri, Oct 18, 199 S Sobel I Martin Mon, Oct 28, 199	16 Labeling Safety L	Jpdate			
B22364 14	Fri, Oct 18, 199 S Sobel I Martin	16 Labeling Safety U				

IND/NDA/DM	F#: 20-720	NDA D	oc Type:	FDA CORRE	SPONDENC	E	12/17/96	Page 4
	•	•	Sub1	Гуре:	NDA			
∵	9:	91	Sub	Date:		7/31/96	N. E.	7
		<u>.                                    </u>	7	Doto				
Generic:			Appi	Date:				
Product Name							ا بره الادمال المراجعة المعارضية	
	Control of the Tales			tite san vii s Le gart	<u></u>	4		
Barcode Ser/		RE/ Rep	ort Title/	Report No.				
Ref#		Contents/Repor	140.7					
	From:							
Table Table								
B22364 10	6 Fri, Nov 01, 199	6 Minor Amendm	ent Revise	d Confidentia	I Environme	ntal Asse	ssment	
र्वे.	S Sobel							**
i	S Brennan	]		*		7	1	
B22364 1	7 Fri, Nov 01, 199	6 Minor Amendm	ent Revise	ed FOI Environ	mental Ass	essment		
	S Sobel				• • •	191	0.1	2
Page 10 a	S Brennan		100			100		
[222224   4		C Donding Novy C		iccion				
B22364 1	8 Tue, Nov 05, 199 S Sobel	o rending ivew L	Jug Subin	1551011				1 1 1 1 1 1 1
	I Martin	-						
	<u> </u>		<u> </u>	30		<u> </u>	3.1.7	
B22364   1	9 Wed, Nov 06, 199	6 Minor Draft La	beling Ame	endment (Imm	ediate Cont	ainer Lab	els)	
A	S. Sobel							
	I. Martin							
B22645 2	0 Fri, Nov 15, 199	6 Drug Interaction	n Study					
	S. Sobel		<b>福建学</b> 、	The same of the			7×34-22	。1987年(1984)
	I. Martin							
B22645 2	1 Fri, Nov 15, 199	6 Draft Briefing	<u>्रवेशक्तिकार</u> Document	20 8 9 9 4 4 5 6 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	MANAGEMENT AND S	· · · · · · · · · · · · · · · · · · ·	(Carronal Control (C	province resolute a marco
20643	S. Sobel	5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.00 × 5.	158 274	Company of the Compan		14.9	Market .	######################################
	I. Martin						essen in	
	AND					- 19		
B22645	Mon, Nov 25, 199	6 Briefing Docun	nent	sman costostata	material and a contract of the	(Become	42 45 PM 40 800	3.480.18.18.18.18.18.18.18.18.18.18.18.18.18.
	K Reedy							
	Martin		3. 37					
B22645 2	2 Tue, Nov 26, 199	6 Additional Saf	ety Informa	ation				
	S Sobel		Av.					
	l Martin							
B22680 2	3 Wed, Dec 04, 199	6 Request for In	formation				25-2 / W. 198	
DZ2000   2	S Sobel	12652						
	l Martin	7	•					3.5
				•			1	<i>5</i>
B22687 2	4 Thu, Dec 05, 199	Hequest for In	rormation	· · · · ·	7 2		1.00 Tell 1	
	S Sobel	102						
\$	l Martin				y. A	100		
B22687	0 Thu, Dec 05, 199	6 Desk Copy: R	esponse to	FDA Reques	t for Inform	ation		
***************************************	R Misbin							
	l Martin	_],			:			8.

IND/NDA/DMF#: 20-720	NDA Doc Type: FDA CORRESPON	NDENCE 12/17/96 Page 5
	SubType: NDA	
3+;CI#: 32.23	991 Sub Date:	7/31/96
Generic:	Appr Date:	
The second secon		
	SOUTH COMPANY SERVICE	and the state of t
Barcode #Ser/ Date Rer# To:	RE/ Report Title/ Report No.	
From:		
25 Fri, Dec 13	, 1996 Response to Request for Information	
S Sobel I Martin		
The state of the s		